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PROPOSITIONS
1. Macrophages residing in different tissues should be considered as 
unique cell types.
(this thesis)
2. Obese adipose tissue would benefit from having more rather than 
fewer macrophages.
(this thesis)
3. Access to scientific publications, experimental setups and data is 
not sufficient to achieve true open science.
4. The gap between what is expected from science on the one hand 
and feasible for scientists to provide on the other fuels public 
distrust in science.
5. Whereas scientific research orders the universe, it increases 
entropy in personal life.
6. Just as in fashion, trends dominate the scientific agenda. 
7. The reliability of scientific data is determined by the methods and 
materials used yet is too often appreciated as being directly linked 
to individuals or journals.
8. Dealing with serendipity makes up an essential part of a PhD-track.
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1 General introduction
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Circulating in the bloodstream or nested in tissues, monocytes and macrophages protect 
against invaders and support tissue development and function. Central to these acts is their 
capacity to recognize and ingest foreign particles or microbes; a process called phagocytosis, 
and damaged or dying cells; a process called efferocytosis (1,2). Monocytes and macrophages 
are, however, not only involved in the clearance of stressors, but also modulate immune 
responses via antigen presentation and the release of cytokines, chemokines and growth 
factors (3). Their great phenotypic plasticity allows for such functional polarization and 
underlies their capacity to maintain or regain homeostasis while being challenged by a 
variety of environmental stressors (4). 
Activation through Toll-like receptors
Pattern recognition receptors (PRRs) play a crucial role in recognition of various stressors. 
They enable immune cells including monocytes and macrophages to respond to structural 
components of microbes, called pathogen-associated molecular patterns (PAMPs), or 
structures formed upon tissue injury, so-called damage-associated molecular patterns 
(DAMPs). Despite their relatively recent discovery, the family of Toll-like receptors (TLRs) 
are the most extensively studied class of PRRs (5). To date, thirteen members have been 
identified in mammals (6). Located either on the cell surface or intracellular membranes 
of endosomes or lysosomes, TLRs recognize specific entities of pathogens (7). Whereas 
bacterial lipids and proteins are recognized by TLRs residing on the plasma membrane (TLR1, 
-2, -4, -5, -6, and -10), nucleic acids form the most prominent ligand of intracellular TLRs 
(TLR3, -7, -8, and -9) (7, 8). Being composed of at least two of the three main ligand entities 
(lipids, proteins, or nucleic acids), a pathogen generally activates more than one TLR (8). Such 
simultaneous activation of multiple TLRs or TLRs in combination with other PRRs enables the 
initiation of pathogen-tailored immune responses (8). 
Upon ligand binding TLRs dimerize and activate adaptor molecules ultimately 
cumulating into effector functions including pathogen uptake, chemokine and cytokine 
release, and antigen presentation (7, 9). After the initial pro-inflammatory responses upon 
TLR activation that facilitate immune cell infiltration and pathogen killing, anti-inflammatory 
signalling is needed for resolution of inflammation and restoration of tissue homeostasis (10). 
This involves efferocytosis of infiltrated neutrophils and monocytes that have undergone 
apoptosis, and the release of anti-inflammatory cytokines including IL-10 and TGF-β (11, 12). 
Classical versus alternative activation
The sharp contrast between phenotypes directly after activation versus those at later stages 
has led to the classification of macrophages into pro-inflammatory or classically activated on 
the one hand (13) versus anti-inflammatory or alternatively activated on the other hand (14). 
In vitro, stimulation with IFN-γ, often in combination with the TLR4 ligand lipopolysaccharide 
(LPS), generates a macrophage phenotype resembling classical activation (15, 16), whereas 
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IL-4, sometimes in combination with IL-13, induces an alternative macrophage phenotype 
(14, 17). Nowadays, these two divergent phenotypes are named ‘M1’ for classically activated 
versus ‘M2’ for alternatively activated macrophages (18). 
Diversification of macrophage phenotypes into M1 versus M2 has enabled the in 
vitro investigation of functional polarization of macrophages as well as the identification 
of pathways or transcriptional patterns underlying macrophage polarization. Accordingly, 
several transcription factors including signal transducer and activator of transcription (STAT) 
proteins have been identified to initiate transcriptional patterns specifically required for a 
functional M1 or M2 response (19). On the one hand STAT1 is critically involved in activating 
transcription of opsonic receptors and pro-inflammatory cytokines and chemokines 
characterizing a M1 response (e.g. IL-12 and CCL5), whereas STAT6 predominantly drives the 
expression of mannose receptors and anti-inflammatory cytokines and chemokines like IL-10 
and CCL24 (20).   
Through recent years intracellular metabolism has regained attention as fundamental 
driver of immune responses (21). Although initially the M1 versus M2 classification was 
based on arginine metabolism either driving the production of nitric oxide (NO) or ornithine 
respectively (18), the last decade many other metabolites and metabolic pathways have 
been identified to underlie macrophage activation. Currently intracellular metabolism is 
generally acknowledged to promote macrophage function through the generation of energy, 
production of building blocks, and synthesis of signalling molecules (21, 22). 
Metabolism as determinant of function
Upon activation immune cells strongly enhance glucose uptake and secrete high amounts of 
lactate (23). As such, they display great similarity with Warburg’s observation in tumour cells 
opting for the fermentation of glucose despite sufficient oxygen and functional mitochondria 
(24). Importantly, enhanced glycolysis in classically activated macrophages is accompanied by 
impaired oxidative phosphorylation (OXPHOS). Although the yield of ATP is much lower per 
molecule of glucose, a shift from OXPHOS toward glycolysis allows for a more rapid increase 
in ATP production required for cytokine and chemokine secretion as well as phagocytic 
capacity. In addition, it enables immune cells to feed the pentose phosphate pathway (PPP) 
and use tricarboxylic acid (TCA) cycle intermediates and mitochondria for purposes other 
than ATP production. Indeed, the PPP supplies building blocks for nucleic acids and amino 
acids, and NADPH needed for fatty acid (FA) synthesis and reactive oxygen species (ROS) 
formation through NADPH oxidase (22, 25). Mechanistically, the TCA cycle is disrupted at 
two sites, allowing for the accumulation of the TCA intermediates citrate and succinate 
that respectively fuel FA synthesis required for proliferation and HIF-1α stabilisation that 
promotes IL-1β transcription (22, 26). Moreover, rather than being used for ATP production, 
mitochondria have been shown to fuel ROS formation through reverse electron transport 
(27). Hence, by activation of glycolysis in expense of OXPHOS M1 macrophages facilitate 
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bacterial killing, cytokine release, cell growth and proliferation. At the other side of the 
spectrum, M2 macrophages display an intact TCA cycle and enhanced mitochondrial activity, 
and mainly rely on OXPHOS in mitochondria for ATP production (25, 28). 
Recent insights, however, point to metabolic choices of M1 versus M2 macrophages 
being less straight-forward than initially thought. For example, instead of FAs (29), M2 
macrophages likely predominantly use glycolysis to fuel the TCA cycle for mitochondrial 
ATP production (30, 31). On the other hand, M1 macrophages that predominantly rely on 
glycolysis for pro-inflammatory functions, have been shown to require FA oxidation for 
inflammasome activation and IL-1β secretion as well (32). 
Metabolic diversity in vivo
Whether metabolic profiles similar to those observed in M1 or M2 macrophages exist in vivo 
remains ambiguous. Given the great versatility and plasticity of macrophages, and complex 
combination of stressors – either pathogenic or non-pathogenic of origin – present in vivo, 
metabolic profiles of M1 versus M2 macrophages are not expected to generally reflect 
monocyte or macrophage phenotypes.
Indeed, growing evidence suggests that activation of different PRRs or stimulation 
with distinct cytokines drives unique intracellular signalling routes that translate into diverse 
macrophage phenotypes (33). Nutrient availability further increases the complexity of 
responses in vivo by driving metabolic choices made by monocytes or macrophages. For 
instance, lactate has been shown to inhibit glycolysis and pro-inflammatory M1 activity (34), 
whereas glutamine deprivation interferes with M2 polarization (35). Recently, it was shown 
that M1 macrophages switch toward using OXPHOS for ATP production in glucose-deprived 
medium (36). Interestingly, this did not affect their pro-inflammatory trait, suggestive of a 
complex interplay between intracellular metabolism and macrophage function that may 
critically depend on both the presence of stressors and nutrients.  
Tissues are characterized by a distinctive combination of stressors and nutrients, 
and have indeed been shown to accommodate unique populations of macrophages that 
adopt tissue-specific ‘default settings’ to prevent continuous inflammation (37). This 
opens an interesting field of exploration to understand how macrophages in various tissue 
environments adopt intracellular metabolic routes that can be used to fuel tissue-tailored 
functional requirements.
Tissue-resident macrophages
Conventionally, monocytes and macrophages were seen as intermediate and end-
point within one maturation flow in which pro-monocytes from the bone marrow enter 
the bloodstream to become monocytes that randomly infiltrate tissues at steady-state 
ultimately differentiating into macrophages (38). Nowadays, however, we know that 
infiltration of monocytes solely occurs in tissues depending on external replenishment (39-
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41), or during injury or infection (42, 43). It has become apparent that virtually all tissues are 
characterized by a stable population of macrophages that mostly establishes before birth 
and maintains itself throughout adulthood (44-46). Although immune surveillance is part of 
their task, most tissue macrophages are predominantly occupied by clearing cellular debris 
and apoptotic cells as part of homeostatic turnover (2, 37, 47). In addition, they adopt various 
tailor-made phenotypes and functions driven by micro-environmental cues and tissue-
specific challenges (3, 48). For example, consequential to their direct exposure to external 
stressors, macrophages populating the lungs display a high phagocytic capacity needed for 
clearing pathogens (49). In contrast, macrophages in the sterile environment of the testis 
have been shown actively involved in steroidogenesis by producing 25-hydroxycholesterol 
(50). Accordingly, each tissue harbours a unique population of macrophages executing highly 
specific functions and clearly distinguishable on transcriptional level (51, 52).
White adipose tissue as immunological organ
White adipose tissue plays a crucial role in cold insulation and protection of vital organs. 
Yet rather than being a passive storage entity for excess energy, research done in the last 
twenty-five years has revealed that the adipose tissue also is a highly dynamic organ that 
ensures metabolic flexibility. Via the uptake of glucose and FAs for storage into triglycerides 
(TGs) when energy is abundant, and breakdown of these TGs when energy is needed, the 
adipose tissue rapidly responds to metabolic needs (53). Moreover, it affects whole body 
metabolism by releasing a variety of signalling molecules called adipokines that may impact 
on food intake and key metabolic enzymes in peripheral organs including the liver (54). 
The observation of increased levels of TNF-α (55) and identification of macrophages 
as source of TNF-α (56, 57) in obese adipose tissue instigated a plethora of studies that 
have identified the adipose tissue as an important immunological organ that accommodates 
various immune cells from the innate and the adaptive immune system both in lean and obese 
conditions (58). Accumulating evidence emphasizes tight interactions between immune cells 
and adipocytes and a pivotal role for immune cells in adipose tissue functioning (58, 59). 
Ever since the discovery of enhanced numbers in obese adipose tissue, macrophages 
have gained particular attention and have been extensively studied. These studies revealed 
adipose tissue macrophages (ATMs) to be critically involved in adipose tissue functioning 
and whole body homeostasis. For example, in conditions of high adipocyte lipolysis as 
apparent during weight loss or induced by β-adrenergic stimulation, macrophages rapidly 
infiltrate the adipose tissue, locate around adipocytes, and adopt a lipid-laden appearance 
(60, 61). By buffering lipids released by adipocyte lipolysis, ATMs ensure gradual release 
of free fatty acids (FFAs) into the circulation and shield other tissues from potentially toxic 
levels of circulating FFAs (61). Moreover, they effectively remove adipocytes that have died 
as a consequence of continuous lipolysis (60, 61) or upon targeted activation of caspase-8 
(62), and further facilitate tissue turnover by promoting extracellular matrix remodelling, 
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adipogenesis, and angiogenesis (59, 60, 63, 64). Although these ATM functions have been 
identified upon experimental manipulation, adipocyte turnover has been shown to exist at 
steady-state as well. Indeed, calculations of adipocyte replacement range from 10-100% 
cellular replacement a year (65, 66), suggestive of a continuous cycle of cell death and 
replenishment. Considering the above, ATMs presumably play a key role in this process. 
The development of obesity is characterized by adipocyte hypertrophy and high 
numbers of cell death (67). As with the targeted adipocyte cell death in lean adipose 
tissue, adipocyte cell death in obese adipose tissue is accompanied by a sharp increase in 
the number of macrophages (56, 57) that surround dying or dead adipocytes in so-called 
crown-like structures (CLSs) and display a lipid-laden appearance (68-71). In contrast to the 
lean state, however, lipid-laden macrophages in CLSs of obese adipose tissue adopt a pro-
inflammatory phenotype (67, 72-74), displaying profound similarity with foam cells present 
in atherosclerotic plaques (72). Importantly, the presence of CLSs in obese adipose tissue 
correlates with the development of insulin resistance in both mice and humans (68, 75, 76). 
The exact cause of inflammatory activation of ATMs in obese adipose tissue is still 
under debate. Similarly to what has been reported for foam cells that display lipid-induced ER 
stress in atherosclerotic plaques (77, 78), ongoing lipid accumulation may cause lipotoxicity 
and thereby pro-inflammatory activation of ATMs part of obese adipose tissue (79). Indeed, 
ER stress has recently been shown to be enhanced in ATMs during obesity, and ablation of 
IRE-1α – a key sensor of ER stress – curtailed the inflammatory trait of ATMs (80). Otherwise, 
FAs but also other factors coming from stressed or dead hypertrophic adipocytes, such as 
HMGB1 (81, 82) or DNA (83), may act as DAMPs activating macrophages in obese adipose 
tissue via PRRs including TLRs (84). 
Role for Toll-like receptors in obese adipose tissue
The family of TLRs may provide a link between nutrient abundance and adipose tissue 
inflammation (85). Especially TLR2 and TLR4 have gained attention because of their 
activation by various metabolic products, among which FAs (86). Although direct binding to 
TLRs is questionable (87), FAs may activate TLRs via the circulating plasma protein Fetuin-A 
(88). Alternatively, saturated FAs may modulate the propensity of TLR dimerization hence 
TLR activation via promoting the formation of lipid rafts and subsequent TLR translocation 
into lipid rafts, or through binding to co-receptors including the FA-transporter CD36 (89). 
Interestingly, the expression of both TLR2 and TLR4 is increased during atherosclerosis and 
obesity and associates with diabetes outcome (90). In murine models of diet-induced obesity, 
deletion or truncation of TLR2 or TLR4 has been shown to improve disease outcome by 
abating weight gain, attenuating adipose tissue inflammation, or improving insulin sensitivity 
(86, 88, 91-94). 
Of the thirteen TLR family members, ten are expressed in humans and twelve in mice. 
Interestingly, all twelve TLRs expressed in mice were shown upregulated in obese adipose 
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tissue (95), some of them much more than could be explained solely by macrophage influx. 
Importantly, TLRs are expressed both in immune cells and adipocytes (96) and may affect 
adipose tissue inflammation via adipocyte-macrophage cross-talk as has been shown 
for TLR4 (97). However, the exact role of TLRs in interactions between macrophages and 
adipocytes in lean versus obese adipose tissue, or in the development of adipose tissue 
inflammation and Type 2 Diabetes in obese individuals, is not yet fully understood. 
Metabolic activation of macrophages in obese adipose tissue
Because most of the studies on ATM activation have been done in mice or in vitro (most often 
using mouse cells), the relevance for humans remains ambiguous. Importantly, however, 
both human and mouse ATMs display a unique inflammatory phenotype, characterized 
by the expression of M1 as well as M2 markers (98-102). Recently, it has been shown that 
instead of pathogens or cytokines, a combination of insulin, glucose and palmitic acid drives 
macrophage activation toward a phenotype resembling ATMs part of obese adipose tissue 
(103). These ‘metabolically activated’ ATMs are characterized by enhanced expression of 
genes involved in lipid uptake (Cd36), storage (Plin2) and export (Abcg1) (103). Intriguingly, 
metabolic reprogramming in ATMs is in line with a previous study that revealed increased 
lysosomal biogenesis and activity in ATMs part of obese adipose tissue (104). Because 
macrophages in human adipose tissue display similar metabolic activation (103, 104), one 
could speculate activation of metabolism to be a general characteristic of ATMs that may 
importantly underlie their inflammatory trait in obese adipose tissue. How intracellular 
metabolism relates to inflammatory activation of ATMs in lean or obese conditions is, 
however, an intriguing aspect that is not yet understood.  
Outline of this thesis
In this thesis we focus on the interface of metabolism and immunity, generally referred to as 
‘immunometabolism’. By examining the role of intracellular energy metabolism in activation 
and function of monocytes or macrophage exposed to various environmental cues, and by 
studying ATM activation and function in lean and obese conditions, we aim to enhance our 
understanding of metabolic choices and functions of monocytes and macrophages either 
challenged by pathogenic stimuli or residing in the complex environment of the adipose 
tissue.
Changes in intracellular metabolism upon stimulation of TLR4 with LPS are relatively well 
understood and have often been extrapolated to other forms of inflammatory activation 
of mononuclear phagocytes, presuming general characteristics of metabolic rewiring 
upon activation. We evaluated whether LPS-induced metabolic rewiring holds true upon 
stimulation of other TLRs in human monocytes. As such, in Chapter 2 we describe metabolic 
reprogramming in freshly isolated human monocytes stimulated with various microbial 
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pathogens, and dig further into distinct metabolic rewiring as well as its consequences for 
functional outcome by using the synthetic TLR-ligands LPS and Pam
3
CysSK
4
 (P3C). This provides 
the basis for further elaboration on the role of intracellular metabolism for macrophage 
functioning in the adipose tissue; a more complex environment that accommodates a variety 
of stimuli. First, in Chapter 3, a contemporary overview of the origin and function of ATMs 
in both lean and obese adipose tissue is provided, as well as of stressors that may contribute 
to their inflammatory activation during obesity. Building upon studies that have plead for 
metabolic rather than inflammatory activation of ATMs (103, 104), we examine real-time 
energy metabolism in ATMs isolated from obese or lean adipose tissue in Chapter 4, and, by 
using various inhibitors of different metabolic routes, demonstrate the contribution of ATM 
metabolism to cytokine production. Moreover, we evaluate the role of HIF-1α, a key regulator 
linking energy metabolism to cytokine release (105), in metabolic rewiring and inflammatory 
activation of ATMs during obesity by feeding myeloid-specific Hif-1α knock-out versus wild-
type mice a high-fat diet (HFD). Then, we zoom into the role of lipids as potential drivers of 
the ATMs phenotype. During obesity ATMs have been shown to enhance the expression 
of several genes involved in lipid uptake, including lipoprotein lipase (Lpl), that is crucial 
for breakdown of extracellular TGs, and cluster of differentiation 36 (Cd36), facilitating FA 
uptake (79, 103, 106). By exposing wild-type macrophages as well as macrophages lacking 
angiopoietin-like 4 (ANGPTL4), a well-known inhibitor of LPL, to adipose tissue-conditioned 
medium or a TG emulsion, we evaluate the role of TGs versus FAs in driving the inflammatory 
phenotype observed in macrophages in an adipose tissue environment in Chapter 5. In 
Chapter 6, we explore clearance of dead adipocytes by macrophages in the context of obese 
adipose tissue. Clearance of dead adipocytes by macrophages has only recently been studied 
in detail and so far its relevance during obesity and potential differences between the lean 
and obese state are far from completely understood. We therefore study regulation of the 
efferocytic machinery in ATMs, interfere with the phagocytic machinery in obese mice, and 
measure the uptake of lipids from dead adipocytes and subsequent inflammatory activation 
of macrophages primed with either obese or lean adipose tissue in vitro. In Chapter 7 we 
investigate whether TLR10 is of relevance during the development of obesity. This TLR family 
member has been detected in human adipose tissue (96) and is the only TLR attributed 
with anti-inflammatory properties (107). In our study, we examine plasma adipokines and 
cell counts in the adipose tissue of obese and lean individuals carrying single nucleotide 
polymorphisms in TLR10 or bearing wild-type alleles of TLR10, and include an animal 
experiment in which mice carrying a human TLR10 transgene and wild-type controls are fed 
a HFD for 16 weeks. Lastly, in Chapter 8 the insights obtained in this thesis are evaluated 
and integrated in a more broader exploration and discussion on the therapeutic potential of 
targeting intracellular metabolism for restricting inflammatory activation of macrophages, 
with particular emphasis on ATMs in obese individuals.
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ABSTRACT
Microbial stimuli such as lipopolysaccharide (LPS) induce robust metabolic rewiring in 
immune cells known as the Warburg effect. It is unknown whether this increase in glycolysis 
and decrease in oxidative phosphorylation (OXPHOS) is a general characteristic of monocytes 
that have encountered a pathogen. Using CD14+ monocytes from healthy donors, we 
demonstrated that most microbial stimuli increased glycolysis, but that only stimulation 
of Toll-like receptor (TLR) 4 with LPS led to a decrease in OXPHOS. Instead, activation of 
other TLRs, such as TLR2 activation by Pam
3
CysSK
4
 (P3C), increased oxygen consumption 
and mitochondrial enzyme activity. Transcriptome and metabolome analysis of monocytes 
stimulated with P3C versus LPS confirmed the divergent metabolic responses between 
both stimuli, and revealed significant differences in the tricarboxylic acid cycle, OXPHOS 
and lipid metabolism pathways following stimulation of monocytes with P3C versus LPS. 
At a functional level, pharmacological inhibition of complex I of the mitochondrial electron 
transport chain diminished cytokine production and phagocytosis in P3C- but not LPS-
stimulated monocytes. Thus, unlike LPS, complex microbial stimuli and the TLR2 ligand P3C 
induce a specific pattern of metabolic rewiring that involves upregulation of both glycolysis 
and OXPHOS, which enables activation of host defence mechanisms such as cytokine 
production and phagocytosis.
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INTRODUCTION
Otto Warburg first described the concept of metabolic rewiring in tumour cells in the 
1930s and showed that differentiated cells rely on mitochondrial oxidative phosphorylation 
(OXPHOS) to generate ATP, whereas tumour cells switch to aerobic glycolysis under normoxic 
conditions1. In recent years, immunologists have discovered that this metabolic shift also 
underpins the activation and function of immune cells.
T-helper cells, such as activated TH1 and TH17 cells, are characterized by active 
glycolysis2, whereas quiescent T cells, such as regulatory and memory T cells, rely on OXPHOS 
and fatty acid oxidation for their ATP production2,3. Similar parallels can be drawn between 
polarized macrophages, where pro-inflammatory M1 macrophages are highly glycolytic, but 
anti-inflammatory M2 macrophages rely mainly on OXPHOS and fatty acid oxidation4,5. These 
metabolic adaptations are thought to accommodate various functional outputs. For instance, 
intracellular metabolites such as succinate6 and itaconate7 serve not only as tricarboxylic acid 
(TCA) cycle intermediates but are also closely linked to cytokine production, macrophage 
polarization and microbial killing.
As such, the shift from OXPHOS to glycolysis following activation, known as the 
Warburg effect, has been adopted as a core paradigm in the field of immunology8. Currently, 
the field is dominated by studies in the murine system, which have primarily investigated 
the influence of Toll-like receptor (TLR) ligands, such as lipopolysaccharide (LPS), on cellular 
metabolism4,7,9,10. Few studies have investigated this switch in human immune cells11, and it is 
unclear whether all microbial stimuli induce the Warburg effect. To build on this, we examined 
whether different microbial stimuli could induce the Warburg effect in human monocytes. 
Whole-pathogen lysates were used to represent both Grampositive and Gram-negative 
bacteria, whereas TLR4 (LPS) and TLR2 (Pam
3
CysSK
4 
(P3C)) ligands were used at different 
concentrations for mechanistic studies. Additionally, we investigated the consequences of 
metabolic rewiring on two functional outputs: cytokine production and phagocytosis.
Surprisingly, we discovered that a shift from OXPHOS to glycolysis was observed only 
in monocytes stimulated with concentrations of 1–100 ng ml−1 LPS, and not in monocytes 
stimulated with P3C or other bacterial lysates. In monocytes stimulated with P3C, increased 
OXPHOS was needed for retention of their phagocytic capacity and cytokine production. 
These findings therefore challenge the notion that a shift from OXPHOS to glycolysis underlies 
activation of all immune cells upon microbial stimulation. Instead, we propose that each 
individual stimulus induces a complex set of metabolic programmes that govern the function 
of a given immune cell.
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MATERIAL AND METHODS
Healthy volunteers
PBMCs were isolated from blood donated by healthy male volunteers after informed consent. 
Ethical approval was obtained from the CMO Arnhem-Nijmegen (NL32357.091.10).
Isolation of PBMCs and CD14+ monocytes
Isolation of PBMCs was performed by differential centrifugation over Ficoll-Paque PLUS 
(GE Healthcare Biosciences). Monocytes were separated from the PBMCs by hyperosmotic 
density gradient centrifugation over Percoll (Sigma-Aldrich) and washed once with PBS. Cells 
were counted in a Coulter counter (Coulter Electronics). Alternatively, CD14+ monocytes 
were purified from freshly isolated PBMCs using MACS microbeads for positive selection, 
according to the manufacturer’s instructions (Miltenyi Biotec).
Stimulation experiments
Monocytes (2 × 105 per well) were used for Seahorse measurements, while 1 × 106 monocytes 
per well were used for cytokine, RNA and western blot analysis. Monocytes were cultured 
in Roswell Park Memorial Institute (RPMI) 1640 medium (no glucose; Gibco) supplemented 
with 10 µg ml−1 gentamicin (Gibco), 10 mM pyruvate (Gibco), 10 mM HEPES (Sigma-Aldrich), 
5.5 mM glucose (Sigma-Aldrich) and 10% human pooled serum, and stimulated with RPMI 
1640, 0.1–10 µg ml−1 P3C (EMC Microcollections), 0.1–100 ng ml−1 LPS from E. coli (Sigma-
Aldrich), 10 µg ml−1 poly(I:C) (Invivogen), 5 µg ml−1 Mycobacterium tuberculosis (strain H37Rv) 
lysate, 1 × 106 organisms ml−1 E. coli (ATCC 35218) or 1 × 106 organisms ml−1 S. aureus (clinical 
isolate). Unless stated otherwise, monocytes were stimulated with 10 ng ml−1 LPS or 10 µg 
ml−1 P3C for 24 h.
Monocytes were treated with 2DG (Sigma-Aldrich) to block glycolysis, with rotenone 
(Sigma-Aldrich) in combination with antimycin A to block complex I of the ETC, with TRIF 
inhibitory peptide (Pepinh-TRIF; InvivoGen) or with control peptide (Pepinh-Control; 
InvivoGen) to inhibit TRIF signalling, with GW9962 (Sigma-Aldrich) to inhibit PPAR-γ, with 
rosiglitazone (Sigma-Aldrich) to activate PPAR-γ, or with dimethyl itaconate (Sigma-Aldrich). 
For experiments related to hypoxia, monocytes were stimulated with LPS or P3C for 24 h and 
then incubated in hypoxic (1% oxygen) or normoxic (20% oxygen) conditions for 2 h before 
measuring the phagocytic capacity of the monocytes.
Cell culture supernatants were collected and stored at −20 °C. Cells were lysed in TRIzol 
reagent (Invitrogen) and stored at −80 °C until RNA isolation was performed, or stored at −80 
°C until processed for western blot analysis as described below.
Cytokine measurements
The production of IL-1β and TNF-α was measured using commercial enzyme-linked 
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immunosorbent assay (ELISA) kits (R&D Systems), and IL-6 and IL-10 concentrations were 
also measured by ELISA (Sanquin).
Lactate measurements
Lactate was measured from cell culture supernatants after perchloric acid precipitation. 
The resulting supernatants were neutralized with NaOH. An enzymatic assay, in which 
lactate was oxidized and the resulting H
2
O
2
 was coupled to the conversion of Amplex Red 
reagent to fluorescent resorufin by horseradish peroxidase, was used to determine lactate 
levels. Either 30 µl lactate standard or 200-fold diluted sample was added to a black, 96-
well, flat-bottomed plate, followed by 30 µl reaction mix, which consisted of 0.6 µl 10 U ml−1 
horseradish peroxidase (Sigma-Aldrich), 0.6 µl 100 U ml−1 lactate oxidase (SigmaAldrich), 0.3 
µl 10 mM Amplex Red reagent (Life Technologies) and 28.5 µl PBS. The assay was incubated 
for 20 min at room temperature, and the fluorescence of resorufin (excitation/emission 
maxima of 570/585 nm) was measured on a 96-well plate reader (Biotek).
Extracellular flux analysis
Real-time OCR and ECARs of monocytes were analysed using an XF-96 Extracellular Flux 
Analyzer (Seahorse Bioscience). In short, basal metabolic rates of monocytes seeded in 
quintuplicate were determined during four consecutive measurements in unbuffered 
Seahorse medium (8.3 g DMEM powder, 0.016 g phenol red and 1.85 g NaCl in 1 l Milli-Q 
water, pH set at 7.4 at 37 °C; sterile filtered) containing 5.5 mM glucose and 2 mM L-glutamine. 
After three basal measurements, three consecutive measurements were taken following the 
addition of 1.5 µM oligomycin, 1 mM carbonyl cyanide-4-(trifluoromethoxy) phenylhydrazone 
(FCCP) and 2 µM antimycin together with 1 µM rotenone. Glucose (20 mM) and pyruvate 
(1 mM) were added together with FCCP to fuel maximal respiration. All compounds used 
during the Seahorse runs were acquired from Sigma-Aldrich. SRC was determined as the 
absolute increase in OCR after FCCP injection compared with basal OCR. Equal cell numbers 
in the wells were assessed by measuring total DNA content using a Quant-iT dsDNA Assay kit 
(Thermofisher Scientific). The 96-well plates for Seahorse measurements were pretreated 
with Cell-Tak Cell and Tissue Adhesive (Corning).
Mitochondrial respiratory chain enzyme measurements
Assays for the measurements of the activity of the mitochondrial respiratory chain enzymes 
and citrate synthase were based on previously described methods32–34. The assays were 
performed on a KoneLab autoanalyser as described previously35.
Western blotting
Monocytes were lysed in 100 µl lysis buffer (1 M Tris buffer, pH 7.4, 0.5 M EDTA, 5 M NaCl, 
10% ND40, 0.5 M NaF, 2.5% sodium deoxycholate, PhosSTOP (Roche) and cOmplete (Roche)). 
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The cell homogenate was frozen, thawed and processed for western blot analysis according 
to the manufacturer’s instructions. Western blotting was carried out using Mini-PROTEAN 
TGX precast gels (Bio-Rad). Proteins were transferred using the Trans-Blot Turbo system (Bio-
Rad) according to the manufacturer’s instructions. Primary antibodies against the following 
proteins were used: actin (Sigma-Aldrich), phospho-AKT (S473) (Cell Signalling), total AKT 
(Cell Signalling), hydroxylated HIF-1α (Cell Signalling), PARP (Cell Signalling) and caspase-3 
(Cell Signalling).
Phagocytosis assay
For the phagocytosis assay, 1.5 × 105 CD14+ monocytes were seeded into a 96-well plate 
and stimulated for 24 h with RPMI 1640, LPS (10 ng ml−1) or P3C (10 µg ml−1) (four replicates 
each). Inhibitors (1 µM rotenone or 1 mM 2DG) were added to the cells 30 min before the 
phagocytosis assay. Phagocytosis was assessed using a Vybrant Phagocytosis Assay kit 
(Molecular Probes).
Cell viability assessment by annexin V staining
The percentage of cells that underwent early or late apoptosis was determined by labelling 
with annexin V–fluorescein isothiocyanate (Biovision) and staining with propidium iodide 
(Sigma-Aldrich), according to the manufacturer’s instructions. Treated CD14+ cells were 
gently scraped after incubation with Versene solution (Gibco) for 15 min on ice, washed with 
PBS and resuspended in 200 µl RPMI 1640. The cells were incubated on ice in the dark with 
1 µl annexin V–fluorescein isothiocyanate for 15 min, followed by a 5 min incubation with 
1.5 µl propidium iodide. The relative level of apoptotic cells was detected by flow cytometry 
within 1 h, using a FC500 flow cytometer (Beckman Coulter), and the data were analysed 
using Kaluza 1.3 software (Beckman Coulter).
RNA isolation and real-time quantitative PCR (qPCR)
RNA was isolated from CD14+ cells using TRIzol reagent (Invitrogen), according to the 
manufacturer’s protocol. RNA was transcribed into complementary DNA by reverse 
transcription using an iScript cDNA Synthesis kit (Bio-Rad). Primer sequences used for the 
qPCR are listed in Supplementary Table 1. Power SYBR Green PCR Master Mix (Applied 
Biosystems) was used for qPCR in an AB Step One Plus Real-time PCR System (Applied 
Biosystems) or a CFX384 Real-Time PCR Detection System (Bio-Rad). qPCR data were 
normalized to the housekeeping gene human β2-microglobulin.
Metabolite measurements
CD14+ monocytes (3 × 106) were seeded in each well of a six-well plate and stimulated 
for 24 h with RPMI 1640, LPS (10 ng ml−1) or P3C (10 µg ml−1) (two replicates each). Dry 
cell pellets were flash frozen and stored at −80 °C. Of note, the same samples were used 
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for both transcriptomics and metabolomics. Samples were shipped to Metabolon for 
processing and measurement. A total of 512 compounds of known structural identity 
were detected. Samples were prepared using the automated MicroLab STAR system from 
Hamilton Company. Raw data were extracted, peak identified and quality-control processed 
using Metabolon’s hardware and software. Peaks were quantified by measurement of the 
area under the curve. Metabolite data normalized to protein concentration (measured by 
a Bradford assay; Metabolon) was used for all analyses. MetaboAnalyst 3.0 was used to 
explore and characterize the data set. Data were autoscaled, and an unsupervised analysis 
using PCA was performed to determine clustering and separation36. A heatmap representing 
the top 25 metabolites ranked by analysis of variance was generated.
Microarray analysis
RNA was purified from human CD14+ monocytes using TRIzol reagent (Invitrogen), followed 
by an additional round of purification with RNeasy Minikit columns (Qiagen). RNA quality was 
assessed using RNA 6000 nanochips on an Agilent 2100 Bioanalyzer (Agilent). Purified RNA 
(100 ng) was labelled with a WT PLUS Reagent kit (Affymetrix) and hybridized to a Human 
Gene 1.1 ST array plate (Affymetrix). Hybridization, washing and scanning were carried out 
on a GeneTitan platform (Affymetrix) according to the manufacturer’s instructions. Arrays 
were normalized using the robust multiarray average method37,38. Probe sets were defined 
according to the method of Dai et al39. In this method, probes are assigned to Entrez IDs as 
a unique gene identifier. The P values were calculated using an intensity-based moderated 
t-statistic40. The microarray data have been submitted to the Gene Expression Omnibus 
(accession no. GSE78699). Expression changes in whole blood ex vivo (GSE55375)41 and in 
vivo (GSE6269)42 were extracted from publically available microarray data sets using the 
analysis pipeline described above.
Electron microscopy
For electron microscopy analysis of mitochondria, cells were fixed in 2% glutaraldehyde 
in 0.1 M phosphate buffer (pH 7.4) and postfixed for 1 h in 1% osmium tetroxide and 1% 
potassium ferrocyanide in 0.1 M cacodylate buffer. After being washed in buffer, the cells 
were dehydrated in an ascending series of aqueous ethanol solutions and subsequently 
transferred via a mixture of propylene oxide and Epon to pure Epon 812 as embedding 
medium. Ultrathin grey sections (60–80 nm) were cut, contrasted with aqueous 2% uranyl 
acetate, rinsed and counterstained with lead citrate, air dried and examined in a JEM1010 
electron microscope (JEOL) operating at 80 kV.
Statistics
For normally distributed parametric data, Student’s t-test was used. For non-parametric 
data, the Wilcoxon signed-rank test was used.
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Data availability
The data that support the findings of this study are available from the corresponding author 
on request. Microarray data is publically available in the Gene Expression Omnibus under 
accession no. GSE78699.
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RESULTS
LPS uniquely downregulates OXPHOS compared with other bacterial stimuli 
CD14+ human monocytes were stimulated with a panel of commonly used concentrations 
of TLR ligands (LPS or P3C) or whole-pathogen lysates (Escherichia coli, Staphylococcus 
aureus or Mycobacterium tuberculosis) for 24 h to investigate changes in metabolism and 
cytokine production. An increased extracellular acidification rate (ECAR) (Fig. 1a) and lactate 
production (Fig. 1b) in response to all stimuli suggested a universal increase in glycolysis 
following microbial stimulation. This was accompanied by changes in gene expression of 
enzymes in the glycolysis pathway. Specifically, expression of the first enzyme of glycolysis, 
hexokinase 2 (HK2), and the rate limiting enzyme fructose 6-phosphofructo-2-kinase/
fructose-2,6-bisphosphatase 3 (PFKFB3) was increased by all stimuli (Fig. 1c). Cytokine 
production (tumour-necrosis factor-α (TNF-α), interleukin (IL)-6, IL-1β and IL-10), a function 
that has been linked to changes in cellular metabolism6, was also increased by all stimuli (Fig. 
1d).
Next, we assessed the oxidative capacity of monocytes by measuring oxygen 
consumption rate (OCR) and spare respiratory capacity (SRC). SRC is an indicator of the total 
mitochondrial capacity of a cell, which represents the amount of spare energy available 
during periods of stress12. As reported previously13, LPS lowered the basal OCR and SRC 
of human monocytes. In contrast, P3C and bacteria lysates increased basal OCR and SRC 
(Fig. 2a,b). Supporting these results, LPS decreased the activity of several enzymes in the 
mitochondrial electron transport chain (ETC), whereas P3C increased their activity (Fig. 2c). 
Similarly, microarray analysis revealed lower expression levels of genes that comprise the 
five ETC complexes in monocytes stimulated with LPS compared with P3C (Fig. 2d).
Protein levels of classical regulators of energy metabolism, AKT and HIF-1α, were 
equally activated after LPS or P3C stimulation (Fig. 2e), suggesting that these regulators are 
unlikely to control OXPHOS. Mitochondrial function has recently been suggested to be linked 
to mitochondrial morphology14. Using electron microscopy, the mitochondria appeared to 
be larger in LPS- compared with P3C-stimulated monocytes (Fig. 2f). 
The transcriptome of LPS- versus P3C-treated monocytes reveals specific patterns 
of metabolic rewiring 
To validate the expression profiles of LPS- and P3C-stimulated monocytes, we used a publically 
available data set of ex vivo LPS- or P3C-stimulated whole blood. Principle component analysis 
(PCA) using genes of selected metabolic pathways derived from the Kyoto Encyclopedia of 
Genes and Genomes (KEGG) revealed a clear separation of untreated versus LPS- versus 
P3C-treated cells in both data sets (Fig. 3a,b). We then compared the expression levels of 
individual genes in each metabolic pathway and, as expected, observed robust changes in 
gene expression induced by LPS- or P3C-stimulated monocytes (Supplementary Fig. 1a). 
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P3C) or whole-pathogen lysates (Escherichia coli, Staphylococcus
aureus or Mycobacterium tuberculosis) for 24 h to investigate
changes in metabolism and cytokine production. An increased
extracellular acidiﬁcation rate (ECAR) (Fig. 1a) and lactate
production (Fig. 1b) in response to all stimuli suggested a
universal increase in glycolysis following microbial stimulation. This
was accompanied by changes in gene expression of enzymes in the
glycolysis pathway. Speciﬁcally, expression of the ﬁrst enzyme of
glycolysis, hexokinase 2 (HK2), and the rate limiting enzyme
fructose 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3
(PFKFB3) was increased by all stimuli (Fig. 1c). Cytokine
production (tumour-necrosis factor-α (TNF-α), interleukin (IL)-6,
IL-1β and IL-10), a function that has been linked to changes in
cellular metabolism6, was also increased by all stimuli (Fig. 1d).
Next, we assessed the oxidative capacity of monocytes by measur-
ing oxygen consumption rate (OCR) and spare respiratory capacity
(SRC). SRC is an indicator of the total mitochondrial capacity of a
cell, which represents the amount of spare energy available during
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Figure 1 | Glycolysis is upregulated in human monocytes after stimulation with various pathogenic stimuli for 24 h. a–d, ECAR (a), lactate production (b),
expression of glycolytic enzymes (c) and cytokine production (d) of human monocytes treated with TLR ligands or whole-pathogen lysates were measured.
All data (means ± s.e.m.) are from two experiments with a total of six to eight donors. *P < 0.05, **P < 0.01, ***P < 0.001 (paired two-tailed Student’s t-test).
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Figure 1 | Glycolysis is upregulated in human monocytes after stimulation with various pathogenic stimuli 
for 24 h. 
a–d, ECAR (a), lactate production (b), expression of glycolytic enzymes (c) and cytokine production (d) of human 
monocytes treated with TLR ligands or whole-pathogen lysates were measured. All data (means ± s.e.m.) are 
from two experiments with a total of six to eight donors. *P < 0.05, **P < 0.01, ***P < 0.001 (paired two-tailed 
Student’s t-test).
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Figure 2 | LPS is unique in downregulating OXPHOS in human monocytes. a, Basal OCR and real-time changes in the OCR of human monocytes stimulated
with TLR ligands or whole-pathogen lysates, assessed during sequential treatment with oligomycin, carbonyl cyanide-4-(triﬂuoromethoxy)phenylhydrazone
(FCCP) and antimycin A + rotenone. b, Basal OCR and SRC of monocytes treated with TLR ligands or whole-pathogen lysates. c, Enzyme activity of
mitochondrial complexes (C) I–IV (Q, ubiquinone) and citrate synthase (CS) in monocytes stimulated with LPS or P3C, normalized to untreated monocytes.
d, Gene expression data of mitochondrial complexes I–V of monocytes stimulated with LPS or P3C. Expression levels are presented as signal log ratios (SLR),
with red representing higher and blue lower gene expression in LPS- versus P3C-stimulated monocytes. e, Immunoblot of phosphorylated AKT (pAKT), total
AKT and hydroxylated HIF-1α in human monocytes stimulated with LPS or P3C for 30 or 120 min. R denotes untreated cells. HSP90 served as a loading
control. f, Mitochondrial morphology analysed by electron microscopy. Data (means ± s.e.m.) are from two experiments with a total of six to eight donors (a,b),
two experiments with a total of seven donors (c), one experiment with ﬁve donors (d), a representative experiment with three donors (e) or one experiment
with one donor (f). *P < 0.05, **P < 0.01 (paired two-tailed Student’s t-test).
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Figure 2 | LPS is unique in downregulating OXPHOS in human monocyt s. 
a, Basal OCR and real-time changes in the OCR of human monocytes stimulated with TLR ligands or whole-
pathogen lysates, assessed during sequential treatment with oligomycin, carbonyl cyanide-4-(trifluoromethoxy)
phenylhydrazone (FCCP) and antimycin A + rotenone. b, Basal OCR and SRC of monocytes treated with TLR 
ligands or whole-pathog n lysates. c, Enzyme activity of mitochondrial complexes (C) I–IV (Q, ubiquinone) and 
citrate synthase (CS) in on cyte  timulated with LPS or P3C, normalized to untreated monocytes. d, Gene 
expression data of mitochondrial complexes I–V of monocytes stimulated with LPS or P3C. Expression levels are 
presented as signal log ratios (SLR), with red representing higher and blue lower gene expression in LPS- versus 
P3C-stimulated monocytes. e, Immunoblot of phosphorylated AKT (pAKT), total AKT and hydroxylated HIF-1α in 
human monocytes stimulated with LPS or P3C for 30 or 120 min. R denotes untreated cells. HSP90 served as a 
loading control. f, Mitochondrial morphology analysed by electron microscopy. Data (means ± s.e.m.) are from 
two experiments with a total of six to eight donors (a,b), two experiments with a total of seven donors (c), one 
experiment with five donors (d), a representative experiment with three donors (e) or one experiment with one 
donor (f). *P < 0.05, **P < 0.01 (paired two-tailed Student’s t-test).
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Overall, LPS led to a decrease in expression of metabolic genes compared with P3C, most 
noticeably those in the TCA cycle, OXPHOS and peroxisome proliferator-activated receptor 
(PPAR) signalling pathways (Fig. 3c and Supplementary Fig. 1a). These observations were 
validated in the ex vivo whole-blood data set (Fig. 3d). 
Of note, a similar PCA performed with publically available expression data of 
peripheral blood mononuclear cells (PBMCs) from individuals with acute E. coli versus S. 
aureus infections showed clustering that was not as distinct as LPS- versus P3C-stimulated 
monocytes (Supplementary Fig. 1b). Similarly, the metabolic gene expression profiles of 
LPS- versus P3C-stimulated monocytes showed little overlap with the expression profiles 
of PBMCs from individuals with acute E. coli versus S. aureus infection (Supplementary Fig. 
1c). Unlike a pure population of monocytes, PBMCs are a heterogeneous mix of circulating 
immune cells with distinct bioenergetic profiles and distribution of respiratory chain 
proteins15.
LPS-treated monocytes displayed a pronounced decrease in the expression of genes 
involved in lipid handling and usage (Fig. 3d and Supplementary Fig. 1a). Many genes in this 
pathway, including PPAR-γ and its targets (LPL, FABP4 and PDK4), had lower expression in LPS- 
versus P3C-stimulated monocytes, suggesting that PPAR-γ may regulate the difference in 
OXPHOS between the two stimuli (Fig. 3e). To test this hypothesis, we inhibited PPAR-γ using 
the antagonist GW9662 and found that basal OCR was mostly unaffected (Supplementary Fig. 
2a). GW9662 decreased IL-1β and increased IL-10 levels (Supplementary Fig. 2b). Treatment 
with rosiglitazone, a PPAR-γ agonist, had little effect on OCR and cytokine production in 
LPS- and P3C-stimulated monocytes (Supplementary Fig. 2a,b). Together, these results do 
not implicate PPAR-γ as the primary regulator of the oxidative capacity of P3C-stimulated 
monocytes. Instead, PPAR-γ may be upregulated as a consequence of the higher levels of 
polyunsaturated fatty acids found in monocytes stimulated with P3C compared with LPS 
(Fig. 3f). These fatty acids would function as natural ligands of PPAR-γ.
The TIR-domain-containing adapter-inducing interferon-β (TRIF) pathway is specifically 
activated downstream of TLR4 but not TLR2. Therefore, we tested whether poly(I:C), a TLR3 
ligand that signals exclusively via TRIF, would induce a similar pattern of metabolic rewiring 
to LPS. As with P3C, stimulation with poly (I:C) increased ECAR and OCR (Supplementary 
Fig. 2c), suggesting that TRIF is not involved in the metabolic rewiring of LPS-treated cells. 
Additionally, inhibition of TRIF using an inhibitory peptide did not affect cytokine secretion or 
metabolic gene expression of LPS-treated cells (Supplementary Fig. 2d,e).
LPS has dose-dependent effects on OXPHOS in human monocytes
The concentrations of 10 ng ml−1 LPS and 10 µg ml−1 P3C used in our experiments are those 
used most commonly in the literature. To test whether the differences in regulation of 
OXPHOS were dose dependent, we stimulated monocytes with a range of LPS (from 0.1 to 
100 ng ml−1) or P3C (from 0.1 to 10 µg ml−1) doses and measured metabolic and functional 
outcomes. Various doses of LPS (1–100 ng ml−1) induced greater levels of IL-1β (Fig. 4a) and 
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2
affect cell death, as assessed by annexin V/propidium iodide staining
and measurement of cleaved caspase-3 and poly(ADP–ribose)
polymerase (PARP) (Supplementary Fig. 5c,d).
Next, we determined the phagocytic capacity of stimulated mono-
cytes and found that LPS lowered phagocytic rates compared with P3C
(Fig. 5c). To determine whether OXPHOS facilitated the higher
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Figure 3 | Human monocytes stimulated with LPS versus P3C show differential expression of metabolic genes. a–d, Microarray analysis of human
monocytes stimulated with LPS (10 ng ml−1) or P3C (10 µg ml−1) for 24 h (monocytes), and whole blood stimulated with LPS (1 ng ml−1) or P3C (200 ng ml−1)
for 24 h (whole blood; data retrieved from Gene Expression Omnibus accession no. GSE55375). Shown are PCA plots based on genes from selected KEGG-
derived metabolic pathways, showing the percentage of explained variance (expl. var.) (a,b); heat map of genes from selected KEGG-derived metabolic
pathways in human monocytes. Expression data are presented as the SLR of LPS versus P3C. For each pathway, signiﬁcantly different upregulated (red) or
downregulated (blue) genes (q <0.01) are shown (c); and heat map of genes from selected KEGG-derived metabolic pathways in human monocytes and
whole blood. Expression data are presented as SLR of LPS versus P3C. For each pathway, the top 15 most differentially higher (red) or lower (blue) expressed
genes in LPS- versus P3C-stimulated monocytes are shown. Signiﬁcantly different regulated genes (q <0.01) are shown in bold (d). e, Relative gene expression
of LPS- and P3C-stimulated monocytes measured by real-time quantitative PCR. Heat map showing the relative abundance of polyunsaturated fatty acids in
LPS- versus P3C-stimulated monocytes per donor (A–E). Data (means ± s.e.m.) are from one experiment with ﬁve donors (a,c,d,f) or from two experiments
with a total of eight donors (e). *P <0.05, **P < 0.01; (paired two-tailed Student’s t-test).
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Figure 3 | Human monocytes stimulated with LPS v sus P3C sh w differential xpression of metabolic ge es. 
a–d, Microarray analysis of human monocytes stimulated with LPS (10 ng l−1) or P3C (10 µg ml−1) for 24 h 
(monocytes), and whole blood stimulated with LPS (1 ng ml−1) or P3C (200 ng ml−1) for 24 h (whole blood; data 
retrieved from Gene Expression Omnibus accession no. GSE55375). Shown are PCA plots based on genes from 
selected KEGGderived metabolic pathways, showing the percentage of explained variance (expl. var.) (a,b); heat 
map of gene  from selected KEGG-derived metabolic pathw ys in human monocytes. Expression ata ar  presented 
as the SLR of LPS versus P3C. For each pathway, significa tly diff rent upregulated (red) or downregulat d (blue) 
genes (q < 0.01) are shown (c); and heat map of genes from selected KEGG-derived metabolic pathways in human 
monocytes and whole blood. Expression data are presented as SLR of LPS versus P3C. For each pathway, the 
top 15 most differentially higher (red) or lower (blue) expressed genes in LPS- versus P3C-stimulated monocytes 
are shown. Significantly different regulated genes (q < 0.01) are shown in bold (d). e, Relative gene expression 
of LPS- and P3C-stimulated monocytes measured y real-time quantitative PCR. Heat m p showing the relative 
abundance of polyunsaturated fatty acids in LPS- versus P3C-stimulated monocytes per donor (A–E). Data (means 
± s.e.m.) are from one experiment with five donors (a,c,d,f) or from two experiments with a total of eight donors 
(e). *P < 0.05, **P < 0.01; (paired two-tailed Student’s t-test).
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other cytokines (Supplementary Fig. 3a) compared with P3C, whereas the lowest dose 
of LPS (0.1 ng ml−1) was similar to P3C. Basal ECAR was similar for all conditions (Fig. 4b); 
however, OCR and SRC varied across the different doses of LPS but not P3C (Fig. 4c). The 
higher doses of LPS (1–100 ng ml−1) decreased the oxidative capacity of monocytes, whereas 
the lowest dose (0.1 ng ml−1) increased OXPHOS similarly to P3C.
To test whether these changes were reflected at a transcriptional level, we measured 
the expression of genes involved in glycolysis (PFKFB3 and GAPDH) and fatty acid metabolism 
(PPAR-γ, LPL, LIPA and CPT-1α) (Fig. 4d,e). In line with our findings, expression of these 
genes in monocytes stimulated with the low dose of LPS (0.1 ng ml−1) was comparable with 
monocytes stimulated with P3C (10 µg ml−1), but not with 10 ng ml−1 LPS.
Lastly, time-dependent differences in OXPHOS were observed between the standard 
doses of 10 ng ml−1 LPS and 10 µg ml−1 P3C. At 4 h post-treatment with LPS, the basal OCR and 
SRC of stimulated monocytes were increased. With the exception of E. coli, the stimuli had 
no effect on OCR and SRC at 4 h post-stimulation. (Fig. 4f). Glycolysis, as measured by ECAR 
and lactate production, was similar among all stimuli (Supplementary Fig. 3b,c). Differences 
in expression of genes involved in glycolysis and fatty acid metabolism were less pronounced 
after 4 h compared with 24 h between the two conditions (Fig. 4g,h). These transcriptional 
differences in kinetics were validated in the whole-blood data set stimulated with LPS versus 
P3C (Supplementary Fig. 3d,e).
Although metabolic rewiring can be dependent on the maturation and activation 
state of cells, measurement of human leukocyte antigen (HLA)-DR revealed no differential 
effect on activation by 0.1 or 10 ng ml−1 LPS or by 10 µg ml−1 P3C (Supplementary Fig. 4a,b). 
P3C-stimulated monocytes expressed slightly more CD11c and CD83 compared with LPS. 
Nevertheless, stimulation with 0.1 ng ml−1 LPS and 10 ng ml−1 LPS led to a similar maturation 
pattern, despite differences in OXPHOS, suggesting that the extent of monocyte maturation 
probably cannot explain differences in metabolic rewiring following LPS and P3C stimulation.
Functional consequences: OXPHOS is needed for phagocytosis, while cytokine 
production relies on both OXPHOS and glycolysis in P3C-stimulated monocytes 
We next investigated how cytokine production and phagocytosis are influenced by the 
different metabolic programmes induced by LPS or P3C. As described elsewhere16, inhibition 
of glycolysis with 2-deoxy-D-glucose (2DG) decreased IL-1β (Fig. 5a) and other cytokines 
(Supplementary Fig. 5a) in both conditions. Inhibition of OXPHOS using the complex I 
inhibitor rotenone lowered cytokine production only in P3C-stimulated cells (Fig. 5b). 
This points to a P3C-specific reliance on OXPHOS for cytokine production. In contrast to 
the results of Kelly et al.17, IL-10 levels were decreased in rotenone-treated cells after LPS 
stimulation (Supplementary Fig. 5b). Rotenone did not affect cell death, as assessed by 
annexin V/propidium iodide staining measurement of cleaved caspase-3 and poly(ADP–
ribose) polymerase (PARP) (Supplementary Fig. 5c,d).
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2
phagocytic capacity of P3C- versus LPS-treated cells, we inhibited
complex I of the ETC with rotenone. Treatment with rotenone signiﬁ-
cantly decreased the phagocytic capacity of P3C-stimulated mono-
cytes, whereas untreated or LPS-treated monocytes were unaffected.
However, lowering of oxygen consumption using hypoxic culture
conditions (1 versus 5% O2) had no effect (Supplementary Fig. 5e).
2DG also did not affect the phagocytic capacity of stimulated mono-
cytes, suggesting that OXPHOS, but not glycolysis, is an important
determinant of the phagocytic capacity of human monocytes (Fig. 5c).
Metabolite analysis reveals pronounced differences in TCA cycle
metabolites between LPS- and P3C-stimulated monocytes. To
increase our understanding of differences in metabolic rewiring
between LPS- and P3C-treated monocytes, we measured
intracellular levels of over 500 metabolites. PCA conﬁrmed a
robust separation in metabolic responses following LPS and P3C
stimulation (Fig. 5d). A heat map of the top 25 differentially
regulated metabolites showed increased levels of succinate, citrate
and itaconate speciﬁcally in LPS-treated cells, whereas gulonate
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Figure 4 | Dose- and time-dependent metabolic rewiring in human monocytes. a–e, IL-1β production (a), basal ECAR (b), basal OCR and SRC (c), and
relative gene expression (d,e) of human monocytes treated with various doses of LPS and P3C for 24 h. f–h, Basal OCR and SRC (f) and relative gene
expression (g,h) of human monocytes treated with TLR ligands or whole-pathogen lysates for 4 h. Data (means ± s.e.m.) are from one experiment with ﬁve
donors (a–e), from two experiments with a total of ﬁve to six donors (f) or from two experiments with a total of eight donors (g,h). *P <0.05, **P <0.01;
exact p values are also indicated in the graphs (paired two-tailed Student’s t-test).
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Figure 4 | Dose- and time-dependent metabolic rewiring in human monocytes. 
a–e, IL-1β production (a), basal ECAR (b), basal OCR and SRC (c), and relative gene expression (d,e) of human 
monocytes treated with various doses of LPS and P3C for 24 h. f–h, Basal OCR and SRC (f) and relative gene 
expression (g,h) of human monocytes treated with TLR ligands or whole-pathogen lysates for 4 h. Data (means ± 
s.e.m.) are from one experiment with five donors (a–e), from two experiments with a total of five to six donors (f) 
or from two experiments with a total of eight donors (g,h). *P < 0.05, **P < 0.01; exact p values are also indicated 
in the graphs (paired two-tailed Student’s t-test).
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Next, we determined the phagocytic capacity of stimulated monoand cytes and found 
that LPS lowered phagocytic rates compared with P3C (Fig. 5c). To determine whether 
OXPHOS facilitated the higher phagocytic capacity of P3C- versus LPS-treated cells, we 
inhibited complex I of the ETC with rotenone. Treatment with rotenone significantly 
decreased the phagocytic capacity of P3C-stimulated monocytes, whereas untreated or 
LPS-treated monocytes were unaffected. However, lowering of oxygen consumption using 
hypoxic culture conditions (1 versus 5% O
2
) had no effect (Supplementary Fig. 5e). 2DG also 
did not affect the phagocytic capacity of stimulated monocytes, suggesting that OXPHOS, but 
not glycolysis, is an important determinant of the phagocytic capacity of human monocytes 
(Fig. 5c). 
Metabolite analysis reveals pronounced differences in TCA cycle metabolites 
between LPS- and P3C-stimulated monocytes
To increase our understanding of differences in metabolic rewiring between LPS- and 
P3C-treated monocytes, we measured intracellular levels of over 500 metabolites. PCA 
confirmed a robust separation in metabolic responses following LPS and P3C stimulation 
(Fig. 5d). A heat map of the top 25 differentially regulated metabolites showed increased 
levels of succinate, citrate and itaconate specifically in LPS-treated cells, whereas gulonate 
levels were highly increased upon P3C stimulation (Fig. 5e). These findings appear to match 
the two previously described breaks in the TCA cycle at citrate and succinate following LPS 
stimulation18, but indicate that these breaks might be absent in P3C-stimulated monocytes 
(Fig. 5f). An increase in expression of IRG1, which converts citrate to itaconate, in LPS- but not 
in P3C-stimulated cells further supported these findings (Fig. 5g). Moreover, LPS stimulation 
decreased the expression of two TCA cycle enzymes, IDH1 and SDH, present after each break 
in the TCA cycle (Fig. 5g).
As shown above (Fig. 5e), itaconate has been reported to accumulate intracellularly 
in LPS-treated mouse macrophages19. To test whether itaconate plays a functional role in 
cytokine production, membrane-permeable dimethyl itaconate was added before LPS or 
P3C stimulation. Levels of IL-1β, IL-6 and IL-10 were all decreased, whereas levels of TNF-α 
were mainly unaffected following LPS or P3C stimulation (Supplementary Fig. 6a). Moreover, 
dimethyl itaconate did not change glycolytic metabolism, as assessed by lactate production, 
in either LPS- or P3C-stimulated monocytes (Supplementary Fig. 6b). These results highlight 
the importance of intracellular metabolites in the regulation of immune cell function and 
demonstrate their immunomodulatory potential independent of the pathogenic stimulus.
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levels were highly increased upon P3C stimulation (Fig. 5e). These
ﬁndings appear to match the two previously described breaks in
the TCA cycle at citrate and succinate following LPS stimulation18,
but indicate that these breaks might be absent in P3C-stimulated
monocytes (Fig. 5f). An increase in expression of IRG1, which
converts citrate to itaconate, in LPS- but not in P3C-stimulated
cells further supported these ﬁndings (Fig. 5g). Moreover, LPS
stimulation decreased the expression of two TCA cycle enzymes,
IDH1 and SDH, present after each break in the TCA cycle (Fig. 5g).
As shown above (Fig. 5e), itaconate has been reported to
accumulate intracellularly in LPS-treated mouse macrophages19.
To test whether itaconate plays a functional role in cytokine pro-
duction, membrane-permeable dimethyl itaconate was added
before LPS or P3C stimulation. Levels of IL-1β, IL-6 and IL-10
were all decreased, whereas levels of TNF-α were mainly unaffected
following LPS or P3C stimulation (Supplementary Fig. 6a).
Moreover, dimethyl itaconate did not change glycolytic metabolism,
as assessed by lactate production, in either LPS- or P3C-stimulated
monocytes (Supplementary Fig. 6b). These results highlight the
importance of intracellular metabolites in the regulation of
immune cell function and demonstrate their immunomodulatory
potential independent of the pathogenic stimulus.
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Evidence acquired mostly from in vitro stimulation of myeloid cells
with LPS has pinpointed an increase in glycolysis and a decrease in
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Figure 5 | Differential metabolic rewiring of hu an monocytes stimulated with LPS or P3C leads to functional 
differences in cytokine production and phagocytosis. 
a,b, IL-1β production of monocytes pre-treated with 2DG (a) or roten ne (b) for 1 h before addition of LPS 
or P3C for 24 h. c, Phagocytosis of on cytes stimula ed with LPS or P3C for 24 h and treated with 2DG o  
rotenone for 30 min before the start of the assay. d, PCA plot based on intracellular metabolites. e, Heatmap of 
the top 25 metabolites most differentially regulated in monocytes stimulated with LPS or P3C for 24 h, with red 
representing higher and blue representing lower abundance. f, Scheme showing the relative abundance of TCA 
cycle intermediates in monocytes stimulated with LPS or P3C for 24 h. Units on the y axis are given as relative 
metabolite levels normalized to cellular protein content. g, Relative expression of genes involved in regulating 
levels of TCA cycle intermediates. Data (means ± s.e.m.) are from two experiments with a total of five donors (a–c) 
or from one experiment with five donors (d–g). *P < 0.05, **P < 0.01 (paired two-tailed Student’s t-test).
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DISCUSSION
Evidence acquired mostly from in vitro stimulation of myeloid cells with LPS has pinpointed 
an increase in glycolysis and a decrease in OXPHOS as characteristic of activated pro-
inflammatory innate immune cells20. Our study recapitulates these findings in human 
monocytes exposed to LPS, but also demonstrated that a decrease in OXPHOS following 
activation of myeloid cells is not a universal response to pathogenic stimuli. Furthermore, 
we have linked different metabolic routes adopted by human monocytes following microbial 
stimulation to host defence functions, such as cytokine release and phagocytosis.
Increased glucose utilization following activation with TLR ligands or bacterial stimuli 
has been demonstrated previously9 and has led to the identification of various upstream 
regulators of glycolysis, including AKT and HIF-1α6. Our studies confirmed these findings 
in human monocytes6, as inhibition of glycolysis with 2DG reduced IL-1β production after 
stimulation with LPS or P3C. Although some conflicting results in murine dendritic cells9 
versus macrophages6 have been reported, in human monocytes 2DG also decreased TNF-α, 
IL-6 and IL-10 production. Together with higher glycolytic rates, LPS-stimulated monocytes 
displayed decreased OXPHOS and metabolic flexibility. In contrast, stimulation with P3C or 
lysates from E. coli, S. aureus or M. tuberculosis resulted in increased or unaltered OXPHOS 
and metabolic flexibility. Thus, the classical Warburg effect induced by LPS is not a universal 
prerequisite for pro-inflammatory cytokine responses.
Pathogen-specific metabolic rewiring may fuel different functional outputs. In this 
study, we showed that the phagocytic capacity of human monocytes is related to their 
oxidative capacity. LPS stimulation lowered OXPHOS as well as the phagocytic capacity of 
monocytes in comparison with P3C stimulation. Similarly, inhibition of complex I of the ETC 
with rotenone decreased the phagocytic capacity of P3C-stimulated monocytes. Phagocytosis 
is an energy-demanding process21, and OXPHOS, unlike glycolysis, is characterized by a high 
ATP yield. Thus, OXPHOS seems to be more capable of supporting the bioenergetic demands 
of phagocytosis. Interestingly, the phagocytic capacity of monocytes was unaffected by 
short-term hypoxia, which, while activating HIF-1α, may not result in complete inhibition of 
mitochondrial respiration.
Previous studies have shown that macrophages are dependent on several metabolic 
pathways for phagocytosis22,23, making it likely that other pathways, such as fatty acid 
oxidation, also contribute to phagocytosis. Similarly, as seen for phagocytosis, inhibition 
of OXPHOS decreased cytokine production from P3C- but not LPS-stimulated monocytes, 
further emphasizing the fact that different stimuli may use convergent or redundant 
metabolic pathways to execute their inflammatory functions.
We attempted to delineate the differences in OXPHOS between LPS- and P3C-stimulated 
monocytes in several ways. First, we examined the contribution of TRIF signalling, as both 
stimuli induce MyD88 signalling, whereas only LPS has been shown to activate TRIF. Poly(I:C), 
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a TLR3 ligand exclusively recruiting TRIF24, increased the oxidative capacity of monocytes, 
thus making it unlikely that signalling via TRIF contributes to the LPS-induced decrease in 
OXPHOS. Second, we looked at PPAR-γ, which has been shown to promote OXPHOS and 
stimulate mitochondrial biogenesis in mouse macrophages25 and has been linked to the 
regulation of phagocytosis in human macrophages26. Although expression of PPAR-γ was 
greater in P3C- than in LPS-stimulated cells, stimulation or inhibition of PPAR-γ did not affect 
OXPHOS or the cytokine production of LPS- or P3C-stimulated monocytes. It is more likely 
that the activation of PPAR-γ by P3C is a consequence of stimulation rather than responsible 
for P3C-induced metabolic rewiring. Third, mitochondrial morphology was visualized. A 
recent study linked changes in mitochondrial morphology to the metabolic differences 
observed between glycolytic T-effector cells and OXPHOS-dependent T-memory cells. 
Mitochondrial fusion in T-memory cells favoured OXPHOS and fatty acid oxidation, whereas 
fission in T-effector cells led to loosening of the cristae, which resulted in less efficient 
transport of electrons through the ETC and in turn promoted glycolysis as an alternative fuel 
source27. Electron microscopy revealed larger mitochondria after LPS stimulation, suggesting 
that changes in mitochondrial morphology might contribute to differences in OXPHOS and 
metabolic rewiring after LPS versus P3C stimulation. Last, metabolome analysis was executed 
and revealed an increased presence of metabolites that have been shown to accumulate in a 
broken TCA cycle in LPS-stimulated murine macrophages6,7 in LPS- but not in P3Cstimulated 
human monocytes. These metabolites, such as citrate, succinate and itaconate, have been 
identified as important regulators of intracellular metabolism and inflammatory activation. 
For example, excess citrate is transported into the cytosol, where it is converted into acetyl-
CoA for fatty acid synthesis, and into oxaloacetate, which promotes nitric oxide production, 
which can inhibit components of the mitochondrial ETC via nitrosylation28. These metabolites 
may thus serve to maintain the reduced respiratory capacity of LPS-stimulated monocytes.
Itaconate treatment of LPS-stimulated mouse macrophages has been shown to 
dampen the inflammatory response by modulating mitochondrial respiration29. Likewise, 
pretreatment of monocytes with itaconate lowered cytokine release not only in LPS- but 
also in P3C-stimulated cells, demonstrating that itaconate can modulate the inflammatory 
response of human monocytes, irrespective of the stimulus. The modulatory effects of 
itaconate may be relevant in septic patients, in whom IRG1, the enzyme responsible for 
itaconate production, was found to be highly upregulated in their PBMCs30. Itaconate also 
plays a key role in LPS-induced tolerance in mouse macrophages30.
Additionally, we identified gulonate to be specifically induced in P3C-stimulated 
monocytes. Gulonate is part of the glucuronic acid pathway, an alternative pathway for 
the oxidation of glucose that produces activated UDP-glucuronate. Gulonate is ultimately 
converted to D-xylulose 5-phosphate, which enters the pentose phosphate pathway. 
Therefore, gulonate and gulonate-derived metabolites may represent an alternative pathway 
to oxidize glucose in P3C-treated cells. Specific metabolites that accumulate in P3C-treated 
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cells, including gulonate, may preserve OXPHOS through as yet unidentified mechanisms.
Although LPS and P3C are often used as a model for Gram-negative bacteria (such 
as E. coli) and Gram-positive bacteria (such as S. aureus) respectively, ex vivo stimulations 
of human monocytes with LPS, E. coli, P3C or S. aureus led to varied metabolic profiles. In 
the case of LPS, a low dose (0.1 ng ml−1) induced similar metabolic changes to P3C, whereas 
higher doses led to the characteristic decrease in OXPHOS. This suggests that differences in 
signalling strength, rather than qualitative signalling differences between LPS and P3C, may 
explain the divergent metabolic phenotype. Of much interest, however, are the parallels of 
low-dose LPS (0.1 ng ml−1) with acute in vivo infections of E. coli, and of high- dose LPS (1 –100 
ng ml−1) with sepsis, which has recently been characterized by defects in OXPHOS and energy 
metabolism in leukocytes31. Concentrations of LPS above 0.1 ng ml−1 seem to cross a certain 
signalling threshold at which not only is glycolysis increased but OXPHOS is also reduced to 
maintain ATP production. These dose-related effects therefore emphasize the complexity of 
intracellular metabolic adaptations and the importance of selecting representative in vitro 
models for disease.
This study highlights the complexity of metabolic rewiring in activated human immune 
cells and demonstrates the importance of understanding pathogen-specific metabolic 
reprogramming. We propose that each pathogen induces a highly specific metabolic 
programme in human innate immune cells, thereby determining the functional output of the 
cells. While some functional outputs, such as cytokine release, may be relatively similar, the 
underlying metabolic routes may vary significantly. Targeting metabolic routes to alleviate 
inflammatory conditions or improve antimicrobial host defence thus holds therapeutic 
promise, but tailor-made approaches are warranted.
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Supplementary Figure 1 
Microarray analysis of the following datasets: human monocytes stimulated with LPS (10 ng/mL) 
or P3C (10 μg/mL) for 24 h (ex vivo: monocytes), or PBMCs isolated from patients with an E. coli 
or S. aureus infection (in vivo: PBMCs; data retrieved from GSE6269). (a) Heat map of genes from 
selected KEGG-derived metabolic pathways in the ex vivo monocyte dataset. Expression data are 
presented as signal log ratio (SLR) of LPS vs. P3C, LPS vs. RPMI or P3C vs. RPMI. For each 
pathway significantly different regulated genes (q<0.01) are shown. Genes with a SLR>1.5 or 
SLR<-1.5 are highlighted in bold. (b) PCA plot of the in vivo PBMC dataset based on genes part of 
selected KEGG-derived metabolic pathways. (c) Heat map of genes of selected KEGG-derived 
metabolic pathways. Expression data are presented as signal log ratio (SLR) of LPS vs. P3C or E. 
coli vs. S. aureus. For each pathway the top fifteen most differentially higher (red) and lower 
(blue) expressed genes in LPS- vs. P3C- stimulated monocytes are shown.  
 
Supplementary Figure 1 | Microarray analysis of the following datasets: human monocytes stimulated with LPS 
(10 ng/mL) or P3C (10 μg/mL) for 24 h (ex vivo: monocytes), or PBMCs isolated from patients with an E. coli or S. 
aureus infection (in vivo: PBMCs; data retrieved from GSE6269). (a) Heat map of genes from selected KEGG-derived 
metabolic pathways in the ex vivo monocyte dataset. Expression data are presented as signal log ratio (SLR) of 
LPS vs. P3C, LPS vs. RPMI or P3C vs. RPMI. For each pathway significantly different regulated genes (q<0.01) are 
shown. Genes with a SLR>1.5 or SLR<-1.5 are highlighted in bold. (b) PCA plot of the in vivo PBMC dataset based 
on genes part of selected KEGG-derived metabolic pathways. (c) Heat map of genes of selected KEGG-derived 
metabolic pathways. Expression data are presented as signal log ratio (SLR) of LPS vs. P3C or E. coli vs. S. aureus. 
For each pathway the top fifteen most differentially higher (red) and lower (blue) expressed genes in LPS- vs. P3C- 
stimulated monocytes are shown. 
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Supplementary Figure 2 
(a) Basal oxygen consumption rate (OCR) of human monocytes pretreated with the PPARγ-inhibitor 
GW9662 for 1 h before addition of LPS or P3C for 24 h. (b) Cytokine production of human monocytes 
pretreated with GW9662 or the PPARγ-activator rosiglitazone for 1 h before addition of LPS or P3C for 
24 h. (c) Basal extracellular acidification rate (ECAR), OCR and spare respiratory capacity (SRC) of 
human monocytes treated with various TLR ligands for 24 h. (d, e) Cytokine production (d) and gene 
expression (e) of  human monocytes pretreated with either a TRIF-specific inhibitory peptide or a control 
peptide for 1 h before addition of LPS or P3C for 24 h. Data (mean ± s.e.m.) are from one experiment 
with five donors (a), one experiment with three to five donors (b), two experiments with a total of eight 
donors (c) or one experiment with three donors (d, e). * p<0.05, ** p<0.01 (paired two-tailed t-test).  
 
Supplementary Figure 2 | (a) Basal oxygen consumption rate (OCR) of human monocytes pretreated with 
the PPARγ-inhibitor GW9662 for 1 h before addition of LPS or P3C for 24 h. (b) Cytokine production of human 
monocytes pretreated with GW9662 or the PPARγ-activator rosiglitazone for 1 h before addition of LPS or P3C 
for 24 h. (c) Basal extracellular acidification rate (ECAR), OCR and spare respiratory capacity (SRC) of human 
monocytes treated with various TLR ligands f r 24 h. (d, e) Cytokine production (d) and gene expression (e) of 
human monocytes pretreated with either a TRIF-specific inhibitory peptide or a c ntrol peptide for 1 h before 
addition of LPS or P3C for 24 h. Data (mean ± s.e.m.) are from one experiment with five donors (a), one experiment 
with three to five donors (b), two experiments with a total of eight donors (c) or one experiment with three donors 
(d, e). * p<0.05, ** p<0.01 (paired two-tailed t-test). 
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Supplementary Figure 3 
(a) Cytokine production of human monocytes treated with several doses of LPS and P3C for 24 h. (b) 
Basal extracellular acidification rate (ECAR) and lactate production of human monocytes stimulated with 
TLR ligands or whole pathogen lysates for 4 h. (c) Basal oxygen consumption rate (OCR) and real-time 
changes in OCR of human monocytes stimulated with TLR ligands or whole pathogen lysates for 4 h, 
assessed during the sequential treatment with oligomycin, FCCP and antimycin A/rotenone. (d, e) 
Microarray analysis of the following datasets: human monocytes stimulated with LPS (10 ng/mL) or P3C 
(10 μg/mL) for 24 h (ex vivo: monocytes), and whole blood stimulated with LPS (1 ng/mL) or P3C (200 
ng/mL) for 1-24 h (ex vivo: whole blood; data retrieved from GSE55375). (d) PCA plot of the whole blood 
dataset based on genes part of selected KEGG-derived metabolic pathways. (e) Heat map of genes part of 
selected KEGG-derived metabolic pathways. Expression data are presented as signal log ratio (SLR) of 
LPS vs. P3C. For each pathway the top fifteen most differentially increased (red) or decreased (blue) genes 
in LPS- vs. P3C-stimulated monocytes are shown. Data (mean ± s.e.m.) are from one experiment with five 
donors (a) or from two experiments with a total of five to six donors (b-c). * p<0.05, ** p<0.01 (paired 
two-tailed t-test).  
 
Supplementary Figure 3 | (a) Cytokine production of human monocytes treated with several doses of LPS 
and P3C for 24 h. (b) Basal extracellular acidification rate (ECAR) and lactate production of human mon cytes
stimulated with TLR ligands or whole pathogen lysates for 4 h. (c) Basal oxygen consumption rate (OCR) and 
real-time changes in OCR of human monocytes stimulated with TLR ligands or whole pathogen lysates for 4 h, 
assessed during the sequential treatment with oligomycin, FCCP and antimycin A/rotenone. (d, e) Microarray 
aly is of the following d tasets: human monocytes stimulated with LPS (10 ng/mL) r P3C (10 μg/mL) for 24 h 
(ex vivo: monocytes), and whole blood stimulated with LPS (1 ng/mL) or P3C (200 ng/mL) for 1-24 h (ex vivo: whole 
blood; data retrieved from GSE55375). (d) PCA plot of the whole blood dataset based on genes part of selected 
KEGG-derived metabolic pathways. (e) Heat map of genes part of selected KEGG-derived metabolic pathways. 
Expression data are pr sented as signal log ratio (SLR) of LPS vs. P3C. For each pathway the top fifteen most 
differentially increased (red) or decreased (blue) genes in LPS- vs. P3C-stimulated monocytes are shown. Data 
(mean ± s.e.m.) are from one experiment with five donors (a) or from two experiments with a total of five to six 
donors (b-c). * p<0.05, ** p<0.01 (paired two-tailed t-test). 
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Supplementary Figure 4 
Maturation markers present on human monocytes stimulated with LPS or P3C for 24 h. (a) 
Representative flow cytometry plots from one donor. (b) Mean fluorescent intensity (MFI) representing 
the presence of maturation markers in monocytes of three donors. Data (mean ± s.e.m.) are from one 
experiment with three donors.  
Supplementary Figure 4 | Maturation markers present on human monocytes stimulated with LPS or P3C for 24 
h. (a) Repres tative flow cytometry plots from one donor. (b) Mean fluorescent intensity (MFI) representing the 
presence of maturation markers in monocytes of three donors. Data (mean ± s.e.m.) are from one experiment 
with three donors. 
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Supplementary Figure 5 
(a, b) Cytokine production of monocytes pretreated with either 2-Deoxyglucose (2DG) (a) or rotenone 
(b) for 1 h before addition of LPS or P3C for 24 h. (c, d) Cell death in monocytes pretreated with 
rotenone for 1 h prior to addition of LPS or P3C for 24 h, assessed by annexinV-PI-staining (c) and 
Western blot for PARP and cleaved caspase-3 (d). (e) Phagocytic capacity of monocytes stimulated with 
LPS or P3C for 24 h and held under normoxic or hypoxic conditions for 2 h prior to the start of the 
assay. Data (mean ± s.e.m.) are from two experiments with a total of five donors (a-b), or one 
experiment with three donors (c-e). * p<0.05, ** p<0.01 (paired two-tailed t-test).  
Supplementary Figure 5 | (a, b) Cytokine production of monocytes pretreated with either 2-Deoxyglucose (2DG) 
(a) or rotenone (b) for 1 h before addition of LPS or P3C for 24 h. (c, d) Cell death in monocytes pretreated with 
rotenone for 1 h prior to addition of LPS or P3C for 24 h, assessed by annexinV-PI-staining (c) and Western blot 
for PARP and cleaved caspase-3 (d). (e) Phagocytic capacity of monocytes stimulated with LPS or P3C for 24 h and 
held under normoxic or hypoxic conditions for 2 h prior to the start of the assay. Data (mean ± s. .m.) are from 
two experiments with a total of five donors (a-b), or one experiment with three donors (c-e). * p<0.05, ** p<0.01 
(paired two-tailed t-test). 
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Supplementary Figure 6 
Cytokine (a) and lactate (b) production of human monocytes pretreated with dimethyl itaconate (DI) 
for 1 h before addition of LPS or P3C for 24 h. Data (mean ± s.e.m.) are from one experiment with 
three donors. * p<0.05, ** p<0.01 (paired two-tailed t-test).  
Supplementary Figure 6 | Cytokine (a) and lactate (b) production of human monocytes pretreated with dimethyl 
itaconate (DI) for 1 h before addition of LPS or P3C for 24 h. Data (mean ± s.e.m.) are from one experiment with 
three donors. * p<0.05, ** p<0.01 (paired two-tailed t-test). 
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Supplementary Table 1 | Primer sequences used to examine gene expression levels by RT-qPCR. 
3' primer 5' primer
B2M ATGAGTATGCCTGCCGTGTG CCAAATGCGGCATCTTCAAAC
CD36 GTGCTGTCCTGGCTGTGTTT TCACTTCCTGTGGATTTTGC
CPT1α TCCAGTTGGCTTATCGTGGTG TCCAGAGTCCGATTGATTTTTGC
FABP4 CAGGAAAGTCAAGAGCACCAT GCATTCCACCACCAGTTTATC
GAPDH GAAGGTGAAGGTCGGAGTC GAAGATGGTGATGGGATTTC
HK2 TGCCACCAGACTAAACTAGACG CCCGTGCCCACAATGAGAC
IDH1 GGAAAAGCTCGGACCTACCC CGCTCACAAGCTCAGACTCA
IRG1 GTTCCTGGGAACCACTACGG GATGTCTGGCTGACCCCAAA
LIPA CCCACGTTTGCACTCATGTC CCCAGTCAAAGGCTTGAAACTT
LPL CATTCCCGGAGTAGCAGAGT GGCCACAAGTTTTGGCACC
PDK4 GGAGCATTTCTCGCGCTACA ACAGGCAATTCTTGTCGCAAA
PFKFB3 ATTGCGGTTTTCGATGCCAC GCCACAACTGTAGGGTCGT
SDHa TGCCATCCACTACATGACGG GCTCTGTCCACCAAATGCAC
PPARγ ATTGACCCAGAAAGCGATTCC TCTTCCATTACGGAGAGATCCAC
Supplementary Table 1 
Primer sequences used to examine gene expression levels by RT-qPCR. 
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ABSTRACT
Inflammation originating from the adipose tissue is considered to be one of the main driving 
forces for the development of insulin resistance and type 2 diabetes in obese individuals. 
Although a plethora of different immune cells shapes adipose tissue inflammation, this review 
is specifically focused on the contribution of macrophages that reside in adipose tissue in 
lean and obese conditions. Both conventional and tissue-specific functions of adipose tissue 
macrophages (ATMs) in lean and obese adipose tissue are discussed and linked with metabolic 
and inflammatory changes that occur during the development of obesity. Furthermore, we 
will address various circulating and adipose tissue-derived triggers that may be involved in 
shaping the ATM phenotype and underlie ATM function in lean and obese conditions. Finally, 
we will highlight how these changes affect adipose tissue inflammation and may be targeted 
for therapeutic interventions to improve insulin sensitivity in obese individuals.
Highlights
• Macrophages play a significant role in regulating adipose tissue functioning
during health and disease
• In addition to conventional functions such as clearing cellular debris and
participating in tissue immune surveillance, lipid buffering is an important
function of ATMs
• Obesity-induced inflammation, characterised by an elevated number of pro-
inflammatory macrophages in adipose tissue, has been suggested to contribute to
systemic insulin resistance
• Their origin, as well as a combination of peripheral changes and adipose tissue-
derived stressors, probably contribute to ATM dysfunction and inflammatory
traits during obesity
• Identification of transcriptional differences between ATMs from lean vs obese
adipose tissue at several key points during the development of obesity and insulin
resistance may reveal upstream triggers, regulatory factors and intracellular
pathways that shape ATM function
• Targeting metabolic capacity rather than the inflammatory phenotype of ATMs
may hold potential to restore ATM function and adipose tissue homeostasis in
obese individuals
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INTRODUCTION
Historically, adipose tissue is known to perform a number of functions including storage of 
excess energy, cold insulation and protection of vital organs. Intense research efforts over 
the last decades have greatly furthered our understanding of adipose tissue biology and 
led to the identification of various additional functions. The adipose tissue—composed of 
adipocytes and non-adipocyte cells, including endothelial cells, pre-adipocytes and various 
types of immune cells [1]—is known to produce and secrete a wide variety of so-called 
adipokines. The release of adipokines enables communication with other cells and tissues 
throughout the body involved in the regulation of energy metabolism, satiety and various 
other processes.
The central role of adipose tissue in homeostasis becomes apparent during the 
development of obesity, which is a major risk factor for the development of insulin resistance 
[2]. During the development of obesity, storage of excess amounts of triacylglycerol in 
adipose tissue is associated with altered release of adipokines and cytokines that control 
local and systemic inflammatory processes and interfere with insulin signalling [3]. At the 
cellular level, it has been well established that obesity promotes robust changes in adipose 
tissue morphology [4]. In particular, hypertrophy of adipocytes and significant alterations 
in the number and composition of immune cells promote a state of chronic low-grade 
inflammation during obesity that is strongly associated with the development of insulin 
resistance and type 2 diabetes [1].
Macrophages are immune cells that have gained much attention as important 
contributors to adipose tissue functioning. Whereas macrophages in lean mice and humans 
make up around 5% of the cells in adipose tissue, during obesity they constitute up to 50% 
of all adipose tissue cells [5]. As well as increasing in number, adipose tissue macrophages 
(ATMs) change their localisation and inflammatory features during obesity. Contrary to the 
lean state, in which ATMs are distributed throughout the adipose tissue exposing limited 
inflammatory properties, ATMs in obese adipose tissue are located around dead adipocytes 
and form so-called crown-like structures (CLSs) while displaying profound pro-inflammatory 
features [6–8]. Macrophage presence in CLSs within obese adipose tissue has been directly 
linked with insulin resistance [9, 10]. Notably, however, the importance of macrophage-
mediated inflammation in determining insulin resistance is related to long-term exposure 
to a high-fat diet (HFD) whereas the initial stage of insulin resistance is independent of 
macrophage action [11].
In contrast to mice, inflammatory changes in human adipose tissue during obesity are 
somewhat less pronounced, although the presence of CLSs is positively correlated with a 
worsening in insulin resistance levels [12]. Furthermore, inter-individual differences in the 
degree of adipose tissue inflammation are likely to exist in humans and the importance of 
macrophage-mediated adipose tissue inflammation on the development of insulin resistance 
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will vary between obese individuals.
In addition to macrophages, numerous other types of immune cells populate the 
adipose tissue and affect its function [5, 13]. Indeed, dendritic cells [14], mast cells [15], 
neutrophils [16], B cells [17, 18] and T cells [19–21] have been found to reside in adipose tissue 
during obesity and contribute to the development of adipose tissue inflammation and insulin 
resistance. In particular, neutrophils and CD8+ T-cells have recently gained considerable 
attention because of the observed early influx into adipose tissue upon HFD-feeding and 
their potential contribution either to attracting macrophages or affecting their phenotype 
[16, 19, 22]. On the other hand, forkhead box (FOX)P+ regulatory CD4+ T cells have been found 
to reduce in number prior to the accumulation of macrophages in obese adipose tissue [23]. 
In line with their well-established role in dampening pro-inflammatory signalling, reduced 
presence of regulatory CD4+ T cells in adipose tissue might explain the accumulation and/or 
pro-inflammatory signalling of ATMs during obesity. Overall, these findings suggest a strong 
interplay between adaptive and innate immunity that together determine the inflammatory 
characteristics of obese adipose tissue. An excellent overview of the contribution of various 
immune cells to adipose tissue biology can be found elsewhere [24, 25]. This review will 
primarily focus on the function of macrophages in adipose tissue and their contribution to 
the inflammatory traits of obese adipose tissue.
Macrophages are unique in their capacity to quickly adapt to a changing environment, 
causing them to embrace a variety of phenotypes ranging from anti-inflammatory to pro-
inflammatory. In virtually every tissue, macrophages are actively involved in maintaining 
tissue homeostasis by clearing cellular debris, participating in tissue immune surveillance 
and resolving inflammation [26]. Although ATMs have been extensively associated with the 
development of obesity and adipose tissue inflammation, they are known to populate lean 
adipose tissue as well, executing numerous functions crucial for maintaining adipose tissue 
homeostasis [27].
In this review, we will touch upon both well established and recently identified functions 
of macrophages in lean and obese adipose tissue. The origin of macrophages residing in 
lean and obese adipose tissue will be addressed and several triggers that may account 
for an increase in number and a phenotypical switch of ATMs during the development of 
obesity will be discussed. Finally, this knowledge is used to pinpoint relevant future research 
directions to establish potential therapeutic targets for shifting macrophage phenotype and 
function in order to promote adipose tissue health.
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What are the functions of macrophages in adipose tissue?
ATMs and efferocytosis 
In 1908, Elie Metchnikoff received the Nobel Prize for his important discovery of the 
phagocytic activity of macrophages. Nowadays phagocytosis is still considered to be the 
most prominent function of macrophages. Although Metchnikoff specifically described 
the engulfment of microbes, phagocytosis also encompasses the engulfment of apoptotic 
endogenous cells in a process termed ‘efferocytosis’ [28]. Efficient efferocytosis licenses 
anti-inflammatory removal of aged or damaged cells by macrophages and is crucial to 
maintain homeostasis in tissues where cellular turnover occurs [28, 29]. Cellular turnover is 
also active in adipose tissue, characterised by continuous removal of adipocytes and their 
replacement by new adipocytes. Depending on the study population, the adipose tissue 
depot studied and the methodology used, calculations of the rate of adipocyte turnover in 
adults range from 10% per year [30] to up to 58–106% per year [31]. Since the total number 
of adipocytes in adipose tissue is thought to be set during childhood and thus to remain 
stable in adults [30, 32], probably a continuous cycle of cell death and replenishment exists in 
which macrophages presumably play a key role. Indeed, studies in which excessive adipocyte 
death is induced through activation of caspase 8 [33] or ongoing stimulation of lipolysis 
[34] have revealed anti-inflammatory macrophage accumulation around dead adipocytes, 
pointing to the need for macrophages during removal of dead adipocytes and the capacity 
of ATMs to clear high numbers of dead adipocytes while maintaining an anti-inflammatory 
state. The importance of efficient efferocytosis becomes apparent in several chronic 
inflammatory diseases, such as cystic fibrosis, chronic obstructive pulmonary disease and 
asthma, where ineffective clearance of dead cells has been identified as important source 
of pro-inflammatory signalling [29]. In obese adipose tissue, macrophages surrounding 
dead adipocytes in CLSs demonstrate pro-inflammatory features [6–8]. Since efficient 
efferocytosis is known to be accompanied by an anti-inflammatory macrophage trait, the 
presence of pro-inflammatory ATMs surrounding dead adipocytes in the obese state might 
reflect futile adipocyte clearance contributing to adipose tissue inflammation.
ATMs, adipocyte lipolysis and lipid buffering 
Building upon their unique role as professional phagocytes, recent data suggest that 
macrophages facilitate acute metabolic tasks executed by the adipose tissue. During 
lipolysis induced by either fasting or pharmacologic adrenergic activation, macrophages 
rapidly infiltrate the adipose tissue and adopt an anti-inflammatory phenotype [35]. In 
adipose tissue, macrophages buffer lipolysis by taking up and storing excessive amounts of 
adipocyte-released lipids, supervising gradual lipid release into the bloodstream [35–37]. 
Recently, macrophages have also been linked to controlling adipocyte lipolysis during cold 
exposure. Upon exposure to cold, anti-inflammatory macrophages have been reported to 
secrete catecholamines to stimulate adipocyte lipolysis in both inguinal and brown adipose 
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tissue [36, 38–40]. These acute challenges appear to promote macrophage mobility and 
quick adaptation to a changing environment facilitating tissue flexibility.
Interestingly, 7 days of continuous infusion of a β3-adrenergic receptor agonist to 
induce adipocyte lipolysis not only results in an influx of anti-inflammatory macrophages 
that adopt a lipid-laden cell appearance, it also increases the presence of dead adipocytes 
and the formation of CLSs. Within these CLSs, anti-inflammatory macrophages have been 
found to recruit and stimulate platelet-derived growth factor receptor (PDGFR)α+ adipocyte 
progenitors to differentiate [34]. Intriguingly, these adipogenic clusters near CLSs point 
to a direct link between efferocytosis, lipid buffering and adipose tissue remodelling by 
macrophages in lean adipose tissue.
In obese adipose tissue, macrophages surrounding dead adipocytes in CLSs also 
form multiple intracellular lipid droplets and activate transcriptional programs involved in 
lysosomal lipolysis [41]. The presence of lipid-filled macrophages in CLSs of obese adipose 
tissue in both humans [42] and mice [8] is indicative of macrophages attempting to buffer 
and process excessive amounts of lipids originating from adipocytes in a similar fashion to 
that observed in lean adipose tissue. However, increased spilling of NEFAs during obesity is 
suggestive of unsuccessful lipid buffering by ATMs. Thus, although engulfment and storage 
of lipids by ATMs seems to hold functional relevance in both lean and obese adipose tissue, 
in obesity the lipid buffering capacity of ATMs appears to be insufficient.
ATMs and adipogenesis 
The close correlation between adipocyte death and new cell formation through adipogenesis 
that has been observed in lean adipose tissue may not hold true during obesity. While 
macrophages in obese adipose tissue have been found to populate adipogenic clusters and 
facilitate angiogenesis and adipogenesis, adipogenic clusters are formed at sites away from 
CLSs [34, 43, 44]. This might relate to the pro-inflammatory state of macrophages in CLSs 
in obese adipose tissue. Although it has been proposed that pro-inflammatory signalling 
is needed for efficient adipogenesis to occur [45], multiple cell culture experiments 
have demonstrated that pro-inflammatory macrophages inhibit both proliferation 
and differentiation of adipogenitor cells [46–49]. The pro-inflammatory phenotype of 
macrophages in CLSs of obese adipose tissue may suppress adipogenesis and thus explain 
the appearance of adipogenic clusters away from inflammatory CLSs [34].
In contrast to studies postulating a role for macrophages in adipogenesis, other studies 
have argued that ATMs inhibit adipogenesis in obese adipose tissue [49, 50]. For example, it 
was found that exposure of adipocyte progenitors to conditioned medium of CD14+ cells from 
obese adipose tissue blocks adipogenesis [49]. A prominent factor involved in suppressing 
adipogenesis is Wnt-5a, which is abundantly expressed in ATMs and circulating monocytes 
from individuals with obesity and type 2 diabetes compared with lean individuals [50]. Overall, 
the effect of macrophages on adipogenesis in obese adipose tissue is still being debated. 
One might hypothesise that the role of macrophages shifts during the progression of obesity 
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from a predominant role in stimulating adipogenesis at the start of adipose tissue expansion 
to inhibiting adipogenesis once obesity progresses. The observation that adipogenic clusters 
containing macrophages appear at an early stage of adipose tissue expansion during obesity, 
yet decline in number upon the progression of obesity, supports this hypothesis [43]. 
Reduced adipogenesis at later stages of obesity would promote hypertrophy of adipocytes 
to allow for storage of the excess amounts of lipids entering the adipose tissue, which is in 
turn linked to metabolic dysfunction such as adipocyte insulin resistance [51, 52]. Indeed, 
increased adipocyte size has been found to correlate with macrophage presence in obese 
adipose tissue [53, 54]. However, future in vivo studies will be needed to further unravel the 
role of ATMs in adipogenesis and adipocyte hypertrophy in both lean and obese adipose 
tissue. In conclusion, multiple functions of macrophages in lean adipose tissue, including the 
prevention of lipid spill over into the circulation and licensing adipose tissue remodelling, 
appear to be impaired in obese adipose tissue. It is likely that impairment of these functions 
executed by ATMs contributes to loss of adipose tissue homeostasis in obese individuals. 
Differential metabolic and inflammatory traits of ATMs residing in either lean or obese 
adipose tissue may underlie shifts in its functional output and thus total adipose tissue 
functioning. Hence, careful identification of ATM phenotypes in lean and obese individuals 
might provide evidence for functional rewiring of ATMs upon the development of obesity.
What are the effects of the adipose tissue environment on macrophage 
phenotype?
Macrophage phenotype in lean vs obese adipose tissue 
Besides increasing in number, ATMs are known to dramatically change their phenotype during 
obesity. It has been suggested that the majority of the macrophage population in adipose 
tissue of obese mice consists of F4/80+CD11c+ or ‘classically activated’ M1 macrophages, 
characterised by increased expression levels of TNFα and inducible nitric oxide synthase 
(iNOS) [8]. By contrast, most of the macrophages in lean adipose tissue can be identified 
as F4/80+CD206+CD301+CD11c− macrophages, resembling an alternatively activated M2 
phenotype that is characterised by the expression of genes encoding anti-inflammatory 
proteins including Ym1, arginase 1 and IL-10 [8, 27]. A balanced ‘M0’ F4/80+CD206−CD11c− 
phenotype has also been reported [55], supporting an even greater diversity of inflammatory 
macrophage subtypes in the adipose tissue. However, in light of the metabolic functions 
performed by ATMs, a classification based on their inflammatory properties may not suffice. 
In line with this hypothesis, both M1 and M2 markers have been identified on a phenotypical 
heterogeneous population of macrophages in obese adipose tissue [56]. Interestingly, a 
metabolic classification has recently been put forward, characterised by increased lysosomal 
biogenesis and subsequent lipid catabolism as a hallmark of ATMs in obese adipose tissue 
[41]. Rather than cytokine-driven pro-inflammatory activation of ATMs, fatty acids (FAs) 
are the main trigger for metabolic activation of ATMs in obese adipose tissue. Importantly, 
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metabolic changes in lipid metabolism may predominantly underlie inflammatory activation 
of macrophages in adipose tissue, promoting an inflammatory phenotype of ATMs that may 
not fit into any of the classically defined inflammatory macrophage subtypes [57].
Macrophages in human vs mouse adipose tissue 
In parallel with an increase in ATMs during obesity in mice, macrophage numbers have 
also been found to increase in human obese adipose tissue [5, 7]. In contrast to the pro-
inflammatory phenotype of macrophages found in many animal studies, an ‘M2-type’ 
macrophage with remodelling capacity, yet still capable of secreting substantial quantities 
of pro-inflammatory cytokines, has been identified in adipose tissue of obese individuals 
[58]. The mixed inflammatory phenotype of ATMs in obese individuals is further illustrated 
by the presence of both CD206 and CD11c on the ATM membrane, markers generally used 
to distinguish between M2- and M1-type macrophages [59]. Despite their anti-inflammatory 
characteristics, this population of CD11c+CD206+ macrophages has been associated with 
insulin resistance [60]. Interestingly, the M2 macrophage marker CD163 has even been 
proposed to be the single macrophage marker that significantly correlates with HOMA-IR 
[61]. As mentioned before, less pronounced correlations between ATM numbers and insulin 
resistance have been found in humans, compared with mice [62–64]. It is likely that inter-
individual differences in the development of adipose tissue inflammation during obesity 
exist and contribute to the inconsistency in reported correlations between ATMs, adipose 
tissue inflammation and the development of insulin resistance in humans.
Location: visceral vs subcutaneous adipose tissue 
Adipose tissue is stored at various locations throughout the body, characterised by specific 
metabolic and inflammatory properties. Both subcutaneous (scAT) and visceral (vAT) storage 
depots exist, which are identified based on their anatomical location and differentially 
contribute to the development of metabolic abnormalities [65]. Epidemiological evidence 
demonstrates that vAT mass is a dominant risk factor for the development of metabolic 
abnormalities including insulin resistance [65]. Ex vivo experiments have shown that the 
inflammatory status, determined by the release of cytokines, is elevated in vAT compared 
with scAT [66]. This would imply that the number and/or phenotype of macrophages differ 
between the two adipose tissue depots. Indeed, various studies have shown an enhanced 
number of macrophages in vAT vs scAT [62, 67]. However, others have failed to report any 
differences in macrophage cell numbers [66]. In animal studies, bigger adipocytes were 
found in scAT compared with vAT, which negatively correlated with the number of CLSs in 
the adipose tissue depots [10]. Moreover, distinct rates of adipocyte turnover, adipocyte 
lipolysis and blood flow, with consequences for oxygen and nutrient availability, have been 
detected in scAT vs vAT [68, 69]. Although controversy about the different characteristics 
exists, distinct microenvironments in the adipose tissue depots might importantly affect 
macrophage phenotypes. Phenotypical differences in macrophages that populate either vAT 
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or scAT may be exemplified by the higher expression of pro-inflammatory cytokines by ATMs 
in vAT [67, 70, 71].
In general, most studies are mainly focused on determining the inflammatory 
phenotypes of ATMs. However, in line with the metabolic functions executed by ATMs, 
inflammatory markers may not suffice to distinguish functional from dysfunctional ATMs. It 
would be interesting to unravel whether macrophages within human adipose tissue display 
a metabolically activated phenotype, as has been identified recently in mice [57]. Moreover, 
deciphering what type of metabolic and inflammatory changes in ATMs finally result in 
functional differences in obese vs lean adipose tissue might improve our understanding of 
obesity-induced adipose tissue inflammation. Multiple triggers may underlie the macrophage 
phenotype, explaining the distinct responses of ATMs to several challenges in obese and lean 
adipose tissue. In order to shed light on such triggers, one should consider how and where 
the phenotype of the ATMs is being affected.
From where do adipose tissue macrophages originate?
Contrasting with the prevalent idea that all tissue macrophages are derived from circulating 
monocytes, novel techniques that allow fate mapping have revealed that not all tissue-
resident macrophages originate from monocyte precursors [72]. Many resident tissue 
macrophages are established during early embryonic development and are maintained 
during adulthood independently of an influx of blood monocytes [73]. However, inflammation 
has been shown to drive the recruitment of blood monocyte-derived macrophages that 
replace embryonically established resident macrophage populations in the myocardium 
and other tissues [74]. Surprisingly little is known about the origin of adipose tissue-resident 
macrophages and the maintenance of this population.
Monocyte recruitment 
It is well established that adipocytes are able to produce specific adipokines that function 
as chemoattractants for circulating monocytes. Monocyte chemoattractant protein-1 (MCP-
1) is one such chemokine that is known to be produced in large amounts by adipocytes 
and is robustly increased in obesity [75]. Indeed, overexpression of MCP-1 in adipose tissue 
promotes macrophage accumulation [76]. Interestingly, the presence of the C–C chemokine 
receptor (CCR) type 2, which allows monocytes to respond to MCP-1, is a typical characteristic 
of newly recruited macrophages that is used to distinguish them from resident macrophages 
in a variety of tissues [74] including fat [7]. These observations imply that monocyte 
recruitment through MCP-1 is important in populating adipose tissue with macrophages, 
and that this pathway is enhanced in the presence of obesity.
In addition to increased secretion of MCP-1 by adipose tissue, obesity is characterised 
by a significantly increased number of CCR2 molecules on circulating monocytes [77]. 
Moreover, monocytes from obese individuals demonstrate a higher chemotactic activity, 
which is associated with both insulin resistance and CCR2 expression [77]. Interestingly, the 
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migratory behaviour itself might be an important influence on macrophage phenotype. This 
is illustrated by the finding that the inflammatory state is linked to the migratory capacity of 
macrophages into adipose tissue [6, 8, 78]. In addition to a higher degree of chemotaxis, CCR2+ 
tissue macrophages may have an increased inflammatory phenotype compared with CCR2− 
tissue macrophages, which is illustrated by an induction of genes involved in the regulating of 
the NLRP3 inflammasome, at least in the myocardium [74]. The NLRP3 inflammasome allows 
processing and release of active IL-1β. IL-1β controls inflammatory responses and is involved 
in the development of insulin resistance [79, 80]. Similar differences appear to exist in ATMs 
isolated from obese animals shown by enhanced expression of CCR2 and inflammatory 
cytokines compared with the ATMs of lean animals [7]. However, monocyte recruitment 
to adipose tissue may not solely depend on MCP-1-controlled pathways, as the absence of 
MCP-1 does not completely curtail monocyte influx into adipose tissue [81]. Indeed, other 
chemokine receptor/ligand complexes have been shown to play a role in these processes, 
including CCR5 [82].
Bone marrow myelopoiesis 
Recent evidence has shed light on mechanisms and signals that have a vital role in controlling 
the recruitment of monocytes during obesity and go beyond MCP-1 and other chemokine-
signalling modules. Indeed, the bone marrow has been identified as an important contributor 
to the ATM pool [5, 83]. The development of obesity has been found to stimulate bone 
marrow myelopoiesis, which licenses the ongoing infiltration of monocytes into adipose 
tissue [84, 85]. Interestingly, it appears that signals from obese adipose tissue actively 
enhance bone marrow myelopoiesis partly via local activation of the alarmin S100A8/A9, 
which drives production of IL-1β [84].Other adipokines have also been shown to govern 
myelopoiesis, including leptin [85], further corroborating the observation that adipose tissue 
appears to determine bone marrow function via remote control. It is worth noting that fat 
residing within the bone marrow is known to express various cytokines and adipokines that 
change during the development of obesity and type 2 diabetes and might also be involved 
in the remodelling and activation of bone marrow cell populations [86]. Even though 
these observations shed some light on the mechanism of action involved, many issues 
concerning recruitment remain unresolved. In addition to adipose tissue-derived IL-1β, are 
haematopoietic factors involved in the control of myelopoiesis during obesity as well? Are 
signals from the adipose tissue also responsible for controlling bone marrow myelopoiesis 
in lean conditions? And are monocytes phenotypically different when originating from bone 
marrow during lean vs obese conditions? One line of evidence suggests that monocytes 
originating from bone marrow of lean or obese animals have a similar migration capacity. 
Using PKH26 staining to track monocytes, ATM accumulation was found to be enhanced 
in obese recipient mice compared with lean mice, independently of the origin of donor 
monocytes from either obese or lean animals [87]. These results imply that adipose tissue-
derived signals determine local macrophage numbers. Nonetheless, it has been demonstrated 
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that bone-derived macrophages from HFD-fed mice display an enhanced inflammatory 
phenotype compared with macrophages derived from bone marrow of lean animals [88]. 
Moreover, haematopoietic stem cells from obese mice harbour an enhanced capacity to 
develop into inflammatory CD11c+ ATMs after bone marrow transplantation [89]. Together 
these data suggest that adipose tissue-derived factors determine both the infiltration and 
differentiation of monocytes and that obesity affects the characteristics of the bone marrow 
cell population, ultimately translating into phenotypically different monocytes infiltrating 
lean and obese adipose tissue.
Local regulation of ATM numbers 
In addition to recruitment during obesity, multiple lines of evidence suggest that adipose 
tissue is equipped with tools allowing for local regulation and proliferation of ATM pools 
independently of the influx of blood precursors. vAT that is part of human omentum displays 
enhanced myelopoiesis during acute inflammatory conditions, which is suggestive for in situ 
production of cell populations in the abdomen [90, 91]. In line with these results, the presence 
of haematopoietic stem/progenitor cell populations in mouse white adipose tissue has been 
reported. The capacity of these cells to differentiate into myeloid and lymphoid lineages was 
similar to that of bone marrow-derived haematopoietic cells [92], yet no evidence currently 
exists supporting a fundamental role for local myelopoiesis in determining ATM numbers 
in obese adipose tissue. Another pathway contributing to influx-independent pathways 
that nourish ATM numbers concerns the involvement of pre-adipocytes that have been 
assigned with characteristics that closely resemble macrophages. 3T3-L1 pre-adipocytes, a 
frequently used model to study adipogenesis in vitro, display macrophage-like functions that 
are lost upon differentiation towards adipocytes [93]. Moreover, pre-adipocytes isolated 
from adipose tissue carry out many macrophage-like functions including phagocytosis and 
express macrophage-specific antigens including F4/80, macrophage 1 antigen (Mac-1) and 
CD45 [94]. Overall, these results imply closely resembling phenotypes of pre-adipocytes and 
macrophages. When receiving the appropriate signals, pre-adipocytes may efficiently and 
rapidly adapt and execute ATM functions.
Besides the contribution of local precursors, local proliferation has been held 
responsible for increasing ATM numbers during obesity [95]. Moreover, ATMs in obese 
adipose tissue have been postulated to have reduced migration capacity through increased 
netrin-1 expression that traps them in adipose tissue [96]. Finally, reduced apoptosis of 
resident ATMs has been suggested to account for enhanced ATM numbers during obesity, 
independently of monocyte influx [97].
To summarise, the origin of ATMs in lean and obese adipose tissue is still a matter 
of debate. The presence of specific cell surface markers on ATMs might help us learn 
more about their origin. Moreover, lineage tracing of ATMs using time-lapse microscopy, 
cell labelling and/or genetic markers will help us understand the origin of ATMs. On the 
basis of the currently available data, ATMs appear to be mainly derived from bone marrow-
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controlled pathways involving adipose-derived signals. Other lines of evidence suggest 
that local mechanisms may determine macrophage numbers in adipose tissue, including 
prolonged survival or increased retention of ATMs. Probably, various pathways at multiple 
levels are at work to set ATM numbers in adipose tissue. Whether the number of ATMs is 
primarily regulated at the level of the bone marrow or is determined by local factors in the 
adipose tissue will need further study.
Drivers of the adipose tissue macrophage phenotype
Both during myelopoiesis and in the circulation, monocytes can be primed by different factors 
that will eventually contribute to their migration and inflammatory fate after infiltration 
into the adipose tissue. It is likely that adipose tissue-derived factors will further determine 
the final ATM phenotype, which may differ between lean and obese adipose tissue. Some 
important triggers that shape the metabolic, inflammatory and functional traits of ATMs will 
be discussed below.
As explained earlier, other immune cells residing in the adipose tissue probably shape 
ATM phenotype as well, but these will not be discussed in this review. The same also applies 
to various adipokines that are known to be differentially secreted by lean rather than obese 
adipose tissue. Their role in affecting the phenotype of macrophages has been reviewed 
elsewhere [98, 99].
Hypoxia 
Both in humans and mice, rapid adipose tissue mass expansion during the development of 
obesity occurs without a concurrent increase in blood flow towards the tissue [100]. Indeed, 
animal studies have demonstrated that obese adipose tissue is characterised by hypoxic 
areas and an increased expression of hypoxia-related genes including HIF1α [19, 101–103]. In 
humans, oxygen levels in the adipose tissue are much harder to measure, and this technical 
challenge likely contributes to the contradictory results that have been reported so far, 
ranging from decreased oxygen tension [104, 105], unaltered oxygen tension, and even to 
increased oxygen tension [106] in obese adipose tissue.
As a result of their profound increase in size upon the development of obesity, 
adipocytes are generally thought to suffer from hypoxia in obese adipose tissue. Hypoxic 
conditions in adipocytes promote angiogenesis and fibrotic remodelling and have often 
been associated with the development of adipose tissue insulin resistance [102, 103, 107].
Only recently has attention been directed to the effects of hypoxic conditions on 
macrophages in the adipose tissue. In line with adipocytes, ATMs from obese adipose tissue 
have increased expression levels of hypoxia-related genes [101, 108]. It is not unthinkable 
that prolonged hypoxia is one of the driving forces behind the pro-inflammatory phenotype 
of macrophages in obese adipose tissue. When CD14+ cells from human obese vAT are 
exposed to hypoxic conditions, the secretion of pro-inflammatory cytokines is enhanced in 
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comparison with culturing under normoxic conditions [70]. Moreover, human macrophages 
derived from circulating monocytes held under hypoxic conditions show an increased 
inflammatory response when exposed to the saturated fatty acid (SFA) palmitate [109]. 
Interestingly, in vivo, M1-like macrophages accumulate more pimonidazole, a hypoxia probe, 
than do anti-inflammatory macrophages in the adipose tissue of obese mice, and display 
higher expression levels of hypoxia-related genes including Hif1α [101]. Together these data 
underline a direct link between the hypoxic state of ATMs and their inflammatory phenotype 
in obese adipose tissue.
Importantly, the response of macrophages to hypoxia might depend on their initial 
inflammatory state. Indeed, it has been proposed that stimulation of bone marrow-
derived macrophages with IL-4 prior to hypoxia exposure decreases the expression of 
pro-inflammatory genes, while leaving hypoxia-related gene expression unaltered [101]. 
Alternatively, differential responses of macrophages to hypoxia could also relate to the 
presence of two different isoforms of hypoxia-inducible factor (HIF). HIF1α is the most 
well-known isoform and mediates a shift towards glycolysis, known as the Warburg effect 
[110]. Inflammatory stimuli are prominent stimulants of HIF1α activity, inducing rapid ATP 
production independent of oxygen [110, 111]. During hypoxic conditions HIF1α activity is 
also considered to be crucial to maintain energy levels [100], although other transcription 
factors probably play an additional role [109]. In addition to fuelling a metabolic switch, 
HIF1α enhances pro-inflammatory signalling via IL-1β transcription [110]. The control of 
IL1β expression might provide a direct link between HIF1α activity in obese ATMs, either 
activated via hypoxia or inflammatory signalling, and the presence of insulin resistance.
The isoform HIF2α is also upregulated under low oxygen levels. While HIF1α increases 
the glycolytic flux and pro-inflammatory signalling, HIF2α is associated with a more anti-
inflammatory macrophage phenotype [112, 113]. Interestingly, in obese adipose tissue HIF2α 
is predominantly upregulated in M2-like macrophages [108] and peritoneal macrophages 
overexpressing HIF2α show a blunted increase in TNFα expression on co-culturing with 
obese adipose tissue [108]. Adipocyte-specific deletion of Hif2α has been linked to adipose 
tissue inflammation, glucose intolerance and insulin resistance [114] but so far no studies 
specifically targeting HIF2α in macrophages have been conducted.
Overall, the inflammatory state of macrophages might be linked to the relative 
presence of HIF isoforms that may influence the metabolic and inflammatory response of 
ATMs under hypoxic conditions. Importantly, in addition to hypoxia, one should not ignore 
the fact that HIF-dependent gene expression can also be regulated independently of oxygen 
availability, through the involvement of inflammatory-related signals. In addition to direct 
effects of hypoxia on macrophages, signals originating from hypoxic adipocytes may also 
shape the phenotype of ATMs in obese adipose tissue. Indeed, in vitro experiments have 
revealed that adipocytes exposed to hypoxic conditions release potential stressors that 
affect macrophage function.
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Examples include the pro-inflammatory adipokines IL-6, visfatin, leptin and macrophage 
migration inhibitory factor (MIF) [100]. Importantly, prolonged exposure to hypoxia might 
also lead to adipocyte cell death and release of intracellular content which subsequently 
affects the phenotype of ATMs.
Adipocyte cell death 
In animal studies, cell death in obese adipose tissue has been well established. Dead 
adipocytes that have lost membrane integrity are surrounded by macrophages that cluster 
in CLSs and together form pro-inflammatory, fibrotic lesions [115]. Signals released from 
dying cells are known to act as strong chemoattractants and affect immune responses 
[116, 117].One example is the nuclear protein high mobility group box 1 (HMGB1), which 
acts as a danger signal that attracts and activates immune cells [118]. Interestingly, HMGB1 
levels are increased in obese adipose tissue and are associated with inflammation [119, 
120]. In addition to HMGB1, other cellular proteins with intrinsic inflammatory features are 
released upon cell death and may skew ATM phenotypes in obese adipose tissue. Uric acid, 
adenosine, ATP and galectins are among some of these so-called ‘danger signals’ that affect 
inflammatory macrophage responses [116, 117, 121].
The type of adipocyte cell death occurring in adipose tissue may determine the 
inflammatory phenotype of macrophages as well. Apoptotic cells induce a predominant anti-
inflammatory response, whereas necrotic cells stimulate pro-inflammatory cytokine secretion 
[117]. Dead cells that are not effectively cleared are known to turn into secondary necrotic 
cells releasing their noxious content to induce pro-inflammatory signalling, autoimmunity 
and tissue damage [122–125]. Although impaired clearance of dead cells has been causally 
linked to various chronic inflammatory diseases [29], to date there have been no extensive 
studies on the contribution of adipocyte death to inflammation during obesity. Some studies 
have reported necrotic adipocyte cell death in obese adipose tissue, with membrane rupture 
and release of cell content [9]. However, others postulate programmed necrotic cell death 
[126], programmed pyroptosis [127] or even apoptosis [128] of adipocytes in obese adipose 
tissue, making it difficult to draw conclusions on the effect of adipocyte cell death on the 
ATM phenotype. Considering the profound consequence for macrophage phenotype found 
in other organs, examination of the type of adipocyte cell death occurring in obese adipose 
tissue, but also during regular cell turnover in lean adipose tissue, is of relevance.
Importantly, adipocyte cell death is unique in the fact that it leads to the release of 
substantial amounts of lipids and one might hypothesise that prolonged exposure to excess 
lipids affects ATM phenotype.
Lipotoxicity 
A lipid-rich environment during the development of obesity may represent an important 
metabolic stressor for ATMs. In general, there are three ways through which ATMs are 
exposed to lipids; via chylomicrons or VLDLs, by adipocyte lipolysis, or after adipocyte cell 
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death. Hyperlipidaemia seems not to lead to macrophage accumulation in obese adipose 
tissue [129], indicating that lipids resulting from adipocyte lipolysis and adipocyte cell death 
represent the main causes of excessive lipid accumulation in ATMs during obesity. However, 
the exact contribution of adipocyte lipolysis is also somewhat controversial. On the one hand 
higher basal rates of lipolysis have been observed in adipocytes of obese individuals [130]. In 
line with this, adipocyte hypertrophy and TNFα exposure, which are both elevated in obese 
adipose tissue, have been linked to increased adipocyte lipolysis [131–133]. On the other 
hand, decreased basal lipolytic rates [134] and reduced catecholamine-induced lipolysis by 
insulin resistant adipocytes in obese adipose tissue [135, 136] have been reported as well, 
and are indicative of lower lipolysis rates in obese adipose tissue. Nonetheless, although the 
exact source is still a matter of debate, macrophages in obese adipose tissue are exposed 
to excess lipids as illustrated by their lipid-laden appearance. Exposure to FAs is known to 
influence macrophage phenotype profoundly. Importantly, SFAs induce a pro-inflammatory 
macrophage phenotype via Toll-like receptor (TLR)-induced NF-kB activation [137]. The 
TLR-family member 4 (TLR 4) translates most of the pro-inflammatory effects of SFAs that 
trigger TLR4 activation via binding to its adaptor molecule fetuin-A [138, 139], although 
some argue that the effects of SFAs are partly TLR-independent [57, 140]. Another source 
of pro-inflammatory signalling finds it origin intracellularly, as an increase in intracellular FAs 
is associated with endoplasmic reticulum (ER) stress and oxidative stress, enhancing pro-
inflammatory signalling and inducing insulin resistance in vivo [141]. Moreover, SFAs and 
their derivatives, including ceramides, are classified as danger-associated molecular patterns 
(DAMPs) that are recognised by the NLRP3 inflammasome and lead to IL-1β secretion via 
caspase 1 activation [142]. However, the response of macrophages upon lipid uptake does 
not necessarily have to be pro-inflammatory in nature [143]. Although it has been suggested 
that internalised palmitate, a very well-known SFA, promotes lipid metabolism and limits 
inflammation [57], in general only unsaturated FAs, particularly n-3 FAs, are recognised 
for their anti-inflammatory properties [139, 144]. Hence, FA species present in adipocytes 
may for a large part determine the degree of lipid toxicity in macrophages. Alternatively, 
one might speculate that the metabolic and inflammatory state of macrophages could also 
be involved in determining its response to different FAs. Overall, mechanisms by which 
intracellular FAs determine the inflammatory traits of macrophages are relatively unclear. 
Importantly, lipid-overloaded macrophages in obese adipose tissue [42] may trigger the 
production of pro-inflammatory cytokines such as TNFα and IL-1β, as has been observed 
in macrophages exposed to FAs in vitro [138, 145–147], and thus contributing to the 
development of insulin resistance. The type of FAs stored in the adipocyte, the timespan of 
lipid exposure, the inflammatory phenotype of the macrophage and the presence of various 
other inflammatory signalling molecules might explain the predominant anti-inflammatory 
response of ATMs in lean adipose tissue vs the pro-inflammatory response in obese adipose 
tissue following lipid exposure.
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Hyperinsulinaemia 
Obesity-induced adipose tissue inflammation is associated with systemic insulin resistance 
and hyperinsulinaemia in obese rodents and humans. Multiple lines of evidence suggest 
that insulin itself directly affects inflammatory processes. In fact, insulin has been assigned 
with both anti- and pro-inflammatory properties. In circulating mononuclear cells of obese 
individuals, insulin inhibits NFkB activity, suggesting an anti-inflammatory effect [148]. By 
contrast, other studies have shown that hyperinsulinaemia promotes pro-inflammatory 
responses by affecting T cell regulatory function [149].
It is difficult to pinpoint the sole effects of insulin in vivo during the development of 
obesity, as changes in many other circulating factors accompany hyperinsulinaemia. However, 
several lines of evidence suggest that insulin directly contributes to ATM homing. The start 
of insulin therapy in patients diagnosed with type 2 diabetes has been shown to promote the 
appearance of macrophages in scAT [150]. Intriguingly, in both humans and mice, circulating 
insulin positively correlates with inflammatory cytokine expression in the adipose tissue, 
independently of body weight differences [151]. Recently, a mechanism of action whereby 
insulin may control propagation of adipose tissue inflammation was uncovered. Even though 
adipocytes become insensitive to insulin-dependent glucose uptake during obesity, insulin is 
able to enhance adipocyte MCP-1 gene expression levels aggravating the influx of monocytes 
[151].
Insulin resistance has also been shown to negatively affect macrophage function itself, 
especially in the context of atherosclerotic disease. Although glucose uptake primarily takes 
place via insulin-independent pathways involving GLUT1, circulating monocytes express the 
insulin receptor machinery and develop resistance to the effects of insulin. Interestingly, 
insulin receptor deficiency on macrophages reduces their influx into the adipose tissue and 
alleviates the development of low-grade inflammation and systemic insulin resistance in 
mice on an HFD [152]. Functional consequences of insulin resistance include a failure to 
deal with ER stress, which enhances the risk of macrophage apoptosis and subsequent loss 
of function [153]. In addition to apoptosis, primary macrophages isolated from ob/ob mice 
have a defect in efferocytosis that was associated with defective phosphoinositide (PI)3 
kinase activity, whereas cells lacking the insulin receptor were protected [154].
It remains to be determined whether insulin resistance develops in ATMs in obese 
adipose tissue. Moreover, the functional consequences and possible contributions to 
adipose tissue inflammation are currently unknown. Another interesting aspect involves 
the development of insulin resistance in circulating monocytes [155]. It is not unthinkable 
that insulin resistance in circulating monocytes may promote functional changes leading to 
altered migration and inflammatory properties. Studies involving monocytes lacking specific 
parts of the insulin signalling machinery would shed light on the role of this pathway in 
shaping ATM phenotypes both during lean and obese conditions.
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Hyperglycaemia 
Chronic hyperglycaemia is known to induce insulin resistance by mechanisms that may 
partly be conveyed by an enhanced inflammatory state. Indeed, there is a substantial 
amount of evidence demonstrating pro-inflammatory effects of prolonged periods of 
hyperglycaemia. In humans, hyperglycaemia is associated with inflammation in individuals 
with diabetes [156]. Similar data has been generated using various animal models where the 
induction of hyperglycaemia using streptozotocin (STZ)-mediated disruption of pancreatic 
beta cells drives monocyte recruitment to tissues and promotes inflammation [157]. Other 
approaches to induce short-term periods of hyperglycaemia, including clamping, trigger pro-
inflammatory responses in adipose tissue of rats as well [158].
In both adipocytes and macrophages, harmful effects of prolonged exposure to high 
levels of glucose have been reported. In vitro approaches in which adipocytes are cultured in 
medium with 25 mmol/l glucose for prolonged periods of time revealed increased production 
of various pro-inflammatory cytokines including IL-6 [158], and similar observations have 
been made in immune cells [159]. Moreover, hyperglycaemia has been shown to interfere 
with IL-4 action to polarise macrophages towards an alternatively activated state illustrated 
by decreased expression of M2 markers and a reduction in arginase functional activity, 
compared with cells treated under normoglycaemic conditions [160]. It has been postulated 
that the induction of reactive oxygen species (ROS) as a consequence of hyperglycaemia 
evokes inflammatory responses. An important molecular switch that translates the presence 
of hyperglycaemia into pro-inflammatory conditions is the thioredoxin-interacting protein 
(TXNIP). TXNIP expression is enhanced by high levels of glucose and in the presence of 
diabetes via the transcription factor carbohydrate response element-binding protein 
(ChREBP) and regulates a variety of processes including redox state and inflammation [161]. 
Deletion of Txnip using small interfering (si)RNA approaches prevents hyperglycaemia-
induced ROS generation and the induction of inflammation [162]. Moreover, TXNIP has been 
linked to inflammasome activation in macrophages [163], a pathway known to contribute 
to adipose tissue inflammation and insulin resistance [79, 164]. In adipose tissue, glucose-
induced activation of TXNIP mediates IL-1β mRNA expression levels and intracellular pro-IL-
1β accumulation [66].
The consequences of hyperglycaemia may also be conveyed via changes in cellular 
metabolism leading to alterations in intermediate metabolites. It has been documented 
that cultured adipocytes exposed to high levels of glucose produce and secrete enhanced 
quantities of lactate [165]. Interestingly, diabetes is associated with markedly increased 
lactate production in adipocytes derived from obese adipose tissue [166]. Lactic acid, 
secreted from tumour cells as a by-product of aerobic or anaerobic glycolysis, has been 
shown to drive an M2like polarisation of tumour-associated macrophages [167]. Whether 
lactic acid secreted by adipocytes may alter ATM phenotype is currently unknown.
High levels of glucose may thus represent an important trigger that activates pro-
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inflammatory changes in macrophages, either directly or indirectly. Interestingly, both 
shorter periods of hyperglycaemia, either during a clamp procedure or postprandially, and 
chronic periods in the presence of obesity and insulin resistance, appear to induce pro-
inflammatory macrophage characteristics. 
A future challenge: identification of key regulators of macrophage 
phenotype
Macrophages can be identified via specific transcription factors that control tissue-tailored 
transcriptional programs and allow the cells to adopt extremely tissue-specific functions. An 
elegant example is the identification of GATA-6 as master regulator of the peritoneal-specific 
gene transcriptional program. By comparing the transcriptome of various tissue macrophages 
including those from lung, liver, adipose tissue and peritoneum [90], the authors identified a 
set of genes controlled by GATA-6 specifically expressed in peritoneal macrophages. Using a 
similar approach, we have re-analysed their dataset to pinpoint ATM-specific genes leading 
to the identification of transforming growth factor (TGF)β and IL-4 as important upstream 
regulators. The identification of anti-inflammatory upstream regulators in ATMs isolated 
from lean animals is not surprising, yet it does demonstrate the usefulness of this approach. 
Comparing transcriptional regulators of ATMs during various conditions may bypass the 
rather complex quest for responsible triggers, and may help to unravel important pathways 
and molecules that underlie the distinct metabolic, inflammatory and functional traits of 
ATMs as a consequence of multiple triggers present in lean vs obese adipose tissue.
Because of the high versatility of macrophages, which have a phenotype largely 
dependent on their environment, conclusions solely based on in vitro studies should be 
taken with caution. Rather, in vivo profiling of macrophage phenotype via several techniques, 
including metabolomics and transcriptomics, and identification of key regulators of distinct 
macrophage phenotypes, residing in different adipose tissue depots and/or during the 
development of obesity and insulin resistance in both humans and mice, will advance our 
knowledge on adipose tissue biology. Determining a causal relationship between triggers, 
a switch in the metabolic and inflammatory status of ATMs and ATM function will be an 
important challenge. This information will be crucial for our understanding of initial triggers 
that ultimately link obesity to adipose tissue inflammation and the development of insulin 
resistance, and might provide us with future therapeutic targets. An overview of stressors 
that may determine the phenotype of ATMs in lean vs obese conditions and the subsequent 
consequences for adipose tissue function are shown in Fig. 1.
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Figure 1. Overview of the different stressors that shape ATM function in lean vs obese adipose tissue.
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Limiting adipose tissue inflammation by targeting macrophage 
metabolism
The presence of adipose tissue inflammation translates the development of obesity into 
insulin resistance and type 2 diabetes. Macrophages play a key role in maintaining adipose 
tissue homeostasis, yet fuel adipose tissue inflammation upon the development of obesity.
Current efforts to unravel adipose tissue-specific functions of macrophages have revealed 
an essential role in lipid buffering for ATMs, alongside their more conventional functions 
such as clearing cellular debris and participating in tissue immune surveillance to maintain 
homeostasis. Importantly, both in lean and obese adipose tissue, lipid storage by macrophages 
prevents spill over into the circulation. However, the metabolically activated macrophage that 
resides in obese adipose tissue appears to be continuously exposed to an overabundance of 
lipids. Chronic lipid overloading of ATMs translates into a pro-inflammatory phenotype and 
may drive dysfunction of ATMs, ultimately fuelling the inflammatory traits of obese adipose 
tissue.
This new knowledge might shift intervention approaches away from targeting the 
inflammatory traits of ATMs, towards targeting their metabolic programming. Interventions 
aimed at increasing metabolic capacity might be used to reprogram macrophage metabolism, 
allowing macrophages to cope with metabolic challenges during obesity, in order to maintain 
adipose tissue homeostasis. 
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ABSTRACT 
Aims/hypothesis Recent studies have identified intracellular metabolism as a 
fundamental determinant of macrophage function. In obesity, proinflammatory 
macrophages accumulate in adipose tissue and trigger chronic low-grade inflammation 
that promotes the development of systemic insulin resistance, yet changes in their 
intracellular energy metabolism are currently unknown. We therefore set out to study 
metabolic signatures of adipose tissue macrophages (ATMs) in lean and obese conditions. 
Methods F4/80-positive ATMs were isolated from obese vs lean mice. High-fat feeding of 
wild-type mice and myeloid-specific Hif1α−/− mice was used to examine the role of hypoxia-
inducible factor-1α (HIF-1α) in ATMs part of obese adipose tissue. In vitro, bone marrow-
derived macrophages were co-cultured with adipose tissue explants to examine adipose 
tissue-induced changes in macrophage phenotypes. Transcriptome analysis, real-time flux 
measurements, ELISA and several other approaches were used to determine the metabolic 
signatures and inflammatory status of macrophages. In addition, various metabolic routes 
were inhibited to determine their relevance for cytokine production. 
Results Transcriptome analysis and extracellular flux measurements of mouse ATMs 
revealed unique metabolic rewiring in obesity characterised by both increased glycolysis and 
oxidative phosphorylation. Similar metabolic activation of CD14+ cells in obese individuals 
was associated with diabetes outcome. These changes were not observed in peritoneal 
macrophages from obese vs lean mice and did not resemble metabolic rewiring in M1-primed 
macrophages. Instead, metabolic activation of macrophages was dose-dependently induced 
by a set of adipose tissue-derived factors that could not be reduced to leptin or lactate. 
Using metabolic inhibitors, we identified various metabolic routes, including fatty acid 
oxidation, glycolysis and glutaminolysis, that contributed to cytokine release by ATMs in lean 
adipose tissue. Glycolysis appeared to be the main contributor to the proin- flammatory trait 
of macrophages in obese adipose tissue. HIF-1α, a key regulator of glycolysis, nonetheless 
appeared to play no critical role in proinflammatory activation of ATMs during early stages 
of obesity. 
Conclusions/interpretation Our results reveal unique metabolic activation of ATMs in 
obesity that promotes inflammatory cytokine release. Further understanding of metabolic 
programming in ATMs will most likely lead to novel therapeutic targets to curtail inflammatory 
responses in obesity. Data availability Microarray data of ATMs isolated from obese or lean 
mice have been submitted to the Gene Expression Omnibus (accession no. GSE84000). 
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INTRODUCTION 
In obesity, macrophages accumulate in adipose tissue and trigger chronic low-grade 
inflammation which promotes the development of systemic insulin resistance [1–3]. Based 
on transcriptional profiles and expression markers derived from in vitro experiments, 
macrophages are generally classified as classically/inflammatory (M1) or alternatively/anti- 
inflammatory (M2) activated [4, 5]. Applying this phenotypical classification to adipose tissue 
macrophages (ATMs) has led to the identification of M2 macrophages in lean adipose tissue vs 
M1 macrophages in obese adipose tissue [6]. In recent years, however, the two-dimensional 
M1/M2 spectrum has been challenged and macrophages in different tissue environments 
have been shown to adopt a variety of inflammatory phenotypes that fall outside this 
classification [7, 8]. Indeed, macrophages in obese adipose tissue display surface-proteins 
that resemble neither classical nor alternative activation, but rather represent a state of 
metabolic activation [9]. Intracellularly, ATMs in obese adipose tissue are characterised by 
lysosomal activity [10], suggestive of robust changes in intracellular energy metabolism of 
ATM in obesity. 
Recent developments in the field of immunology have identified macrophage 
intracellular energy metabolism as a fundamental determinant of its functional response. 
M1 macrophages are characterised by a high glycolytic rate whereas M2 macrophages rely 
mainly on oxidative phosphorylation (OXPHOS) [11, 12]. A central role in driving macrophage 
polarisation has been appointed to hypoxia-inducible factor-1α (HIF-1α), a master regulator 
of glycolysis that is critically involved in the development of the M1 phenotype [13, 14]. 
Profiling of intracellular metabolism in ATMs, as well as identifying key regulators involved, 
is expected to further the understanding of their metabolic functions and may ultimately 
bring forward targets for modulating their inflammatory traits. Using various approaches, 
we identified unique metabolic activation of ATMs in obesity that does not resemble M1 or 
M2 macrophages. Metabolic activation of macrophages, characterised by increased OXPHOS 
and glycolysis, was dose-dependently induced during a co-culture with adipose tissue 
and translated into increased cytokine secretion. Although various metabolic pathways 
contributed to cytokine release by ATMs, glycolysis accounted mostly for the higher cytokine 
production by ATMs from obese mice. Inflammatory activation of ATMs during early stages 
of obesity, however, appeared to be independent of HIF-1α. Further understanding of the 
functional consequences of metabolic programming in macrophages in lean adipose tissue 
and metabolic activation in ATMs residing in obese adipose tissue is expected to lead to 
novel therapeutic targets to curtail inflammatory responses that will ultimately reduce 
obesity-induced metabolic complications. 
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METHODS 
Mice 
Male C57Bl/6 mice (Harlan, Horst, Germany) were on a high-fat diet (HFD) containing either 
45% (D12451) or 60% energy derived from fat (D12492), or on a low-fat diet (LFD) containing 
10% energy derived from fat and matching most other components present in either the 
45% HFD (D12450B) or 60% HFD (D12450J), for 16 weeks. Mice were stratified based upon 
body weight at the start of the LFD or HFD intervention. All procedures were approved by 
the ethics committee for animal experiments at Wageningen University. 
For studying the role of HIF-1α in ATMs during the development of obesity, 9- to 
12-week-old male C57/Bl6 mice with floxed Hif-1α (also known as Hif1a) (exon 2) crossed into 
a background of lysozyme M-driven cre recombinase (LysM Hif-1α−/−) or C57/Bl6 controls not 
carrying lysozyme M-driven cre recombinase (LysM Hif-1α+/+) [15] were exposed to an HFD 
(D12492) for 8 weeks. After 7 weeks, an insulin tolerance test was performed in mice fasted 
for 5 h, by injecting insulin (1 U/kg body weight) intraperitoneally. Blood was taken from 
the tail at specific time points and glucose was measured using Accu-check glucose meters 
(Roche Diagnostics, Almere, the Netherlands). The study was carried out in accordance with 
recommendations in the Guide for the Care and Use of Laboratory Animals of the National 
Research Council. The protocol was approved by the Dartmouth IACUC. 
All mice were individually housed and had ad libitum access to food and water. All 
diets were obtained from Research Diets (New Brunswick, NJ, USA). Experimenters were not 
blinded to group assignment and outcome assessment. 
Cell culture 
ATMs and peritoneal macrophages were isolated from male, wildtype C57Bl/6 mice (Harlan). 
For details of tissue and cell collection, see ESM Methods. 
ATMs 
Freshly isolated ATMs were cultured in RPMI 1640 (Lonza, Verviers, Belgium) supplemented 
with 10% (vol./vol.) FCS and 1% (vol./vol.) penicillin/streptomycin (PS) (RPMI/FCS/PS) for 24 h 
(200,000 cells/well). The contribution of various metabolic pathways to cytokine release was 
examined by providing 5.5 mmol/l 2-deoxy glucose (2-DG) (Merck, Darmstadt, Germany), 50 
μmol/l Etomoxir (Merck), 10 μmol/l UK5099 (Merck) or 10 μmol/l BPTES (Merck) 2 h after 
plating until the end of the 24 h culture period. 
Bone marrow-derived macrophages 
Bone marrow cells were cultured in DMEM (Lonza) supplemented with 10% (vol./ vol.) FCS 
and 1% (vol./vol.) PS (DMEM/FCS/PS) and 5% (vol./vol.) L929-conditioned medium (L929). 
After 3–4 days, adherent bone marrow-derived macrophages (BMDMs) were re-plated and 
exposed for 3 days to an insert containing 25 mg or 100 mg of minced epididymal adipose 
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tissue collected from LFD-fed or HFD-fed mice. Control BMDMs were held in DMEM/FCS/PS 
containing 5% (vol./vol.) L929 with an empty insert for the same length of time. M1 and M2 
macrophages were generated by 24 h incubation with 10 ng/ml lipopolysac- charide (LPS) 
(M1) or 25 ng/ml IL-4 (M2). For measuring cytokine and lactate production of BMDMs after 
adipose tis- sue priming, inserts were removed and BMDMs were held in fresh DMEM/FCS/
PS for an additional 24 h. For extracellular flux analysis, BMDMs were scraped, counted and 
re-plated in a 96-well Seahorse microplate (Seahorse Bioscience, Santa Clara, CA, USA). 
Adipose tissue 
Epididymal adipose tissue was brought into culture and exposed to 17.5 nmol/ml insulin in 
DMEM/PS for 20 min to measure insulin sensitivity. The tissue was kept in DMEM/FCS/PS 
with or without LPS (10 ng/ml) for 24 h to measure IL-6 release or was cultured in DMEM/
FCS/PS for 3 days for leptin and lactate measurements. 
Extracellular flux analysis 
The real-time oxygen consumption rate (OCR) and extracel- lular acidification rate (ECAR) of 
ATMs and BMDMs were analysed using an XF-96 Extracellular Flux Analyzer (Seahorse). See 
ESM Methods for further details. 
Cytokine and lactate measurements 
Levels of IL-6, chemokine (C-X-C motif) ligand-1 (KC), TNF-α, IL-1β, IL-10 and leptin in cell 
culture supernatant fractions were measured with murine DuoSet ELISA Development 
kits (R&D Systems, Abingdon, UK). An enzymatic assay adapted from the Lactate Assay kit 
(Merck) was used to determine lactate levels. 
Immunohistochemistry 
Paraffin-embedded sections of epididymal adipose tissue were stained with an F4/80 
antibody (Bio-Rad, Veenendaal, the Netherlands) and counterstained with haematoxylin. 
Macrophages were visualised with 3,3-diaminobenzidene (Merck). 
Western blot 
Primary antibodies for actin (Merck), AMP-activated protein ki- nase (AMPK) (no. 2532L), 
phospho-AMPK Thr172 (no. 2531) and p-Akt Ser473 (no. 4060) (Cell Signalling, Leiden, the 
Netherlands) were all used at a ratio of 1:1000 according to manufacturers’ instructions, and 
incubated overnight at 4°C. See ESM Methods for further details. 
RNA isolation and qRT-PCR 
RNA from ATMs and peritoneal macrophages isolated from HFD-fed or LFD-fed mice, or 
from BMDMs, was used for quantitative reverse-transcription PCR analysis (qRT-PCR). The 
following genes were measured: Cd11c (also known as Itgax), Cd206 (also known as Mrc1), 
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Cd36, Cd68, Glut1, Hk2, Hif-1α, Ldhα (also known as Ldha), Lipa, Pdk4, Plin2 and Vegfα (also 
known as Vegfa), normalised against 36b4 (also known as Rplp0) (ESM Table 1). For further 
details, see ESM Methods. 
Microarray analysis and interpretation 
Four pools of ATMs isolated from epididymal adipose tissue of male C57Bl/6 mice fed an LFD 
or HFD in four separate exper- iments were subjected to expression profiling by microarray. 
In addition, raw transcriptome data from various tissue macro- phages, including ATMs (GEO 
accession no. GSE56682), from LPS-stimulated BMDMs (GSE53986) and from obese diabetic 
and obese non-diabetic humans (GSE54350) were obtained from the Gene Expression 
Omnibus. Details of the microarray analysis and interpretation are in the ESM Methods. 
Microarray data have been submitted to the Gene Expression Omnibus (accession number 
GSE84000). 
Statistical analysis 
Results are shown as mean ± SEM. Statistically significant differences between two groups 
were calculated using Student’s t test. For comparisons between more than two groups, 
a one-way ANOVA and post hoc Bonferroni’s multi- ple comparison test was done. When 
comparing diet and treatment effects within one experiment, data were analysed with a 
two-way ANOVA with post hoc Bonferroni test (treatment vs control). A p value ≤0.05 was 
considered significant. 
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anti-inflammatory genes, including Cd11c, Myd88, Arg1 and
Il-10 (also known as Il10) in ATMs from obese vs lean mice
not resembling M1 (nor M2) macrophages (Fig. 2c).
Interestingly, metabolic activation as found in the ATM part
of obese adipose tissue was also apparent in CD14+ cells
isolated from visceral adipose tissue of obese humans with
diabetes compared with obese non-diabetic individuals (Fig.
2a, d).
Functional consequences of metabolic activation
of ATMs in obesity
Next, we evaluated whether transcriptional changes in ATMs
translated into differences in energy metabolism. To that end,
OXPHOS and glycolysis rates of freshly isolated ATMs were
examined by measuring OCR and ECAR. In line with in-
creased expression of metabolic genes, ATMs from obese
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Fig. 1 Unique metabolic and inflammatory activation in ATMs during
obesity. (a) PCA of various tissue macrophages, separated based on their
transcriptome. n = 2 for macrophages from peritoneum, small intestine
and adipose tissue; n = 1 for other macrophages. Data are derived from
GEO accession no. GSE53986. Percentage of explained variance (expl.
var.) is shown. (b–d) PCA plot of ATMs from obese (HFD-fed) vs lean
(LFD-fed) mice (four pools of 4–7 HFD- or LFD-fed mice), separated
based on the complete transcriptome (b) or on expression levels of in-
flammatory genes (c) or metabolic genes (d). (e, f) Heat maps reflecting
expression levels of the top 15 most differentially higher (red) or lower
(blue) expressed genes involved in glycolysis (e) or OXPHOS (f) in
ATMs from obese vs lean mice, presented as log2 ratio difference
(SLR). (g) Expression levels of metabolic genes in peritoneal
macrophages and ATMs. The 2−ΔΔCt method was used to determine fold
change inductions normalised to 36b4. Diet-induced changes in expres-
sion levels (HFD vs LFD) were tested for significance. (h, i) Lactate
production over 24 h by ATMs (h) or peritoneal macrophages (i) from
lean (LFD) or obese (HFD) mice. Peritoneal macrophages: n = 7 (LFD,
white bars) vs n = 6 (HFD, light grey bars) were used for qRT-PCRs and
lactate measurements (g, i). ATMs: four pools (LFD, dark grey bars) vs
six pools (HFD, black bars) of 4–7mice were used for qRT-PCR (g) and a
pool of 9 LFD-fed mice vs a pool of 5 HFD-fed mice was used for lactate
measurements (n = 3) (h). Data are presented as means ± SEM. *p < 0.05,
**p < 0.01 and ***p < 0.001, as shown by brackets, or for obese vs lean
mice in (e, f)
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Fig. 1 Unique metabolic and inflammatory activation in ATMs during obesity. 
(a) PCA of various tissue macrophag s, separated based on their transcriptome. n = 2 for macrophages from 
peritoneum, small intestine and adipose tissue; n = 1 for other macrophages. Data are derived from GEO accession 
no. GSE53986. P rcentage of xplained varianc  (expl. var.) is shown. (b–d) PCA plot of ATMs from obese (HFD-fed) 
vs lean (LFD-fed) mice (four pools of 4–7 HFD- or LFD-fed mice), separated based on the complete transcriptome 
(b) or on expression levels of inflammatory genes (c) or metabolic genes (d). (e, f) Heat maps reflecting expression 
levels of the top 15 most differentially higher (red) or lower (blue) expressed genes involved in glycolysis (e) or 
OXPHOS (f) in ATMs from obese vs lean mice, presented as log2 ratio difference (SLR). (g) Expression levels of 
metabolic genes in peritoneal macrophages and ATMs. The 2−ΔΔCt method was used to determine fold change 
inductions normalised to 36b4. Diet-induced changes in expression levels (HFD vs LFD) were tested for significance. 
(h, i) Lactate production over 24 h by ATMs (h) or peritoneal macrophages (i) from lean (LFD) or obese (HFD) mice. 
Peritoneal macrophages: n = 7 (LFD, white bars) vs n = 6 (HFD, light grey bars) were used for qRT-PCRs and lactate 
measurements (g, i). ATMs: four pools (LFD, dark grey bars) vs six pools (HFD, black bars) of 4–7 mice were used 
for qRT-PCR (g) and a pool of 9 LFD-fed mice vs a pool of 5 HFD-fed mice was used for lactate measurements (n 
= 3) (h). Data are presented as means ± SEM. *p < 0.05, **p < 0.01 and ***p < 0.001, as shown by brackets, or for 
obese vs lean mice in (e, f) 
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Unique metabolic and inflammatory activation of ATMs in obesity 
To examine whether macrophages residing in adipose tissue are transcriptionally distinct 
from other tissue macrophages, we performed a principal component analysis (PCA) using 
publicly available gene expression profiles of macrophages isolated from the peritoneal 
cavity, liver, spleen, lung, intestine and adipose tissue [16]. Indeed, ATMs exhibited unique 
transcriptomes (Fig. 1a). The presence of obesity clearly affected complete transcriptomes 
of ATMs further as demonstrated by distinct clustering of ATMs sorted from obese vs 
lean mice by the pan macrophage-membrane marker Emr1-F4/80 [17, 18] (Fig. 1b). 
Traditionally, macrophages in obese adipose tissue are characterised by an enhanced 
inflammatory state [2]. Using inflammatory genes (ESM Table 2) as input for PCA confirmed 
distinctive inflammatory activation of macrophages residing in obese adipose tissue (Fig. 
1c). Interestingly, expression data for genes involved in glycolysis, OXPHOS and amino acid 
metabolism (ESM Table 2) were also sufficient to distinguish ATMs of obese mice from 
ATMs of lean mice (Fig. 1d), suggestive of robust changes in energy metabolism of ATMs in 
obesity. In fact, many genes involved in glycolysis and OXPHOS were upregulated in ATMs 
from obese vs lean mice (Fig. 1e, f). Noticeably, strong metabolic rewiring upon obesity was 
specific for ATMs, as these changes were not observed in peritoneal macrophages (Fig. 1g, 
i). Indeed, metabolic genes were expressed at much higher levels in ATMs than in peritoneal 
macrophages and were upregulated in obesity (Fig. 1g). In support of our gene expression 
data, ATMs derived from obese vs lean animals produced more lactate ex vivo (Fig. 1h), 
reflective of higher glycolytic rates. By contrast, no robust difference in lactate secretion was 
found in peritoneal macrophages isolated from obese vs lean mice (Fig. 1i). 
Metabolic and inflammatory activation of macrophages in obese adipose tissue 
is distinct from classical activation by LPS and associates with the presence of 
type 2 diabetes in obese humans 
To gain further insight into functional properties of metabolic and inflammatory rewiring 
found in ATMs, gene set enrichment analysis (GSEA) was performed using metabolic and 
inflammatory gene sets as input (ESM Table 3). Overall, far more gene sets were significantly 
(p < 0.01) enriched than depleted (30 vs 2) in ATMs from obese vs lean mice and none of the 
depleted gene sets reflected metabolic pathways. Interestingly, metabolic gene sets including 
glycolysis and OXPHOS were strongly enriched in ATMs upon obesity (Fig. 2a). Noticeably, 
transcriptional regulation in ATMs in obesity was very distinct from classical macrophage 
activation by LPS. Although some pathways were similarly regulated, most metabolic routes, 
including OXPHOS, glycolysis and the pentose phosphate pathway, were less or inversely 
regulated in LPS-activated macrophages compared with ATMs from obese vs lean mice (Fig. 
2b). In line with different metabolic regulation in ATMs vs classically activated macrophages, 
we found diverse regulation of various pro- and anti-inflammatory genes, including Cd11c, 
Myd88, Arg1 and Il-10 (also known as Il10) in ATMs from obese vs lean mice not resembling 
M1 (nor M2) macrophages (Fig. 2c). 
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mice displayed higher rates of OXPHOS (Fig. 3a). Moreover,
a higher glycolytic rate was seen in ATMs from obese mice
(Fig. 3b). Although this difference did not reach statistical
significance, it corroborated the significantly higher levels of
lactate in supernatant fractions of ATMs from obese vs lean
mice after a 24 h culture period (Fig. 1h). As expected based
on previous findings [2, 19–21], ATMs from obese mice pro-
duced more IL-6 and KC than macrophages isolated from lean
adipose tissue (Fig. 3c, d). In contrast, less TNF-αwas secret-
ed by ATMs from obese vs lean mice (Fig. 3e), even though
expression of Tnf was increased in ATMs (Fig. 2c). Of note,
neither IL-1β nor IL-10 could be detected in the supernatant
fractions of ATMs.
Exposing macrophages to adipose tissue explants
ex vivo dose-dependently induces metabolic
activation and cytokine release
To examine whether changes in the adipose tissue environ-
ment drive metabolic and inflammatory activation of ATMs in
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Fig. 2 Metabolic and
inflammatory activation of
macrophages in obese adipose
tissue is distinct from classical
activation by LPS and associates
with the presence of type 2
diabetes in obese humans. (a)
Enriched or depleted (p < 0.01)
KEGG-derived gene sets in
ATMs of obese (HFD; n = 4
pools) vs lean (LFD; n = 4 pools)
mice. (b, d) Regulation of these
enriched or depleted gene sets in
LPS-activated (n = 4) vs untreated
BMDMs (n = 4) (b) or in CD14+
cells from obese diabetic (n = 6)
vs obese non-diabetic individuals
(n = 6) (d). Data presented in (b)
are derived from GEO accession
no. GSE53986 and in (d) from
GSE54350. (c) Heat map
showing expression of genes
involved in inflammation in
ATMs from obese vs lean mice
presented as log2 ratio (SLR)
difference with red representing
upregulation and blue
representing downregulation in
ATMs of HFD- vs LFD-fed mice;
*p < 0.05, **p < 0.01 and
***p < 0.001 for obese vs lean
mice
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Fig. 2 Metabolic and inflammatory activation of macrophages in obese adipose tissue is distinct from classical 
activation by LPS and associates with the presence of type 2 diabetes in obese humans. 
(a) Enriched or depleted (p < 0.01) KEGG-derived gene sets in ATMs of obese (HFD; n = 4 pools) vs lean (LFD; n = 4 
pools) mice. (b, d) Regulation of these enriched or depleted gene sets in LPS-activated (n = 4) vs untreated BMDMs 
(n = 4) (b) or in CD14 cells from obese diabetic (n = 6) vs obese non-diabetic individuals (n = 6) (d). Data presented 
in (b) are derived from GEO accession no. GSE53986 and in (d) from GSE54350. (c) Heat map showing expression 
of genes involved in inflammation in ATMs from obese vs lean mice presented as log2 ratio (SLR) difference with 
red representing upregulation and blue representing downregulation in ATMs of HFD- vs LFD-fed mice; *p < 0.05, 
**p < 0.01 and ***p < 0.001 for obese vs lean mice 
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Interestingly, metabolic activation as found in the ATM part of obese adipose tissue was also 
apparent in CD14+ cells isolated from visceral adipose tissue of obese humans with diabetes 
compared with obese non-diabetic individuals (Fig. 2a, d). 
Functional consequences of metabolic activation of ATMs in obesity 
Next, we evaluated whether transcriptional changes in ATMs translated into differences 
in energy metabolism. To that end, OXPHOS and glycolysis rates of freshly isolated ATMs 
were examined by measuring OCR and ECAR. In line with increased expression of metabolic 
genes, ATMs from obese mice displayed higher rates of OXPHOS (Fig. 3a). Moreover, a higher 
glycolytic rate was seen in ATMs from obese mice (Fig. 3b). Although this difference did 
not reach statistical significance, it corroborated the significantly higher levels of lactate in 
supernatant fractions of ATMs from obese vs lean mice after a 24 h culture period (Fig. 1h). 
As expected based on previous findings [2, 19–21], ATMs from obese mice produced more 
IL-6 and KC than macrophages isolated from lean adipose tissue (Fig. 3c, d). In contrast, less 
TNF-α was secreted by ATMs from obese vs lean mice (Fig. 3e), even though expression of 
Tnf was increased in ATMs (Fig. 2c). Of note, neither IL-1β nor IL-10 could be detected in the 
supernatant fractions of ATMs. 
obesity, we co-cultured BMDMs with lean or obese adipose
tissue for 3 days, removed the adipose tissue and examined the
adipose tissue-induced activation of BMDMs in comparison
with classically (LPS) or alternatively (IL-4) activated
BMDMs both directly (metabolism) and after 24 h in fresh
medium (cytokines). As observed with the ATMs from obese
mice, BMDMs exposed to obese adipose tissue exhibited en-
hanced glycolysis and OXPHOS compared with BMDMs ex-
posed to lean adipose tissue, reflected by increased OCR (Fig.
4a) and ECAR (Fig. 4b). Moreover, BMDMs exposed to
obese adipose tissue secreted more IL-6 and KC and less
TNF-α than BMDMs exposed to lean adipose tissue (Fig.
4c–e), like ATMs from obese vs lean mice (Fig. 3c–e).
Interestingly, inflammatory activation was found to be dose-
dependently induced by the adipose tissue explants and ap-
peared distinct from either LPS- or IL-4-activated macro-
phages (Fig. 4c–e). It is worth noting that metabolic rewiring
followed a similar trend, with a dose-dependent increase in
glycolysis in macrophages exposed to either lean or obese
adipose tissue (ESM Fig. 1a) and higher OXPHOS specifical-
ly in macrophages exposed to 100 mg of obese adipose tissue
(ESM Fig. 1b). Our observation of dose-dependent adipose
tissue-induced activation of macrophages, different from clas-
sical activation, points to a role for specific environmental
cues in driving the unique ATM signatures. Adipose tissue is
a source of leptin [22] and lactate [23] which are known to
affect immune cell metabolism and function [24–26]. Despite
higher levels of both lactate and leptin in the supernatant frac-
tions of adipose tissue explants isolated from obese vs lean
mice (ESM Fig. 1c,d), application of neither leptin nor lactate
could induce metabolic activation comparable with that seen
in macrophages exposed to obese adipose tissue (ESM Fig.
1e,f). Of note, as with ATMs, neither IL-1β nor IL-10 were
detected in supernatant fractions of BMDMs after exposure to
adipose tissue.
Glycolysis largely controls cytokine release by ATMs
in obesity
To examine the contribution of metabolic routes for cytokine
production by ATMs wemeasured IL-6, KC and TNF-α upon
inhibition of glucose uptake (2-DG), fatty acid oxidation
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Fig. 3 Functional consequences of metabolic activation in ATMs dur-
ing obesity. (a, b) Basal OCR (a) or ECAR (b) of freshly isolated ATMs
from obese (HFD) or lean (LFD) mice. (c–e) IL-6 (c), KC (d) or TNF-α
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***p < 0.001
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Fig. 3 Functional consequences of met bolic activation in ATMs during obesity. 
(a, b) Basal OCR (a) or ECAR (b) of freshly isolated ATMs from obese (HFD) or lean (LFD) mice. (c–e) IL-6 (c), KC (d) 
or TNF-α (e) secretion over 24 h by ATMs from HFD- or LFD-fed mice. The ATMs (n ≥ 3) were plated from a pool 
of nine (LFD) or five (HFD) mice. Data are presented as means (c, d, e) ± SEM (a, b). *p < 0.05, **p < 0.01 and ***  
< 0.001 
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Exposing macrophages to adipose tissue explants ex vivo dose-dependently 
induces metabolic activation and cytokine release 
To examine whether changes in the adipose tissue environment drive metabolic and 
inflammatory activation of ATMs in obesity, we co-cultured BMDMs with lean or obese 
adipose tissue for 3 days, removed the adipose tissue and examined the adipose tissue-
induced activation of BMDMs in comparison with classically (LPS) or alternatively (IL-4) 
activated BMDMs both directly (metabolism) and after 24 h in fresh medium (cytokines). 
As observed with the ATMs from obese mice, BMDMs exposed to obese adipose tissue 
exhibited enhanced glycolysis and OXPHOS compared with BMDMs exposed to lean adipose 
tissue, reflected by increased OCR (Fig. 4a) and ECAR (Fig. 4b). Moreover, BMDMs exposed 
to obese adipose tissue secreted more IL-6 and KC and less TNF-α than BMDMs exposed to 
lean adipose tissue (Fig. 4c–e), like ATMs from obese vs lean mice (Fig. 3c–e). Interestingly, 
inflammatory activation was found to be dose-dependently induced by the adipose tissue 
explants and appeared distinct from either LPS- or IL-4-activated macrophages (Fig. 4c–e). 
It is worth noting that metabolic rewiring followed a similar trend, with a dose-dependent 
increase in glycolysis in macrophages exposed to either lean or obese adipose tissue (ESM 
Fig. 1a) and higher OXPHOS specifically in macrophages exposed to 100 mg of obese 
adipose tissue (ESM Fig. 1b). Our observation of dose-dependent adipose tissue-induced 
obesity, we co-cultured BMDMs with lean or obese adipose
tissue for 3 days, removed the adipose tissue and examined the
adipose tissue-induced activation of BMDMs in comparison
with classically (LPS) or alternatively (IL-4) activated
BMDMs both directly (metabolism) and after 24 h in fresh
medium (cytokines). As observed with the ATMs from obese
mice, BMDMs exposed to obese adipose tissue exhibited en-
hanced glycolysis and OXPHOS compared with BMDMs ex-
posed to lean adipose tissue, reflected by increased OCR (Fig.
4a) and ECAR (Fig. 4b). Moreover, BMDMs exposed to
obese adipose tissue secreted more IL-6 and KC and less
TNF-α than BMDMs exposed to lean adipose tissue (Fig.
4c–e), like ATMs from obese vs lean mice (Fig. 3c–e).
Interestingly, inflammatory activation was found to be dose-
dependently induced by the adipose tissue explants and ap-
peared distinct from either LPS- or IL-4-activated macro-
phages (Fig. 4c–e). It is worth noting that metabolic rewiring
followed a similar trend, with a dose-dependent increase in
glycolysis in macrophages exposed to either lean or obese
adipose tissue (ESM Fig. 1a) and higher OXPHOS specifical-
ly in macrophages exposed to 100 mg of obese adipose tissue
(ESM Fig. 1b). Our observation of dose-dependent adipose
tissue-induced activation of macrophages, different from clas-
sical activation, points to a role for specific environmental
cues in driving the unique ATM signatures. Adipose tissue is
a source of leptin [22] and lactate [23] which are known to
affect immune cell metabolism and function [24–26]. Despite
higher levels of both lactate and leptin in the supernatant frac-
tions of adipose tissue explants isolated from obese vs lean
mice (ESM Fig. 1c,d), application of neither leptin nor lactate
could induce metabolic activation comparable with that seen
in macrophages exposed to obese adipose tissue (ESM Fig.
1e,f). Of note, as with ATMs, neither IL-1β nor IL-10 were
detected in supernatant fractions of BMDMs after exposure to
adipose tissue.
Glycolysis largely controls cytokine release by ATMs
in obesity
To examine the contribution of metabolic routes for cytokine
production by ATMs wemeasured IL-6, KC and TNF-α upon
inhibition of glucose uptake (2-DG), fatty acid oxidation
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Fig. 4 Dose-dependent adipose tissue-induced activation of macrophages ex vivo. 
(a, b) Basal OCR (a) and ECAR (b) of BMDMs co-cultured (co AT) with 100 mg of obese (Ob) or lean (Le) adipose 
tissue for 3 days. (c–e) Secretion of IL-6 (c), KC (d) or TNF-α (e) by BMDMs exposed to lean or obese adipose tissue 
(AT), or activated by LPS (M1) or IL-4 (M2). Effects of diet (obese vs lean) and dose of adipose tissue (25 mg vs 100 
mg) were tested for significance. n ≥ 3 for all experiments. Data are presented as means (c, d, e) ± SEM (a, b); 
*p < 0.05, **p < 0.01 
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activation of macrophages, different from classical activation, points to a role for specific 
environmental cues in driving the unique ATM signatures. Adipose tissue is a source of leptin 
[22] and lactate [23] which are known to affect immune cell metabolism and function [24–
26]. Despite higher levels of both lactate and leptin in the supernatant fractions of adipose 
tissue explants isolated from obese vs lean mice (ESM Fig. 1c,d), application of neither leptin 
nor lactate could induce metabolic activation comparable with that seen in macrophages 
exposed to obese adipose tissue (ESM Fig. 1e,f). Of note, as with ATMs, neither IL-1β nor 
IL-10 were detected in supernatant fractions of BMDMs after exposure to adipose tissue. 
Glycolysis largely controls cytokine release by ATMs in obesity 
To examine the contribution of metabolic routes for cytokine production by ATMs we 
measured IL-6, KC and TNF-α upon inhibition of glucose uptake (2-DG), fatty acid oxidation 
(Etomoxir), glucose oxidation (UK5099) or glutamine influx into the tricarboxylic acid cycle 
(BPTES). Minimal morphological changes were observed in ATMs after treatment with 
these compounds. Although several metabolic routes appeared to contribute to cytokine 
release in ATMs from lean mice, overall, 2-DG treatment had the most profound effects 
(Etomoxir), glucose oxidation (UK5099) or glutamine influx
into the tricarboxyli acid cycle (BPTES). Minimal morpho-
logical changes were observed in ATMs after treatment with
these compounds. Although several metabolic routes ap-
peared to contribute to cytokine release in ATMs from lean
mice, overall, 2-DG treatment had the most profound effects
on cytokine release in ATMs from both lean and obese mice
(Fig. 5a–c). Importantly, inhibition of glycolysis with 2-DG
abolished basal differences in cytokine release by ATMs from
obese vs lean mice, demonstrating that glycolysis makes an
important contribution to the increased inflammatory cytokine
production by ATMs in obese adipose tissue (Fig. 5a–c). By
competing with glucose, 2-DG may reduce both lactate pro-
duction and glucose oxidation. Because UK5099 affected cy-
tokine release by ATMs to a lesser extent than 2-DG, likely
anaerobic glycolysis and not glucose oxidation is important
for cytokine secretion by ATMs, especially in the obese state.
Indeed 2-DG was the only inhibitor that strongly reduced
lactate secretion byATMs (Fig. 5d), supporting a link between
lactate production and cytokine release by ATMs, particularly
in obese conditions.
Myeloid-specific Hif-1α does not affect adipose tissue
inflammation in HFD-fed mice
Key metabolic regulators such as AMPK and HIF-1α link
intracellular metabolism to inflammatory activation [14,
27] . Metabol ic s t ress- react ive AMPK enhances
OXPHOS a d fatty acid oxidation upon its activation
through phosphorylation and was clearly induced in mac-
rophages in an obese adipose tissue environment (ESM
Fig. 2a). The transcription factor HIF-1α, a regulator of
genes involved in glycolysis, was predicted to be activat-
ed in ATMs part of obese adipose tissue as well
(Ingenuity Pathway Analysis: z score 2.460, p value over-
lap <0.01). Moreover, Hif-1α itself and its target genes
were upregulated in macrophages in an obese adipose
tissue environment, with higher levels in BMDMs ex-
posed to obese vs lean adipose tissue (Fig. 6a).
Unexpectedly, however, deletion of Hif-1α in myeloid
cells did not affect the inflammatory state of obese adi-
pose tissue after 8 weeks of HFD feeding, as demonstrat-
ed by equal IL-6 secretion by complete adipose tissue
isolated from LysM Hif-1α−/− and LysM Hif-1α+/+ mice,
both basally (Fig. 6b) and upon LPS stimulation (Fig. 6c).
Analysis of macrophage and inflammatory marker expres-
sion (Cd68, Cd11c, Cd206) in the adipose tissue revealed
no protection against adipose tissue inflammation in
HFD-fed mice lacking Hif-1α in the myeloid compart-
ment (data not shown). Moreover, no robust differences
were found in either total body insulin sensitivity (Fig.
6d) or in adipose tissue-specific insulin sensitivity (Fig.
6e) in LysM Hif-1α−/− vs LysM Hif-1α+/+ mice after
8 weeks of HFD feeding. We did observe slightly higher
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Fig. 5 Glycolysis largely controls cytokine release by ATMs during obesity. 
Secretion of IL-6 (a), KC (b), TNF-α (c) or lactate (d) by ATMs isolated from lean (grey circles) or obese (bl ck ci cles) 
mice. Cytokines were measured basally (Ctrl) or upon stimulation of ATMs with various metabolic inhibitors for 
24 h. Effects of diet (obese vs lean) and treatment (metabolic inhibitors vs control) were tested for significance. 
Secretion of TNF-α by ATMs from obese mice tended to be reduced upon treatment with 2-DG (p = 0.06). ATMs 
(n = 3) were plated from a pool of 9 LFD-fed mice and 5 HFD-fed mice. Data are presented as means; *p < 0.05, 
**p < 0.01 and ***p < 0.001 for indicated comparisons (vs Ctrl obese or lean as shown) or for obese vs lean within 
each treatment 
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on cytokine release in ATMs from both lean and obese mice (Fig. 5a–c). Importantly, 
inhibition of glycolysis with 2-DG abolished basal differences in cytokine release by ATMs 
from obese vs lean mice, demonstrating that glycolysis makes an important contribution 
to the increased inflammatory cytokine production by ATMs in obese adipose tissue (Fig. 
5a–c). By competing with glucose, 2-DG may reduce both lactate production and glucose 
oxidation. Because UK5099 affected cytokine release by ATMs to a lesser extent than 2-DG, 
likely anaerobic glycolysis and not glucose oxidation is important for cytokine secretion 
by ATMs, especially in the obese state. Indeed 2-DG was the only inhibitor that strongly 
reduced lactate secretion by ATMs (Fig. 5d), supporting a link between lactate production 
and cytokine release by ATMs, particularly in obese conditions. 
Myeloid-specific Hif-1α does not affect adipose tissue inflammation in HFD-fed 
mice 
Key metabolic regulators such as AMPK and HIF-1α link intracellular metabolism to 
inflammatory activation [14, 27]. Metabolic stress-reactive AMPK enhances OXPHOS and 
fatty acid oxidation upon its activation through phosphorylation and was clearly induced in 
macrophages in an obese adipose tissue environment (ESM Fig. 2a). The transcription factor 
HIF-1α, a regulator of genes involved in glycolysis, was predicted to be activated in ATMs 
part of obese adipose tissue as well (Ingenuity Pathway Analysis: z score 2.460, p value over- 
lap <0.01). Moreover, Hif-1α itself and its target genes were upregulated in macrophages in 
an obese adipose tissue environment, with higher levels in BMDMs ex- posed to obese vs 
lean adipose tissue (Fig. 6a). Unexpectedly, however, deletion of Hif-1α in myeloid cells did 
not affect the inflammatory state of obese adipose tissue after 8 weeks of HFD feeding, as 
demonstrated by equal IL-6 secretion by complete adipose tissue isolated from LysM Hif-1α−/− 
and LysM Hif-1α+/+ mice, both basally (Fig. 6b) and upon LPS stimulation (Fig. 6c). Analysis 
of macrophage and inflammatory marker expression (Cd68, Cd11c, Cd206) in the adipose 
tissue revealed no protection against adipose tissue inflammation in HFD-fed mice lacking 
Hif-1α in the myeloid compartment (data not shown). Moreover, no robust differences were 
found in either total body insulin sensitivity (Fig. 6d) or in adipose tissue-specific insulin 
sensitivity (Fig. 6e) in LysM Hif-1α−/− vs LysM Hif-1α+/+ mice after 8 weeks of HFD feeding. We 
did observe slightly higher glucose levels, as well as a steeper rebound phase of the insulin 
tolerance test, in LysM Hif-1α−/− vs LysM Hif-1α+/+ mice (Fig. 6d), pointing to impaired fasting 
glucose. However, the LysM Hif-1α−/− mice were heavier than the LysM Hif-1α+/+ mice (ESM 
Fig. 2b,c), resulting in higher adipose tissue weight (ESM Fig. 2d), which may have accounted 
for the higher fasting glucose. It is worth noting that differences in body weight could not 
be explained by food intake, which was similar in both genotypes (data not shown), and 
may rather be due to differences in locomotor activity or energy absorption, although this 
requires further study. 
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We observed increased spare respiratory capacity (SRC) of macrophages in an adipose tissue 
environment compared with control macrophages (Fig. 6f), indicative of enhanced cellular 
flexibility and capacity to manage stressful situations [28, 29]. Interestingly, macrophages 
lacking Hif-1α had lower SRC than wild-type BMDMs (Fig. 6g) and appeared to be less 
glycolytic (Fig. 6h, i). The absence of compensation for lower glycolytic rates by Hif-1α−/− 
BMDMs (i.e. by increasing oxygen consumption) (Fig. 6j), is suggestive of reduced metabolic 
capacity and flexibility in the absence of Hif-1α and this may outweigh the potential anti-
inflammatory effects of lower glycolysis in an adipose tissue environment. 
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glucose levels, as well as a steeper rebound phase of the
insulin tolerance test, in LysM Hif-1α−/− vs LysM Hif-
1α+/+ mice (Fig. 6d), pointing to impaired fasting glucose.
However, the LysM Hif-1α−/− mice were heavier than the
LysM Hif-1α+/+ mice (ESM Fig. 2b,c), resulting in higher
adipose tissue weight (ESM Fig. 2d), which may have
accounted for the higher fasting glucose. It is worth not-
ing that differences in body weight could not be explained
by food intake, which was similar in both genotypes (data
not shown), and may rather be due to differences in loco-
motor activity or energy absorption, although this requires
further study.
We observed increased spare respiratory capacity (SRC) of
macrophages in an adipose tissue environment compared with
control macrophages (Fig. 6f), indicative of enhanced cellular
flexibility and capacity to manage stressful situations [28, 29].
Interestingly, macrophages lacking Hif-1α had lower SRC
than wild-type BMDMs (Fig. 6g) and appeared to be less
glycolytic (Fig. 6h, i). The absence of compensation for lower
glycolytic rates by Hif-1α−/− BMDMs (i.e. by increasing ox-
ygen consumption) (Fig. 6j), is suggestive of reduced meta-
bolic capacity and flexibility in the absence of Hif-1α and this
may outweigh the potential anti-inflammatory effects of lower
glycolysis in an adipose tissue environment.
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Fig. 6 Myeloid-specific absence of HIF-1α does not affect adipose
tissue inflammation in HFD-fed mice. (a) Fold change expression of
Hif-1α and its target genes in BMDMs held in L929-conditioned medium
(white bars) or exposed to 100 mg lean adipose tissue explant (grey bars)
or obese adipose tissue explant (black bars) for 3 days. Starting quantities
were used for normalisation against 36b4. (b, c) IL-6 production by
epidydimal adipose tissue isolated from LysM Hif-1α+/+ (+/+) or LysM
Hif-1α−/− (−/−) mice, either unstimulated (b) or stimulated with 10 ng/ml
LPS for 24 h (c). (d) Glucose measured in plasma of LysM Hif-1α+/+
(white circles) or LysM Hif-1α−/− (black circles) mice upon the injection
of insulin at 0 min. (e) Total Akt (t-Akt) and p-Akt protein levels in
epidydimal adipose tissue from LysM Hif-1α+/+ or LysM Hif-1α−/− mice
unstimulated (−) or stimulated with insulin (+) for 20 min. (f) SRC as
percentage increase from basal OCR in BMDMs in 5% (vol./vol.) L929
(Ctrl) or upon 3 days of co-culture (co AT) with 100 mg adipose tissue
isolated from lean (Le) or obese (Ob) mice. (g) SRC as percentage in-
crease from basal OCR in BMDMs isolated from LysM Hif-1α+/+ (+/+)
or LysM Hif-1α−/− (−/−) mice. (h) Lactate secretion over 24 h by
BMDMs isolated from LysM Hif-1α+/+ (+/+) or LysM Hif-1α−/− (−/−)
mice. (i, j) Basal ECAR (i) and OCR (j) in BMDMs fromLysMHif-1α+/+
(+/+) or LysMHif-1α−/− (−/−) mice. Basal ECARwere lower in BMDMs
of LysM Hif-1α−/− vs LysM Hif-1α+/+ mice (although the difference did
not reach statistical significance, p < 0.051). For the in vivo study, n = 8
animals per genotype/diet were included. n = 3 for all in vitro experi-
ments. Data are presented as means ± SEM. *p < 0.05, **p < 0.01 and
***p < 0.001
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Fig. 6 Myeloid-specific absence of HIF-1α does not affect adipose tissue inflammation in HFD-fed mice. 
(a) Fold change expression of Hif-1α and its target genes in BMDMs held in L929-conditioned medium (white bars) 
or exposed to 100 mg lean adipose tissue explant (grey bars) or obese adipose tissue explant (black bars) for 3 
days. Starting quantities were used for normalisation against 36b4. (b, c) IL-6 production by epidydimal adipose 
tissue isolated from LysM Hif-1α+/+
 
(+/+) or LysM Hif-1α−/−
 
(−/−) mice, either unstimulated (b) or stimulated with 
10 ng/ml LPS for 24 h (c). (d) Glucose measured in plasma of LysM Hif-1α+/+ (white circles) or LysM Hif-1α−/− (black 
circles) mice upon the injection of insulin at 0 min. (e) Total Akt (t-Akt) and p-Akt protein levels in epidydimal 
adipose tissu  from LysM Hif-1α+/+
 
or LysM Hif-1α−/− mice unstimulated (−) or stimulated with insulin (+) for 20 min. 
(f) SRC as percent ge increase from basal OCR in BMDMs in 5% (vol./vol.) L929 (Ctrl) or upon 3 day  of co-culture 
(co AT) with 100 mg a ipose tissue isolated from lean (Le) or obese (Ob) mice. (g) SRC as percentage in rease from 
basal OCR in BMDMs isolated from LysM Hif-1α+/+
 
(+/+) or LysM Hif-1α−/−
 
(−/−) mice. (h) Lactate secretion over 24 h 
by BMDMs isolated from LysM Hif-1α+/+
 
(+/+) or LysM Hif-1α−/−
 
(−/−) mice. (i, j) Basal ECAR (i) and OCR (j) in BMDMs 
from LysM Hif-1α+/+
 
(+/+) or LysM Hif-1α−/−
 
(−/ ) mice. Basal ECAR were lower in BMDMs of LysM Hif-1α−/−
 
vs LysM 
Hif-1α+/+
 
mice (although the difference did not reach statistical significance, p < 0.051). For the in vivo study, n = 8 
animals per genotype/diet were included. n = 3 for all in vitro experi- ments. Data are presented as means ± SEM. 
*p < 0.05, **p < 0.01 and ***p < 0.001 
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DISCUSSION 
In obesity, macrophages fuel adipose tissue inflammation, promoting the development of 
insulin resistance and type 2 diabetes [30]. The inflammatory state of ATMs has been studied 
extensively. To our knowledge, however, we are the first to measure real-time metabolic 
fluxes in freshly isolated ATMs. Interestingly, our data strongly point to unique metabolic 
activation that drives cytokine release by ATMs in obesity, resembling neither the metabolic 
nor inflammatory signatures seen in M1- or M2-primed macrophages or peritoneal 
macrophages. 
Cumulative evidence from the field of immunology shows that robust metabolic 
rewiring fuels differential inflammatory activation of macrophages. On the one hand, M2 
macrophages require OXPHOS for responses, whereas M1 macrophages rely on aerobic 
glycolysis [11, 12]. In contrast to these two extremes, we found that macrophages in an 
adipose tissue environment adopt a unique metabolic profile in obesity, characterised by 
activation of various metabolic routes including both OXPHOS and glycolysis. Metabolic and 
inflammatory adaptations in obesity were specific for ATMs, as no metabolic rewiring was 
found in peritoneal macrophages. In line with our finding of unique metabolic rewiring in 
ATMs and supportive of various studies reporting diverse inflammatory activation of ATMs 
in obese adipose tissue [9, 16, 31, 32], we found inflammatory activation of ATMs to be 
different from that of classically activated macrophages. 
Interestingly, macrophages co-cultured with obese adipose tissue developed similar 
phenotypical adaptations in a dose-dependent manner, suggestive of obesity-induced 
changes in the adipose tissue microenvironment shaping the ATM phenotype. Indeed, the 
composition of adipose tissue is importantly affected in obesity, with resultant adipocyte 
hypertrophy and both accumulation and phenotypical changes of immune cells including 
macrophages. In our co-culture system we have used lean and obese adipose tissue explants 
of equal weight. This may not have accounted for all the shifts in relative cell numbers 
occurring in obese adipose tissue, yet strongly points toward the existence of divergent 
factors secreted by obese vs lean adipose tissue that may critically influence the macrophage 
phenotype in a dose-dependent manner. Potential factors may include adipokines, cytokines, 
fatty acids or other metabolites [30]. Interestingly, leptin [24, 25] and lactate [26] have been 
shown capable of remodelling intracellular metabolism and changing the inflammatory state 
of macrophages. We found both to be secreted more by obese adipose tissue than by lean 
adipose tissue, yet neither leptin nor lactate induced metabolic rewiring similar to that seen 
in macrophages in an adipose tissue environment. Additionally, differences in cell death 
between lean and obese adipose tissue in vivo may have an effect on metabolic rewiring 
in macrophages. Most likely, a mixture of signals is responsible for shaping ATM metabolic 
phenotypes in the lean and obese state, although this needs further investigation. 
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Importantly, metabolic activation of ATMs contributes to their inflammatory cytokine 
release. First, metabolically active ATMs from obese mice secreted far more IL-6 and KC 
than the less metabolically active ATMs isolated from lean mice. Second, we found that 
interference with metabolic routes directly affected cytokine release by ATMs. Especially in 
ATMs from lean mice, several metabolic routes including fatty acid oxidation, glycolysis and 
glutaminolysis contribute to cytokine release. Glycolysis appears to play a dominant role in 
fuelling the inflammatory trait of ATMs from obese adipose tissue, since inhibiting glycolysis 
with 2-DG almost completely abolished the greater basal cytokine secretion by ATMs from 
obese vs lean mice. 
Our finding of lower TNF-α secretion by ATMs from obese vs lean mice was unexpected, 
as was the lower level of TNF-α in supernatant fractions of macrophages exposed to obese 
vs lean adipose tissue. Despite lower cytokine levels, we found Tnf upregulated at the mRNA 
level. A similar discrepancy between mRNA and protein level has been reported in ATMs 
before [10]. In obese adipose tissue, however, macrophage influx and proliferation as well 
as an increase in other immune cell populations likely overrules lower TNF-α secretion per 
macrophage and might be responsible for higher TNF-α levels found in the adipose tissue and 
circulation of obese individuals [6, 33–35]. Alternatively, enhanced autocrine TNF signalling 
in ATMs may explain the lower levels of TNF-α measured in ATM supernatant fractions. 
Next to cytokine release, intracellular metabolism most likely controls several other 
macrophage functions. For example, OXPHOS has been found to contribute to phagocytosis 
by human monocytes [36], and lysosomal biogenesis and function in T cells [37]. Both 
phagocytic and lysosomal genes were found to be strongly upregulated in ATMs of obese 
mice and in obese individuals with type 2 diabetes. Phagocytosis of dead adipocytes 
by macrophages [38–40] and lysosomal function of ATMs [10, 39] are considered to be 
important for maintaining adipose tissue homeostasis. Hence, the obesity-induced increase 
in OXPHOS might fuel ATM functions in expanding adipose tissue, not directly related to 
inflammatory cytokine release yet may greatly affect adipose tissue function. 
Our data show that interfering with metabolic routes alters the inflammatory phenotype of 
ATMs and that glycolysis importantly contributes to inflammatory cytokine release by ATMs. 
Unexpectedly, however, myeloid-specific deletion of a previously identified key regulator of 
glycolysis, Hif-1α, did not alleviate inflammatory activation of ATMs during the early stages 
of obesity. Because mice lacking Hif-1α in myeloid cells were significantly heavier yet did 
not display increased adipose tissue inflammation or insulin resistance, one could speculate 
that HIF-1α may be partly protective for the development of obesity-induced adipose tissue 
inflammation, as has been reported before in mice fed an HFD for 18 weeks [41]. One might 
also hypothesise that during the earlier stages of HFD-induced obesity HIF-1α is important for 
controlling other metabolic properties of macrophages not related to cytokine production. 
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For example, our data revealed a decreased SRC in BMDMs from Hif-1α−/− mice, suggestive 
of a role for HIF-1α in maintaining metabolic flexibility of macrophages. Indeed, despite 
decreased capability of using glycolysis as an energy source, Hif-1α−/− macrophages lack the 
flexibility to increase their oxidative capacity [15]. Metabolic flexibility is probably needed for 
ATMs, as we observed enhanced SRC in macrophages in an adipose tissue environment which 
was even further in- creased upon exposure to obese adipose tissue. Reduced metabolic 
flexibility in macrophages lacking Hif-1α in expanding adipose tissue might have overruled 
effects on cytokine release during the development of obesity. 
In conclusion, we identified unique metabolic activation of ATMs in obesity, characterised 
by increased OXPHOS and glycolysis. Blocking metabolic routes in isolated ATMs led to the 
identification of glycolysis as a main contributor to their proinflammatory trait, especially 
in obesity. Interestingly, metabolic signatures, similar to those found in ATMs upon 
obesity, including the induction of OXPHOS and lysosomal genes, were observed in human 
macrophages isolated from adipose tissue of obese individuals with type 2 diabetes. Further 
understanding of metabolic programming in ATMs will most likely lead to novel therapeutic 
targets to modulate macrophage metabolism and curtail inflammatory responses that drive 
insulin resistance and type 2 diabetes in obese individuals. 
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SUPPLEMENTARY METHODS (ESM)
Collection of adipose tissue and macrophages
After cervical dislocation, epididymal adipose tissue was removed and fixated for 
immunohistochemistry, fresh-frozen for RNA isolation, or processed sterile to separate the 
stromal vascular fraction (SVF) from adipocytes using collagenase digestion as described 
previously [1]. Adipose tissue macrophages (ATMs) were purified from the stromal vascular 
fraction by F4/80+ positive selection with magnetic beads (Milteny Biotec, Leiden, The 
Netherlands). Cell pellets were frozen directly for RNA isolation, or were re-suspended and 
brought into culture in RPMI 1640 (Lonza, Verviers, Belgium) supplemented with 10% vol./vol. 
FCS and 1% vol./vol. PS (RPMI/FCS/PS). Peritoneal macrophages were obtained by infusion 
and subsequent collection of ice-cold PBS from the abdominal cavity, and frozen directly 
or brought into culture in Dulbecco’s modified eagle’s medium (Lonza) supplemented with 
10% vol./vol. FCS and 1% vol./vol. PS (DMEM/FCS/PS). Bone marrow cells were isolated from 
femurs and tibia of low-fat diet- or chow-fed mice following a standard protocol. 
Extracellular flux analysis
Basal metabolic rates of ATMs or bone marrow-derived macrophages (BMDMs) seeded 
in quintuplicate were determined during four consecutive measurements in unbuffered 
Seahorse medium (8.3 g DMEM powder, 0.016 g phenol red and 1.85 g NaCl in 1 l milli-Q, pH 
set at 7.4 at 37 °C; sterile-filtered) containing 11 mmol/l glucose (ATMs) or 25 mmol/l glucose 
(BMDMs) and 2 mmol/l L-glutamine (ATMs & BMDMs). After basal measurements, three 
consecutive measurements were taken upon the addition of each 1.5 µmol/l oligomycin, 1.5 
mmol/l FCCP, and 2 µmol/l antimycin together with 1 µmol/l rotenone. Pyruvate (1 mmol/l) 
was added together with FCCP to fuel maximal respiration. Spare Respiratory Capacity 
was calculated as percentage increase in OCR after FCCP injection, with basal OCR set at 
100%. All compounds used during the Seahorse runs were acquired from Merck. Signals 
were normalized to relative DNA content in the wells using the Quant-iT™ dsDNA Assay Kit 
(ThermoFisher Scientific).
Western blot 
Cells were lysed in RIPA buffer (ThermoFisher Scientific, Landsmeer, The Netherlands) 
enriched with protease and phosphatase inhibitors (Roche Diagnostics). Total protein was 
determined using a BCA protein assay (ThermoFischer Scientific) and for each sample 15 µg 
of protein was loaded on a 4-15% Mini-PROTEAN TGX Precast gel (Bio-Rad). Proteins were 
separated by SDS gel electrophoresis and transferred to a PVDF membrane (Bio-Rad) using 
the Transblot Turbo System (Bio-Rad). All incubations were in Tris-buffered saline with 0.1% 
vol./vol. Tween-20 (TBS-T), containing 5% weight/vol. dry milk (β-actin) or 5% weight/vol. 
bovine serum albumin (AMPK, phospho-AMPK, phospho-Akt). HRP-conjugated goat-anti-
rabbit secondary Ab (Merck) was used 1:5000 in TBS-T with 5% weight/vol. dry milk. Blots 
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were visualized using the ChemiDoc MP system (Bio-Rad) and Clarity ECL substrate (Bio-Rad).
RNA isolation and qPCR
Total RNA of ATMs and peritoneal macrophages was isolated with a RNeasy mini- or microkit 
(Qiagen, Venlo, The Netherlands). RNA of BMDMs was isolated using phenol/chloroform 
extraction. The RNA was reverse transcribed with the iScript cDNA synthesis kit (Bio-Rad). 
Real-time quantitative PCR was carried out with a SensiMix SYBR kit (Bioline, Alphen aan 
den Rijn, The Netherlands) in a CFX384 system (Bio-Rad). Relative expression levels were 
calculated after normalization against the housekeeping gene 36b4 using the tC2 �� method 
(ATMs and peritoneal macrophages) or starting quantities (BMDMs). Primer sequences can 
be found in ESM Table 1. For qPCR analysis, four pools of ATMs from LFD-fed, and six pools 
of ATMs from HFD-fed mice were used. Peritoneal macrophages of seven individual mice on 
a LFD and six mice on a HFD were included. 
Microarray analysis and interpretation
Purified total RNA (100 ng per sample) was labelled with the Whole-Transcript Sense Target 
Assay (Affymetrix, Santa Clara, CA, USA; P/N 900652) and hybridized to whole-genome 
Affymetrix Mouse Gene 1.1 ST arrays (Affymetrix). Quality control and data analysis pipeline 
have been described in detail previously [2]. Briefly, normalized expression estimates of probe 
sets were computed by the robust multiarray analysis (RMA) algorithm [3, 4] as implemented 
in the Bioconductor library AffyPLM. Probe sets were redefined according to Dai et al. [5] 
based on annotations provided by the Entrez Gene database, which resulted in the profiling 
of 21,187 unique genes (custom CDF v20). Differentially expressed probe sets (genes) were 
identified by using linear models (library limma) and an intensity-based moderated t-statistic 
[6, 7]. Probe sets that satisfied the criterion of p<0.01 were included for Ingenuity Pathway 
Analysis. The Affymetrix dataset (GSE53986) was reanalysed as described above. The 
Illumina BeadChip experiments (GSE56682 and GSE54350) were reanalysed by background 
correction followed by quantile normalization (neqc) [8], removal of unspecific probes [9], 
where after differentially expressed probes were identified using limma [6, 7]. Principle 
component analysis (PCA) was performed in R using the library mixOmics [10]. Changes in 
gene expression were related to biologically meaningful changes using gene set enrichment 
analysis [11]. Only gene sets comprising more than 15 and fewer than 500 genes were taken 
into account. For each comparison, genes were ranked on their t-value that was calculated 
by the moderated t-test. Statistical significance of GSEA results was determined using 1000 
permutations. The library clusterProfiler was used for visualization and interpretation of the 
GSEA results [12]. 
GSE56682
Peritoneal macrophages: F4/80+ and CD11b+ selection
Alveolar macrophages: CD11b+ and CD11c+ selection
Splenic macrophages: F4/80+ and CD11b+ selection 
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Kupffer cells: F4/80+ and CD11b+ selection 
Intestinal macrophages: F4/80+ CD11b+ selection
GSE54350
Adipose tissue macrophages: CD14+ selection 
A total of n=6 subjects were used per group. The obese individuals part of each study group 
were age- and sex-matched.
GSE53986
Untreated (n=4) versus LPS-stimulated (n=4) (10 ng/mL for 24 h) bone marrow-derived 
macrophages. 
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SUPPLEMENTARY TABLES AND FIGURES (ESM)
Gene 3' primer 5' primer
Cd11c CTGGATAGCCTTTCTTCTGCTG GCACACTGTGTCCGAACTCA
Cd206 GCTTCCGTCACCCTGTATG GTGTGTCATTCTTACACTCCCAT
Cd36 TCCAGCCAATGCCTTTGC TGGAGATTACTTTTCAGTGCAGAA
Cd68 CCAATTCAGGGTGGAAGAAA CTCGGGCTCTGATGTAGGTC
Glut1 GGTCACCATCTTGGAGCTGTTC ACCTGCCTTCTCGAAGATGCT
Hk2 CGTGTCCCTACCTTTGGGTT CCAGGTCAAACTCCTCTCGC
Hif-1α ACCTTCATCGGAAACTCCAAAG CTGTTAGGCTGGGAAAAGTTAGG
Ldhα CATTGTCAAGTACAGTCCACACT TTCCAATTACTCGGTTTTTGGGA
Lipa TGTTCGTTTTCACCATTGGGA CGCATGATTATCTCGGTCACA
Pdk4 TCTACAAACTCTGACAGGGCTTT CCGCTTAGTGAACACTCCTTC
Plin2 GCCTCTCAACTGGCTGGTAG ACAGCAAAAGGGGTCATCTG
Vegfα CGGGCCTCGGTTCCAG CTGGGACCACTTGGCATGG
36B4 ATGGGTACAAGCGCGTCCTG GCCTTGACCTTTTCAGTAAG
ESM Table 1
Primer sequences used to measure gene expression levels with qPCR.
Gene set BSID
Inflammatory activation 511699 & 511700
OXPHOS 83142
Glycolysis 198376
Amino acid metabolism 101155 & 83157
ESM Table 2
KEGG-derived biosystems used for principle component analyses.
ESM Table 3
KEGG networks used as input for gene set enrichment analyses.
KEGG pathway Network
Metabolism 1.0-1.8
Genetic information processing 2.3-2.4
Environmental information processing 3.1-3.2
Cellular processes 4.1
Organismal systems 5.1-5.2
Human diseases 6.7
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ESM Fig. 1 Leptin and lactate are secreted by obese adipose tissue yet do not skew macrophage metabolism 
towards the adipose tissue-induced phenotype
(a,b) Basal extracellular acidification rate (ECAR) (a) or oxygen consumption rate (OCR) (b) measurements of 
BMDMs in 5% vol./vol. L929 (Ctrl) or exposed to 25 mg or 100 mg lean (Le) or obese (Ob) adipose tissue (AT) for 3 
days. (c,d) Leptin (c) and lactate (d) measured in supernatants of a 3-day culture of 100 mg lean or obese adipose 
tissue. (e,f) OCR (e) and ECAR (f) of BMDMs exposed to leptin or lactate for 24 h were compared to BMDMs 
exposed to 5% vol./vol. L929 (-). n=3 for all experiments. Data are presented as means ± SEM. * p<0.05, ** p<0.01, 
*** p<0.01.
Metabolic activation of adipose tissue macrophages in obesity
105
4
a
b
+/+ -/-
0
1
2
3
A
di
po
se
 ti
ss
ue
 w
ei
gh
t (
g) *
AMPK
P-AMPK
+ Lean AT + Obese AT
Actin
1 2 3 4 5 6 7 8
0
20
25
30
35
40
45
HFD intervention (wk)
B
od
y 
w
ei
gh
t (
g)
*
* *
*
* *
* *
1 2 3 4 5 6 7 8
90
100
110
120
130
140
HFD intervention (wk)
B
od
y 
w
ei
gh
t g
ai
n 
(%
)
c d
ESM Fig. 2 Higher bodyweight and adipose tissue weight in LysM Hif-1α-/- vs LysM Hif-1α+/+ mice fed a HFD for 8 
weeks
(a) Presence of phospho-AMPK (P-AMPK) and AMPK protein levels in BMDMs exposed to 100 mg of obese or 
lean adipose tissue (AT) for 3 days. Actin serves as loading control. (b,c) Bodyweight (b) and bodyweight gain (c) 
of LysM Hif-1α+/+ and LysM Hif-1α-/- mice over the 8-week high-fat diet (HFD) intervention period. (d) Epidydimal 
adipose tissue weight of LysM Hif-1α+/+ and LysM Hif-1α-/- mice after 8 weeks on a HFD. White bars or circles; LysM 
Hif-1α+/+, black bars or circles; LysM Hif-1α-/-. Data are presented as means ± SEM. * p<0.05.
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ABSTRACT
Macrophages are key players in the development of adipose tissue inflammation during 
obesity. In addition to free fatty acids (FFAs) present in the adipose tissue that can be readily 
taken up, adipose tissue macrophages (ATMs) are also exposed to triglycerides (TGs) that 
require hydrolysis by the enzyme lipoprotein lipase (LPL) to allow for FA uptake. To learn more 
about the relevance of this pathway we studied macrophages in lipid-rich environments 
including the adipose tissue, and particularly examined inflammatory responses. In addition, 
we explored the relevance of angiopoietin-like 4 (ANGPTL4), a well-known endogenous 
inhibitor of LPL, for macrophages in a lipid-enriched environment. 
Compared to other tissue macrophages, ATMs displayed enhanced expression of 
various genes involved in lipid uptake and handling, including Lpl. High fat diet-feeding 
promoted further upregulation of Lpl accompanied by the presence of ER stress and 
increased expression of various pro-inflammatory genes. In vitro, culturing BMDMs in 
adipose tissue-conditioned medium induced a similar pro-inflammatory response and led 
to metabolic activation of macrophages, a specific phenotype of macrophages residing 
in  obese adipose tissue. Interestingly, Angptl4, the endogenous inhibitor of LPL, was also 
strongly enhanced in BMDMs residing in lipid-rich environments suggestive of the presence 
of a negative feedback mechanism to limit LPL activity and thus excessive uptake of FAs from 
TGs. Indeed, absence of Angptl4 in macrophages led to increased inflammatory responses 
during exposure to adipose tissue-conditioned medium. However, these effects appeared to 
be independent from lipid uptake. To further evaluate the specific contribution of TGs, we 
treated macrophages with Intralipid, a TG emulsion. Intralipid boosted Angptl4 expression 
and led to metabolic activation of macrophages similarly to adipose tissue-conditioned 
medium. In macrophages exposed to Intralipid, however, absence of Angptl4 did increase 
lipid loading but only partially prevented pro-inflammatory responses. 
In conclusion, our results demonstrate that TGs drive metabolic activation of 
macrophages. Although ANGPTL4 is involved in modulating inflammatory activation of 
macrophages, its mode of action appears to be independent of LPL-inhibition and control 
of lipid uptake. 
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INTRODUCTION
Macrophages populate various tissues throughout our body adopting different phenotypes 
and performing different functions driven by local environmental cues (1). The adipose tissue 
encompasses a microenvironment dominated by lipids. In addition to high levels of free fatty 
acids (FFAs) released by adipocytes during lipolysis (2, 3), adipose tissue macrophages (ATMs) 
are also exposed to triglycerides (TGs) either originating from circulating lipoproteins or from 
adipocytes undergoing turnover and clearance (4-7). During health, ATMs actively participate 
in maintaining tissue homeostasis by performing several tasks including the direct regulation 
of adipocyte lipolysis and lipid buffering for gradual release into the bloodstream (3, 8).  
In contrast to their contribution to adipose tissue homeostasis in the lean state, 
ATMs populating obese adipose tissue promote inflammation that ultimately contributes 
to the development of metabolic abnormalities including Type 2 Diabetes (9). Lipotoxicity 
as a consequence of lipid overloading in obese adipose tissue may be the culprit for the 
inflammatory trait of ATMs residing in obese adipose tissue (7). Indeed, the foam-cell-like 
appearance of macrophages in obese adipose tissue is similar to that seen in macrophages 
residing in atherosclerotic plaques in which excessive oxLDL uptake drives inflammatory 
activation (10). 
Fatty acids activate multiple inflammatory pathways in macrophages. Extracellularly, they 
have been shown to activate Toll-like receptor (TLR)-signalling either via fetuin A-dependent 
binding of TLR4 (11), or through binding to other receptors that may stimulate TLR signalling, 
as has been shown for CD36 in atherosclerosis (12, 13). Intracellularly, FAs can induce ROS 
accumulation (14) and ER stress (15). As a result, the NLRP3 inflammasome is activated to 
induce caspase-1 cleavage and promoting inflammatory responses in macrophages and 
adipose tissue (15-17). 
Although the effects of FFAs on macrophage activation are well-studied, much less is 
known about TGs, that are unable to pass the cellular membrane and first require hydrolysis. 
This process is tightly controlled by the enzyme lipoprotein lipase (LPL) that facilitates TG 
hydrolysis in various cell types including macrophages. In the vessel wall, LPL present in 
macrophages has been shown to be involved in the uptake of atherogenic lipoproteins (18-
20). Absence of LPL in macrophages protects against atherosclerotic lesion development 
whereas overexpression enhances atherosclerosis progression (18-20).
Angiopoietin-like 4 (ANGPTL4) controls LPL activity via mechanisms involving dimer-
to-monomer conversion of the LPL protein and competitive inhibition (21, 22). Indeed, 
ANGPTL4 has been shown to be involved in preventing lipid loading of macrophages in the 
arterial wall (23, 24), as well as in macrophages residing in mesemteric lymph nodes (25, 26). 
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We set out to study the contribution of TG-mediated lipotoxicity in macrophages residing 
in in a lipid-rich environment including the adipose tissue, and examined the involvement 
of ANGPTL4. Our results demonstrate profound regulation of various genes involved in lipid 
uptake, including Lpl and the fatty acid transporter Cd36, in macrophages in an adipose 
tissue environment. Pro-inflammatory ATMs of obese mice displayed further regulation of 
these genes involved in lipid handling and activation of ER stress, pointing to lipid-induced 
toxicity and inflammatory activation of ATMs during obesity. Interestingly, Angptl4 was 
robustly upregulated in macrophages in lipid-rich environments including that of the adipose 
tissue, suggestive of a role for ANGPTL4 in limiting aberrant lipid uptake by ATMs. However, 
in contrast to macrophages in a pure TG-enriched environment in which ANGPTL4 inhibited 
lipid loading, we observed no differences in lipid loading or handling between Angptl4-/- 
and wild-type macrophages exposed to adipose tissue-conditioned medium. Interestingly, 
ANGPTL4 appeared to modulate inflammatory responses in an adipose tissue environment 
independent of its role in controlling macrophage FA uptake from TGs. 
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MATERIALS AND METHODS
Mice
All cells or tissues were isolated from four to six months old male Angptl4 knock-out 
(Angptl4-/-) (27) or wild-type (Angptl4+/+) mice that had been on a C56BL/6J background for 
more than 10 generations.
Twelve weeks old male wild-type and Angptl4-/- mice were intraperitoneally injected with 
10 µg/gram bodyweight of ultrapure lipopolysaccharide (LPS) (Sigma-Aldrich, Darmstadt, 
Germany) or an equal volume of PBS. Mice were euthanized 48 hours after LPS injection, 
and the adipose tissue and liver were collected for qPCR analysis. The study protocol was 
approved by the Animal Ethics Committee at Wageningen University.
Cell culture
Bone marrow cells were isolated from femurs of wild-type or Angptl4-/- mice following 
standard protocol and differentiated into macrophages (BMDMs) during 6-8 day culturing 
in Dulbecco’s modified eagle’s medium (DMEM; Lonza, Verviers, Belgium) containing 10% 
Foetal Calf Serum (FCS) and 1% Penicyllin Streptomycin (PS) (DMEM/FCS/PS) supplemented 
with 10% L929-conditioned medium (L929). After 6-8 days non-adherent cells were removed 
and adherent cells were washed and plated in 6-, 12-, 24-, or 48-wells plates in DMEM/FCS/
PS + L929. After 24 hours, the cells were washed with PBS and received their treatment in 
culture medium without L929 and FCS (DMEM/PS). 
Intralipid
Bone marrow-derived macrophages were exposed to 1-2 mM Intralipid (Sigma-Aldrich) in 
DMEM/PS for 6 hours as indicated at each figure. Orlistat (Sigma-Aldrich) was used at a 
concentration of 25 µM and was co-incubated with Intralipid for the same period of time. 
Adipose tissue-conditioned medium
Epididymal adipose tissue from wild-type mice was isolated, minced in sterile conditions, 
and brought into culture for 48 hours in DMEM/PS containing 1% free fatty acid-free BSA 
(Sigma-Aldrich) to generate conditioned medium (CM AT). BMDMs were exposed to 75% of 
CM AT in DMEM/PS, or DMEM/PS containing 0.75% BSA (Cntrl). 
Adipocytes
Human Simpson-Golabi-Behmel syndrome (SGBS) cells were maintained in DMEM/F12 
(Lonza) supplemented with 10% FCS, 1% PS, 33 µM Biotin (Sigma-Aldrich) and 17 µM 
panthotenat (Sigma-Aldrich), and differentiated into adipocytes over a period of 21 days as 
has been described previously (28). Differentiated SGBS cells were exposed to 25 mJ/cm2 
UV-C light using a Stratalinker 1800 UV cross linker (Stratagene (Agilent), Middelburg, The 
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Netherlands) to induce cell death, and left in culture for 18 hours before they were collected 
using trypsin, pelleted with centrifugation, dissolved in DMEM/FCS/PS and co-cultured with 
BMDMs for 24 hours in a 1:1 ratio (for more information see Chapter 6). 
LPS
Bone marrow-derived macrophages treated with Intralipid or CM AT (or corresponding 
controls) were washed with PBS and subsequently challenged with 1 ng/mL LPS (Sigma-
Aldrich) in fresh culture medium (DMEM/FCS/PS) for an additional 24 hours.
Microscopy
For visualization of lipid droplets, treated BMDMs of Angptl4+/+ and Angptl4-/- mice were 
washed with PBS, fixated in 4% formaldehyde, and subsequently stained with 1 ng/mL 
bodipy (ThermoFisher Scientific, Landsmeer, The Netherlands). Lipid droplets in adipose 
tissue macrophages from low-fat (LFD) versus high-fat diet (HFD)-fed mice were visualized 
using bright light. 
Extracellular flux analysis
Real-time oxygen consumption rates (OCR) and extracellular acidification rates (ECAR) of wild-
type or Angptl4-/- BMDMs were analysed using an XF-96 Extracellular Flux Analyzer (Seahorse 
Bioscience, Santa Clara, CA, USA). Basal metabolic rates of BMDMs seeded in quintuplicate 
were determined during three consecutive measurements in unbuffered Seahorse medium 
(8.3 g DMEM powder, 0.016 g phenol red and 1.85 g NaCl in 1 L milli-Q, pH set at 7.4 at 
37 °C; sterile-filtered) containing 25 mmol/l glucose and 2 mmol/l L-glutamine. After basal 
measurements, three consecutive measurements were taken upon the addition of each 
1.5 µmol/l oligomycin, 1.5 mmol/l carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone 
(FCCP), and 2 µmol/l antimycin together with 1 µmol/l rotenone. Pyruvate (1 mmol/l) was 
added together with FCCP to fuel maximal respiration. All compounds used during the 
Seahorse runs were acquired from Merck. Signals were normalized to relative DNA content 
in the wells using the Quant-iT™ dsDNA Assay Kit (ThermoFisher).
Cytokine measurements
Levels of TNF-α, IL-6 and IL-10 were measured in cell culture supernatants with murine 
DuoSet ELISA Development kits (R&D Systems, Abingdon, UK).
RT-qPCR
Total RNA was isolated using TRIzol (ThermoFisher), either via phenol/chloroform extraction 
(BMDMs), or with the RNeasy microkit (Qiagen, Venlo, The Netherlands) (epididymal adipose 
tissue and liver of Angptl4+/+ and Angptl4-/- mice). Reverse transcription was executed using 
the iScript cDNA synthesis kit (Bio-rad, Veenendaal, The Netherlands). Real-time quantitative 
PCR was carried out with a SensiMix SYBR kit (Bioline, Alphen aan den Rijn) in a CFX384 
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system (Bio-rad). Relative expression levels were calculated after normalization against 
the housekeeping gene 36B4 using the ΔΔC(t) method. Primer sequences can be found in 
supplementary Table 1.
Western blot 
Cells were lysed in RIPA buffer (ThermoFisher) enriched with protease and phosphatase 
inhibitors (Roche Diagnostics). Total protein was determined using a BCA protein assay 
(ThermoFischer) and for each sample 15-60 µg of protein was loaded on a 10% Criterion 
TGX Precast Midi protein gel (Bio-Rad). Proteins were separated by SDS gel electrophoresis 
and transferred to a PVDF membrane (Bio-Rad) using the Transblot Turbo System (Bio-
Rad). Primary antibodies for spliced XBP1 (AB_2562960; BioLegend, London, UK) and CHOP 
(Ab11419; Abcam, Cambridge, UK) were used at a ratio of 1:1000 and incubated overnight at 
4 ⁰C. All incubations were in Tris-buffered saline with 0.1% v/v Tween-20 (TBS-T), containing 
5% w/v dry milk. HRP-conjugated rabbit-anti-mouse secondary antibody (Merck) was used 
1:5000 in TBS-T with 5% w/v dry milk. Blots were visualized using the ChemiDoc MP system 
(Bio-Rad) and Clarity ECL substrate (Bio-Rad).
Microarray analysis
Four pools of ATMs isolated from epididymal adipose tissue of male C57Bl/6 mice fed a LFD 
or HFD diet in four separate experiments (ATMs HFD vs. LFD) were subjected to expression 
profiling by microarray. Moreover, complete RNA from CD14+ monocytes isolated from the 
blood, and subcutaneous (SAT) or visceral adipose tissue (VAT) of five healthy donors was 
used for microarray analysis, in which expression profiles of monocytes in the adipose tissue 
(SAT+VAT) was compared to the expression profile of circulating monocytes using paired 
analysis (ATMs vs. monocytes). Publically available raw transcriptome data from various 
tissue macrophages including ATMs (GSE56682; ATMs vs. other tissue macrophages) and 
from THP-1 macrophages incubated with LPL hydrolysis versus non-hydrolysed end products 
of lipoproteins (GSE84791) were obtained from the Gene Expression Omnibus. Details of 
the microarray analysis and interpretation can be found in the supplementary material and 
methods section of chapter 4. 
Statistical analysis
Results are shown as mean + SEM. Statistically significant differences between two groups 
were calculated using Student’s t-tests. For evaluating the effect of treatment (treatment vs. 
control) and genotype (Angptl4-/- vs. Angptl4+/+), a two-way ANOVA and Bonferroni post hoc 
test was done. P < 0.05 were considered significant. 
Chapter 5
114
RESULTS
Adipose tissue-specific regulation of genes involved in lipid uptake and handling, 
and in inflammation
The adipose tissue provides a unique environment that is highly enriched in lipids. Compared 
to other tissue macrophages, adipose tissue macrophages (ATMs) display overall higher 
expression of various genes well-known for their role in lipid uptake (Figure 1A). Interestingly, 
comparing human ATMs with circulating monocytes reveals a similar pattern with strong 
regulation of genes involved in lipid uptake in adipose tissue-based macrophages (Figure 
1B). During obesity, macrophages are increasingly exposed to lipids and develop a lipid-laden 
appearance (5, 7, 29). Expression patterns of genes involved in lipid uptake (Figure 1C), as 
well as lipid droplet formation (Figure 1D) in ATMs isolated from mice fed a high-fat diet 
(HFD) versus mice fed a low-fat diet (LFD) corroborate increased lipid uptake and storage 
by ATMs during obesity. Moreover, in line with previous studies reporting inflammatory 
activation of ATMs during obesity that is different from classical macrophage activation, 
we found a diverse expression pattern of several marker genes involved in inflammatory 
cytokine secretion in ATMs from obese (HFD) versus lean mice (LFD) (Figure 1E). Our finding 
of an enrichment of pathways involved in ER stress in ATMs isolated from obese versus lean 
mice (Figure 1F), is suggestive of the existence of a link between increased lipid exposure, 
ER stress and inflammatory activation of ATMs part of obese adipose tissue, as has been 
previously shown in macrophages residing in atherosclerotic plaques (30, 31). 
Figure 1. Expression signatures of adipose tissue macrophages reflect lipid uptake, ER stress and inflammation.
Heat map reflecting the expression of selected well-known genes involved in lipid uptake in mouse adipose tissue 
macrophages (ATMs) vs. other tissue macrophages (A), human ATMs versus circulating monocytes (B), and ATMs 
isolated from mice fed a high-fat diet (HFD) vs. low-fat diet (LFD) (C). D Representative picture of lipid droplet 
formation in ATMs isolated from mice on a HFD vs. LFD. E Regulation of several marker genes for pro- vs. anti-
inflammatory activation in ATMs from mice on a HFD vs. LFD. F Predicted activation of pathways representing 
ER stress in ATMs from HFD- vs. LFD-fed mice upon analysis of their complete transcriptomes using Ingenuity 
Pathway Analysis, presented as a Normalized Enrichment Score (NES). 
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Figure 2. Macrophages in an adipose tissue environment take up lipids, are inflammatory activated and 
increase Angptl4 expression.
A Representative picture of bone marrow-derived macrophages (BMDMs) stained for neutral lipids using Bodipy 
after exposure to regular culture medium (Cntrl) or adipose tissue-conditioned medium (CM AT) for 24 h. B Pro- 
(TNF-α, IL-6) and anti- (IL-10) inflammatory cytokines in supernatants of BMDMs pre-exposed to regular culture 
medium or CM AT for 24 h and subsequently challenged with 1 ng/mL LPS in fresh culture medium for an additional 
24 h. Cytokines were measured after the 24 h LPS challenge. C Western blot for markers of ER stress, being XBP1-s 
(spliced form) and CHOP, in BMDMs in regular culture medium or CM AT for 24 h. Expression levels of Angptl4 in: 
BMDMs cultured in CM AT (D) or co-cultured with dying adipocytes (E), and various tissue macrophages including 
adipose tissue macrophages (F). SIM: Small intestine macrophages, PM: Peritoneal macrophages, KM: Kupffer 
cells, SM: Splenic red pulp macrophages, AM: Alveolar macrophages, ATM: Adipose tissue macrophages. Data are 
presented as means + SEM. * p<0.05, ** p<0.01.
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Macrophages in an adipose tissue environment in vitro resemble ATMs in vivo 
and display enhanced expression of Angptl4
Next, we mimicked ATMs in vitro by culturing BMDMs in adipose tissue-conditioned medium 
(CM AT) for 24 h to further examine the link between lipid loading and inflammatory 
activation of macrophages in an adipose tissue environment. As expected, BMDMs exposed 
to CM AT take up lipids and display profound lipid droplet formation (Figure 2A). Moreover, 
CM AT induced pro-inflammatory activation of BMDMs, characterized by enhanced 
secretion of TNF-α and IL-6, two pro-inflammatory cytokines, yet reduced secretion of 
the anti-inflammatory cytokine IL-10 (Figure 2B). In line with our finding in ATMs in vivo, 
BMDMs exposed to CM AT in vitro display signs of ER stress, with increased presence of 
the ER stress marker proteins XBP1 (spliced form) and CHOP (Figure 2C). Macrophages in 
an adipose tissue environment may either be exposed to lipids in the form of triglycerides 
(TGs) or as free fatty acids (FFAs). Interestingly, we found profound upregulation of Angptl4, 
a well-known endogenous inhibitor of lipoprotein lipase (LPL), in BMDMs cultured in CM AT 
(Figure 2D). In addition, Angptl4 expression was also enhanced in BMDMs co-cultured with 
dying adipocytes that release their lipid content (Figure 2E) and appeared to be specifically 
higher in ATMs compared to other tissue macrophages (Figure 2F). Upregulation of Angptl4 
in ATMs in vivo and upon exposure to CM AT in vitro is suggestive of the presence of a 
negative feedback mechanism to limit LPL activity and thus excessive uptake of TG-derived 
FAs by macrophages in an adipose tissue environment.  
Macrophages in an adipose tissue environment display enhanced lipid uptake, 
storage and metabolic activation regardless of ANGPTL4
To learn more about the relevance of TG-derived FAs for activation of macrophages in an 
adipose tissue environment we compared BMDMs from wild-type (Angptl4+/+) with BMDMs 
from Angptl4-/- mice. No gross differences in lipid droplet formation between Angptl4+/+ and 
Angptl4-/- mice was observed (Figure 3A). This was further supported on gene expression level. 
Both Angptl4+/+ and Angptl4-/- BMDMs display pronounced upregulation of Plin2 and Cd36 
(Figure 3B,C), previously identified as marker genes of metabolically activated ATMs during 
obesity (32), yet no differences between the genotypes were found. Of note, expression of 
Fabp4 was enhanced in wild-type BMDMs as well, fitting the ATM-specific phenotype found 
in vivo (Figure 1A,B). To check whether intracellular lipid handling was affected by ANGPTL4 
in macrophages, we examined the expression of genes involved in lipid export (Abcg1, Abca1), 
autophagy (Atg7), lipid breakdown (Lipa) and FA oxidation (Cpt1α) in Angptl4+/+ and Angptl4-/- 
BMDMs. Whereas no differences in expression of genes involved in export nor in Lipa were 
observed (Supplementary Figure 1), Atg7 and Cpt1α appeared slightly higher expressed 
in Angptl4-/- versus Angptl4+/+ BMDMs (Figure 3D). Because an increase in Atg7 and Cpt1α 
may be suggestive of enhanced FA oxidation in the mitochondria, we examined real time 
metabolic fluxes using the Seahorse machine. Both BMDMs expressing and lacking Angptl4 
displayed enhanced metabolic activity of both glycolysis (ECAR measurement) and oxidative 
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Figure 3. ANGPTL4 does not strongly affect lipid uptake, storage or metabolism in macrophages in an adipose 
tissue environment.
A Representative picture of Angptl4+/+ and Angptl4-/- bone marrow-derived macrophages (BMDMs) stained with 
Bodipy after 24 h in regular culture medium (Cntrl) or in adipose tissue-conditioned medium (CM AT). Expression 
levels of the lipid droplet protein Plin2 (B) various genes involved in lipid uptake (C), or in autophagy and lipid 
breakdown (D) in Angptl4+/+ and Angptl4-/- BMDMs in control conditions and after exposure to CM AT for 24 h. 
E Basal extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) of Angptl4+/+ and Angptl4-/- 
BMDMs in regular culture medium or CM AT for 24 h. Measurements were done in unbuffered medium. F Real 
time changes in OCR of Angptl4+/+ and Angptl4-/- BMDMs exposed to CM AT for 24 h, assessed in unbuffered 
medium during sequential injections with Oligomycin, carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone 
(FCCP), and Antimycin A + rotenone. Data are presented as means + SEM. * p<0.05, ** p<0.01.
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phosphorylation (OCR measurement) (Figure 3E), again corroborating metabolic activation 
of macrophages in an adipose tissue environment (Chapter 4). The absence of differences in 
basal oxidative phosphorylation (OXPHOS) and only minor differences in maximal OXPHOS 
between Angptl4+/+ and Angptl4-/- BMDMs (Figure 3F), together with modest alterations 
on gene expression level between the two genotypes, however, are suggestive of similar 
intracellular lipid handling by Angptl4+/+ and Angptl4-/- macrophages. 
ANGPTL4 protects against inflammatory activation in an adipose tissue 
environment
In line with substantial lipid loading by macrophages in an adipose tissue environment yet 
relatively similar lipid handling by BMDMs expressing or lacking Angptl4, we measured 
enhanced levels of proteins representative for ER stress both in Angptl4+/+ and Angptl4-/- 
macrophages cultured in CM AT without observing any differences in these markers 
between the two genotypes (Figure 4A). Interestingly, however, several genes involved 
in inflammatory activation and cytokine secretion were higher expressed by Angptl4-/- 
versus Angptl4+/+ BMDMs during culturing in CM AT (Figure 4B). Supportive of increased 
inflammatory activation of BMDMs lacking Angptl4 in an adipose tissue environment, the pro-
inflammatory cytokines TNF-α and IL-6 were enhanced in supernatants of Angptl4-/- versus 
Angptl4+/+ BMDMs stimulated with LPS specifically upon pre-exposure to CM AT (Figure 4C). 
Hence, although lipid uptake and intracellular handling appears relatively similar for BMDMs 
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Figure 4. Angptl4-/- macrophages display increased inflammatory activation in an adipose tissue environment.
A Western blot for the ER stress markers XBP1-s (spliced form) and CHOP in A gptl4+/+ and Angptl4-/- bone marrow-
derived macrophages (BMDMs) held in control medium (Cntrl) or in adipose tissue-conditioned medium (CM AT) 
for 24 h. B Expression levels of various pro- and anti-inflammatory genes in Angptl4-/- vs. Angptl4+/+ macrophages 
exposed to CM AT for 24 h, presented in a heat map as log 2 ratio difference (SLR) with higher expressed genes in 
red and lower expressed genes in blue. C Pro- (TNF-α, IL-6) and anti- (IL-10) inflammatory cytokines in supernatants 
of Angptl4+/+ and Angptl4-/- BMDMs pre-exposed to regular culture medium or CM AT for 24 h and subsequently 
challenged with 1 ng/mL LPS in fresh culture medium for an additional 24 h. Cytokines were measured after the 24 
h LPS challenge. Data are presented as means + SEM. * p<0.05, ** p<0.01.
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with or without ANGPTL4, macrophages lacking Angptl4 favour pro-inflammatory activation 
in an adipose tissue environment.
ANGPTL4 reduces lipid uptake by macrophages in a TG-enriched environment 
without affecting intracellular metabolism
To learn more about the consequences of absence of Angptl4 during uptake of TG-derived 
FAs by macrophages, we cultured Angptl4+/+ and Angptl4-/- BMDMs in a synthetic TG emulsion 
called Intralipid. Firstly, Angptl4 was strongly induced in BMDMs exposed to Intralipid (Figure 
5A). Induction of Angptl4 expression appeared to be a consequence of LPL activity, since 
hydrolysis products liberated from lipoproteins by LPL appeared to enhance Angptl4 levels in 
a human macrophage cell line (THP-1) as compared to non-hydrolysis products of lipoproteins 
(33) (Figure 5B). As expected, ANGPTL4 inhibits lipid loading of macrophages exposed 
to Intralipid. Most probably this was achieved via inactivation of LPL because Orlistat, an 
inhibitor of lipases including LPL, could abrogate increased lipid loading of Angptl4-/- versus 
Angptl4+/+ BMDMs exposed to Intralipid (Figure 5C). Similar to macrophages in an adipose 
tissue environment, BMDMs exposed to Intralipid display enhanced expression of Plin2, Cd36 
and Fabp4 (Figure 5D,E). Apart from Cav1, which was found higher expressed in Angptl4-/- 
versus Angptl4+/+ BMDMs (Figure 5E), no differences between the two genotypes were 
found (Figure 5E, Supplementary Figure 2). In line with this finding and supportive of lipid-
induced metabolic activation of macrophages, both Angptl4+/+ and Angptl4-/- BMDMs display 
increased glycolysis (ECAR) and OXPHOS (OCR) rates when exposed to the TG emulsion, 
similarly to what we found in ATMs (Chapter 4) and BMDMs exposed to AT CM (Figure 3F). 
Macrophages lacking Angptl4 in a TG-enriched environment tend to react 
stronger to a subsequent  pro-inflammatory stressor 
Despite increased lipid droplet formation in BMDMs lacking Angptl4, no signs of increased 
ER stress in Angptl4-/- versus Angptl4+/+ BMDMs was found in a TG-enriched environment, 
as based on the presence of spliced XBP1 (Figure 6A) (CHOP could not be detected). Similar 
to macrophages in an adipose tissue environment, Angptl4-/- BMDMs exposed to Intralipid 
do display enhanced mRNA levels of Tnf and Cxcl2 (Figure 6B). Pre-exposure to Intralipid, 
however, did not translate in enhanced inflammatory activation of Angptl4-/- versus 
Angptl4+/+ BMDMs upon stimulation with LPS (Figure 6C). Interestingly, on gene expression 
level Angptl4-/- BMDMs pre-exposed to Intralipid did display strong inflammatory activation 
upon stimulation with LPS compared to Angptl4+/+ BMDMs (Figure 6D). Of note, Orlistat 
could rescue the enhanced expression of pro-inflammatory genes in Angptl4-/- macrophages, 
both directly after exposure to Intralipid and upon subsequent stimulation with LPS (data not 
shown), in line with a role for ANGPTL4 in inhibition of lipid uptake via LPL. It is noteworthy 
that Intralipid in general appeared to trigger anti-inflammatory macrophage responses, 
exemplified by reduced ER stress markers (Figure 6A) and cytokine secretion (Figure 6C) in 
or by macrophages of both genotypes. 
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Figure 5. Absence of ANGPTL4 in macrophages increases lipid droplet formation in macrophages exposed to 
triglycerides without affecting lipid handling on mRNA level or real-time metabolism.
Expression of Angptl4 in bone marrow-derived macrophages (BMDMs) cultured in 2 mM Intralipid; an emulsion 
of triglycerides (A), and BMDMs exposed to products formed upon lipoprotein lipase-mediated hydrolysis of 
lipoproteins vs. non-hydrolysed lipoprotein products (B). C Representative picture of Angptl4+/+ and Angptl4-/- 
BMDMs in regular culture medium (Cntrl), or after a 6 h culture in 1 mM Intralipid or 1 mM Intralipid + Orlistat. 
Neutral lipids were visualised using Bodipy. Expression levels of the lipid droplet protein Plin2 (D) or various 
genes involved in lipid uptake (E) in Angptl4+/+ and Angptl4-/- BMDMs in control conditions and after exposure 
to 2 mM Intralipid for 6 h. F Basal extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) of 
Angptl4+/+ and Angptl4-/- BMDMs exposed to regular culture medium or medium containing 1 mM Intralipid for 6 h. 
Measurements were done in unbuffered medium. G Real time changes in OCR of Angptl4+/+ and Angptl4-/- BMDMs 
exposed to 1 mM Intralipid for 6 h, assessed in unbuffered medium during sequential injections with Oligomycin, 
carbonyl cyanide-4-(trifluoromethoxy)phenylhydrazone (FCCP), and Antimycin A + rotenone. Data are presented 
as means + SEM. * p<0.05, ** p<0.01.
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Figure 6. Macrophages lacking ANGPTL4 display no signs of increased ER stress in a triglyceride-rich 
environment but appear more prone to react pro-inflammatory to a second stressor.
A Western blot for the ER stress marker XBP1-s (spliced form) in Angptl4+/+ and Angptl4-/- bone marrow-derived 
macrophages (BMDMs) held in control medium (Cntrl) or in 1 mM Intralipid with or without Orlistat for 6 h. B 
Expression of various pro- and anti-inflammatory genes in Angptl4-/- vs. Angptl4+/+ BMDMs exposed to 2 mM 
Intralipid for 6 h. 
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To examine the relevance of Angptl4 for the inflammatory trait of ATMs in vivo, we measured 
inflammatory markers in the adipose tissue, both basally and upon challenging the mice by 
injecting LPS, and compared the inflammatory state of the adipose tissue with that of the 
liver; a tissue-environment not enriched in lipids. Overall no gross differences between lean 
Angptl4-/- versus Angptl4+/+ mice were detected in the adipose tissue or liver (Figure 6E,F), 
not basally (PBS) nor upon LPS injection. However, a trend toward differential inflammatory 
responses between the genotypes was observed in the adipose tissue (Figure 6E), whereas 
differences appeared smaller in the liver (Figure 6F). The expression of several other 
inflammatory marker including Gdf15, Cox2, Il-1β, Il-5 and Il-15 was not changed (data not 
shown). 
C Pro- (TNF-α, IL-6) and anti- (IL-10) inflammatory cytokines in supernatants of Angptl4+/+ and Angptl4-/- BMDMs 
pre-exposed to regular culture medium or 1 mM Intralipid for 6 h and subsequently challenged with 1 ng/mL 
LPS in fresh culture medium for an additional 24 h. Cytokines were measured after the 24 h LPS challenge. D 
Expression of various pro- and anti-inflammatory genes in Angptl4-/- vs. Angptl4+/+ BMDMs pre-exposed to 2 mM 
Intralipid for 6 h and subsequently challenged with 1 ng/mL LPS for 24 h. Expression of various cytokines in the 
adipose tissue (E) or liver (F) of lean Angptl4+/+ and Angptl4-/- mice 48 hours after i.p. injection of PBS or LPS (10 
µg/kg bodyweight). Expression levels in C and D are presented in a heat map as log 2 ratio difference (SLR) with 
higher expressed genes in red and lower expressed genes in blue. Data are presented as means + SEM. * p<0.05, 
** p<0.01.
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DISCUSSION
Adipose tissue macrophages (ATMs) are confronted with large amounts of lipid species 
that both include free fatty acids (FFAs) and triglycerides (TGs) released during adipocyte 
lipolysis or cell death (2, 3, 5). In contrast to FFAs that can readily be taken up into the cell 
by designated transporters, TGs require the action of LPL to allow for the uptake of FAs. We 
show that macrophages in an adipose tissue environment in vitro develop a metabolically 
activated and pro-inflammatory phenotype resembling the phenotype of ATMs residing 
in obese adipose tissue. Interestingly, macrophages exposed to TGs become metabolically 
activated as well, suggesting that TGs may represent an important environmental cue 
contributing to adipose tissue inflammation. However, even though both Lpl and Angptl4 
are expressed in ATMs and macrophages in an adipose tissue environment in vitro, we 
detected no difference in lipid uptake, processing, or metabolism between Angptl4-/- and 
wild-type bone marrow-derived macrophages (BMDMs). Intriguingly, macrophages lacking 
Angptl4 do display enhanced inflammatory cytokine production in an in vitro adipose tissue 
environment, suggestive of a role for ANGPTL4 in cytokine production independently of its 
inhibition of LPL. 
As well-known inhibitor of lipoprotein lipase (LPL), ANGPTL4 plays a crucial role in lipid 
metabolism in various tissues (21). In macrophages, ANGPTL4 is involved in regulation of 
uptake of oxidized LDL (oxLDL) and lipids from chyle and accordingly protects against the 
development of atherosclerosis (25). Although ANGPTL4 and LPL have been shown to be 
co-produced and interact in various cell types and tissues (22, 34), so far this has not been 
studied in macrophages residing in lipid-rich environments. Interestingly, our data reveal that 
endogenous ANGPTL4 represses lipid-loading by macrophages in a TG-rich environment. 
The upregulation of Angptl4 in macrophages in an adipose tissue environment is suggestive 
of a role for ANGPTL4 in controlling FA uptake from TGs and ultimately determining 
inflammatory traits of macrophages. Fatty acids, primarily saturated, are known to promote 
inflammatory responses in macrophages via pathways involving ER stress. Activation of 
such route involves several mechanisms, including effects on the lipid composition thus 
structure, motility and integrity of membranes (15, 17, 35-38), and reactive oxygen species 
(ROS) formation in mitochondria, peroxisomes, or the cytosol (14, 39). Interestingly, adipose 
tissue-conditioned medium promoted ER stress in macrophages, however no differences 
between wild-type versus macrophages lacking Angptl4 were observed. Since the amount of 
lipids taken up by the macrophages is most likely closely related to the degree of ER stress, 
this may suggest that long-term exposure to an adipose tissue-like environment results in 
similar lipid uptake in wild-type and Angptl4-/- macrophages. This indeed was confirmed by 
the equal appearance of lipid droplets in Angptl4-/- and Angptl4+/+ macrophages. 
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The enhanced inflammatory responses in Angptl4-/- subsequently argues effects of ANGPTL4 
independently of the amount of lipids taken up by the cell. Indeed, it has been shown that the 
function of Angptl4 is not limited to inhibition of LPL but also inhibits other lipases including 
pancreatic lipase or hormone sensitive lipase (40, 41). Moreover, ANGPTL4 exerts various 
functions in different cell types, and is involved in angiogenesis and tumour metastases (42). 
In myeloid cells, Angptl4 is a target gene of HIF-1α (23), a transcription factor known to be 
involved in pro-inflammatory responses (43). Accordingly, ANGPTL4 may function as part of 
a negative feedback loop preventing excessive inflammatory responses. To what extent such 
a role for ANGPTL4 is completely independent of its control of lipid uptake via LPL inhibition 
will need more study. 
Equal lipid loading of Angptl4-/- and wild-type macrophages exposed to adipose tissue-
conditioned medium is suggestive of a primary role for FFAs that are released by the adipose 
tissue in vitro (data not shown) and do not require LPL for uptake. Free FAs in adipose 
tissue-conditioned medium may have fuelled differences between wild-type and Angptl4-/- 
macrophages by potently upregulating Angptl4 expression in wild-type macrophages via 
peroxisome proliferator-activated receptors (PPARs) (24, 25). In addition, other compounds 
present in adipose tissue conditioned medium may impact on LPL or ANGPTL4 action. 
For example, adipocytes and the adipose tissue have previously been shown to secrete 
exosomes rich in lipids (44), proteins including enzymes involved in lipid metabolism (45, 
46), RNA, and DNA (47), that have been shown to pro-inflammatory activate macrophages 
(48) and may have also contributed to the differential response of Angptl4-/- versus wild-type 
macrophages. Hence, a combination of lipids and other factors produced by the adipose 
tissue may have enhanced the pro-inflammatory phenotype of Angptl4-/- versus wild-type 
macrophages in an adipose tissue environment in vitro. Most likely, FFAs play a primary role 
in our in vitro system, yet we cannot exclude a role for TGs. For example, ANGPTL4 derived 
from adipocytes or other cell types may have been present in the adipose tissue-conditioned 
medium, and may have compensated for the absence of ANGPTL4 in Angptl4-/- macrophages 
thereby equalizing LPL-facilitated TG hydrolysis in Angptl4-/- and wild-type macrophages. 
The role for TGs might be more important in cell-cell contact frequently occurring 
in adipose tissue. Our in vitro results demonstrate that co-culturing of macrophages and 
adipocytes also promotes Angptl4 expression. This may particularly be relevant during 
clearance of damaged/dying adipocytes to tightly control engulfment of its cellular content 
including TGs by macrophages. To evaluate the role of TGs hence importance of the LPL-
inhibitory actions of ANGPTL4 to protect against inflammatory responses, wild-type and 
Angptl4-/- macrophages were exposed to a TG emulsion. This led to robust upregulation of 
Angptl4 in macrophages and promoted metabolic activation of macrophages. Hence, one 
might speculate that enhanced exposure during obesity, for example by adipocyte death and 
the release of adipocyte TGs, may drive this particular ATM phenotype. However, we were 
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unable to observe differences in inflammatory cytokine production between Angptl4-/- and 
wild-type macrophages. This implies that TGs alone are unable to drive pro-inflammatory 
responses, yet it is important to note that Intralipid is mostly composed of unsaturated 
fatty acids that are known to have much lower pro-inflammatory or even anti-inflammatory 
effects compared to saturated fatty acids. This may have blunted potential differences 
between Angptl4-/- and wild-type macrophages. 
Because in vivo TGs together with FFAs and various other compounds will contribute to the 
ATM phenotype, we hypothesized absence of Angptl4 to aggravate the inflammatory trait of 
ATMs. Although there appeared to be a trend toward increased inflammatory differences in 
adipose tissue of Angptl4-/- versus wild-type mice after exposure to LPS, profound variation 
within the treatment groups hindered differences from reaching significance. Interestingly, 
however, differences between Angptl4-/- and wild-type mice appeared less pronounced in 
the liver, suggestive of particular importance of ANGPTL4 in lipid-enriched environments. 
Accordingly, one may speculate that absence of Angptl4 is of particular importance in an 
obese adipose tissue environment. Indeed, our in vitro adipose tissue environment – in which 
Angptl4-/- macrophages displayed increased inflammatory activation compared to wild-
type macrophages – appeared to induce an obese ATM-alike phenotype, characterized by 
profound lipid droplet formation and metabolic and inflammatory activation of macrophages 
(Chapter 4). Therefore, future studies should be aimed at identifying the role of Angptl4 in 
ATMs part of obese adipose tissue, when accumulation of lipids increasingly demands for 
effective lipid handling by macrophages. 
In conclusion, our results identify LPL-dependent TG breakdown as an important contributor 
to lipid accumulation in macrophages driving metabolic activation of these cells. In 
addition, our results suggest a dual mode of action of ANGPTL4 in controlling macrophage 
inflammatory responses that involves both its well-known inhibitory action on LPL, yet also 
seems to be accomplished through other pathways that do not involve direct control of 
lipid uptake. Previous studies have pointed to the importance of careful control of LPL in 
ATMs part of obese adipose tissue, by revealing increased concentrations of circulating 
glucose when LPL is silenced in ATMs specifically (49). Because the anti-inflammatory effects 
of ANGPTL4 in macrophages in an adipose tissue environment appeared independent of 
lipid uptake inhibition, further research into the role of ANGPTL4 in abating inflammatory 
responses of ATMs in obese individuals may well be worthwhile. 
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Supplementary Figure 1. Expression of genes involved in lipid export or lipolysis. 
Expression levels of genes involved in lipid export (Abcg1, Abca1) or lysosomal lipolysis (Lipa) in Angptl4+/+ and 
Angptl4-/- BMDMs in control conditions and after exposure to adipose tissue-conditioned medium (CM AT) for 24 
h. Data are presented as means + SEM. * p<0.05, ** p<0.01.
Supplementary Figure 2. Expression of genes involved in lipid uptake and trafficking.
Relative expression of Lpl and Fatp1 in Angptl4+/+ and Angptl4-/- BMDMs in control conditions and after exposure 
to adipose tissue-conditioned medium (CM AT) for 24 h. Data are presented as means + SEM. * p<0.05, ** p<0.01.
Gene 3' primer 5' primer
36B4 ATGGGTACAAGCGCGTCCTG GCCTTGACCTTTTCAGTAAG
Abca1 CCCAGAGCAAAAAGCGACTC GGTCATCATCACTTTGGTCCTTG
Abcg1 CCTACCACAACCCAGCAGACT CGAGGTCTCTCTTATAGTCAG
Angptl4 GTTTGCAGACTCAGCTCAAGG CCAAGAGGTCTATCTGGCTCTG
Atg7 GTTCGCCCCCTTTAATAGTGC TGAACTCCAACGTCAAGCGG
Cav1 AACATCTACAAGCCCAACAACAAGG GGTTCTGCAATCACATCTTCAAAGTC
Cd36 TCCAGCCAATGCCTTTGC TGGAGATTACTTTTCAGTGCAGAA
Cox2 TGAGCAACTATTCCAAACCAGC GCACGTAGTCTTCGATCACTATC
Cpt1α CTCAGTGGGAGCGACTCTTCA GGCCTCTGTGGTACACGACAA
Cxcl2 CCAACCACCAGGCTACAGG GCGTCACACTCAAGCTCTG
Fabp4 AAGGTGAAGAGCATCATAACCCT TCACGCCTTTCATAACACATTCC
Fatp1 CGCTTTCTGCGTATCGTCTG GATGCACGGGATCGTGTCT
Gdf15 GAACTGCGCTTACGGGTAG CTGCACAGTCTCCAGGTGA
Ifnγ ATGAACGCTACACACTGCATC CCATCCTTTTGCCAGTTCCTC
Il10 CTGGACAACATACTGCTAACCG GGGCATCACTTCTACCAGGTAA
Il1b TGGTGTGTGACGTTCCCATT CAGCACGAGGCTTTTTTGTTG
Il4 GGTCTCAACCCCCAGCTAGT GCCGATGATCTCTCTCAAGTG
Il6 AGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC
Lipa TGTTCGTTTTCACCATTGGGA CGCATGATTATCTCGGTCACA
Lpl GGGAGTTTGGCTCCAGAGTTT TGTGTCTTCAGGGGTCCTTAG
Lrp1 ACTATGGATGCCCCTAAAACT GCAATCTCTTTCACCGTCACA
Mcp1 CCCAATGAGTAGGCTGGAGA TCTGGACCCATTCCTTCTTG
Plin2 GCCTCTCAACTGGCTGGTAG ACAGCAAAAGGGGTCATCTG
Tgfb1 CTTCAATACGTCAGACATTCGGG GTAACGCCAGGAATTGTTGCTA
Tnf CAACCTCCTCTCTGCCGTCAA TGACTCCAAAGTAGACCTGCCC
Supplementary Table 1.
Sequences of primers used for examining mRNA levels using RT-qPCR.
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ABSTRACT
The adipose tissue is a highly dynamic organ. Adipocyte death and removal as part of regular 
tissue turnover or tissue expansion are crucial for adipose tissue functioning and, ultimately, 
whole body homeostasis. Persistent appearance of pro-inflammatory macrophages 
surrounding dead adipocytes in Crown-like structures is suggestive of ineffective adipocyte 
removal during obesity and considered to be a hallmark of chronic tissue inflammation that 
links obesity to insulin resistance. So far, however, the role of clearance (efferocytosis) of dead 
adipocytes by macrophages in obese or lean adipose tissue is incompletely understood. Here, 
we examined the relevance of dead adipocyte clearance by macrophages in obese adipose 
tissue, and compared inflammatory consequences of adipocyte clearance for macrophages 
in an obese versus lean adipose tissue environment. Interestingly, we found profound 
transcriptional regulation of the efferocytic machinery in obese versus lean adipose tissue 
macrophages (ATMs). Moreover, two weeks of daily oral administration of BMS-777607 to 
constrain Mer receptor tyrosine kinase-dependent efferocytosis in obese mice increased 
cell death markers in the adipose tissue. In vitro studies revealed enhanced inflammatory 
activation of macrophages primed by obese versus lean adipose tissue in response to 
dead adipocytes, linking adipocyte removal to inflammatory activation of macrophages in 
the obese state. Interestingly, our data point to a role for interferon (IFN) signalling during 
effective dead adipocyte clearance and link impaired IFN signalling to pro-inflammatory 
macrophage responses in an obese adipose tissue environment. Future studies aimed at 
unravelling regulation of efferocytosis in obese versus lean adipose tissue including IFN 
signalling are warranted and may provide new targets to improve the efferocytic capacity of 
macrophages in order to combat adipose tissue inflammation during obesity.
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INTRODUCTION
Macrophages populate various tissues, supporting normal development and enabling 
tissue plasticity and turnover (1). Central to this role for macrophages in maintaining tissue 
homeostasis is the clearance of damaged or dead cells; a process called ‘efferocytosis’ (2, 
3). The importance of this process becomes evident in conditions of impaired efferocytosis, 
when leakage from post-apoptotic remnants nourishes inflammation and auto-immunity. 
Indeed, impaired efferocytosis is identified to be the underlying cause of various diseases 
characterized by chronic inflammation including cystic fibrosis, chronic obstructive 
pulmonary disease and asthma (2, 3). 
Adipose tissue is a highly flexible organ, responding to acute metabolic needs by storing 
fatty acids as triglycerides in lipid droplets or releasing fatty acids from triglycerides via 
lipid droplet breakdown. Prolonged demand for increased storage capacity during the 
development of obesity is associated with adipocyte hypertrophy and ultimately adipocyte 
cell death, which has been postulated to be one of the main driving factors of infiltration of 
macrophages in obese adipose tissue (4-8). Indeed, obese adipose tissue is characterized by 
Crown-like structures (CLS) formed by macrophages surrounding dying adipocytes (6, 7). The 
pro-inflammatory phenotype of accumulating macrophages in obese adipose tissue fuels 
inflammation that is thought to link obesity with metabolic disturbances including insulin 
resistance (9, 10). 
Although macrophages have long been hypothesized to play a role in clearance of dying 
adipocytes in CLS (6, 7, 9), it was not until recently that interactions between dying adipocytes 
and macrophages have been studied in detail. As such, live cell imaging revealed clearance 
of dying adipocytes by adipose tissue macrophages (ATM) in vitro that appeared to depend 
on arachidonate 15-lipoxygenase (Alox15) and could be enhanced by IL-4 (11). Interestingly, 
macrophages have been shown to actively liberate lipids from adipocytes by forming 
extracellular acidic compartments near dying adipocytes in which they initiate degradation 
of lipids by secreting lysosomal enzymes via exocytosis (12). 
The regulation and consequences of efferocytosis in adipose tissue might differ between 
lean and obese conditions. So far, however, differences in efferocytosis of adipocytes by 
macrophages in lean or obese adipose tissue are incompletely understood. In lean animals, 
high levels of adipocyte cell death instigated via β-adrenergic stimulation (11, 13, 14) or 
targeted activation of caspase-8 (15) initiates accumulation of anti-inflammatory macrophages 
displaying a lipid-laden appearance in adipose tissue, reflective of immunologically silent 
clearance of dead adipocytes. In contrast, sustained presence of lipid-laden macrophages 
with pro-inflammatory characteristics in CLS part of obese adipose tissue (16-19) may be 
suggestive of ineffective efferocytosis of dead adipocytes during obesity. Interestingly, 
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macrophages of patients with Type 2 Diabetes are known to have reduced phagocytic 
capacity (20), contributing to plaque instability in atherosclerosis (21) and impaired wound 
healing (22). 
To gain insight into the relevance of adipocyte clearance by ATMs in the context of obesity, we 
examined gene expression profiles of ATMs from obese versus lean mice, studied interactions 
between adipose tissue-primed macrophages and dead adipocytes in vitro, and interfered 
with the phagocytic machinery in obese mice. As such, we found increased expression of 
the efferocytic machinery in ATMs during obesity, and increased cell death in the adipose 
tissue upon interference with efferocytosis. In vitro, priming with obese versus lean adipose 
tissue enhanced inflammatory activation of macrophages co-cultured with apoptotic 
adipocytes despite equal lipid uptake; suggestive of impaired processing of the engulfed 
cargo. Interestingly, interferon (IFN) signalling appeared involved in adipocyte clearance 
in vitro and was impaired in ATMs part of obese adipose tissue. Further understanding of 
the regulation of adipocyte clearance in lean and obese adipose tissue might provide new 
targets to limit pro-inflammatory activation of macrophages during obesity by increasing 
their efferocytic capacity. 
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MATERIALS AND METHODS
Animal studies
Male C57Bl/6 mice (Harlan, Germany) had ad libitum excess to food and water. Mice (n=12) 
on a high-fat diet (HFD) containing 60% kcal from fat (D12492, Research diets) for 10 weeks 
were then randomly allocated over two groups (both n=6) and received a daily oral gavage 
either containing 25 mg/kg bodyweight BMS-777607 (Seleck Chemicals) dissolved in vehicle, 
or vehicle only (0.1% Tween80, 0.5% carboxymethylcellulose in H
2
O) for two weeks while 
remaining on their HFD. 
Epididymal adipose tissue explants for generation of ATM-like macrophages in vitro 
were isolated from mice on a low fat diet (LFD) containing 10% kcal from fat (D12450J, 
Research diets) or HFD containing 60% kcal from fat (D12492, Research diets) for 13-16 
weeks. All procedures were approved by the ethical committee for animal experiments from 
Wageningen University.
In vitro co-culture systems
Bone marrow cells were isolated from femurs of lean mice following a standard protocol, 
and brought in culture in Dulbecco’s modified eagle’s medium supplemented (Lonza) with 
10% FCS and 1% PS (DMEM/FCS/PS) and 5-10% L929-conditioned medium. For direct co-
cultures with adipocytes, non-adherent cells were removed after 6-7 days and adherent cells 
were washed and plated. Upon adhesion, cells were washed and subsequently co-cultured 
with adipocytes in DMEM/FCS/PS for 24 hours. 
For IFN-γ pre-treatment, plated bone marrow-derived macrophages (BMDMs) were 
cultured in DMEM/FCS/PS containing 10 ng/mL IFN-γ for 18-24 hours before starting the 24-
hour co-culture with adipocytes in DMEM/FCS/PS. 
For adipose tissue priming, non-adherent bone marrow cells were removed after 3-4 
days and adherent cells were washed and plated in 12- or 24-wells plates. After adhesion, 
fresh DMEM/FCS/PS was added together with an insert containing 100 mg of minced live 
or dying epididymal adipose tissue explant collected from LFD-fed or HFD-fed mice. Inserts 
containing adipose tissue were removed after 3 days, after which the adipose tissue-primed 
BMDMs were co-cultured with adipocytes in DMEM/FCS/PS for 24 hours.  
Mouse 3T3-L1 fibroblasts were maintained in DMEM/FCS/PS. At 2 days post-confluence, 
cells were switched to DMEM/FCS/PS containing 0.5 mM IBMX, 10 µM dexamethasone, and 
5 µg/mL insulin (all Sigma) for 2 days to initiate differentiation into adipocytes. Then, the 
cells were maintained in DMEM/FCS/PS with 5 µg/mL insulin for 3 days and subsequently 
held in DMEM/FCS/PS for 5-7 days to complete differentiation into adipocytes. Medium 
was replaced once every 3 days. Differentiated 3T3-L1 cells were used in co-cultures with 
BMDMs for flow cytometry. Human Simpson-Golabi-Behmel syndrome (SGBS) cells were 
maintained in DMEM/F12 (Lonza) supplemented with 10% FCS, 1% PS, 33 µM Biotin (Sigma) 
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and 17 µM panthotenat (Sigma), and differentiated into adipocytes over a period of 21 days 
as has been described previously (23). Differentiated SGBS cells were used in co-cultures 
with BMDMs for isolation of RNA and collection of cytokines. 
Adipocyte and adipose tissue death was induced with UV-C light using a Stratalinker 
1800 UV cross linker (Stratagene). Adipocytes were collected using trypsin, pelleted with 
centrifugation, dissolved in DMEM/FCS/PS and co-cultured with BMDMs in a 1:1 (1) or 1:6 
(1/6) ratio (adipocytes:macrophages). Unless otherwise specified, a 1:1 ratio was used.
Flow cytometry
For quantification of lipid uptake from adipocytes by macrophages, BMDMs were stained 
with PKH26 (Sigma) following manufacturer’s protocol, and co-cultured with apoptotic 
adipocytes. After a 4-hour co-culture, culture medium was aspirated carefully and cells were 
collected in PBS. After minimizing cell clumps by pipetting up and down, cells were fixated 
in 4% formaldehyde for 30 min at 4 ºC. Upon centrifugation, pelleted cells were dissolved in 
PBS containing 1% free fatty acid-free BSA (Sigma) and 2mM EDTA and stained for neutral 
lipids with 1 mg/mL Bodipy (Sigma) for 20 minutes at RT. Cells were washed with PBS once 
and measured by flow cytometry using a FC500 Flow Cytometer (Beckman Coulter). 
Cytokine measurements
Levels of IL-6 and IL-1ra were measured in 24-hour cell culture supernatants of BMDMs co-
cultured with adipocytes by using murine DuoSet ELISA Development kits according to the 
guidelines of the manufacturer (R&D Systems). 
Plasma metabolites
Triglycerides were determined using an enzymatic kit (Roche Molecular Biochemicals). Non-
esterified fatty acids were measured with a NEFA-C kit (Wako Diagnostics). Glucose was 
measured enzymatically using a glucose liquicolor assay kit (Human GmbH). Plasma insulin 
concentrations were obtained by ultra-sensitive mouse insulin ELISA (Crystal Chem Inc.). 
Leptin and adiponectin were determined by ELISA (R&D Systems).  
Immunohistochemistry
Parrafin-embedded sections of epididymal or inguinal adipose tissue were stained with an 
F4/80 antibody (AbD Serotec) and counterstained with haematoxylin. Macrophages were 
visualized with 3,3-diaminobenzidene (DAB, Vector Laboratory).
Western blot
Bone marrow-derived macrophages or adipose tissue were lysed in RIPA buffer (Pierce 
Thermoscientific) enriched with protease and phosphatase inhibitors (Roche). Total protein 
was determined using a BCA protein assay (Pierce Thermoscientific) and for each sample 15 
µg of protein was loaded on a 4-15% Mini-PROTEAN TGX Precast gel (Bio-Rad). Proteins were 
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separated by SDS gel electrophoresis and transferred to a PVDF membrane (Bio-Rad) using 
the Transblot Turbo System (Bio-Rad). Primary antibodies for Cleaved caspase-3 (Bioke), poly 
ADP ribose polymerase (PARP) (Cell Signalling), and b-tubulin (Sigma) were used at a ratio of 
1:1000 and incubated overnight at 4 ⁰C. All incubations were in Tris-buffered saline with 0.1% 
Tween-20 (TBS-T), containing 5% dry milk. HRP-conjugated goat-anti-rabbit secondary Ab 
(Sigma) was used 1:5000 in TBS-T with 5% dry milk. Blots were visualized using the ChemiDoc 
MP system (Bio-Rad) and Clarity ECL substrate (Bio-Rad).
RNA isolation and qPCR
Total RNA was isolated using TRIzol (Life Technologies), either via phenol/chloroform 
extraction (BMDMs), or with the RNeasy microkit (Qiagen) (epididymal or inguinal adipose 
tissue of BMS-treated or Cntrl mice). Reverse transcription was executed using the iScript 
cDNA synthesis kit (Bio-rad). Real-time quantitative PCR was carried out with a SensiMix 
SYBR kit (Bioline) in a CFX384 system (Bio-rad). Relative expression levels were calculated 
after normalization against the housekeeping gene 36B4 using starting quantities. Primer 
sequences can be found in Supplementary Table 4. 
Microarray analysis and interpretation
RNA from BMDMs co-cultured with 100 mg epididymal adipose tissue explant for 3 days 
was purified with an RNAeasy Minikit (Qiagen). After verification of RNA quality with the 
RNA 6000 Nano assay on a Agilent 2100 Bioanalyzer (Agilent Technologies), 100 ng per 
sample) was labelled with the Whole-Transcript Sense Target Assay (Affymetrix, Santa 
Clara, CA, USA; P/N 900652) and hybridized to whole-genome Affymetrix Mouse Gene 1.1 
ST arrays (Affymetrix). Quality control and data analysis pipeline have been described in 
detail (24). Briefly, normalized expression estimates of probe sets were computed by the 
robust multiarray analysis (RMA) algorithm (25, 26) as implemented in the Bioconductor 
library AffyPLM. Probe sets were redefined according to Dai et al. (27) based on annotations 
provided by the Entrez Gene database, which resulted in the profiling of 21,187 unique genes 
(custom CDF v20). Differentially expressed probe sets (genes) were identified by using linear 
models (library limma) and an intensity-based moderated t-statistic (28, 29). Adipose tissue 
macrophages of obese versus lean mice were obtained as previously described (Chapter 4). 
Transcriptomes were analysed similarly as those of BMDMs. 
Changes in gene expression were related to biologically meaningful changes using gene 
set enrichment analysis (GSEA) (30), or Ingenuity Pathway Analysis (IPA) (Qiagen). For each 
comparison, genes were ranked on their t-value that was calculated by the moderated t-test. 
Statistical significance of GSEA results was determined using 1000 permutations. The library 
clusterProfiler was used for visualization and interpretation of the GSEA results (31). Probe 
sets that satisfied the criterion of p<0.01 were included for Ingenuity Pathway Analysis. 
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Statistical analysis
When comparing two groups a student’s t-test was used for statistical analysis. When 
comparing more than two groups, a one-way ANOVA or two-way ANOVA with Bonferroni 
post-hoc test was used as specified at each figure. Statistical analyses were done with 
Graphpad Prism 5 (GraphPad Software). 
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RESULTS
Enhanced expression of the efferocytic machinery in adipose tissue macrophages 
during obesity
Macrophages in obese adipose tissue cluster around dying adipocytes in crown-like structures 
(6, 7). To investigate whether pathways involved in adipocyte clearance are regulated in 
adipose tissue macrophages (ATMs) during obesity, we compared transcriptomes of ATMs 
from obese versus lean mice by microarray and subsequent Ingenuity Pathway Analysis (IPA). 
Interestingly, clusters of genes related to efferocytosis including ‘Phagocytosis’, ‘Endocytosis’ 
and ‘Engulfment of cells’ were predicted to be activated in ATMs from obese versus lean 
mice (Figure 1A). A role for efferocytosis of adipocytes and subsequent requirement for lipid 
processing by macrophages was further corroborated by predicted activation of ‘Metabolism 
of membrane lipid derivatives’ and ‘Transport of lipid’ in ATMs from obese versus lean mice 
(Figure 1B,C). 
Figure 1. Regulation of the efferocytic machinery in ATMs from obese mice. 
Ingenuity Pathway Analysis on the transcriptomes of adipose tissue macrophages (ATMs) isolated from mice on 
a high-fat diet (obese) or low-fat diet (lean). Predicted activation of pathways involved in efferocytosis (A,B) and 
lipid processing (B,C) in ATMs from obese versus lean mice. 
A B 
C 
ATMs 
Obese vs. lean mice 
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Efferocytosis of adipocytes by macrophages
To study efferocytosis of adipocytes by macrophages, we used a co-culture system in which 
plated bone marrow-derived macrophages (BMDMs) were exposed to dead adipocytes. 
Controversy exists about the type of adipocyte cell death occurring in obese adipose tissue 
(32). In our experiments, cell death was induced by irradiation with 25 mJ/cm2 (apoptotic) or 
100 mJ/cm2 (severe apoptotic) UV light. Dying adipocytes were left in regular culture medium 
for 18-24 hours, when Caspase 3 and PARP cleavage became apparent (Figure 2), before 
feeding them to macrophages. Uptake of lipids from dead adipocytes was quantified with 
flow cytometry, by measuring the mean Bodipy signal (lipids) in PKH-positive cells (BMDMs). 
The higher mean Bodipy signal intensity and increased granularity (side scatter (SS) signal) 
found in the BMDMs co-cultured with apoptotic adipocytes for 4 hours compared to BMDMs 
alone is suggestive for macrophages to take up lipids from apoptotic adipocytes (Figure 3). 
To examine transcriptional responses upon efferocytosis, we compared gene expression 
levels in BMDMs co-cultured with apoptotic or severe apoptotic adipocytes with those 
in BMDMs co-cultured with live adipocytes. Interestingly, various genes involved in lipid 
PARP 
Cleaved Casp-3 
25 100 25 100 200 mJ/cm2 
4 h 24 h 
Cleaved PARP 
0 20 50 100 200 0 
3 h 
3T3-L1 cells SGBS cells 
20 50 100 200 0 
18 h 
Figure 2. Cell death in UV-irradiated adipocytes. 
Presence of cleaved Caspase-3 and Poly ADP ribose polymerase (PARP) in human (Simpson-Golabi-Behmel 
Syndrome (SGBS) cells) or murine (3T3-L1 cells) adipocytes at two time points after exposure to several intensities 
of UV irradiation to induce cell death.
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Figure 3. Macrophages take up lipids from apoptotic adipocytes in vitro. 
Representative picture of PKH-stained BMDMs either exposed to apoptotic adipocytes (Co AA) or not (Cntrl) and 
subsequently stained with Bodipy. Selection of macrophages as PKH+ cells (left); mean Bodipy signal in the PKH+ 
fraction presented as density plot (middle) or as bar graph (right). Measurements done with flow cytometry. SS: 
side scatter. 
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uptake and processing; including uptake (Lpl, Cd36), breakdown (Lipa, Atp6V0d2), storage 
(Plin2), and export (Abcg1), were higher expressed in macrophages exposed to apoptotic 
versus live adipocytes (Figure 4A). Expression of these genes appeared dose-dependently 
induced by dead adipocytes (Figure 4A), and was only induced upon prolonged (24 hours) 
exposure to adipocytes with hardly any regulation of these genes found after a 6-hour co-
culture, pointing to enhanced uptake of adipocyte-derived lipids over time (Supplementary 
Figure 1). Of note, no regulation of genes classically involved in efferocytosis; the receptor 
Mertk, bridging molecule Gas6 and adapter protein Elmo1 (Figure 4B), or genes involved 
in glycolysis (Figure 4C) was observed, probably reflecting unique macrophage responses 
adapted to handling of lipid-filled dead adipocytes.
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Figure 4. Dead adipocytes dose-dependently induce expression of genes involved in lipid uptake and 
processing in macrophages. 
Relative expression of various genes involved in lipid uptake or processing (A), classical phagocytosis (B), or 
glycolysis (C) in BMDMs exposed to two concentrations of either live adipocytes (LA), apoptotic adipocytes (AA), 
or severe apoptotic adipocytes (SAA) (1x or 1/6x of the amount of macrophages) for 24 hours. Co-cultures with 
live adipocytes were set to 1. The difference in gene expression in macrophages co-cultured with AA vs. LA or 
SAA vs. LA was tested for significance using an one-way ANOVA with Bonferroni post-hoc test. Data are shown as 
mean + SEM. * p < 0.05, ** p < 0.01.  
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Macrophages in an obese adipose tissue environment react pro-inflammatory on 
dead adipocytes 
We next aimed to uncover whether differences in clearance of adipocytes and/or subsequent 
processing exist between macrophages in an obese or lean adipose tissue environment. 
Therefore, we pre-exposed macrophages to 100 mg of lean (LeAT) or obese (ObAT) adipose 
tissue for 3 days to generate an ATM-alike phenotype in vitro, before co-culturing them 
with apoptotic adipocytes (experimental setup Figure 5A). To our surprise, only in one out of 
three individual flow cytometry experiments a significant yet small increase in the amount 
of neutral lipids taken up from apoptotic adipocytes was found in BMDMs pre-exposed to 
ObAT compared to LeAT (Figure 5B), pointing to relatively equal lipid uptake from apoptotic 
adipocytes by macrophages in a lean or obese adipose tissue environment. 
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Figure 5. Priming with obese adipose tissue provokes pro-inflammatory activation of macrophages in a co-
culture with apoptotic adipocytes. 
A Experimental set-up for studying efferocytosis of adipocytes by adipose tissue-primed macrophages in vitro. 
Medium was refreshed at day 4 and 7. B Mean Bodipy signal in PKH-stained BMDMs primed by adipose tissue 
explants and then co-cultured with apoptotic adipocytes for 4 hours. Three independent flow cytometry 
experiments are shown. C Cytokines measured in the supernatant of BMDMs co-cultured with apoptotic 
adipocytes for 24 hours, after being primed with lean or obese adipose tissue (LeAT or ObAT) for 3 days. D Relative 
gene expression of anti- (Il-10, Il-1rn, Tgf-β) and pro- (Il-6, Tnf-α) inflammatory cytokines in BMDMs exposed to 
live (LA) or apoptotic adipocytes (AA) for 24 hours. Expression in macrophages co-cultured with LA was set to 1. 
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Rather than differing in quantity, efferocytosis of adipocytes in an obese or lean adipose tissue 
environment may elicit different inflammatory responses. To study this, IL-6, IL-1ra, TNF-α and 
IL-10 were measured in supernatants of BMDMs co-cultured with apoptotic adipocytes for 
24 hours, after 3 days priming with LeAT or ObAT (experimental set-up Figure 5A). Whereas 
BMDMs primed with ObAT secreted more IL-6 during a co-culture with apoptotic adipocytes, 
they secreted less TNF-α and IL-1ra in response to apoptotic adipocytes than BMDMs primed 
with LeAT did. No IL-10 could be detected in the supernatants (Figure 5C). Strong inflammatory 
responses upon exposure to apoptotic adipocytes were specific for adipose tissue-primed 
macrophages, since none of the cytokines could be detected in the supernatant of control 
macrophages (held in 5% L929) co-cultured with apoptotic adipocytes (data not shown). 
Interestingly, however, on mRNA level control BMDMs displayed no regulation of Il-6 or 
Il-1rn, but did increase the expression of Tnf-α, Il-10 and Tgf-β in response to apoptotic 
adipocytes (Figure 5D). In contrast, gene expression levels in BMDMs primed with ObAT 
versus LeAT were in line with what we found on cytokine level, displaying enhanced Il-6 
yet reduced Il-1rn and Tnf-α expression upon efferocytosis of adipocytes (Figure 5E). Thus, 
Inflammatory activation of macrophages primed with obese versus lean adipose tissue did 
not resemble the inflammatory phenotype of control macrophages, and may be indicative of 
a disrupted response on apoptotic adipocytes. In line with this hypothesis, genes involved in 
lipid metabolism that were strongly induced in control BMDMs exposed to apoptotic versus 
live adipocytes (Figure 4A) were lower expressed in BMDMs primed with ObAT versus LeAT 
(Figure 5F). 
In obese adipose tissue, adipocyte number and size may overwhelm macrophages (32). 
Interestingly, however, we have found pro-inflammatory responses of macrophages primed 
by obese versus lean adipose tissue in a co-culture with equal numbers of apoptotic 
adipocytes, suggestive of distinct regulation in macrophages confronted with cell death in 
an obese versus lean adipose tissue environment irrespective of the dead adipocyte load. To 
study this, we looked for differentially regulated gene sets in BMDMs exposed to UV-irradiated 
(dying) ObAT versus LeAT tissue (100 mJ/cm2 UV-C light) (Figure 6A) for 3 days. By applying 
gene set enrichment analysis (GSEA) on complete transcriptomes, we found enrichment of 
gene sets representing ER stress and oxidative stress in macrophages exposed to dying ObAT 
versus dying LeAT (Figure 6B). This result was corroborated by the identification of reactive 
oxygen species as upstream regulator in macrophages exposed to dying ObAT versus dying 
LeAT using IPA (activation z-score 2.528, p<0.01). Interestingly, ER stress and oxidative stress 
appeared to be specifically enhanced in macrophages exposed to dying versus live obese but 
not lean adipose tissue (Figure 6C). Hence, cell death in an obese adipose tissue environment 
E Relative gene expression of anti- (Il-10, Il-1rn, Tgf-β) and pro- (Il-6, Tnf-α) inflammatory cytokines in BMDMs 
exposed to AA for 24 hours after being primed with LeAT or ObAT for 3 days. Expression in macrophages primed 
with LeAT was set to 1. F Relative expression of genes involved in lipid processing in BMDMs primed with LeAT or 
ObAT for 3 days and subsequently exposed to AA for 24 hours. Expression in macrophages primed with LeAT was 
set to 1. Significance was calculated using student’s t-tests. Data are shown as mean + SEM. * p < 0.05, ** p < 0.01. 
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activates ER stress and oxidative stress in macrophages, which may fuel their inflammatory 
responses (33). Direct contact with apoptotic adipocytes, however, did not induce oxidative 
stress or ER stress markers in the ObAT-primed BMDMs (data not shown). It is therefore 
unlikely that oxidative stress or ER stress underlies the inflammatory response on apoptotic 
adipocytes found in BMDMs primed with ObAT versus LeAT. 
Interferon signalling is impaired in macrophages in an obese adipose tissue 
environment
Next to activation of oxidative and ER stress, strong depletion of both type I and type II 
interferon (IFN) signalling was found in macrophages exposed to dying ObAT versus dying 
LeAT (Figure 7A, experimental set-up as in Figure 6B), which was confirmed by IPA reporting 
a reduction in interferons as upstream regulators (activation z-score -5.605, p<0.01). The 
IFN gene sets were only depleted in BMDMs exposed to dying versus live ObAT (Figure 7B, 
experimental set-up as in Figure 6C), suggestive of disruption of IFN signalling in macrophages 
in an obese adipose tissue environment specifically. Interestingly, IFN signalling appeared to 
have in vivo relevance as well, evident by depletion of IFN signalling in ATMs from obese 
versus lean mice (Figure 7C). An overview of significantly enriched or depleted gene sets in 
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Figure 6. Cell death in obese adipose tissue explants promotes ER stress and oxidative stress in BMDMs. 
A Presence of cleaved Caspase-3 and b-Tubulin (loading control) in adipose tissue explant at two time points 
after irradiation with UV or treatment with Staurosporine (Stau). Enrichment of gene sets related to ER stress 
and oxidative stress in BMDMs exposed to UV-irradiated ObAT compared to BMDMs exposed to UV-irradiated 
LeAT for 3 days (B), and BMDMs exposed to UV-irradiated AT (lean or obese) compared to BMDMs exposed to 
non-treated AT (lean or obese) for 3 days (C). Gene Set Enrichment Analysis was done on the complete BMDM 
transcriptomes. 
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the different datasets of BMDMs exposed to adipose tissue can be found in Supplementary 
Table 1-3. 
Enhanced interferon signalling in macrophages relates to immunologically silent 
responses toward apoptotic adipocytes in vitro
Interferon signalling has been shown involved in the regulation of efferocytic capacity of 
macrophages (34). We therefore reasoned that IFN signalling might be essential for efficient 
efferocytosis of adipocytes by macrophages and that reduced IFN signalling in macrophages 
in an obese adipose tissue environment may underlie disrupted processing of apoptotic 
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Figure 7. Interferon signalling is induced upon adipocyte clearance but impaired in macrophages in an obese 
adipose tissue environment.
Interferon (IFN) signalling in BMDMs exposed to UV-irradiated obese (ObAT) versus UV-irradiated lean (LeAT) 
adipose tissue for 3 days (A), in BMDMs exposed to UV-irradiated versus non-treated ObAT (obese) or UV-
irradiated versus non-treated LeAT (lean) for 3 days (B), or in adipose tissue macrophages isolated form obese 
versus lean mice (C); identified by Gene Set Enrichment Analysis using complete transcriptomes as input. D 
Expression of IFN-related genes in BMDMs co-cultured with live adipocytes (LA), apoptotic adipocytes (AA), or 
severe apoptotic adipocytes (SAA) for 24 hours. Expression in macrophages co-cultured with LA was set to 1. E 
Expression of IFN-related genes in BMDMs co-cultured with AA for 24 hours after being primed with LeAT or ObAT. 
Expression in macrophages primed with LeAT was set to 1. The difference in gene expression in macrophages 
co-cultured with AA vs. LA or SAA vs. LA was tested for significance using an one-way ANOVA with Bonferroni 
post-hoc test. Differences between ObAT- versus LeAT-primed macrophages were tested for significance using 
student’s t-tests. Data are shown as mean + SEM. * p < 0.05, ** p < 0.01.
Chapter 6
148
adipocytes and/or inflammatory responses. In line with this reasoning genes part of IFN 
signalling pathways, namely Irf7, Stat1, Ifi44, Ifi47, Isg15 and Tap1, were or tended to be 
higher expressed in BMDMs co-cultured with apoptotic versus live adipocytes (Figure 7D). 
Interestingly, these genes were lower or not differentially expressed in response to apoptotic 
adipocytes by BMDMs primed with ObAT versus LeAT (Figure 7E). Of note, no clear difference 
between regulation of Type I-specific (Ifi-44, Isg15) versus Type II-specific (Ifi47, Tap1) (35) 
genes was found. Hence, more work is needed to conclude on the relative involvement of 
the two IFN signalling pathways. 
To decipher whether activated IFN signalling is indeed of importance during efferocytosis of 
adipocytes, macrophages were pre-treated with the type I interferon IFN-γ (10 ng/mL) before 
co-culturing them with apoptotic adipocytes for 6 or 24 hours. However, no clear difference 
in expression of the efferocytosis marker genes involved in lipid uptake and processing was 
found between IFN-γ pre-treated and control macrophages (Supplementary Figure 2A), nor 
in the expression of cytokines (Supplementary Figure 2B). Importantly, however, we used 
IFN-γ pre-treatment as tool for enhancing IFN signalling, yet found many genes involved in 
both Type I and Type II IFN responses to be reduced upon the pre-treatment (Supplementary 
Figure 2C). Because Ifn-α,-β, and -γ, nor their receptors Ifnar and Ifngr were regulated in 
macrophages exposed to dead adipocytes, IFNs itself are likely not responsible for enhanced 
IFN signalling in macrophages clearing dead adipocytes.
Relevance of efferocytosis in an obese adipose tissue environment
To examine the relevance of the phagocytic machinery in obese adipose tissue, when 
adipocyte cell death becomes clearly apparent, we interfered with efferocytosis in mice fed 
a high-fat diet (HFD) for 10 weeks. To do so, HFD-fed mice were given a daily oral gavage 
with either vehicle (Cntrl, n=6) or 25 mg BMS-777607 (BMS, n=6) per kg bodyweight for two 
weeks while remaining on a HFD (experimental set-up Figure 8A). BMS is an inhibitor of the 
Mer receptor tyrosine kinase (MerTK) (36), which is involved in phagocytosis and has been 
shown to affect efferocytosis in fatty tissues upon oral delivery (37). Both total bodyweight 
and weight of two main adipose tissue depots, inguinal (iWAT) and gonadal (gWAT) adipose 
tissue, did not change upon BMS treatment (Figure 8B), nor did the weight of any other 
tissue (data not shown). In both iWAT and gWAT no gross histological differences could be 
observed between BMS-treated and control mice (Figure 8C). Interestingly, however, the 
expression of several cell death markers was increased in iWAT of mice exposed to BMS 
(Figure 8D). Although increased cell death was not apparent in gWAT (Figure 8E), microarray 
analysis and subsequent GSEA of gWAT of BMS-treated mice revealed strong depletion of IFN 
signalling (Figure 8F). Given our finding of reduced IFN signalling in macrophages exposed 
to cell death in an obese adipose tissue environment (Figure 7), depleted IFN signalling in 
gWAT of BMS-treated animals may be suggestive of impaired efferocytosis. To examine 
whether BMS treatment affected the inflammatory state of adipose tissue, we measured 
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the expression of some macrophage markers (F4/80, Cd206, Cd11c). In general, there was a 
trend toward lower macrophage marker expression in the adipose tissue of mice treated with 
BMS, although only a reduction in F4/80 expression reached significance in iWAT (Figure 8G) 
but not gWAT (Figure 8H). We found no differences in plasma glucose, insulin, triglycerides, 
non-esterfied fatty acids (NEFA), adiponectin, or leptin (Supplementary Figure 3). Hence, 
although BMS-treated animals show signs of impaired efferocytosis in adipose tissue, this did 
not yet translate into adipose tissue inflammation or gross metabolic disturbances. 
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Figure 8. Relevance of the efferocytic machinery in adipose tissue of obese mice.
A Experimental design to examine the role for efferocytosis in adipose tissue of obese mice. In short, mice on a 
high-fat diet (HFD) for 10 weeks were given a daily oral gavage with either vehicle (Cntrl) or BMS-777607 (BMS) 
for two weeks (to inhibit the Mer receptor tyrosine kinase that is involved in phagocytosis) while remaining on a 
HFD. B Bodyweight (BWt), and weight of inguinal (iWAT) and gonadal (gWAT) adipose tissue of BMS-treated (BMS) 
and control (Cntrl) mice. C Representative imagines of iWAT and gWAT stained for F4/80 in BMS-treated and Cntrl 
mice. Relative expression of several cell death markers in iWAT (D) and gWAT (E) of BMS-treated and Cntrl mice. 
F Depleted Type I and Type II IFN gene sets in gWAT of BMS-treated compared to Cntrl mice, identified by Gene 
Set Enrichment Analysis using complete transcriptomes as input. Relative expression of macrophage markers in 
iWAT (G) and gWAT (H) of BMS-treated and Cntrl mice. Expression in Cntrl mice was set to 1. Differences in gene 
expression between BMS-treated and Cntrl animals were tested for significance using student’s t-tests. Data are 
shown as mean + SEM. * p < 0.05, ** p < 0.01.  
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DISCUSSION
Adipocyte death, clearance, and de novo adipogenesis are crucial for adipose tissue 
functioning and, ultimately, whole body homeostasis (32). Persistent appearance of crown-
like structures (CLS) defined by pro-inflammatory macrophages around dead adipocytes in 
obese adipose tissue points to ineffective adipocyte removal (6, 9, 16, 18). Here, we show 
that the efferocytic machinery is activated during obesity and that its inhibition increases 
markers of cell death in obese adipose tissue. In vitro studies, however, point to disrupted 
macrophage responses toward apoptotic adipocytes in an obese adipose tissue environment. 
Interestingly, interferon (IFN) signalling appeared to be involved in effective efferocytosis of 
dead adipocytes, yet was impaired in ATMs part of obese adipose tissue, suggestive of a link 
between reduced IFN signalling and ATM functioning during obesity. 
In lean conditions, adipocyte cell death induced by weight loss or prolonged lipolysis initiates 
rapid formation of CLS and clearance of dead adipocytes in an anti-inflammatory fashion (13, 
14, 38). Recently, clearance of adipocytes by macrophages in CLS has been demonstrated in 
vitro (11, 12, 16), as well as in obese adipose tissue (12). We observed lipid uptake from dead 
adipocytes by macrophages primed by obese or lean adipose tissue and found enhanced 
regulation of the efferocytic machinery in ATMs isolated from obese mice, confirming a role 
for efferocytosis in the adipose tissue, especially during obesity. Macrophages have been 
shown to start clearing adipocytes in CLS within an hour (12). Indeed, we found uptake 
of lipids from adipocytes by macrophages after a 4-hour co-culture. However, most likely 
complete adipocyte clearance is relatively slow compared to clearance of smaller apoptotic 
target cells (39), as suggested by a previous study (11) and corroborated by our in vitro 
transcriptional data revealing little regulation in macrophages after a 6-hour, but profound 
regulation of genes involved in lipid uptake and processing after a 24-hour co-culture with 
dead adipocytes. 
Classically, efferocytosis is an immunologically silent process, driving the release of anti-
inflammatory cytokines (3, 40, 41). Macrophages part of CLS in obese adipose tissue, 
however, display pro-inflammatory characteristics (9, 16, 18). Incomplete uptake of foreign 
bodies, sometimes referred to as ‘frustrated phagocytosis’, fuels inflammatory macrophage 
responses via the release of noxious content (3, 40, 42) and is most often seen when 
macrophages are confronted with a target much bigger than themselves (42). As such, 
one could think of a state of ‘frustrated efferocytosis’ in obese adipose tissue, in which 
adipocyte size is of particular relevance. On the other hand, one may speculate that the 
increased apoptotic adipocyte cargo in obese adipose tissue overwhelms macrophages. 
Naturally, processing dead cell material comes with high levels of metabolic stress. In case of 
adipocytes, macrophages need to deal with extremely high levels of lipids. Not surprisingly, 
we found enhanced expression of various genes involved in lipid processing in macrophages 
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co-cultured with apoptotic adipocytes. Importantly, L929-derived (Cntrl) macrophages 
responded to apoptotic adipocytes in a primarily immunologically silent manner. First, we 
could not detect any cytokines in the supernatants of control macrophages co-cultured 
with apoptotic adipocytes. Moreover, on gene expression level a rather pro-efferocytic 
inflammatory profile was detected, with increased expression of Il-10 and Tgf-β; both well-
known to be produced by macrophages during effective, immunologically silent clearance of 
dead cells (40, 41). Unexpectedly, however, Tnf-α was upregulated as well. Although TNF-α 
is generally considered to interfere with efferocytosis (43), its induction in macrophages co-
cultured with dead adipocytes might hold relevance during adipocyte clearance specifically. 
This is, however, highly speculative and warrants further investigation. Intriguingly, compared 
to macrophages primed with lean adipose tissue, macrophages primed with obese adipose 
produced more IL-6, yet less TNF-a and IL-1ra in response to apoptotic adipocytes. This is the 
opposite of what we observed in control macrophages, suggestive of a disrupted response 
toward dead adipocytes by macrophages primed with obese versus lean adipose tissue. 
Although lipid uptake from apoptotic adipocytes was found to be equal in flow cytometry 
measurements, our finding of reduced expression of genes involved in lipid processing in 
macrophages primed with obese versus lean adipose tissue corroborates the hypothesis of 
disrupted responses toward adipocytes by obese adipose-primed macrophages. However, 
based on our results we are unable to draw any conclusions regarding causal relationships 
between lipid processing and inflammatory activation upon adipocyte clearance by 
macrophages. 
Interestingly, our data show that priming of macrophages in an obese adipose tissue 
environment affects future responses toward dead adipocytes, suggestive of obesity-
specific rewiring of macrophage pathways involved in efferocytosis of adipocytes. Interferon 
signalling appeared strongly depleted in macrophages in an obese versus lean adipose tissue 
environment. Because various IFN-related genes were upregulated during efferocytosis 
of adipocytes by control macrophages, we hypothesize that IFN signalling is important for 
effective clearance of dead adipocytes. However, several questions remain to be answered. 
For example, what drives IFN-related gene expression in macrophages co-cultured with 
apoptotic adipocytes? Is IFN signalling in macrophages functionally important during 
adipocyte clearance? If so, are Type I and Type II IFN signalling equally activated and do 
they both contribute to cellular clearance? Lastly, why is IFN-signalling downregulated in 
macrophages in an obese versus lean adipose tissue environment?
Initiation of Type I IFN signalling, among which IFN-α and IFN-β, upon recognition 
of exogenous DNA by innate immune cells is well-described and, together with the Type 
II interferon IFN-γ, mediates antiviral responses (44, 45). As such, DNA from apoptotic 
adipocytes engulfed by macrophages may drive expression of IFN-related genes. Although it 
is not unthinkable that IFN signalling has an exogenous origin, IFN-γ itself was not detectable 
in the supernatant of adipose tissue, nor in BMDM co-cultured with adipocytes or adipose 
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tissue.
Interestingly, IFNs may directly affect efferocytosis by macrophages; IFN-α has been 
shown to enhance phagocytosis of latex beads (34), and IFN-γ stimulates the uptake 
of apoptotic cells or pathogens (46-48). Not only the uptake itself, but also macrophage 
responses upon uptake may be affected by IFN signalling. For example, several anti-
inflammatory properties have been attributed to Type I IFNs (49), and T-cell-derived IFN-γ 
has been shown to be involved in immunosuppressive responses of dendritic cells upon 
efferocytosis (50). Intriguingly, IFN signalling downstream the Type I IFN receptor IFNAR has 
been shown to enhance expression of the family of TAM receptor tyrosine kinases including 
Mer tyrosine kinase (MerTK), which, on their turn, reduce inflammatory cytokine production 
via IFN signalling involving STAT1 and SOCS1 and -3 (51). Hence, IFN signalling may on the one 
hand affect efferocytosis itself via regulation of its receptors and on the other hand shape 
inflammatory activation upon efferocytosis of apoptotic cells. As such, impaired IFN signalling 
in the obese state may be responsible for pro-inflammatory macrophage responses upon 
efferocytosis of apoptotic adipocytes. Noteworthy, IFNs also reprogram cellular metabolism, 
including fatty acid oxidation, and affect lipid uptake and processing (52), which on their turn 
regulate IFN signalling (53). 
Hence, many relations between IFN signalling and lipid metabolism, as well as efficient, 
immunologically silent clearance of dead cells exist and may play a role in adipocyte clearance. 
Alternatively, given the crucial role for IFNs during macrophage development and functioning 
(54, 55), reduced IFN signalling might be an a-specific consequence of impaired macrophage 
functioning. Interestingly, administration of IFN-τ, a Type I IFN, during the development of 
diet-induced obesity reduced the presence of macrophages displaying classical inflammatory 
markers in the adipose tissue and could alleviate the development of insulin resistance in 
mice (56). On the other hand, reducing Type I IFN signalling in adipocytes by adiponectin-
driven deletion of Ifnar1 increased weight gain and impaired glucose tolerance in mice on a 
high-fat diet (57). Considering the tight interactions between adipocytes and macrophages, 
one could speculate that impaired IFN signalling and production by ATMs affects adipose 
tissue functioning via reducing IFN signalling in adipocytes. Future studies are warranted to 
elucidate the relevance of IFN signalling in macrophages and adipocytes part of obese adipose 
tissue. Moreover, the role of IFN signalling during efferocytosis, i.e. uptake and processing of 
adipocytes, and during the shaping of inflammatory responses upon efferocytosis remains 
to be elucidated, as well as the relevance for Type I versus Type II IFN signalling in ATMs.
Functional impairment of MerTK has been shown to fuel atherosclerosis in humans and mice 
(58, 59). MerTK recognizes phosphatidylserine on membranes of apoptotic cells by binding 
to bridging molecules like GAS6 and has been shown critically involved in efferocytosis and 
anti-inflammatory responses in macrophages (60, 61). Interestingly, despite a relatively low 
turnover rate of adipocytes – estimated to range from 10%-100% per year in lean individuals 
yet currently unknown for obese individuals (32) – MerTK inhibition by BMS-777607 (BMS) in 
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obese mice increased cell death markers in the inguinal adipose tissue (iWAT), and reduced 
IFN-signalling in gonadal adipose tissue (gWAT), both pointing to impaired clearance of dead 
adipocytes. Of note, as described above IFN signalling and TAM receptors functioning among 
which MerTK have shown to be intertwined (51), and inhibition of MerTK in BMS-treated 
mice might have directly affected IFN signalling.
Differences in adiposity and adipocyte turnover, and immune cell populations 
including macrophages in iWAT versus gWAT are well-characterized (62), and may explain 
the distinct transcriptional responses upon BMS-treatment in the different adipose tissue 
depots. For example, high rates of adipocyte cell death in gWAT (7) may have overruled small 
changes in adipocyte cell death markers upon treatment with BMS. Alternatively, variation 
in the inflammatory trait of macrophages that directly relates to their efferocytic capacity 
and MerTK expression (7, 11, 61) may have contributed to depot-specific differences. 
Methodologically, oral administration of BMS may have unequally reached the two adipose 
tissue depots as well. 
Although we did observe changes in the adipose tissue transcriptome hinting toward 
reduced efferocytosis upon BMS treatment, inhibition of MerTK did not affect adipose tissue 
inflammation or plasma parameters in obese mice. Absence of strong phenotypical changes 
may relate to a fundamental role for efferocytosis in obese adipose tissue that would facilitate 
compensatory pathways to ensure adipocyte clearance in BMS-treated mice. Alternatively, 
classical efferocytosis might hold little relevance in the adipose tissue. Electron microscopy 
of adipose tissue from obese mice has shown extrusion of lipid droplets from dying 
adipocytes, taken up by macrophages nearby in CLS (11). Moreover, macrophages have been 
found to degrade lipids in extracellular acidic compartments at sites of contact with dying 
adipocytes in CLS (12). Both observations are clearly different from classical efferocytosis 
of dying cells and appear to depend on lipid catabolism rather than the classical phagocytic 
machinery. Our in vitro and in vivo observation of enhanced expression of genes involved in 
lipid processing but not those involved in classical efferocytosis is in line with these studies 
pointing to unique regulation for adipocyte clearance by ATMs, and may advocate against an 
important role for MerTK. 
In conclusion, we reveal activation of the efferocytic machinery involving lipid processing 
in ATMs during obesity. In vitro we found disrupted responses toward apoptotic adipocytes 
when macrophages were primed with obese adipose tissue. Interestingly, this observation 
is suggestive of changes in the efferocytic response of ATMs irrespective of lipid load, since 
macrophages primed with obese or lean adipose tissue were exposed to equal numbers 
of adipocytes. In vivo, however, obesity-driven changes in adipocyte cargo, for example 
via increased adipocyte number and size (63, 64) or alterations in composition of lipids 
stored (65-67), may further impede adipocyte clearance by macrophages and thereby 
further contribute to inflammatory activation of ATMs. Future studies aimed at unravelling 
regulation of efferocytosis in obese versus lean adipose tissue including the IFN signalling 
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route are warranted and may provide new targets to improve macrophage functioning and 
abate adipose tissue inflammation during obesity.
ACKNOWLEDGEMENTS
This study was supported by a Vidi grant from the Netherlands Organization for Scientific 
Research (#91713311) and a Senior Fellowship from the Dutch Diabetes Foundation 
(#2015.82.1824).
Chapter 6
156
REFERENCES
1. Pollard JW (2009) Trophic macrophages in development and disease. Nature reviews. Immunology 9(4):259-
270.
2. Kerr JF, Wyllie AH, & Currie AR (1972) Apoptosis: a basic biological phenomenon with wide-ranging 
implications in tissue kinetics. British journal of cancer 26(4):239-257.
3. Poon IK, Lucas CD, Rossi AG, & Ravichandran KS (2014) Apoptotic cell clearance: basic biology and 
therapeutic potential. Nature reviews. Immunology 14(3):166-180.
4. Alkhouri N, et al. (2010) Adipocyte Apoptosis, a Link between Obesity, Insulin Resistance, and Hepatic 
Steatosis. Journal of Biological Chemistry 285(5):3428-3438.
5. Feng D, et al. (2011) High-fat diet-induced adipocyte cell death occurs through a cyclophilin D intrinsic 
signaling pathway independent of adipose tissue inflammation. Diabetes 60(8):2134-2143.
6. Cinti S, et al. (2005) Adipocyte death defines macrophage localization and function in adipose tissue of 
obese mice and humans. Journal of lipid research 46(11):2347-2355.
7. Strissel KJ, et al. (2007) Adipocyte death, adipose tissue remodeling, and obesity complications. Diabetes 
56(12):2910-2918.
8. Murano I, et al. (2008) Dead adipocytes, detected as crown-like structures, are prevalent in visceral fat 
depots of genetically obese mice. Journal of lipid research 49(7):1562-1568.
9. Lumeng CN, DelProposto JB, Westcott DJ, & Saltiel AR (2008) Phenotypic switching of adipose tissue 
macrophages with obesity is generated by spatiotemporal differences in macrophage subtypes. Diabetes 
57(12):3239-3246.
10. Weisberg SP, et al. (2003) Obesity is associated with macrophage accumulation in adipose tissue. The 
Journal of clinical investigation 112(12):1796-1808.
11. Kwon HJ, Kim SN, Kim YA, & Lee YH (2016) The contribution of arachidonate 15-lipoxygenase in tissue 
macrophages to adipose tissue remodeling. Cell Death Dis 7(6):e2285.
12. Haka AS, et al. (2016) Exocytosis of macrophage lysosomes leads to digestion of apoptotic adipocytes and 
foam cell formation. Journal of lipid research 57(6):980-992.
13. Lee YH, Petkova AP, & Granneman JG (2013) Identification of an adipogenic niche for adipose tissue 
remodeling and restoration. Cell metabolism 18(3):355-367.
14. Lee YH, Kim SN, Kwon HJ, Maddipati KR, & Granneman JG (2016) Adipogenic role of alternatively activated 
macrophages in beta-adrenergic remodeling of white adipose tissue. American journal of physiology. 
Regulatory, integrative and comparative physiology 310(1):R55-65.
15. Fischer-Posovszky P, Wang QA, Asterholm IW, Rutkowski JM, & Scherer PE (2011) Targeted deletion of 
adipocytes by apoptosis leads to adipose tissue recruitment of alternatively activated M2 macrophages. 
Endocrinology 152(8):3074-3081.
16. Gericke M, Weyer U, Braune J, Bechmann I, & Eilers J (2015) A method for long-term live imaging of tissue 
macrophages in adipose tissue explants. American journal of physiology. Endocrinology and metabolism 
308(11):E1023-1033.
17. Shapiro H, et al. (2013) Adipose tissue foam cells are present in human obesity. The Journal of clinical 
endocrinology and metabolism 98(3):1173-1181.
18. Lumeng CN, Deyoung SM, Bodzin JL, & Saltiel AR (2007) Increased inflammatory properties of adipose 
tissue macrophages recruited during diet-induced obesity. Diabetes 56(1):16-23.
19. Prieur X, et al. (2011) Differential lipid partitioning between adipocytes and tissue macrophages modulates 
macrophage lipotoxicity and M2/M1 polarization in obese mice. Diabetes 60(3):797-809.
20. Abrass CK & Hori M (1984) Alterations in Fc receptor function of macrophages from streptozotocin-induced 
diabetic rats. Journal of immunology 133(3):1307-1312.
21. Schrijvers DM, De Meyer GR, Kockx MM, Herman AG, & Martinet W (2005) Phagocytosis of apoptotic 
cells by macrophages is impaired in atherosclerosis. Arteriosclerosis, thrombosis, and vascular biology 
25(6):1256-1261.
22. Khanna S, et al. (2010) Macrophage dysfunction impairs resolution of inflammation in the wounds of 
diabetic mice. PloS one 5(3):e9539.
23. Fischer-Posovszky P, Newell FS, Wabitsch M, & Tornqvist HE (2008) Human SGBS cells - a unique tool for 
studies of human fat cell biology. Obesity facts 1(4):184-189.
24. Lin K, et al. (2011) MADMAX - Management and analysis database for multiple ~omics experiments. Journal 
of integrative bioinformatics 8(2):160.
25. Bolstad BM, Irizarry RA, Astrand M, & Speed TP (2003) A comparison of normalization methods for high 
density oligonucleotide array data based on variance and bias. Bioinformatics 19(2):185-193.
26. Irizarry RA, et al. (2003) Exploration, normalization, and summaries of high density oligonucleotide array 
probe level data. Biostatistics 4(2):249-264.
27. Dai MH, et al. (2005) Evolving gene/transcript definitions significantly alter the interpretation of GeneChip 
Efferocytosis of adipocytes by macrophages in the adipose tissue
157
6
data. Nucleic Acids Res 33(20).
28. Ritchie ME, et al. (2015) limma powers differential expression analyses for RNA-sequencing and microarray 
studies. Nucleic Acids Res 43(7):e47.
29. Sartor MA, et al. (2006) Intensity-based hierarchical Bayes method improves testing for differentially 
expressed genes in microarray experiments. BMC bioinformatics 7:538.
30. Subramanian A, et al. (2005) Gene set enrichment analysis: a knowledge-based approach for interpreting 
genome-wide expression profiles. Proceedings of the National Academy of Sciences of the United States of 
America 102(43):15545-15550.
31. Yu GC, Wang LG, Han YY, & He QY (2012) clusterProfiler: an R Package for Comparing Biological Themes 
Among Gene Clusters. Omics 16(5):284-287.
32. Boutens L & Stienstra R (2016) Adipose tissue macrophages: going off track during obesity. Diabetologia 
59(5):879-894.
33. Garg AD, et al. (2012) ER stress-induced inflammation: does it aid or impede disease progression? Trends in 
molecular medicine 18(10):589-598.
34. Yanguez E, et al. (2013) ISG15 regulates peritoneal macrophages functionality against viral infection. PLoS 
pathogens 9(10):e1003632.
35. Der SD, Zhou A, Williams BR, & Silverman RH (1998) Identification of genes differentially regulated by 
interferon alpha, beta, or gamma using oligonucleotide arrays. Proceedings of the National Academy of 
Sciences of the United States of America 95(26):15623-15628.
36. Schroeder GM, et al. (2009) Discovery of N-(4-(2-amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-
ethoxy-1-(4-fluorophenyl )-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a selective and orally 
efficacious inhibitor of the Met kinase superfamily. Journal of medicinal chemistry 52(5):1251-1254.
37. Stanford JC, et al. (2014) Efferocytosis produces a prometastatic landscape during postpartum mammary 
gland involution. The Journal of clinical investigation 124(11):4737-4752.
38. Kosteli A, et al. (2010) Weight loss and lipolysis promote a dynamic immune response in murine adipose 
tissue. The Journal of clinical investigation 120(10):3466-3479.
39. Elliott MR & Ravichandran KS (2016) The Dynamics of Apoptotic Cell Clearance. Developmental cell 
38(2):147-160.
40. Voll RE, et al. (1997) Immunosuppressive effects of apoptotic cells. Nature 390(6658):350-351.
41. Fadok VA, Warner ML, Bratton DL, & Henson PM (1998) CD36 is required for phagocytosis of apoptotic cells 
by human macrophages that use either a phosphatidylserine receptor or the vitronectin receptor (alpha v 
beta 3). Journal of immunology 161(11):6250-6257.
42. Medzhitov R (2008) Origin and physiological roles of inflammation. Nature 454(7203):428-435.
43. McPhillips K, et al. (2007) TNF-alpha inhibits macrophage clearance of apoptotic cells via cytosolic 
phospholipase A2 and oxidant-dependent mechanisms. Journal of immunology 178(12):8117-8126.
44. Barbalat R, Ewald SE, Mouchess ML, & Barton GM (2011) Nucleic acid recognition by the innate immune 
system. Annual review of immunology 29:185-214.
45. Pierce AT, et al. (2005) Beta interferon and gamma interferon synergize to block viral DNA and virion 
synthesis in herpes simplex virus-infected cells. The Journal of general virology 86(Pt 9):2421-2432.
46. Marodi L, et al. (1993) Enhancement of macrophage candidacidal activity by interferon-gamma. Increased 
phagocytosis, killing, and calcium signal mediated by a decreased number of mannose receptors. The 
Journal of clinical investigation 91(6):2596-2601.
47. Schiff DE, Rae J, Martin TR, Davis BH, & Curnutte JT (1997) Increased phagocyte Fc gammaRI expression and 
improved Fc gamma-receptor-mediated phagocytosis after in vivo recombinant human interferon-gamma 
treatment of normal human subjects. Blood 90(8):3187-3194.
48. Fernandez-Boyanapalli R, et al. (2010) Impaired phagocytosis of apoptotic cells by macrophages in 
chronic granulomatous disease is reversed by IFN-gamma in a nitric oxide-dependent manner. Journal of 
immunology 185(7):4030-4041.
49. Billiau A (2006) Anti-inflammatory properties of Type I interferons. Antiviral research 71(2-3):108-116.
50. Ren G, et al. (2008) Apoptotic cells induce immunosuppression through dendritic cells: critical roles of IFN-
gamma and nitric oxide. Journal of immunology 181(5):3277-3284.
51. Rothlin CV, Ghosh S, Zuniga EI, Oldstone MB, & Lemke G (2007) TAM receptors are pleiotropic inhibitors of 
the innate immune response. Cell 131(6):1124-1136.
52. Wu D, et al. (2016) Type 1 Interferons Induce Changes in Core Metabolism that Are Critical for Immune 
Function. Immunity 44(6):1325-1336.
53. York AG, et al. (2015) Limiting Cholesterol Biosynthetic Flux Spontaneously Engages Type I IFN Signaling. 
Cell 163(7):1716-1729.
54. Farrar MA & Schreiber RD (1993) The molecular cell biology of interferon-gamma and its receptor. Annual 
review of immunology 11:571-611.
55. Gough DJ, Messina NL, Clarke CJ, Johnstone RW, & Levy DE (2012) Constitutive type I interferon modulates 
homeostatic balance through tonic signaling. Immunity 36(2):166-174.
Chapter 6
158
56. Ying W, et al. (2014) Interferon tau alleviates obesity-induced adipose tissue inflammation and insulin 
resistance by regulating macrophage polarization. PloS one 9(6):e98835.
57. Wieser V, et al. (2016) Adipose type I interferon signalling protects against metabolic dysfunction. Gut.
58. Thorp E, Cui D, Schrijvers DM, Kuriakose G, & Tabas I (2008) Mertk receptor mutation reduces efferocytosis 
efficiency and promotes apoptotic cell accumulation and plaque necrosis in atherosclerotic lesions of 
apoe-/- mice. Arteriosclerosis, thrombosis, and vascular biology 28(8):1421-1428.
59. Liao D, et al. (2009) Human protein S inhibits the uptake of AcLDL and expression of SR-A through Mer 
receptor tyrosine kinase in human macrophages. Blood 113(1):165-174.
60. Scott RS, et al. (2001) Phagocytosis and clearance of apoptotic cells is mediated by MER. Nature 
411(6834):207-211.
61. Zizzo G, Hilliard BA, Monestier M, & Cohen PL (2012) Efficient clearance of early apoptotic cells by human 
macrophages requires M2c polarization and MerTK induction. Journal of immunology 189(7):3508-3520.
62. van Beek L, et al. (2015) The limited storage capacity of gonadal adipose tissue directs the development of 
metabolic disorders in male C57Bl/6J mice. Diabetologia 58(7):1601-1609.
63. Jo J, et al. (2009) Hypertrophy and/or Hyperplasia: Dynamics of Adipose Tissue Growth. PLoS computational 
biology 5(3):e1000324.
64. Spalding KL, et al. (2008) Dynamics of fat cell turnover in humans. Nature 453(7196):783-787.
65. Caesar R, et al. (2010) A combined transcriptomics and lipidomics analysis of subcutaneous, epididymal 
and mesenteric adipose tissue reveals marked functional differences. PloS one 5(7):e11525.
66. Duarte JA, et al. (2014) A high-fat diet suppresses de novo lipogenesis and desaturation but not elongation 
and triglyceride synthesis in mice. Journal of lipid research 55(12):2541-2553.
67. Yew Tan C, et al. (2015) Adipose tissue fatty acid chain length and mono-unsaturation increases with 
obesity and insulin resistance. Scientific reports 5:18366.
Efferocytosis of adipocytes by macrophages in the adipose tissue
159
6
SUPPLEMENTARY FIGURES AND TABLES
1/6
 LA
1/6
 A
A
1/6
 S
AA 1 L
A
1 A
A
1 S
AA
0.0
0.5
1.0
1.5
Li
pa
 e
xp
re
ss
io
n
1/6
 LA
1/6
 A
A
1/6
 S
AA 1 L
A
1 A
A
1 S
AA
0.0
0.5
1.0
1.5
C
d3
6
ex
pr
es
si
on
1/6
 LA
1/6
 A
A
1/6
 S
AA 1 L
A
1 A
A
1 S
AA
0.0
0.5
1.0
1.5
P
lin
2
ex
pr
es
si
on
1/6
 LA
1/6
 A
A
1/6
 S
AA 1 L
A
1 A
A
1 S
AA
0.0
0.5
1.0
1.5
Ab
cg
1
ex
pr
es
si
on
1/6
 LA
1/6
 A
A
1/6
 S
AA 1 L
A
1 A
A
1 S
AA
0.0
0.5
1.0
1.5
2.0
** **
Lp
le
xp
re
ss
io
n
1/6
 LA
1/6
 A
A
1/6
 S
AA 1 L
A
1 A
A
1 S
AA
0.0
0.5
1.0
1.5
At
p6
v0
d2
ex
pr
es
si
on
Supplementary Figure 1. No regulation of genes involved in lipid uptake and processing yet after a 6-hour 
co-culture with dead adipocytes.
Relative expression of several genes involved in lipid uptake and processing in BMDMs exposed to two 
concentrations of either live adipocytes (LA), apoptotic adipocytes (AA), or severe apoptotic adipocytes (SAA) (1x 
or 1/6x of the amount of macrophages) for 6 hours. Expression in macrophages co-cultured with LA was set to 1. 
Significance was calculated using one-way ANOVA with Bonferroni post-hoc tests (AA vs. LA and SAA vs. LA). Data 
are shown as mean + SEM. * p < 0.05, ** p < 0.01.  
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Supplementary Figure 2. Pre-treatment with IFN-γ does not enhance IFN signalling in macrophages neither 
affects expression of genes involved in adipocyte clearance.
Relative expression of genes involved in lipid processing (A), genes encoding cytokines (B), or genes involved 
in IFN signalling (C) measured in BMDMs co-cultured with live adipocytes (LA), apoptotic adipocytes (AA), or 
severe apoptotic adipocytes (SAA) for 24 hours. The BMDMs were either pre-treated with 10 ng/mL IFN-γ for 24 h 
(IFN-γ) or not (Cntrl). Expression in Cntrl BMDMs co-cultured with LA was set to 1. Significant differences in gene 
expression were calculated using two-way ANOVA with Bonferroni post-hoc test comparing pre-treatment (IFN-γ 
vs. cntrl) and response upon cell death (AA vs. LA and SAA vs. LA). Data are shown as mean + SEM. * p < 0.05, ** p 
< 0.01 (AA vs. LA or SAA vs. LA), or # p < 0.05, ## p < 0.01 (IFN-γ vs. Cntrl).
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Supplementary Figure 3. Plasma parameters upon BMS-treatment in obese mice.
A Levels of glucose, insulin, triglycerides, non-esterfied fatty acids (NEFA), adiponectin and leptin measured in 
plasma of mice given BMS-777607 (BMS) or vehicle (Cntrl). Significance was calculated with student’s t-tests. Data 
are shown as mean + SEM. * p < 0.05, ** p < 0.01.  
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Supplementary Table 1.
A List of significantly (p<0.01) enriched gene sets identified by Gene Set Enrichment Analysis using the complete 
transcriptome of BMDMs exposed to UV-irradiated obese adipose tissue (ObAT) versus BMDMs exposed to UV-
irradiated lean adipose tissue for 3 days. Enriched gene sets in BMDMs exposed to UV-irradiated ObAT with a 
normalized enrichment score (NES)-score higher than 1.7 were included in the list. All significantly depleted gene 
sets in BMDMs exposed to UV-irradiated ObAT were included. 
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Supplementary Table 1.
B List of significantly (p<0.01) depleted gene sets identified by Gene Set Enrichment Analysis using the complete 
transcriptome of BMDMs exposed to UV-irradiated obese adipose tissue (ObAT) versus BMDMs exposed to UV-
irradiated lean adipose tissue for 3 days. Enriched gene sets in BMDMs exposed to UV-irradiated ObAT with a 
normalized enrichment score (NES)-score higher than 1.7 were included in the list. All significantly depleted gene 
sets in BMDMs exposed to UV-irradiated ObAT were included. 
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Supplementary Table 2.
A List of significantly (p<0.01) enriched gene sets identified by Gene Set Enrichment Analysis using the complete 
transcriptome of BMDMs exposed to UV-irradiated lean adipose tissue (LeAT) versus BMDMs exposed to 
non-treated LeAT for 3 days. Enriched gene sets in BMDMs exposed to UV-irradiated LeAT with a normalized 
enrichment score (NES)-score higher than 1.7 were included in the list. All significantly depleted gene sets in 
BMDMs exposed to UV-irradiated LeAT were included. 
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63 KEGG_STEROID.BIOSYNTHESIS 1,83
64 CELL.JUNCTION.ORGANIZATION 1,82
65 G2.M.CHECKPOINTS 1,82
66 G1.S.TRANSITION 1,82
67 HOMOLOGOUS.RECOMBINATION.REPAIR.OF.REPLICATION.INDEPENDENT.DOUBLE.STRAND.BREAKS 1,82
68 KSRP.DESTABILIZES.MRNA 1,82
69 E2F.MEDIATED.REGULATION.OF.DNA.REPLICATION 1,82
70 SEMAPHORIN.INTERACTIONS 1,81
71 SYNTHESIS.AND.INTERCONVERSION.OF.NUCLEOTIDE.DI.AND.TRIPHOSPHATES 1,81
72 DARPP.32.EVENTS 1,81
73 RNA.POLYMERASE.I.TRANSCRIPTION.TERMINATION 1,81
74 NUCLEAR.IMPORT.OF.REV.PROTEIN 1,8
75 WP1983.SPLICING.FACTOR.NOVA.REGULATED.SYNPATIC.PROTEINS 1,8
76 CHONDROITIN.SULFATE.DERMATAN.SULFATE.METABOLISM 1,8
77 SYNDECAN.INTERACTIONS 1,8
78 BIOC_CELLCYCLEPATHWAY 1,8
79 SIGNAL.TRANSDUCTION.BY.L1 1,79
80 DNA.REPAIR 1,78
81 KEGG_CELL.CYCLE 1,78
82 REGULATION.OF.CHOLESTEROL.BIOSYNTHESIS.BY.SREBP.SREBF. 1,78
83 WP1268.DIURNALLY.REGULATED.GENES.WITH.CIRCADIAN.ORTHOLOGS 1,78
84 TRNA.AMINOACYLATION 1,77
85 RNA.POLYMERASE.III.TRANSCRIPTION 1,77
86 NUCLEOTIDE.EXCISION.REPAIR 1,76
87 RNA.POLYMERASE.III.ABORTIVE.AND.RETRACTIVE.INITIATION 1,76
88 MRNA.SPLICING.MAJOR.PATHWAY 1,76
89 RNA.POLYMERASE.I.TRANSCRIPTION.INITIATION 1,76
90 CELL.CELL.COMMUNICATION 1,75
91 WP523.REGULATION.OF.ACTIN.CYTOSKELETON 1,75
92 BIOC_GHPATHWAY 1,75
93 S.PHASE 1,75
94 ACTIVATION.OF.GENE.EXPRESSION.BY.SREBF.SREBP. 1,75
95 CELL.CELL.JUNCTION.ORGANIZATION 1,75
96 ADRENALINE.NORADRENALINE.INHIBITS.INSULIN.SECRETION 1,75
97 KEGG_FOCAL.ADHESION 1,74
98 SMAD4.MH2.DOMAIN.MUTANTS.IN.CANCER 1,74
99 MRNA.SPLICING 1,74
100 LOSS.OF.FUNCTION.OF.SMAD4.IN.CANCER 1,74
101 TGFBR2.KINASE.DOMAIN.MUTANTS.IN.CANCER 1,74
102 TRANSPORT.OF.MATURE.TRANSCRIPT.TO.CYTOPLASM 1,74
103 TGFBR1.LBD.MUTANTS.IN.CANCER 1,74
104 SIGNALING.BY.TGF.BETA.RECEPTOR.COMPLEX 1,73
105 LOSS.OF.FUNCTION.OF.TGFBR2.IN.CANCER 1,73
106 LOSS.OF.FUNCTION.OF.SMAD2.3.IN.CANCER 1,73
107 SIGNALING.BY.TGF.BETA.RECEPTOR.COMPLEX.IN.CANCER 1,73
108 SEMA4D.IN.SEMAPHORIN.SIGNALING 1,73
109 REV.MEDIATED.NUCLEAR.EXPORT.OF.HIV.RNA 1,73
110 WP2185.PURINE.METABOLISM 1,72
111 LOSS.OF.FUNCTION.OF.TGFBR1.IN.CANCER 1,72
112 SMAD2.3.PHOSPHORYLATION.MOTIF.MUTANTS.IN.CANCER 1,72
113 ABORTIVE.ELONGATION.OF.HIV.1.TRANSCRIPT.IN.THE.ABSENCE.OF.TAT 1,72
114 A.TETRASACCHARIDE.LINKER.SEQUENCE.IS.REQUIRED.FOR.GAG.SYNTHESIS 1,72
115 TGFBR2.MSI.FRAMESHIFT.MUTANTS.IN.CANCER 1,71
116 OPIOID.SIGNALLING 1,71
117 KEGG_SIGNALING.PATHWAYS.REGULATING.PLURIPOTENCY.OF.STEM.CELLS 1,71
118 VIRAL.MESSENGER.RNA.SYNTHESIS 1,71
119 BASE.EXCISION.REPAIR 1,71
120 RNA.POLYMERASE.I.PROMOTER.ESCAPE 1,71
121 TRANSPORT.OF.THE.SLBP.DEPENDANT.MATURE.MRNA 1,71
122 WP258.TGF.BETA.RECEPTOR.SIGNALING.PATHWAY 1,7
123 SMAD2.3.MH2.DOMAIN.MUTANTS.IN.CANCER 1,7
124 KEGG_NUCLEOTIDE.EXCISION.REPAIR 1,7
125 WP509.NUCLEAR.RECEPTORS 1,7
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Supplementary Table 2.
B List of significantly (p<0.01) depleted gene sets identified by Gene Set Enrichment Analysis using the complete 
transcriptome of BMDMs exposed to UV-irradiated lean adipose tissue (LeAT) versus BMDMs exposed to 
non-treated LeAT for 3 days. Enriched gene sets in BMDMs exposed to UV-irradiated LeAT with a normalized 
enrichment score (NES)-score higher than 1.7 were included in the list. All significantly depleted gene sets in 
BMDMs exposed to UV-irradiated LeAT were included. 
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Supplementary Table 3.
A List of significantly (p<0.01) enriched gene sets identified by Gene Set Enrichment Analysis using the complete 
transcriptome of BMDMs exposed to UV-irradiated obese adipose tissue (ObAT) versus BMDMs exposed to 
non-treated ObAT for 3 days. Enriched gene sets in BMDMs exposed to UV-irradiated ObAT with a normalized 
enrichment score (NES)-score higher than 2 were included in the list. All significantly depleted gene sets in 
BMDMs exposed to UV-irradiated ObAT were included. 
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Supplementary Table 3.
B List of significantly (p<0.01) depleted gene sets identified by Gene Set Enrichment Analysis using the complete 
transcriptome of BMDMs exposed to UV-irradiated obese adipose tissue (ObAT) versus BMDMs exposed to 
non-treated ObAT for 3 days. Enriched gene sets in BMDMs exposed to UV-irradiated ObAT with a normalized 
enrichment score (NES)-score higher than 2 were included in the list. All significantly depleted gene sets in 
BMDMs exposed to UV-irradiated ObAT were included. 
Efferocytosis of adipocytes by macrophages in the adipose tissue
173
6
Supplementary Table 4.
Sequences of primers used for examining mRNA levels using RT-qPCR.
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7 A role for TLR10 in obesity and adipose tissue morphology
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ABSTRACT
Toll like receptors (TLRs) are expressed in adipose tissue and promote adipose tissue 
inflammation during obesity. Recently, anti-inflammatory properties have been attributed 
to TLR10 in myeloid cells, the only member of the TLR family with inhibitory activity. In order 
to assess whether TLR10-induced inhibition of inflammation may be protective during the 
development of obesity and metabolic abnormalities we used transgenic human TLR10 mice 
(hTLR10tg) and wild type (WT) controls on a C57B6J background. HFD-feeding enhanced 
TLR10 expression in the adipose tissue, and HFD-fed hTLR10tg mice displayed reduced 
adipocyte size, adipose tissue weight, and a trend toward lower plasma insulin levels 
compared to WT mice.
In humans, obese individuals with polymorphisms in the TLR10 gene displayed reduced 
macrophage infiltration in the adipose tissue accompanied by a trend to lower leptin levels 
and higher adiponectin levels in plasma. In healthy individuals with the same polymorphisms 
in the TLR10 gene we did not observe any difference in plasma concentrations of leptin and 
adiponectin.
We conclude that TLR10 impacts adipose tissue morphology in obesity. Larger studies 
in humans are warranted to assess its potential value as therapeutic target in metabolic 
syndrome and type 2 diabetes. 
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INTRODUCTION
The prevalence of obesity is rising worldwide promoting the development of the metabolic 
syndrome and closely related metabolic disturbances such as insulin resistance and type 2 
diabetes [1]. Adipose tissue from obese individuals is characterized by an increased presence 
of pro-inflammatory macrophages [2]. Various animal studies have shown similar outcomes 
and subsequently demonstrated that the pro-inflammatory macrophage phenotype 
contributes to the development of inflammation that interferes with insulin signaling 
pathways. Ultimately, this pro-inflammatory trait leads to the development of insulin 
resistance during obesity [1, 3].
Toll-like receptors (TLRs) have been shown to contribute to the development of obesity-
induced inflammation [4]. As innate immunity pattern recognition receptors (PRR), TLRs 
sense pathogen-components to induce an inflammatory response. Moreover, recently 
endogenous activators of TLRs have been identified, among which free fatty acids [5]. In the 
adipose tissue TLRs are expressed on both macrophages and adipocytes and were described 
to be involved in the development of metabolic abnormalities including insulin resistance 
[4, 6].
Numerous in vitro studies have shown that TLR2 and TLR4 activation promotes insulin 
resistance by inducing activation of JNK, p38 and IKK kinases that inhibit the phosphorylation 
of the insulin receptor substrate thus disturbing insulin signaling [4, 6-8]. In support of these 
results, several studies in murine experimental models revealed that absence of TLR2 or 
TLR4 protects against the development of obesity-induced insulin resistance [9]. In obese 
individuals, high levels of free fatty acids are thought to either directly or indirectly drive the 
TLR4-signaling cascade in adipose tissue resulting in pro-inflammatory cytokine secretion 
and subsequent deterioration in insulin signalling pathways [10].
Recently, TLR10, a member of the TLR family receiving little attention so far, has been 
described to be the only TLR with anti-inflammatory properties in human myeloid cells. 
Blocking TLR10 in monocytes was proven to increase pro-inflammatory cytokine production 
upon stimulation with various stimuli [11]. Moreover, single nucleotide polymorphisms 
(SNPs) in the TLR10 gene correlated with altered levels of cytokine production [11]. Various 
mechanisms of action may explain the anti-inflammatory effects of TLR10. First, TLR10 
can form dimmers with other TLRs such as TLR1, TLR2 and TLR6, blocking their signaling 
upon ligand binding. Second, TLR10 has been shown to promote the production of the anti-
inflammatory cytokine IL-1Ra [11]. Moreover, a recent study showed that TLR10 has the 
capacity to block signals from other TLRs by suppressing both MyD88- and TRIF-dependent 
signaling [12]. 
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In order to investigate whether TLR10 has anti-inflammatory properties in adipose tissue 
and to decipher the role of this receptor during the development of obesity and associated 
metabolic abnormalities, we used various approaches involving both animal and human 
studies. Firstly, we investigated the impact of a high-fat diet (HFD) versus low-fat diet (LFD) 
in TLR10 transgenic mice. Secondly, we evaluate metabolic effects of polymorphisms in the 
TLR10 gene in two human cohorts including both obese individuals and healthy controls. 
Our results revealed upregulation of hTLR10 in adipose tissue of mice during HFD-
feeding. Moreover, despite similar weight gain upon LFD- or HFD-feeding, hTLR10tg mice 
had reduced adipose tissue weight, smaller adipocytes, and a trend towards less crown-like 
structures (CLSs) and lower circulating insulin levels than their wild type controls. In obese 
individuals carrying SNPs in the TLR10 gene we observed reduced macrophage numbers in 
the adipose tissue and a trend to lower leptin plasma levels and higher adiponectin plasma 
levels whereas no differences in adipokine levels were observed in healthy controls carrying 
the same SNPs in TLR10.
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MATERIALS AND METHODS
Human cohorts
302 obese individuals (IN-CONTROL study of the Cardiovascular research Netherlands 
Project)  and more than 500 individuals (500 Functional Genomics Project) from the 
Human Functional Genomics project (HGFP) were genotyped as described before [13]. Of 
all individuals of the IN-CONTROL study and a total of 427 individuals of the 500 Functional 
Genomics Project, BMI and adipokines levels (leptin and adiponectin) could be measured 
and compared between individuals carrying a SNP and individuals with wild type (WT) alleles 
of the TLR10 gene. Leptin and adiponectin concentrations in plasma were measured by ELISA 
according to manufacturer’s protocol (R&D, The Netherlands). 
In addition, subcutaneous adipose tissue was obtained from 265 out of 302 obese 
individuals by performing needle biopsy after informed consent was obtained. The tissue 
was formalin fixed and paraffin-embedded and cross-sections (5µm) were stained by 
using the DAB (3’3 diaminobenzidine) method and anti-human CD68 antibody (Bio Rad, 
Veenendaal, The Netherands). Adipocyte size and the number of CLSs could be determined 
for 265 individuals. The HGFP was approved by the Ethical Committee of Radboud University 
Medical Center, Nijmegen (no. 42561.091.12). Experiments were conducted according 
to the principles expressed in the Declaration of Helsinki. Samples of venous blood were 
drawn after informed consent was obtained. For more information see http://www.
humanfunctionalgenomics.org/site/.
Animal study
Because mice lack a functional TLR10 gene, a constitutive human TLR10 knock-in mouse 
was generated by Taconic Artemis using targeted transgenesis. Using recombination-
mediated cassette exchange (RMCE), a CAG promoter cassette, the human TLR10 open 
reading frame (ORF), and the hGH polyadenylation signal and an additional polyadenylation 
signal, were inserted into the ROSA26 locus. This obtained RMCE vector was transfected 
into the TaconicArtemis-C57BL/6 ES cell line. Positive Neomycin selection was used to 
select recombinant clones. Positively selected blastocytes were transferred into embryos 
through which chimeric mice were attained. Using a Caliper LabChip GX device, sample 
analysis has been performed. Animals were fully back-crossed to a C57/Black6 background 
before they were used for experiments. Genotyping of the mice was performed using 
PCR and 1.5% agarose gel electrophoresis with the following primers: wild type forward: 
5' CTCTTCCCTCGTGATCTGCAACTCC; wild type reverse: 5' CATGTCTTTAATCTACCTCGATGG; 
TLR10 cond-forward: 5' GACAGCAGAGGGTGATGCTC; TLR10 cond-reverse: 5' 
CTTCCTCACAGATAGGCATGG; positive control forward: 5' GAGACTCTGGCTACTCATCC; 
positive control reverse: 5' CCTTCAGCAAGAGCTGGGGAC. The PCR conditions were: 95 °C 
for 5min; 35 cycles of 95 °C for 30 s, 60 °C for 30 s, 72 °C for 60 s, followed by 72 °C for 10 min.
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Human TLR10 transgenic (hTLR10tg) and C57BL/6j (WT) male mice aged between 12-16 
weeks were given a low-fat diet (LFD) or a high-fat diet (HFD) with 10%, respectively 45%, of 
energy derived from fat [14] for 16 weeks (n=9 for the HFD-fed mice, n=10 for the LFD-fed 
mice). Bodyweight and food intake was measured weekly. Glycaemic control was assessed 
by an oral glucose tolerance test (oGTT). Mice were fasted overnight after which glucose 
was administered (2g/kg) followed by measurements of circulating glucose at 20, 40, 60, 90 
and 120 minutes after glucose administration. Blood glucose concentration was measured 
with an Accu-chek glucosemeter (Roche Diagnostics, Almere, The Netherlands). The study 
was approved by the animal experimental committee in Nijmegen, The Netherlands, and 
all experiments were performed according to approved guidelines (Legislation for the 
protection of animals used for scientific purposes - Environment - European Commission).
Plasma measurements
Triglycerides (TG) were determined using commercially available enzymatic kits from Roche 
Molecular Biochemicals (Indianapolis, IN). Free fatty acids (FFAs) were measured using the 
NEFA-C kit from Wako Diagnostics (Instruchemie, Delfzijl, The Netherlands). Plasma insulin 
concentrations were measured by ELISA according to the manufacturer’s instructions (ultra 
sensitive mouse insulin ELISA kit, Crystal Chem Inc., IL, USA). Glucose (Liquicolor, Human GmbH, 
Wiesbaden, Germany) was measured enzymatically following manufacturer’s protocols. 
Leptin, adiponectin and IL-1Ra were determined by ELISA according to manufacturer’s 
protocol (R&D Systems, The Netherlands). Serum amyloid A (SAA) was measured with an 
ELISA assay (Tridelta Development Ltd., Maynooth, Ireland). 
Liver, pancreas and adipose tissue histology
Liver and gonadal adipose tissue (gWAT) were formalin-fixed and paraffin-embedded, and 
cross-sections (5 µm) were stained by the DAB (3’3 diaminobenzidine) method using an 
anti-F4/80 antibody (AbD Serotec). Inflammation was assessed by determining the number 
of crown-like structures (CLSs) in four non-overlapping fields (at 20x magnification) using 
software as previously described [15].
Pancreatic tissue was stained with the DAB (3’3 diaminobenzidine) method using an 
anti-insulin antibody from Santa Cruz biotechnology. The Langerhans islets surface was 
determined using the software Image J (https://imagej.net/Welcome).
RNA isolation and gene expression analysis 
After dissection, tissues were snap frozen using liquid nitrogen and stored at -80 before 
further processing. RNA was isolated using TRIzol reagent (Life Technologies Europe BV, 
Bleiswijk, The Netherlands) and quantity was measured with a Nano Drop Spectrophotometer 
(Nanodrop technologies, Montchanin, DE, USA). 
For gene expression analysis, cDNA was generated using reverse transcription with 
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iScript (Biorad) following manufacturer’s instructions. Gene expression analysis was done by 
quantitative PCR using SYBR green-based quantification (Applied Biosystems, Foster City, CA, 
USA). Primers were selected from the Harvard Primer Bank and are available upon request. 
36b4 was used as housekeeping gene.
Statistical analysis
Data are represented as mean + SEM. Graphs were made and statistical analysis was done 
with Graphpad Prism 5.03 (La Jolla, USA). To examine the effects of both diet and genotype 
in our murine model we used a two-way ANOVA analysis with Bonferroni posthoc testing. 
For human data, the relation between two variables was tested with correlation studies and 
differences between two groups were tested with an unpaired Mann-Whitney t-test. The 
difference between allele frequencies was calculated using a chi-square test. A p-value <0.05 
was considered significant. 
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RESULTS
Animal study
To learn more about the role of TLR10 during diet-induced obesity, wild type (WT) and 
human TLR10 transgenic (hTLR10tg) mice were fed a low-fat diet (LFD) or high-fat diet (HFD) 
for 16 weeks. As shown in Figure 1A, WT and hTLR10tg HFD-fed animals displayed a similar 
increase in bodyweight compared to animals receiving the LFD (p<0.0001). Noticeably, food 
intake was similar between groups as well (Figure 1B). The HFD induced an increase in brown 
adipose tissue (BAT) and inguinal white adipose tissue (iWAT) in both WT and hTLR10tg mice 
and an increase in liver weight only in transgenic mice. Interestingly, the transgenic mice 
had lower white adipose tissue mass with significantly less iWAT and gonadal white adipose 
tissue (gWAT) than WT controls (Figure 1C). 
Next, we measured several circulating parameters related to metabolism in both 
LFD- and HFD-fed animals. As shown in Figure 1D and 1E, plasma triglyceride (TG) and non-
esterified fatty acid (FFA) levels were similar across genotypes and significantly higher in mice 
on a HFD. To learn more about the potential role of TLR10 on obesity-induced inflammation, 
circulating concentrations of IL-1 receptor antagonist (IL-1Ra) and serum amyloid a (SAA) were 
measured. IL-1Ra, a marker of inflammation [16] and produced by the adipose tissue [17], 
was similarly increased by HFD-feeding in both genotypes (Figure 1F). SAA levels, an acute 
phase protein produced by the liver and adipose tissue [18], neither were not significantly 
different between genotypes (Figure 1G).
We subsequently zoomed in on potential effects of TLR10 in adipose tissue by 
measuring circulating concentrations of two adipokines. Whereas leptin was enhanced by 
HFD-feeding in both genotypes (Figure 1H) no significant differences were found between 
adiponectin levels upon a HFD (Figure 1I). Interestingly, there was a trend to lower leptin 
levels in the hTLR10tg mice versus WT mice on a HFD (Figure 1H).
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Figure 1. Bodyweight, organ weight and plasma parameters in WT and hTLR10tg mice on a low- or high-fat 
diet
Bodyweight (BWt) (A,C) and food intake (B) of wild type (WT) and transgenic mice (hTLR10tg) on a high-fat diet 
(HFD) or a low-fat diet (LFD) for 16 weeks. (C) Weight of the liver, interscapular brown adipose tissue (BAT), 
inguinal white adipose tissue (iWAT) and gonadal white adipose tissue (gWAT) at the end of a 16 week LFD or 
HFD intervention. Plasma triglycerides (TG) (D), non-esterified fatty acids (FFA) (E), the inflammatory markers 
interleukin-1 receptor antagonist (IL-1Ra) (F) and serum amyloid A (SAA) (G), and the adipokines leptin (H) and 
adiponectin (I) in WT and transgenic mice on a LFD or HFD for 16 weeks. All data are expressed as mean + SEM; 
*p<0.05, **p<0.001, ***p<0.0001 effect of the diet; #p<0.05, ##p<0.001 effect of the genotype.
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TLR10-dependent effects on HFD-induced adipose tissue inflammation
During the development of obesity, several robust morphological changes occur in the 
adipose tissue: adipocytes increase in volume to accommodate fat mass expansion and 
macrophages are invading the adipose tissue and form so-called crown-like structures (CLSs) 
when surrounding dying adipocytes [19]. 
Interestingly, we observed up-regulation of hTLR10 expression in gWAT of HFD-fed 
hTLR10tg mice compared to transgenic animals on a LFD (Figure 2A), suggestive of activation 
of the TLR10 pathway in the adipose tissue during obesity. Zooming in on adipose tissue 
morphology, we observed that hTLR10tg mice had smaller adipocytes than WT animals 
(p<0.05) (Figure 2B). In addition, there was a trend to less macrophages surrounding 
dead adipocytes in so-called CLSs in the transgenic group (Figure 2C). Besides numbers, 
phenotypical changes of macrophages are important in determining adipose tissue 
inflammation. Therefore, we measured expression levels of macrophage marker genes in 
gWAT. As shown in Figure 2D expression levels of macrophage markers F4/80, Cd68, Cd11c, 
Cd11b, Cd206 and Arg1 and the pro-inflammatory receptor Tlr2 were significantly increased 
by the HFD intervention in hTLR10 transgenic mice. Interestingly, gene expression levels of 
Cd206, a marker for anti-inflammatory macrophages [20], was significantly enhanced in 
HFD-fed hTLR10tg mice compared to WT controls on the same diet. Of note, we checked 
the expression levels of T-cell marker Cd4, but we did not observe any difference between 
the four mice groups (data not shown). Next, we measured expression levels of downstream 
effector genes related to inflammation. As shown in Figure 2E, the HFD intervention caused 
an increased expression of the chemokine Mcp-1 in both WT and transgenic mice. In 
hTLR10tg mice, expression levels of Tnfα, but also the anti-inflammatory cytokines Il-10 and 
Il-1rn tended to be higher than in WT mice upon a HFD (Figure 2E).
Besides the adipose tissue, the liver importantly contributes to metabolic abnormalities 
during obesity. HFD-feeding induced steatosis in both genotypes and hepatic gene expression 
changes were similar between WT and hTRL10tg animals (Figure 2F and 2G), suggesting that 
the liver is largely unaffected by hTLR10 expression in mice on a HFD.
A disturbance in glycaemic control is a common consequence in the development of 
obesity. Inflammation of the adipose tissue may partly be setting off detrimental changes in 
glycaemic control [21]. To evaluate the role of TLR10 in this process, both genotypes were 
exposed to an oral glucose tolerance test (oGTT). As shown in Figure 3A and 3B there were 
no differences in glucose tolerance between hTLR10tg and WT mice, although in the LFD 
group higher glucose levels were measured in transgenic animals 60 minutes after glucose 
injection. Interestingly, measurements of plasma insulin revealed a tendency to lower levels 
in animals with TLR10 expression, suggestive of improved insulin sensitivity in the hTLR10tg 
mice and a potential protective role for TLR10 against the development of  insulin resistance 
(Figure 3C). The differences in plasma insulin levels appeared to be unrelated to β-cell size 
(Figure 3D and 3E).
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Figure 2. Inflammatory state of the adipose tissue and liver
(A) Human TLR10 expression in gonadal adipose tissue (gWAT) of transgenic (hTLR10tg) mice after a low-fat diet 
(LFD) or high-fat diet (HFD) intervention for 16 weeks. (B) Adipocyte size in HFD-fed hTLR10tg vs wild type (WT) 
mice after 16 weeks of diet intervention. (C) Representative images of gWAT stained for F4/80 in wild type (WT) 
and hTLR10tg mice after 16 weeks of HFD intervention at a 10x magnification with arrows indicating the presence 
of crown-like structures (CLSs), and average number of CLSs in the HFD groups. (D) Relative gene expression of 
F4/80, Cd68, Cd11b, Cd11c, Cd206, Arg-1 and Tlr2 of WT and hTLR10tg mice on a LFD or HFD. (E) Relative gene 
expression levels of the chemokine Mcp-1 and several inflammatory cytokines in gWAT of WT and hTLR10tg mice. 
(F) Representative image of the liver stained for F4/80 in the HFD groups at a 10x magnification. (G) Relative mRNA 
levels of several inflammatory markers in the liver of WT and hTLR10tg mice on a LFD or HFD for 16 weeks (H). 
All data are expressed as mean + SEM; *p<0.05, **p<0.001, ***p<0.0001 effect of the diet; #p<0.05 effect of the 
genotype.
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Human studies 
Finally, we set out to validate our findings in humans. To do so, we compared adipocytes 
and macrophages numbers in the subcutaneous adipose tissue between obese individuals 
carrying SNPs in the TLR10 gene versus obese individuals with WT alleles. In addition, BMI 
and plasma levels of the adipokines adiponectin and leptin were compared between either 
obese or lean individuals carrying SNPs in TLR10 and individuals carrying WT alleles. 
As expected, BMI positively correlated with plasma leptin levels, and negatively 
correlated with plasma adiponectin levels in both lean (Figure 4A) and obese individuals 
(Figure 4B). Three polymorphisms in TLR10 associated with altered inflammatory responses 
were evaluated: rs11096955, rs11096957, rs4129009 [11, 22, 23]. Due to the fact that 
rs11096955 and rs11096957 are in strong linkage disequilibrium as calculated with LDlink 
(LDlink | An Interactive Web Tool for Exploring Linkage Disequilibrium in Population Groups), 
they are carried by the same individuals and data for both SNPs are shown in one graph. No 
difference in SNP frequencies was observed between obese versus lean subjects (data not 
shown). 
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Figure 3. Glucose homeostasis
An oral glucose tolerance test (oGTT) performed at the end of the low-fat diet (LFD) (A) or high-fat diet (HFD) (B) 
intervention in wild type (WT) and transgenic (hTLR10tg) mice. (C) Plasma levels of insulin. (D) Relative presence 
of insulin islets in the pancreas of WT and hTLR10tg mice determined by calculating average islet surface area 
over average pancreas surface. (E) Pancreas slides stained for β cells. All data are expressed as mean + SEM; 
***p<0.0001 effect of the diet; #p<0.05 effect of the genotype.
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7In both cohorts there was no difference in BMI between individuals carrying the mutant allele and individuals carrying WT alleles (Figure 4C, 4D, and Supplementary Figure 1). In contrast, plasma leptin levels were significantly lower in obese individuals carrying the 
rs4129009 mutant allele (Figure 4D) and a similar trend was observed for rs11096955 and 
rs11096957 (Figure 4C). In the same cohort of obese individuals plasma adiponectin levels 
tended to be higher in individuals carrying either SNP in TLR10 as compared to individuals 
bearing WT alleles (Figure 4C and 4D). In lean individuals we did not observe a difference 
in plasma leptin and adiponectin levels between individuals with a mutation versus those 
carrying WT alleles (Supplementary Figure 1).
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Figure 4. BMI, circulating adipokine levels and cell counts in the adipose tissue of individuals carrying SNPs 
in the TLR10 gene 
The Body Mass Index (BMI) calculated for 302 obese individuals and 427 healthy controls genotyped for three SNPs 
in the TLR10 gene: rs11096955, rs11096957 and rs4129009. BMI plotted against plasma leptin and adiponectin 
in healthy controls (A) and obese individuals (B). BMI, plasma leptin and plasma adiponectin levels of obese 
individuals carrying the rs11096955 or rs11096957 allele (C), or the rs4129009 allele (D) compared to obese 
individuals carrying wild type (WT) alleles of TLR10. Number of adipocytes (E) and macrophages (CD68+ cells) (F) 
counted at a 40x magnification in obese individuals bearing WT alleles, the rs11096955 and/or rs11096957 SNP, 
or the rs4129009 SNP in TLR10. All data are represented as mean + SEM. *p<0.05, **p<0.01.
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In our cohort of obese subjects we went on by assessing adipocytes number and 
macrophage infiltration in subcutaneous adipose tissue (Figure 4E and 4F). There was no 
difference in adipocyte counts between individuals carrying the WT allele versus individuals 
carrying the mutant allele (Figure 4E). In contrast, macrophage numbers were significantly 
lower in individuals bearing the rs11096955 or rs11096957 mutant allele compared to 
individuals bearing WT alleles, whilst no such difference was observed for rs4129009 (Figure 
4F). 
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DISCUSSION
Pattern recognition receptors, including Toll-like receptors (TLRs), not only sense foreign 
danger signals but can also be activated by endogenous signals including fatty acids [5]. 
During obesity, TLR signalling is thought to contribute to pro-inflammatory responses and 
metabolic abnormalities [24]. Interestingly, within the family of TLRs, TLR10 is the only 
receptor assigned with anti-inflammatory properties [11] and therefore may have the 
potential to modulate the development of metabolic disturbances during obesity. Using 
a transgenic mouse model expressing human TLR10, we demonstrate a role for TLR10 in 
adiposity illustrated by reduced adipose tissue weight and adipocyte size in hTLR10tg 
compared to wild type (WT) mice, despite equal bodyweight gain. In addition, plasma insulin 
levels tended to be lower in animals bearing hTLR10. 
Analysing a cohort of obese individuals we observed that polymorphisms in the TLR10 
gene do not affect adipocyte numbers but appear to reduce macrophage numbers in the 
adipose tissue. Interestingly, individuals bearing the rs4129009 mutation have lower plasma 
levels for leptin compared to individuals bearing wild type (WT) alleles and a trend towards 
higher plasma adiponectin levels suggesting a possible effect of TLR10 on adipose tissue 
homeostasis. Together, these results are suggestive of an implication for TLR10 in adipose 
tissue remodelling and homeostasis. In lean individuals, polymorphisms in TLR10 appeared 
not to affect BMI, plasma leptin or adiponectin, pointing to an interaction between TLR10 
activation and adipose tissue homeostasis specifically in obesity and states characterized by 
low-grade chronic inflammation. 
Earlier work from our group has shown that TLR10 is expressed in both adipocytes and 
non-adipocyte cells of human adipose tissue [25]. The function of TLR10 in adipocytes vs. 
non-adipocyte cells is currently unknown. Based on our in vivo results TLR10 affects both 
macrophages and adipocytes in the adipose tissue of mice, and cell-specific TLR10 transgenic 
models will be valuable for elucidating the role of TLR10 in adipocytes and macrophages 
specifically during the development of obesity.
The TLR10 expressed in adipose tissue macrophages may affect adipose tissue 
inflammation by determining macrophage phenotype. Based on our results, one might 
speculate that the presence and/or activation of TLR10 in macrophages drives polarization 
towards a more anti-inflammatory trait. This may partly be explained by the inhibitory 
effects of TLR10 on other TLRs that are known to promote pro-inflammatory properties 
of these cells [26]. To decipher what molecular pathways controlled by TLR10 may impact 
macrophage polarization, more research is needed. Moreover, potential ligand(s) driving 
TLR10 activation have not been identified yet. In the context of adipose tissue, certain types 
of saturated fatty acids, shown to activate other TLRs [5], may also have the potential to 
drive TLR10 stimulation. One approach may therefore be to test the effects of diets differing 
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in fatty acid composition and to perform in vitro studies with various fatty acids to decipher 
the contribution of different types of fatty acids on TLR10 activation in macrophages. 
Interestingly, our results demonstrate that the presence of TLR10 lowers adipocyte 
size during HFD-feeding. Similarly, inhibition of TLR2 has been previously shown to reduce 
adipocyte hypertrophy [27]. Since human TLR10 specifically inhibits TLR2-mediated 
responses in vivo and in vitro [11], the decrease in adipocyte size in hTLR10tg animals may 
partly be explained by this mechanism of action. The Tlr2 gene was significantly up-regulated 
by the diet intervention in transgenic mice only and tended to be higher in hTLR10tg versus 
WT mice on a HFD, suggestive of a relation between TLR10 and TLR2. Using a cross-linking 
antibody for TLR10 in an in vitro system that contains activators of other TLRs that are of 
relevance during obesity, for example fatty acids, may provide insight into the role for these 
interactions between TLR10 and pro-inflammatory TLRs like TLR2 in adipocyte hypertrophy, 
as well as in driving macrophage phenotypes.
On a systemic level, the effects of TLR10 on glucose homeostasis were modest. 
However, plasma insulin concentrations tended to be lower in animals expressing TLR10, 
suggestive of increased insulin sensitivity. Hence, activating TLR10 during obesity may have 
some beneficial metabolic effects. 
One may argue, however, that over-expressing the human TLR10 gene into a mouse 
model also has downsides. Although it allowed us to establish the effects of TLR10 in 
various tissues during the development of obesity, several important issues still need to be 
addressed. For example, is the molecular machinery for a fully functional TLR10 pathway 
present in adipose tissue? Are there unknown endogenous pathways that either promote or 
interfere with TLR10 signalling in the transgenic animal model? Does the Tlr10 pseudogene 
present in in mice [28] interact with the human TLR10 gene, thereby affecting our results?
Our results in humans demonstrate that obese individuals carrying the rs11096955 or 
rs11096957 SNP in TLR10 have significantly reduced macrophage numbers. Moreover, 
individuals bearing the rs4129009 mutation have significantly lower levels of leptin in 
plasma compared to individuals bearing the WT allele, and display a trend towards higher 
plasma adiponectin levels. Similar trends in plasma leptin and adiponectin were observed 
in individuals bearing either the rs11096955 or rs11096957 allele. Together these results 
are suggestive of a protective role of TLR10 SNPs in humans. Interestingly, this interaction 
between TLR10 activation and adipose tissue homeostasis was specific for obese individuals, 
suggestive of a role for TLR10 only when a state of low-grade chronic inflammation has 
developed. Additional measurements assessing adipose tissue inflammation and insulin 
sensitivity in obese individuals carrying one of the three SNPs in TLR10 will be needed to 
evaluate whether the observed reduction in macrophage number affects adipose tissue 
functioning as well. In addition, the functional consequences of the analysed polymorphisms 
in TLR10 are not clear. Our data imply that certain SNPs in TLR10 would result in a gain 
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of function and subsequently could ameliorate disturbances in adipose tissue homeostasis 
during obesity. The TLR10 SNPs described above are the consequence of missense mutations 
which, among nonsynonymous mutations (mutation that affect protein structure), can have 
a large palette of functional manifestations. Since it is difficult to separate the effects of our 
mutations from interactions with the environment and genomic profile of each individual, 
further studies using mice carrying these SNPs in TLR10 might help clarifying their functional 
consequences [29]. Ultimately, cross-linking TLR10 in the adipose tissue of obese individuals 
could be useful to understand the influence of TLR10 on adipose tissue metabolism and 
metabolic disturbances during obesity. 
In conclusion, although more work is needed, our results demonstrate a role for TLR10 
in adipose tissue morphology during obesity. 
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Supplementary Figure 1. BMI and circulating adipokine levels of lean individuals carrying SNPs in the TLR10 
gene
BMI, plasma leptin and plasma adiponectin levels of lean individuals carrying the rs11096955 or rs11096957 allele 
(A), or the rs4129009 allele (B) compared to lean individuals carryi g wild type (WT) alleles of TLR10.
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Macrophages and their monocyte precursors are challenged with a plethora of stressors on 
a daily basis. Regardless of the numerous occasions at which they succeed in maintaining or 
re-establishing homeostasis, macrophages are particularly known for their role in a variety 
of pathologies that are associated with systemic chronic inflammation. These pathologies 
include various metabolic diseases, such as Type 2 Diabetes and cardiovascular disease, 
in which systemic chronic inflammation is an integral part of disease progression and 
outcome (1). Already in the early ‘90s, expanding adipose tissue was identified to be an 
important source of inflammatory cytokines that interfere with insulin sensitivity in obese 
individuals (2-6). Macrophages were pinpointed as predominant source of these elevated 
pro-inflammatory cytokines in obese adipose tissue, following from an increase in number 
and shift toward a pro-inflammatory phenotype during obesity (7-10). Since then, multiple 
other immune cells have been shown to populate the adipose tissue, including dendritic 
cells, mast cells, neutrophils, B-cells and T-cells (1, 11). Although most likely alterations in 
the composition and number of immune cells together contribute to the development of a 
state of low-grade inflammation in obese adipose tissue (1, 11), macrophages have retained 
particular interest. On the one hand they build upon their role as phagocytes by clearing 
dead adipocytes (12, 13), yet also acquire several adipose tissue-tailored functions including 
lipid buffering (14), and communicate with other immune cells to maintain immune balance 
in the adipose tissue (15, 16). Consequential to being a central player for adipose tissue 
homeostasis in the lean state, continuous pro-inflammatory activation of ATMs in the obese 
state severely affects adipose tissue functioning. As such, ATMs constitute an important link 
between obesity and metabolic disturbances including insulin resistance and, eventually, 
Type 2 Diabetes (7, 10, 17). 
Due to their pivotal role during the development of adipose tissue inflammation there is 
a strong urge for understanding mechanisms underlying macrophage activation in obese 
adipose tissue. Although considerable progress has been made, the underlying causes and 
phenotypical and functional characteristics of macrophage activation in obese adipose 
tissue are still far from completely understood. In this thesis, several aspects related 
to activation of macrophages and their monocyte precursors were evaluated. First, we 
revealed and clarified specificity in metabolic routes used by human monocytes in response 
to stimulation with various microbial stimuli (Chapter 2). From these insights into the role 
of intracellular metabolism upon activation of core immunological pathways in macrophage 
precursors, we went on by examining intracellular metabolism in macrophages residing in 
the complex adipose tissue environment. We identified adipose tissue macrophages (ATMs) 
to be uniquely metabolically activated during obesity, and showed that several metabolic 
routes critically contribute to their inflammatory activation (Chapter 4). The ATM origin, 
phenotype and function, as well as potential factors that may drive the ATM phenotype were 
reviewed in Chapter 3, and the relevance of lipids as driver of the ATM phenotype further 
investigated in Chapter 5. We evaluated clearance of adipocytes by macrophages in an obese 
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versus lean adipose tissue environment, and showed that immunologically silent responses 
to dead adipocytes are disrupted in macrophages primed by obese adipose tissue (Chapter 
6). Lastly, we examined the impact of TLR10 on the adipose tissue in lean and obese mice and 
humans (Chapter 7). The different insights on ATM metabolism and inflammatory activation 
as obtained in this thesis are presented in Figure 3. In this final chapter, the potential of 
targeting intracellular metabolism for shaping functional output of ATMs and, ultimately, 
abrogating adipose tissue inflammation, will be evaluated. In this light, the relevance and 
implications of our findings are discussed and suggestions for future research are made.
Retrieving constructive adipose tissue macrophages during obesity 
First, it is important to realize that whatever the cause of the inflammatory activation of 
macrophages is, the initial purpose was to conquest a stressor – either microbial or non-
microbial of origin – that is or could be potentially harmful (18). In case of the adipose tissue, 
ATMs are known to buffer lipids released during pronounced adipocyte lipolysis or from 
over-engorged adipocytes, in order to protect other tissues from high and potentially toxic 
levels of lipids (14, 19). Moreover, they clear dead adipocytes from the adipose tissue that 
may otherwise release their noxious content into the interstitial fluid (13, 18, 20). In the lean 
state these actions are effectively executed in an immunologically silent or anti-inflammatory 
manner. Obese adipose tissue, however, is characterized by a state of chronic inflammation 
reflective of homeostatic imbalance that may be importantly fuelled by macrophages 
incapable to effectively execute the above mentioned functions. A future challenge will be 
to initiate ATM adaptations that support their functioning conform increasing demands of 
the obese adipose tissue environment. In this way, we may prevent or combat pathological 
inflammatory activation of macrophages during obesity that contributes to the development 
of insulin resistance. 
Intracellular metabolism translates environmental factors into 
functional output
The last decade, new insights in the field of ‘immunometabolism’ have brought forward 
intracellular metabolism as essential driver of macrophage function including inflammatory 
cytokine release and phagocytosis (21-23). As such, macrophage metabolism is currently being 
viewed as potential target for therapeutic interventions aimed at curtailing inflammation in 
various pathologies that are defined by excessive macrophage activation. 
Monocytes and macrophages can be activated by various stimuli or ‘stressors’. These 
may include pathogens or pathogen-associated molecular patterns (PAMPs) on the one 
hand, and dead cells or damage-associated molecular patterns (DAMPs) on the other. 
These stressors require functional responses of monocytes or macrophages, for example 
phagocytosis, that are fuelled by specific metabolic routes (Figure 1, arrow I and III). 
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Indeed, metabolic reprogramming of macrophages highly depends on the type of stressor 
that activates them (21). This is clearly illustrated by the diverging degree to which various 
metabolic routes are used by human monocytes stimulated with different microbial stimuli 
(Chapter 2). We found that both lipopolysaccharide (LPS) and Pam
3
CysSK
4
 (P3C), as well 
as whole bacterial lysates, increase glycolysis yet predominantly vary in the activation of 
oxidative phosphorylation (OXPHOS) after stimulation. In fact, LPS was unique in minimizing 
mitochondrial spare respiratory capacity (SRC) of human monocytes, disabling monocytes 
to use their mitochondria for ATP production. Importantly, other environmental ‘cues’ like 
nutrient availability, cytokines, growth factors and oxygen will also significantly shape the 
metabolic trait of monocytes or macrophages (22) (Figure 1, arrow II). For example, human 
monocytes stimulated with LPS that essentially use glucose for ATP generation via glycolysis, 
have been shown to switch toward OXPHOS as source for ATP production upon glucose 
deprivation (24). In a tissue environment, a combination of stressors and cues demands for 
specific macrophage functions and drives unique metabolic traits. Indeed, the metabolic 
trait of ATMs – characterized by increased OXPHOS and glycolysis (Chapter 4) – is not only 
driven by stressors that are most likely non-pathogenic of origin, including factors derived 
from stressed or dying adipocytes, but also by cytokines, nutrients and various other local 
cues. 
Following this line of reasoning, intracellular metabolism of macrophages is the cumulative 
outcome of environmental stressors, either pathogenic or non-pathogenic of origin, and 
other environmental cues, like nutrient availability or cytokines. Together these stressors 
and cues tailor functional macrophage responses in an environment with specific spatial 
and temporal characteristics and demands. Changing the metabolic routes used by 
macrophages will affect their functional output (25)(Chapter 2 & 4) (Figure 1, arrow III), 
and alter the environment, for example via the secretion of lactate (Figure 1, arrow IV). In 
addition, execution of function will change the environment (e.g. by removing the stressor) 
(Figure 1, arrow V) and demand for new metabolic choices (e.g. introduce the need for 
metabolic processing of an embodied stressor) (Figure 1, arrow VI). Hence, the environment, 
macrophage metabolism, and macrophage function are highly intertwined with intracellular 
metabolism as central spill translating environmental factors into macrophage function. 
As a consequence, targeting intracellular metabolism for shaping or directing macrophage 
function requires full understanding of 1) metabolic routes driving certain macrophage 
outputs and 2) what and how stressors and cues affect macrophage metabolism in a given 
environment. 
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Intracellular metabolism to support function: cytokine release and 
phagocytosis
Knowing what metabolic routes underlie different functional outputs of monocytes or 
macrophages is undoubtedly essential if one aims to target intracellular metabolism for 
therapeutic gain. Interestingly, we found that glycolysis importantly contributes to cytokine 
release in monocytes and macrophages irrespective of the manifested stressor (Chapter 
2 & 4). First, monocytes stimulated with LPS or P3C were both characterized by cytokine 
release and enhanced glycolysis, and inhibition of glycolysis using 2-deoxyglucose (2-DG) 
strongly reduced cytokine secretion (Chapter 2). Similarly, ATMs from obese adipose tissue 
and obese adipose tissue-primed macrophages displayed increased glycolysis and higher 
cytokine secretion as compared to their lean counterparts. Accordingly, competing with 
glycolysis using 2-DG decreased cytokine release by ATMs (Chapter 4). A dominant role for 
3.1 Cytokine secretion
3.2 Phagocytosis
3. Function1. Environment
2. Metabolism
2.2 OXPHOS
2.1 Glycolysis
1.1a Pathogens
1.2a Nutrients
1.2b Cytokines
1.1c Dead cells
1.1d DAMPs
1.1b PAMPs
II IIIIV
I
VI
V
Figure 1. Representation of interactions between the environment, monocyte or macrophage metabolism, 
and their function. 
In each different environment, being the circulation or a specific tissue, monocytes or macrophages are confronted 
with a unique spectrum of stimuli (1) that together shape their phenotype (2+3). These stimuli encompass 
pathogens and dead cells including their derivatives; danger associated molecular patterns (DAMPs) and pathogen 
associated molecular patterns (PAMPs) (1.1), but also include other molecules present in the environment, such as 
cytokines and nutrients (1.2). For the sake of clarity, these stimuli will be referred to as ‘stressors’ (1.1) and ‘cues’ 
(1.2). Stressors demand for a specific action of monocyte or macrophages (function), for example phagocytosis or 
cytokine production (I), but may also shape intracellular metabolism via binding Toll-like receptors that activate 
several intracellular signalling pathways affecting metabolic choices (II). Cues do not directly demand for a specific 
function but can shape macrophage functioning, including via reprogramming intracellular metabolism (II) that is 
needed for monocyte or macrophage function (III). By removing nutrients from the environment, and secreting 
end-products of intracellular metabolism (IV) on the one hand, and removing a stressor, or secreting cytokines 
(V) on the other hand, monocytes or macrophages change their environment as well. Lastly, monocytes or 
macrophages adapt their intracellular metabolism upon the execution of a certain function, for example to enable 
processing of engulfed stressors (VI). 
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glycolysis in cytokine release has been proven to generally hold truth in innate immune cells 
stimulated with various pathogenic stimuli (26-28). However, two things should be taken 
into account. First, 2-DG but also other inhibitors widely used to block glycolysis or other 
metabolic routes induce considerable off-target effects, blunting the interpretation of data 
obtained using these inhibitors. Robust examination of metabolic pathways involved in 
macrophage functioning is considered a future challenge and will be addressed accordingly 
later in this discussion. Second, most data including ours are derived from in vitro experiments 
using medium in which glucose (and glutamine) is prominently available, yet that lacks some 
other primary nutrients like fatty acids (FAs). As a consequence, macrophages in vivo may 
use a more complex combination of nutrients hence metabolic pathways upon activation 
depending on local nutrient availability. In case of the adipose tissue, lipids may compose 
an important metabolic substrate. It would therefore be worthwhile to combine ex vivo 
measurements with measurements of metabolites or enzyme activity in snap-frozen ATMs, 
to verify the in vivo findings of metabolic reprogramming and learn more about underlying 
pathways leading to the specific metabolic trait of these cells. Nevertheless, GLUT1, the 
dominant glucose transporter in macrophages, is highly expressed by macrophages in crown-
like structures (CLSs) of obese adipose tissue, pointing to a role for glycolysis in activated 
ATMs in vivo as well (29). 
The contribution of OXPHOS to cytokine release appears to particularly rely on the 
stressor involved. Specifically, monocytes stimulated for twenty-four hours with P3C display 
dependency on OXPHOS for fuelling cytokine secretion, while no such dependency was found 
in monocytes stimulated with LPS (Chapter 2). In ATMs we did not use Rotenone to impair 
OXPHOS via inhibition of Complex I of the electron transport chain, yet found lower cytokine 
release upon the inhibition of glucose oxidation and, to a lesser extent, fatty acid oxidation 
(FAO), especially in ATMs derived from lean adipose tissue (Chapter 4). Hence, OXPHOS does 
– to some extent – contribute to cytokine release in ATMs as well as P3C- but not LPS-
stimulated monocytes. In innate immune cells OXPHOS may, however, particularly fuel other 
functions than cytokine release, for example phagocytosis (30). Indeed, we found OXPHOS to 
contribute to phagocytosis in P3C-stimulated but not LPS-stimulated monocytes, the latter 
being characterized by lower mitochondrial capacity and phagocytic capacity to start with 
(Chapter 2). Other studies, however, did find a role for glycolysis during phagocytosis by 
monocytes or macrophages (31, 32). Although many reasons may explain this discrepancy, it 
might well be reflective of the different phagocytosis assays used in the experiments, further 
corroborating stressor-specific remodelling of monocyte and macrophage metabolism. A 
schematic representation of the contribution of energy metabolism to function in human 
monocytes stimulated with LPS or P3C is provided in Figure 2.
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In contrast to phagocytosis of bacterial components upon activation of Toll-like receptors 
(TLRs), phagocytosis in the adipose tissue most likely involves clearance of damaged, dying 
or dead adipocytes predominantly. In general, uptake of apoptotic cells (efferocytosis) is 
considered to mechanistically differ from phagocytosis of pathogens. In fact, increasing 
evidence suggests adipocyte clearance to be different from ‘classical’ efferocytosis as well 
(33). Instead of engulfing the complete dying cell and subsequent intracellular breakdown 
(34), adipocytes are probably far too big for complete uptake by the markedly smaller 
macrophages. Indeed, macrophages were found to process bits of adipocytes (35), in line 
with a gradual decrease in size of dead adipocytes part of CLSs (36). Moreover, adipocyte 
clearance has recently been shown to involve exocytosis of lysosomes into extracellular 
acidic compartments formed near dying adipocytes, suggestive of extracellular instead of 
intracellular breakdown of the efferocytic load (13, 20). However, many aspects regarding 
recognition and processing of dead adipocytes by macrophages remain unclear. An 
interesting aspect that warrants further attention is whether or not macrophage clearance 
of dead adipocytes is solely reactive to the release of content due to rupture of the adipocyte 
membrane, or involves specific recognition of cell death markers like phosphatidylserine (PS) 
at the cell surface of a dying adipocyte. Although subtle, we found signs of increased cell 
death in the adipose tissue upon inhibition of receptors of the TAM receptor tyrosine kinase 
family that recognise PS at the dead cell membrane (37)(Chapter 6). This would suggest that 
the well-controlled efferocytic machinery plays a role during adipocyte clearance as well, 
and is potentially sensitive for dysregulation during obesity.
P3C LPS
Cytokine secretion
Glycolysis
OXPHOS
Cytokine secretion
Glycolysis
OXPHOS
Phagocytosis
Figure 2 Representation of metabolic regulation in human monocytes stimulated with P3C or LPS, and its 
relation to their functional output.  
Different pathogenic stimuli, including Pam
3
CysSK
4 
(P3C) and lipopolysaccharide (LPS), uniquely reprogram 
monocyte metabolism to facilitate functioning. Glycolysis is enhanced both by P3C, that activates Toll-like 
receptor (TLR)2, and by LPS, that activates TLR4, and fuels cytokine release upon stimulation with either stimulus. 
In contrast, oxidative phosphorylation (OXPHOS) is enhanced upon P3C-stimulation, but not changed in LPS-
stimulated monocytes. Consequentially, OXPHOS contributes to cytokine release in P3C- but not LPS-stimulated 
monocytes. Moreover, OXPHOS but not glycolysis fuels phagocytosis upon P3C stimulation. In line with reduced 
mitochondrial capacity upon LPS stimulation, the phagocytic capacity of monocytes stimulated with LPS is low.
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Regardless of passive or active recognition of dead adipocytes by ATMs, dead 
adipocytes are complex cells to deal with. Considering the schematic overview given in 
Figure 1, dead adipocytes may be qualified both as stressor and cue; requiring the clearance 
of a corpse as well as high amounts of lipids that demand for effective lipid processing 
by the macrophage. Indeed, macrophages exposed to dead adipocytes display increased 
expression of genes involved in lipid uptake and processing including lysosomal acid lipase 
compared to macrophages exposed to live adipocytes (Chapter 6). Of note, no difference in 
the expression of genes involved in glycolysis was found, suggestive of lipid handling to be a 
specific requirement for effective adipocyte clearance by macrophages. In vivo, ATMs part 
of obese adipose tissue are characterized by enhanced lysosomal biogenesis and activity, 
accompanied by increased expression of several markers of lipid uptake, storage, breakdown 
and export (19, 20, 38)(Chapter 5 & 6). As such, ATMs populating obese adipose tissue have 
been identified to be metabolically rather than inflammatory activated (38). Interestingly, 
the metabolically activated phenotype of ATMs has recently been shown to be crucial for 
adipocyte clearance (20), suggestive of a critical link between intracellular metabolism and 
efferocytosis of adipocytes by ATMs. We observed increased OXPHOS and glycolysis in 
macrophages in an obese adipose tissue environment (Chapter 4), and it would be interesting 
to examine whether OXPHOS and/or glycolysis are of importance during adipocyte clearance. 
To do so, intracellular metabolism should be examined in macrophages that take up or 
have taken up parts of dead adipocytes. Unfortunately, however, it represents a technical 
challenge to determine macrophage metabolism during adipocyte clearance by real time 
energy flux measurements as both macrophages and adipocytes display metabolic activity. 
Nevertheless, considering the profound size and high lipid content of dead adipocytes one 
could speculate that both lysosomal lipases and OXPHOS, in particular fatty acid oxidation 
(FAO), will be crucial for macrophages to effectively process dead adipocytes. 
Of note, in addition to cytokine release and adipocyte clearance, ATMs have been shown 
involved in adipogenesis, angiogenesis, extracellular matrix remodelling and antigen 
presentation (39). Although these functions were not addressed in this thesis, they should be 
taken into account when studying the relation between intracellular energy metabolism and 
ATM functioning. Moreover, although we have and will predominantly focus on catabolic 
routes, metabolism can also be used for the production of building blocks or signalling 
molecules (25). The contribution of such anabolic metabolism to ATM functioning forms an 
interesting field for future studies as well.   
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The adipose tissue environment as driver of macrophage metabolism 
and function
The source and nature of lipids in the adipose tissue
Various compounds present in the adipose tissue environment may affect the ATM phenotype. 
Lipids, however, are generally considered to play a central role. Indeed, already in the lean 
state, we found genes involved in lipid handling to be a unique feature of ATMs (Chapter 5). 
During obesity, the expression of lipid-related genes in ATMs is further upregulated (Chapter 
5 & 6). As described above, ATMs may be exposed to lipids via damaged or dying adipocytes 
that increase in both number and size during obesity (13, 40, 41)(Chapter 6). An alternative 
route of exposure is via adipocyte lipolysis. This has been demonstrated upon weight loss 
or β-adrenergic stimulation that both increase adipocyte lipolysis and drive lipid-loading by 
macrophages (14, 42). During obesity, adipocyte lipolysis is enhanced by virtue of increased 
total fat mass, and may be further increased when adipocytes become resistant to insulin 
(20, 43, 44). Lastly, ATMs may be exposed to lipids through lipoproteins (45). The relevance of 
lipoproteins as source of lipids for ATMs is, however, questionable (46), especially in mouse 
models without any genetic manipulation that ensures the development of dyslipidaemia. 
While adipocyte lipolysis will predominantly enhance the concentration of free fatty 
acids (FFAs) in the direct surroundings of ATMs, stressed adipocytes have been shown 
to secrete small lipid droplets that may contain both FFAs and triglycerides (TGs) (47). 
Moreover, extracellular degradation of apoptotic adipocytes (13) results in either complete 
or partial breakdown of lipid droplets, thereby contributing to the pool of both TGs and FFAs. 
The relative contribution of FFAs versus TGs as drivers of the ATM phenotype is currently 
unclear. Although our in vitro model of macrophages exposed to adipose tissue-conditioned 
medium points to a prominent role for FFAs (Chapter 5), reduced lipid loading upon silencing 
of lipoprotein lipase (LPL) – involved in hydrolysis of extracellular TGs – in ATMs part of 
obese adipose tissue is suggestive of a role for TGs as well (48). In addition, the mechanism 
of uptake of TGs and FAs remains to be elucidated. Although LPL-induced lipid-loading of 
ATMs (48) points to a dominant role for extracellular breakdown of TGs, TGs and FAs itself 
or as part of lipid droplets may also be taken up via endocytosis or phagocytosis. Hence, 
the relevance of FFAs and TGs for shaping the ATM phenotype as well as the mechanism of 
uptake involved needs further study, and may bring to light key pathways involved in driving 
the ATM phenotype that can potentially be targeted for clinical purposes.
Increased lipid exposure as key driver of the ATM phenotype during obesity
We observed increased OXPHOS and glycolysis in macrophages exposed to a synthetic TG 
emulsion called Intralipid (Chapter 5), similar to metabolic activation found in macrophages 
exposed to adipose tissue-conditioned medium (Chapter 5) and in ATMs part of obese 
adipose tissue (Chapter 4). This finding strongly suggests that lipids are an important driver 
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of the unique metabolic phenotype of ATMs in obesity. The lipid-laden appearance of 
ATMs in CLSs part of obese adipose tissue has been directly linked to a pro-inflammatory 
ATM phenotype, suggestive of a crucial role for lipids in driving inflammatory properties 
of ATMs as well (12, 49-51). Indeed, lipids are considered to form the basis of inflammation 
observed in metabolic diseases including atherosclerosis and obesity (52, 53). Via activating 
TLR signalling (54, 55), generation of bioactive lipid mediators (56), and ER stress (57) either 
driven by changes in the composition of lipid membranes (58, 59) or reactive oxygen species 
(ROS) (60), lipids may induce pro-inflammatory macrophage responses. Interestingly, 
because macrophage glycolysis was strongly induced by lipids (Chapter 4 & 5) and appeared 
to predominantly contribute to inflammatory cytokine release by ATMs isolated from obese 
adipose tissue (Chapter 4), one may speculate glycolysis to be an alternative route through 
which lipids fuel inflammatory macrophage responses in obese adipose tissue. Such a relation 
between glycolysis and inflammatory cytokine release did not hold true in bone marrow-
derived macrophages (BMDMs) exposed to Intralipid (Chapter 5), however, and may require 
lipotoxicity involving TLR activation, lipid mediators and ER stress as well. Because Intralipid 
is enriched in unsaturated FAs, it may lack such lipotoxic potential that is associated with 
saturated FAs predominantly (55, 57, 61).  
Macrophages in a lipid-enriched environment as the adipose tissue are expected 
to develop a mechanism to limit lipotoxicity. The formation of lipid droplets is one 
way to neutralize otherwise toxic FFAs (62). Limiting lipid uptake may be an alternative 
approach. Interestingly, we observed strong upregulation of angiopoietin-like 4 (Angptl4) 
in macrophages in lipid-rich environments including the adipose tissue (Chapter 5). As 
endogenous inhibitor of LPL, ANGPTL4 may protect macrophages from lipid overloading 
and thus lipotoxicity. Surprisingly, however, ANGPTL4 appeared not to be involved in lipid 
loading of macrophages in an adipose tissue environment in vitro (Chapter 5). This may 
be explained by a predominant presence of FFAs over TGs in adipose tissue-conditioned 
medium, thus LPL-independent lipid uptake, or may point toward roles other than inhibiting 
LPL for ANGPTL4 in macrophages. Intriguingly, despite equal lipid loading, Angptl4-/- 
BMDMs primed with adipose tissue explants displayed enhanced cytokine release upon 
LPS stimulation compared to wild-type BMDMs. Such increased inflammatory activation of 
macrophages lacking Angptl4 was not apparent without adipose tissue-priming, suggestive 
of the existence of a link between exposure to lipids, ANGPTL4, and inflammatory activation 
of macrophages. In addition to being a well-known target gene of peroxisome proliferator 
activated receptors (PPARs), Angptl4 expression is also regulated via HIF-1α in myeloid cells 
(63). We observed upregulation of Hif-1α and several of its target genes in macrophages in an 
obese adipose tissue environment (Chapter 4). As target of HIF-1α, Angptl4 might be directly 
involved in inflammatory responses of macrophages and be part of a negative feedback 
mechanism limiting pro-inflammatory activation in lipid-enriched environments (Chapter 
4). To what extent and in what manner ANGPTL4 is involved in lipid uptake and lipotoxicity 
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including inflammatory activation of macrophages in the obese adipose tissue environment 
is an interesting question that requires further investigation. 
Additional factors potentially involved in shaping the pro-inflammatory ATM 
phenotype
Intriguingly, macrophages exposed to excessive amounts of lipids in lean adipose tissue do 
acquire a lipid-laden appearance, yet in contrast to the obese state do not develop pro-
inflammatory characteristics (14, 42, 64). In fact, they display an anti-inflammatory phenotype 
and promote adipose tissue remodelling through adipocyte clearance and adipogenesis (14, 
42). It is therefore unlikely that exposure to dead adipocytes or lipids on itself is sufficient 
to explain functional output and inflammatory characteristics of ATMs in the obese state. 
Rather, other changes in the adipose tissue environment make macrophages respond 
differently in obese versus lean adipose tissue. 
Lipid species
In addition to an increase in the amount of lipids, the composition of lipids in the adipose 
tissue has been shown to shift toward a more saturated profile in the obese state (65-68). 
Since saturated FAs are well known for inducing lipotoxicity, this shift in lipid composition 
may contribute to the more pro-inflammatory ATM responses observed during obesity. 
Moreover, saturated FAs may interfere with lipid raft integrity and membrane fluidity that 
are essential for efferocytosis (59, 61, 69, 70), and may be critical for adipocyte clearance as 
well. In general, by inducing a pro-inflammatory phenotype, saturated FAs may indirectly 
interfere with macrophage functions other than cytokine release. Indeed, both stimulation 
of adipogenesis and effective efferocytosis are associated with an anti-inflammatory 
macrophage phenotype (42, 71) and may be disrupted upon lipid-induced inflammatory 
activation of macrophages. 
DAMPs and TLR-signalling
In addition to changes in lipid composition, obesity-induced changes in stressors or cues in the 
adipose tissue environment may affect macrophage functional output directly, or via shaping 
their response toward dead adipocytes or lipids. First, stressed or dying adipocytes release 
DAMPs such as DNA (72) and HMGB1 (73, 74) that may activate ATMs via binding various 
receptors including TLRs. Indeed, TLR expression and signalling, predominantly that of TLR2 
and TLR4, have been shown enhanced in obese adipose. Activation of these receptors was 
found to contribute to adipose tissue inflammation during obesity and, ultimately, impaired 
insulin sensitivity (75, 76). Interestingly, signalling downstream of TLRs may not only affect 
macrophage responses directly, by activation of phagocytosis or cytokine production (77)
(Chapter 2), but also indirectly, by interfering with lipid handling by macrophages. For 
example, LPS-induced activation of TLR4 on macrophages in a lipid-rich environment fuels 
lipotoxicity and cell death by enhancing ceramide production (78) and triggering lysosomal 
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damage and depletion (79).
Recently, TLR10 has been identified to be the first and so far only anti-inflammatory 
member of the TLR family. Via dimerization with other TLRs including TLR2, TLR10 can 
inhibit pro-inflammatory signalling (80). Given that pro-inflammatory activation in obese 
adipose tissue has been shown to involve TLR activation, we hypothesized that introducing 
human TLR10 into the mouse genome would attenuate the development of adipose tissue 
inflammation during obesity. We did, however, not find profound effects of human TLR10 
on the development of adipose tissue inflammation in mice on a high-fat diet for 16 weeks 
(Chapter 7). Interestingly, however, TLR10 transgenic mice displayed reduced adipose tissue 
mass and adipocyte size, pointing toward a role for TLR10 in adiposity. In humans, obese 
individuals carrying single nucleotide polymorphisms (SNPs) in TLR10 had or tended to 
have lower leptin levels in plasma and reduced macrophage numbers in the adipose tissue. 
Intriguingly, no such associations were detected in lean individuals, suggestive of a role 
for TLR10 in adipose tissue specifically in obesity when a state of low-grade inflammation 
develops. Whether or not these SNPs in TLR10 affect adipose tissue inflammation and insulin 
sensitivity, and whether TLR10 mediates its effects in adipocytes, macrophages, or other 
immune cells, requires further investigation.
Adipokines and cytokines
Hypertrophic, stressed adipocytes may also be a source of pro-inflammatory adipokines (81-
83). Leptin is one of the most well-known adipokines that directly correlates with adipose 
tissue mass (84) and favours inflammatory activation of macrophages (85). Although we 
found no changes in intracellular metabolism of macrophages stimulated with leptin in 
vitro (Chapter 4), leptin has been shown to promote lipid body formation in macrophages 
(86). As a consequence, leptin may well affect lipid handling by macrophages in a lipid-rich 
environment such as the adipose tissue, yet this requires further study.
In addition to adipokines, immune cell- or adipocyte-derived cytokines may also affect 
macrophage responses in a lipid-rich environment. For example, IL-4 has recently been 
shown to enhance clearance of adipocytes, most likely by increasing macrophage capacity 
for lipid uptake and FAO (41). The concentration of various cytokines in the adipose tissue 
rises during the development of obesity (87) yet pro-inflammatory cytokines gain relative 
abundance over anti-inflammatory cytokines at progressed stages of obesity, which may 
relate to alterations in the abundance and activation state of immune cell populations (1, 
11). Such a shift in cytokine abundance may importantly affect macrophage metabolism 
and function. On the one hand, anti-inflammatory cytokines, such as IL-4 and IL-10, 
promote OXPHOS in general and FAO specifically (88-91), whereas on the other hand pro-
inflammatory cytokines, including IL-6 and TNF-α, have been shown to enhance glycolysis 
(92, 93). These experiments, however, have been mainly done in vitro and it would therefore 
be relevant to examine how exactly cytokines present in the obese versus lean adipose 
tissue reprogram macrophage responses including intracellular metabolism in a lipid-
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rich environment. Interestingly, we found strong depletion of interferon (IFN)-signalling 
pathways in macrophages in obese adipose tissue (Chapter 6). Whether impaired IFN 
signalling by metabolically activated macrophages in obese adipose tissue is the result of 
reduced presence of external IFNs, reflects reduced initiation of macrophage IFN responses 
upon external cues other than IFNs (for instance exogenous DNA (94)), or can be considered 
a general outcome measure of reduced or altered macrophage functioning, remains to be 
elucidated. In dendritic cells autocrine IFN signalling has been shown to increase FAO (95), 
yet if and how exactly lower IFN signalling affects ATM metabolism warrants future studies 
as well. Interestingly, oral administration of IFN-τ, a Type I IFN, during high-fat diet (HFD)-
feeding of mice reduced the pro-inflammatory trait of ATMs and alleviated insulin resistance 
(96). On the other hand, depletion of IFNAR, a key receptor of Type I IFNs, in adipocytes 
has been shown to increase weight gain and aggravate glucose intolerance in HFD-fed mice 
(97). Given the numerous interactions between macrophages and adipocytes, decreased 
IFN signalling and release by ATMs may importantly affect adipocyte functioning in obese 
adipose tissue. Hence, raising IFN signalling in ATMs during obesity may provide a potential 
mechanism for improving adipose tissue functioning that deserves further attention.
Nutrients
At all times, nutrient availability will critically determine macrophage metabolism. For 
example, lactate has been shown to importantly affect macrophage metabolism in a tumour 
environment (98). Although we found no evidence for lactate on its own driving the ATM 
metabolic phenotype in vitro (Chapter 4), this does not exclude a role for lactate in shaping 
metabolic programming of macrophages in a lipid-rich environment as the adipose tissue. 
The potential of nutrients to interfere with effective lipid processing is clearly illustrated by 
glutamine that fuels lipotoxicity, i.e. lysosomal damage and cell death, in classically activated 
macrophages in a lipid-rich environment (99). In contrast to glutamine, glucose appears not 
to enhance lipid-induced cell death in macrophages (79). However, glucose may importantly 
compete with FAs for processing as a result of the reciprocal relation between glucose and 
FAO known as the Randle cycle; in which metabolic intermediates of one pathway inhibit 
enzymes of the other (100). Because glycolysis itself has been shown crucial for inflammatory 
cytokine release by ATMs (Chapter 4), increased glucose levels during obesity may, similar to 
macrophage activation via TLRs or cytokines that stimulate glycolysis, importantly impact on 
metabolic choices and functional output of ATMs. 
Targeting intracellular metabolism to align adipose tissue macrophage 
functioning with increased environmental demands
Considering the many factors present in obese adipose tissue that all potentially affect 
the ATM phenotype, various different approaches may be undertaken to reduce the pro-
inflammatory trait of ATMs populating obese adipose tissue. Anti-inflammatory approaches 
have been numerous and, following from the tight connections between immunity and 
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metabolism, in animal models often positively affect systemic metabolism as well (101). 
Unfortunately, however, the clinical effect of most anti-inflammatory drugs has been 
somewhat disappointing so far (102, 103). Importantly, acute, short-lived inflammatory 
signalling in the adipose tissue is of functional relevance, not only for combatting pathogens, 
but also for healthy adipose tissue expansion and homeostasis (104). Because processing of 
lipids will always be a key function of ATMs part of obese adipose tissue, it might be more 
effective to aim at reducing the burden of lipids in ATMs. The more because lipotoxicity is 
considered to be an important driver of maladaptive inflammatory activation of ATMs in 
obesity (12, 49). 
Limiting lipid uptake
The most obvious approach for reducing the lipid burden would be to limit lipid uptake. 
Importantly, however, studies interfering with lipid uptake or handling by ATMs during obesity 
point to a similar role for lipid buffering during obesity as during fasting; when ATMs abate 
excessive leakage of potentially toxic FFAs into the circulation (14). First, aggravated lipid 
buffering capacity of ATMs through selective depletion of Lpl results in increased circulating 
FFAs and reduced glucose tolerance in leptin-deficient ob/ob mice without affecting 
bodyweight or adiposity (48). Second, introducing bone marrow that is depleted from Fatp1, 
an acyl-CoA synthetase facilitating intracellular lipid trafficking and involved in FA uptake; 
increases weight gain, adiposity and adipose tissue inflammation, and aggravates glucose 
intolerance in mice fed a HFD (105). Hence, even though lipids may underlie inflammatory 
activation of ATMs during obesity, lipid buffering by ATMs is of great functional relevance. 
Therefore, interfering with lipid uptake of ATMs holds limited therapeutic potential. Rather, 
efforts should be directed at expanding the lipid buffering and handling capacity of ATMs 
to render them capable of bearing the continuous flow of lipids in obese adipose tissue, 
without introducing lipotoxicity. 
Increasing lipid breakdown
Both storage in lipid droplets (LDs) and oxidation in mitochondria are effective ways to 
neutralize otherwise toxic FAs (62, 106). Interestingly, macrophages in obese adipose 
tissue already show enhanced lipid storage as evidenced by their lipid-laden appearance. 
Moreover, increased lysosomal biogenesis and intracellularly activity in ATMs populating 
obese adipose tissue are suggestive of a continuous cycle of lipid processing that involves 
both lipid storage in LDs and subsequent lysosomal degradation of lipids from LDs (19). 
An intriguing question that remains to be answered, however, is whether lipids taken up 
by ATMs in obese adipose tissue – either directly or via lipolysis of LDs – are oxidized for 
ATP production in mitochondria. Interestingly, carnitine palmitoyltransferase 1α (CPT1α), a 
rate-limiting enzyme for FAO, has been detected in ATMs of obese individuals (107). Our 
unpublished data hint toward FAO in macrophages in an obese adipose tissue environment 
as well. However, despite increased exposure to lipids, FAO was not higher in macrophages 
General discussion
209
8
in an obese compared to lean adipose tissue environment, illustrated by a profound (~25%) 
but equal reduction in OXPHOS upon the injection of etomoxir in BMDMs exposed to obese 
or lean adipose tissue explants. Although just as 2-DG, etomoxir has been shown to have 
various side-effects (108, 109), one may speculate FAO to be the missing link in ATMs that 
are increasingly exposed to lipids during the development of obesity.
Importantly, a nutrient overload as present in obesity has been described to lead 
to ‘mitochondrial grid-lock’ in a variety of tissues including the muscle, liver and adipose 
tissue, characterized by impaired fuel switching and a persistent battle for oxidation 
between glucose, fatty acids, and amino acids (110-113). For ATMs, this may have significant 
consequences since oxidation of other metabolites present in the obese adipose tissue 
environment may importantly interfere with FAO. Interestingly, acylcarnitines, the by-
products of incomplete oxidation of FAs, have been shown to promote pro-inflammatory 
cytokine release by macrophages in vitro (114). Although this study provided acylcarnitines 
extracellularly, one could hypothesize that increased lysosomal breakdown of TGs into 
FAs without subsequent (complete) oxidation in mitochondria of ATMs increases the 
concentration of intracellular acylcarnitines to toxic levels, thereby fuelling inflammatory 
activation. This is highly speculative, however, and studies involving isotope tracers of FAs 
will be essential for examining the fate of lipids taken up by ATMs and unravelling the degree 
of (partial) FAO in mitochondria. In vitro, interference with FAO of macrophages in a lipid 
(palmitate)-rich environment increases their inflammatory signalling, whereas enhancing 
FAO reduces inflammatory activation of macrophages (106, 107). Accordingly, raising FAO in 
ATMs part of obese adipose tissue may be effectively enhance their lipid handling capacity 
and decrease inflammatory activation. Ultimately, efficient lipid processing by ATMs may 
not only limit intracellular lipotoxicity, but also allow for timely removal and processing of 
dead adipocytes preventing the deterioration of dead adipocytes and release of DAMPs that 
contribute to inflammation and auto-immunity (18). 
Hence, enhancing mitochondrial capacity and driving metabolic choices toward FAO 
may promote decisive, functional mitochondria that support the ATM capacity to buffer 
lipids released upon high levels of adipocyte lipolysis or cell death during obesity. A future 
challenge will be to identify enzymes or central regulators crucial for enhancing lipid turnover 
in ATMs that may include the nuclear transcription factors PPARγ and –δ, and AMPK, known 
to be central regulators of mitochondrial capacity, OXPHOS, and FAO in macrophages (115). 
Human relevance
Importantly, the majority of studies on ATMs, including ours, have been done in mice or 
using mouse cells. Although the contribution of macrophages to adipose tissue inflammation 
and, ultimately, insulin resistance and Type 2 Diabetes is less robust than results from murine 
models suggest, ATMs do accumulate in obese adipose tissue of humans (116-118) where 
they adopt a lipid-laden appearance (40). Interestingly, despite conflicting inflammatory 
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phenotypes found in the obese adipose tissue of humans (119, 120), ATMs of obese 
individuals have been shown to display similar markers of metabolic activation as mouse 
ATMs (19, 38), corroborating metabolic activation and lipid handling to be a core feature of 
ATMs in obese adipose tissue. Studies aimed at further characterization of metabolic and 
inflammatory activation of freshly isolated ATMs from humans with varying BMI may shed 
light on the therapeutic potential of targeting ATM metabolism in humans. 
Targeting intracellular metabolism of ATMs in humans will be challenging. We already 
observed pronounced inter-individual differences between human monocytes isolated 
from lean, healthy, young individuals (Chapter 2). Obese individuals with adipose tissue 
inflammation, the target population for drugs  directed at ATMs, will be much more diverse 
and complex. They will not only greatly vary in bodyweight and degree of adipose tissue 
inflammation, but may also have comorbidities including hypertension and insulin resistance 
that involves usage of a variety of drugs as well. Not all these individuals will benefit from 
treatment strategies targeting ATM metabolism. Nevertheless, our data as well as that of the 
other studies described in this thesis point to a core role for intracellular metabolism in ATM 
functioning, and ATM functioning for adipose tissue homeostasis. As such, investing into 
research aimed at targeting ATM metabolism is hypothesized to be a worthwhile strategy 
for abating chronic low-grade inflammation in the adipose tissue with the ultimate goal of 
preventing or attenuating insulin resistance in a group of obese individuals.
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Figure 3 Representation of metabolic reprogramming in ATMs part of obese adipose tissue as well as potential 
important molecules and pathways involved. 
Macrophages part of obese adipose tissue are characterized by a high number of intracellular lipid droplets (LDs) 
and profound production of pro-inflammatory cytokines. Most likely, lipids play a key role in shaping this adipose 
tissue macrophage (ATM) phenotype. Hypertrophic, stressed adipocytes in obese adipose tissue increasingly 
release free fatty acids (FFAs) via lipolysis, may secrete small lipid droplets rich in triglycerides (TGs) and FFAs, 
or comprise a source of both TGs and FFAs upon cell death. Dead adipocytes have been shown to be degraded 
extracellularly in acidic compartments, a process that involves lysosomal acid lipase (LAL). Additionally, TGs may 
require extracellular breakdown mediated by lipoprotein lipase (LPL). The relative contribution of LAL versus LPL for 
extracellular TG breakdown warrants further study. A role for LPL would point to involvement of angiopoietin-like 
4 (ANGPTL4), a well-known inhibitor of LPL, in lipid uptake by ATMs. Indeed, we found ANGPTL4 to be upregulated 
in macrophages exposed to adipose tissue-conditioned medium or dead adipocytes, yet its role in lipid uptake in 
obese adipose tissue remains ambiguous. Similarly to FFAs, FAs derived from TG-breakdown may activate Toll-
like receptors (TLRs) on the macrophage surface. Activation of TLRs by FAs initiates inflammatory signalling that 
has been shown to contribute to the pro-inflammatory trait of ATMs part of obese adipose tissue. Expression of 
TLR10, the only anti-inflammatory member of the family of TLRs, could, however, not alleviate the development of 
adipose tissue inflammation in obese mice. Alternatively, FAs may enter the cell via FA-transporters, or (together 
with extracellular TGs) can be engulfed via endocytosis or phagocytosis. Once intracellularly, FAs are either stored 
or oxidized. The lipid-laden appearance of ATMs in obese adipose tissue is suggestive of increased esterification of 
FAs into TGs and subsequent storage as LDs. Rather than being statically maintained, LDs in ATMs of obese adipose 
tissue were shown subjected to breakdown in lysosomal compartments. The exact intracellular fate of lipids taken 
up by ATMs is, however, relatively unclear and requires further investigation. Most likely, increased FA uptake 
as well as LD-breakdown comprises a prominent source for FA oxidation (FAO) in mitochondria. Unexpectedly, 
however, FAO was found unaltered in ATMs from obese versus lean mice, despite increased OXHOS. Glucose and 
glutamine comprise two other nutrient sources that may account for the increased OXPHOS observed in ATMs 
isolated from obese mice. Not OXPHOS, but glycolysis – that also was sharply increased in ATMs isolated from 
obese mice – appeared to predominantly fuel cytokine production by ATMs in the obese state. Interestingly, 
ANGPTL4 was found to inhibit cytokine expression and release by macrophages in an adipose tissue inflammatory 
environment, which appeared to be unrelated to its role as LPL inhibitor yet requires further investigation. 
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Therapeutic potential of targeting adipose tissue macrophage 
metabolism: Future challenges
For targeting intracellular ATM metabolism to become clinical practice, various challenges 
need to be overcome. This last section of the discussion addresses some of the remaining 
challenges that warrant future study, and includes some recommendations for research 
strategies to tackle these challenges. 
Understanding the cause of metabolic activation of ATMs 
Considering the great complexity of the adipose tissue environment, lipids but also many 
other stressors and cues present in the obese adipose tissue environment shape ATM 
functioning. In our experiments, we have mimicked the adipose tissue environment in 
vitro using a co-culture system with adipose tissue explants, or adipose tissue explant-
conditioned medium. This approach takes the complete adipose tissue environment into 
account and, in contrast to studies that still use LPS/IFN-γ or GM-CSF versus IL-4/IL-13 or 
M-CSF stimulation to simulate ATMs from obese versus lean adipose tissue, corroborates 
metabolic and inflammatory activation of ATMs in vivo (19, 38)(Chapter 4). 
Future challenges are to deal with the amount of variation that is introduced because 
of inter-individual differences between adipose tissue donors and due to differences in the 
amount of adipose tissue used for producing the conditioned medium. Moreover, it remains to 
be elucidated what factors exactly are involved in driving the ATM phenotype. A combination 
of insulin, glucose and palmitic acid has been shown to induce the expression of membrane 
markers representative for metabolically activated ATMs or macrophages stimulated with 
adipose tissue-conditioned medium (38). However, although these molecules may be elevated 
in the circulation of patients with metabolic disease (121), dominant presence in the direct 
surroundings of ATMs is questionable. It would therefore be worthwhile to carefully examine 
the adipose tissue environment in order to find molecules that on itself, but most likely in 
combination affect ATMs phenotypes, with particular emphasis on differences between lean 
and obese conditions. This demands for a combination of chromatography and spectroscopy 
approaches to measure proteins, lipids, and metabolites possibly in whole tissue lysates but 
preferably in the interstitial fluid, for example by using open flow microperfusion techniques 
to allow for unfiltered collection (122). In addition to the discovery of potential new factors 
involved in shaping the ATM phenotype, this approach yields important information of 
physiological and relative concentrations of various stressors and cues and, ultimately, may 
provide a standardized way to generate and study ATM-alike macrophages in vitro by using 
a mixture of factors dominantly present in the adipose tissue. In addition, it might bring to 
light new pathways that underlie macrophage activation in obese adipose tissue and that 
can be targeted for therapeutic gain. 
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Understanding metabolic activation of ATMs at different stages of obesity
Macrophages have been shown to increase in number already after three days of HFD-
feeding and further accumulate in expanding adipose tissue (68, 123). Rather than a 
progressive, linear increase in inflammatory activation, ATMs display diverse inflammatory, 
metabolic, and functional phenotypes at different stages during the development of obesity 
(124). Accordingly, metabolic activation of ATMs and its relation to function may deviate 
during the development of obesity and critically depend on changes in the adipose tissue 
environment. For example, the amount of dead adipocytes will be relatively low at early 
stages of adipose tissue expansion, but more pronounced when obesity progresses. This 
is characterized by the appearance of the first CLSs somewhere between eight and twelve 
weeks of HFD-feeding in mice, whereas sixteen weeks of HFD-feeding results in an adipose 
tissue full of CLSs (51). Accordingly, clearance of dead adipocytes probably becomes a critical 
requirement for ATMs only at more advanced stages of obesity. In addition, ATMs may be 
more capable of effectively clearing adipocytes at early stages of obesity than at later stages 
when ATM functioning appears to derail (51, 104). It will be a future challenge to delineate 
macrophage functions required at different stages of adipose tissue expansion, and to unravel 
specific metabolic reprogramming essential for macrophages to execute these functions. 
Approaches linking ATM metabolism to function at distinct stages of obesity might include 
analyses in single cells that enable determination of causal relationships between metabolic 
routes and ATM functioning. This may also bring forward potential markers predictive for 
ATM dysfunction that may ultimately be used for predicting individual therapeutic strategies. 
One of the current challenges of the field encompasses the interpretation of results 
obtained by using metabolic inhibitors. Firstly, given the fundamental role for ATP production 
for every cell, blocking one metabolic pathway will inevitably drive metabolic reprogramming 
to maintain ATP production. As a consequence, deriving a causal relationship from blocking 
one metabolic route is precarious: is the decrease in the one metabolic route or the increase 
in the compensatory route responsible for the observed phenotype? Secondly, unfortunately 
most metabolic inhibitors used in the field, including 2-DG and etomoxir, display off-
target effects that may contribute to the observed effects. Repeating experiments using 
different inhibitors of one metabolic route (to reduce the chance of off-target effects to be 
responsible for the observed phenotype) or a combination of inhibitors blocking multiple 
metabolic routes (leaving one route to be used for ATP production) may take away part of 
these concerns. 
Investigating the therapeutic gain of targeting intracellular metabolism of ATMs 
specifically
Once specific routes have been identified, the next challenge is to reveal the potential 
of targeting these routes for therapeutic gain. Myeloid specific knock-out or -in of genes 
involved in lipid uptake, transport or metabolism have demonstrated the significance of 
lipid handling capacities for macrophages in the adipose tissue during the development of 
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obesity. These experimental models, however, do not specifically target ATMs and reveal 
little about the therapeutic potential of targeting these molecules when obesity already 
has developed. Would it, for example, be possible to raise mitochondrial capacity for FAO 
in ATMs of individuals with severe obesity? Our data (Chapter 4 & 5) as well as that of 
others (19, 38) show that lipid metabolism and OXPHOS are already strongly enhanced in 
ATMs during obesity, and it will be a future challenge to investigate whether mitochondrial 
capacity can be further increased in these cells. While mitochondria have been shown to 
become dysfunctional during obesity in various cell types, it is currently unknown whether 
mitochondrial grid-lock appears in ATMs during obesity. Our findings of high spare respiratory 
capacity (SRC), a measure of the oxidative potential of mitochondria, in ATMs isolated 
from obese adipose tissue (data not shown) and macrophages exposed to obese adipose 
tissue ex vivo (Chapter 4) are suggestive of the potential to increase FAO in mitochondria 
of ATMs, and point to the absence of structural mitochondrial dysfunction that has been 
shown to prevent repolarization of M1 into M2 macrophages (89). Building upon these 
data, increasing mitochondrial capacity to burn FAs predominantly may provide a promising 
therapeutic approach. Yet whether indecisive mitochondria can still be guided to become 
decisive and remain decisive in the complex adipose tissue environment accommodating 
various stressors and cues that may interfere with drug-induced metabolic reprogramming, 
warrants further study. Moreover, whether raising FAO will be beneficial in ATMs part 
of obese adipose tissue remains to be elucidated as well. For instance, FAO may drive 
mitochondrial ROS formation at complex III of the electron transport chain (125), especially 
when mitochondria get overwhelmed (112). Importantly, palmitate-induced JNK activation 
and pro-inflammatory cytokine expression by macrophages has been shown enhanced 
when oxygen tension drops, which could for a great part be attributed to mitochondrial ROS 
formation (126). Since hypoxia is considered a ubiquitous feature of obese adipose tissue 
(127), it remains to be investigated whether increasing FAO in ATMs part of obese adipose 
tissue reduces lipotoxicity and inflammatory activation, or accelerates mitochondrial ROS 
formation and further fuels the pro-inflammatory trait of ATMs. Lastly, one should critically 
evaluate the benefit there is to gain from therapeutically reprogramming ATM metabolism 
at more advanced stages of obesity, that may be accompanied by insulin resistance or even 
Type 2 Diabetes. Most likely, more progressive stages of obesity require additional treatment 
strategies that target insulin production in the pancreas or glucose tolerance in other organs 
than the adipose tissue as well. 
The development of methods specifically targeting ATMs in obese individuals may 
comprise the most difficult yet essential future challenge. So far, drugs carried in liposomes 
(128), glucan shells (129) or linked to glucose polymers coated with polysaccharides (130) 
have been shown to effectively and specifically target ATMs upon intraperitoneal injection 
in obese mice. These methods exploit the intrinsic phagocytic capacity of macrophages to 
readily take up liposomes or foreign (nano)particles. These methods, however, also critically 
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depend on macrophage infiltration into the adipose tissue during obesity. Studies have 
brought forward additional mechanisms contributing to ATM accumulation in obese adipose 
tissue of both humans and mice, including in situ myelopoiesis and local macrophage 
proliferation (131-133) that may not be targeted using these approaches. While β-glucan is 
recognized by Dectin-1, a receptor that is ubiquitously expressed by neutrophils, monocytes 
and macrophages (134), particles may be coated with ligands of receptors or transporters 
specifically or highly expressed on the membrane of ATMs part of obese adipose tissue. 
Conceivably this will enhance ATM-specificity without solely relying on monocyte influx 
into obese adipose tissue. The use of pro-drugs comprises an alternative approach. For 
example, the attachment of an esterase-sensitive motive that is selectively hydrolysed in 
macrophages and monocytes (both expressing the required enzyme carboxylesterase-1) 
to small drugs, has been shown effective for delivering pharmacological activity only 
in monocytes and macrophages (135). Hypothetically, liposome- or particle-mediated 
delivery of a pro-drug that depends on the high metabolic or lysosomal activity of ATMs to 
become pharmacologically active may be a future opportunity for targeting ATMs in obese 
individuals. Otherwise, above mentioned existing macrophage-targeted approaches may 
already sufficiently reach ATMs for achieving clinical benefits.
Importantly, merging immunology and metabolism into a new scientific field named 
‘immunometabolism’ has initiated an avalanche of studies that have greatly enhanced our 
understanding of the impact of intracellular metabolism on immune cell function. Increasing 
evidence illustrates cell- and location-specific macrophage functions and accompanying 
metabolic requirements. Currently, we may have reached a tipping point at which 
immunomodulatory drugs can be clinically tested, yet are short of methods for achieving 
immune cell specificity. Joining forces of scientists across various scientific fields including 
immunology, physiology, and chemistry may be critical to catalyse the development of 
(tissue-)specific macrophage treatment opportunities for conditions that are characterized 
by macrophage-induced inflammation, among which metabolic diseases.
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Macrophages and their monocyte precursors continuously patrol the bloodstream and 
tissues, ready to eliminate unwelcome visitors such as pathogens or foreign particles. 
Tissue-resident macrophages are crucial during development and for maintaining tissue 
homeostasis as well. The engulfment of dying or damaged tissue cells, a process called 
efferocytosis, is a central part of their role to maintain homeostasis, yet is accompanied by 
several other tissue-tailored functions. Accordingly, macrophages display great plasticity by 
adopting unique phenotypes to fulfil tissue-specific needs.  
This thesis is particularly devoted to macrophages residing in the adipose tissue. In 
lean conditions adipose tissue macrophages (ATMs) promote tissue and whole-body 
homeostasis by buffering lipids released by adipocytes and removing dead or damaged cells, 
and ensure tissue dynamics by promoting angiogenesis, adipogenesis, and extracellular 
matrix remodelling. Obese adipose tissue, however, is characterized by low-grade chronic 
inflammation reflective of homeostatic imbalance. Given their pivotal role for maintaining 
homeostasis in lean conditions, ATMs are considered key players in the development of 
adipose tissue inflammation during obesity. Indeed, during obesity ATMs sharply increase 
in number while simultaneously gaining a pro-inflammatory trait. This pro-inflammatory 
activation of ATMs is thought to importantly link obesity to the development of insulin 
resistance and, ultimately, Type 2 Diabetes. 
Notwithstanding the considerable progress made, the underlying causes of macrophage 
activation and phenotypical and functional characteristics of ATMs in obese adipose tissue 
have not yet been fully unravelled. In this thesis, we have investigated various aspects of 
activation of macrophage and their monocyte precursors. First, we have examined metabolic 
reprogramming in monocytes stimulated with various pathogenic stimuli (Chapter 2). This 
research adds to the growing evidence of intracellular metabolism as fundamental driver 
of immune cell functioning. In contrast to the majority of studies in the field that have 
focussed on one single stimulant, we have carefully evaluated intracellular metabolism upon 
activation with different pathogenic stimuli, including whole pathogen lysates and isolated 
Toll-like receptor (TLR) ligands. In line with the current paradigm, we found glycolysis to 
be a general characteristic of monocyte activation irrespective of the present stimulus. 
Interestingly, however, in contrast to the current paradigm, oxidative phosphorylation 
(OXPHOS), the alternative route for ATP production that occupies mitochondria, was found to 
be enhanced by most pathogenic stimuli as well. In fact, the most commonly used stimulant 
for activating monocytes and macrophages, being lipopolysaccharide (LPS), appeared 
unique in aggravating mitochondrial metabolism. Importantly, such stimulus-specific 
metabolic reprogramming appeared to have functional consequences, that we evaluated 
by comparing the two different TLR-ligands LPS (TLR4 ligand) and Pam
3
CysSK
4
 (P3C: TLR2 
ligand). While glycolysis contributed to cytokine release by both LPS and P3C, OXPHOS only 
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contributed to cytokine production in P3C-stimulated monocytes. Moreover, phagocytosis 
appeared to rely on OXPHOS but not glycolysis in monocytes stimulated with P3C. Probably 
consequential to their reduced mitochondrial activity, LPS-stimulated monocytes displayed 
low phagocytic capacity. Together these findings are suggestive of stimulus-tailored 
metabolic rearrangements fuelling functional output of monocytes. 
After reviewing various aspects of ATMs in Chapter 3 – including their origin, activation 
and function in obese versus lean conditions – we examined metabolic rearrangements 
in ATMs, and evaluated their contribution to the pro-inflammatory ATM trait apparent in 
obese adipose tissue (Chapter 4). Not surprisingly given the rather challenging environment 
provided by obese adipose tissue, ATMs were found to be strongly metabolically activated 
during obesity illustrated by enhanced activation of both glycolysis and OXPHOS. 
Interestingly, this metabolic activation appeared to be specific for ATMs, and was not 
manifested in macrophages isolated from the peritoneum of obese versus lean mice. In line 
with recent studies, we showed that both the metabolic and inflammatory trait of ATMs 
was pronouncedly different from that displayed by classically (LPS-)activated macrophages. 
Indeed, the ATM phenotype appeared dose-dependently induced by adipose tissue-derived 
factors. Using metabolic inhibitors, we identified various metabolic routes including fatty acid 
oxidation, glycolysis and glutaminolysis to contribute to cytokine release by ATMs isolated 
from lean mice. Glycolysis, however, contributed the most to cytokine production and was 
responsible for the increased release of inflammatory cytokines by ATMs from obese mice. 
Unexpectedly, however, HIF-1α, a key regulator of glycolysis and inflammatory activation, 
appeared not to be critically involved in the development of a pro-inflammatory ATM trait 
during obesity. 
Because lipids most likely play a central role in shaping the ATM phenotype, we 
evaluated the role of triglycerides (TGs) versus free fatty acids (FFAs) as driver of pro-
inflammatory activation of ATMs in Chapter 5. First we confirmed lipid handling to be a 
fundamental characteristic of ATMs by showing that ATMs, but not other tissue macrophages 
or circulating monocytes from humans and mice, display enhanced expression of genes 
involved in lipid uptake and processing. This associated with increased expression of ER 
stress markers and inflammatory activation of macrophages, pointing to a relation between 
lipid loading and inflammatory activation of ATMs. Interestingly, both lipoprotein lipase 
(Lpl), that breaks down extracellular TGs into FAs that can be taken up, and its endogenous 
inhibitor angiopoietin-like 4 (Angptl4) were upregulated in macrophages in an adipose tissue 
environment, suggestive of the presence of a negative feedback mechanism to limit LPL 
activity and thus excessive uptake of FAs from TGs. Indeed, we observed ANGPTL4 to inhibit 
inflammatory activation of macrophages in an adipose tissue environment. Intriguingly, 
however, reduced inflammatory activation of Angptl4 knock-out macrophages in an adipose 
tissue environment appeared to be independent of lipid loading which most likely occurred 
through uptake of FFAs rather than TGs.
226
 
In Chapter 6, we zoomed into a role for ATMs in efferoctysis of dead adipocytes, 
that may impose an important source of lipids for ATMs. Indeed, we found profound 
transcriptional regulation of the efferocytic machinery in ATMs isolated from obese 
versus lean adipose tissue accompanied by increased expression of genes involved in lipid 
handling and processing of lipid-derivatives. In vitro, dead adipocytes were readily taken 
up by macrophages and induced the expression of various genes involved in lipid handling, 
similar to what we found in ATMs in vivo. Interestingly, macrophages part of obese adipose 
tissue display pronounced down-regulation of Interferon (IFN)-signalling, whereas effective 
efferocytosis in vitro was characterized by enhanced IFN signalling. Accordingly, our data are 
suggestive of a link between impaired IFN signalling and dysfunctional, pro-inflammatory 
ATMs in obese adipose tissue. 
Lastly, in Chapter 7 we have evaluated a role for TLR10, the sole anti-inflammatory TLR 
family member, in adipose tissue of humans and mice. Because mice do not express functional 
TLR10, we fed mice expressing human TLR10 a high-fat diet for 16 weeks. Unexpectedly, 
TLR10 did not attenuate the development of adipose tissue inflammation during obesity. 
Interestingly, however, mice carrying human TLR10 had reduced adipose tissue weight and 
adipocyte size, suggestive of a role for TLR10 in adiposity. In humans, obese but not lean 
individuals carrying single nucleotide polymorphisms (SNPs) in TLR10 had or tended to have 
lower circulating leptin and macrophage numbers in the adipose tissue, reflective of a role 
for TLR10 in the adipose tissue at states of low-grade chronic inflammation specifically. 
In conclusion, we have revealed macrophage metabolic reprogramming to be stimulus-
driven and location-specific and crucial for fuelling functional output in line with specific 
environmental demands. In the adipose tissue, lipid handling is central to macrophage 
functioning, yet ATMs appear to be overwhelmed by lipids during obesity. From a therapeutic 
point of view, we propose stimulation of FA oxidation to support ATM functioning according 
to increasing demands of the obese adipose tissue environment, while simultaneously 
driving them away from glycolysis that appeared to critically underlie their pro-inflammatory 
trait. Future studies, however, are warranted to clarify the therapeutic potential of raising 
mitochondrial FA oxidation in ATMs of obese individuals. 
Summary 
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Gesjees, gepipetteer, gelach, (gebrekkig) geplan, gestress, gemopper, geknal, geschrijf, gedoe, 
gepresenteer, gefiets: de afgelopen jaren als PhD in Wageningen hebben een onuitwisbare 
indruk gemaakt en impact gehad. Mede mogelijk gemaakt door velen die direct of indirect, 
bewust of onbewust, hebben bijgedragen aan dit proefschrift. 
Prof. dr. Kersten, beste Sander. Dankjewel voor je supervisie en je vermogen de touwtjes in 
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wel voor het delen van je enthousiasme en brede kennis.
Beste dr. Stienstra, Rinke! Van één ding was ik vrijwel zeker toen ik naar Oxford vertrok: 
naar Wageningen zou ik niet snel meer terugkeren. Vier jaar later moeten we concluderen 
dat dit toch anders gelopen is. En ik ben daar, aan het einde van de rit, heel blij mee! Met 
een grote dosis enthousiasme en interesse zijn we met veel winden meegewaaid. Vaak van 
hot naar her en soms de verkeerde kant op geblazen, maar wel mooi hier uitgekomen: een 
eindpunt waar we toch vooral trots op mogen zijn. Ik heb je denk ik nog nooit ‘Nee, dat 
gaat niet lukken’ of ‘Nee, dat gaan we niet doen’ horen zeggen. Het traject had dan ook 
gestructureerder gekund, en vast sneller. En misschien beter. Maar ik heb ontzettend veel 
geleerd van jouw wetenschappelijke aanpak, van hoe je in het leven staat (ja, heus!), je 
onmetelijke feitenkennis (showbizz, sport, nieuws en nummerplaten. (Wetenschap)). Ik kon 
altijd bij je terecht met relazen, brainwaves, of anderszins overlegbehoevende zaken. En dat 
waardeer ik zeer! De taxiritjes naar Amsterdam of Nijmegen voor metingen of afspraken, 
die gaandeweg wat minder werden door de aanschaf van de Pompbak, had ik vanwege (of 
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Tjeerd) niet willen missen. Ontzettend bedankt voor je supervisie en het vertrouwen dat je 
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Ook veel dank aan prof. Huub Savelkoul, prof. Casper Schalkwijk, prof. Menno de 
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heel ver weg gevonden hebben, én ondanks dat jullie wel andere dingen aan je hoofd hebben 
(bijvoorbeeld een kind ter wereld brengen en verzorgen), laten jullie de loodjes wat minder 
zwaar wegen door naast mij te staan tijdens de promotie: dank jullie wel toppers! 
Benthe. De derde partner in crime! Met jou was het nooit saaaaaai. ‘Hoe dan?’ Lullen, 
fietsen en lachen; gewoon lullen, fietsen en lachen. Knal-ze nog even, ik heb er het rots-aller-
dikste-vastste vertrouwen in dat je een super boekje aflevert aan het einde van de rit. En 
niks meer opproppen oké? 
All (former) PhDs in Wageningen; Antwi, Anouk, Charlotte, Fenni, Inge, Juri, Katja, Jvalini, 
Mara, Merel, Milène, Miranda, Montse, Nikkie, Neeraj, Parastoo, Philip, Rogier, Roland, 
Sophie, Xanthe and Ya, thanks for all the fun, serieus, short and longer talks in and outside 
the lab, and the best of luck with your experiments, writing, presentations, weddings, new 
houses and (new) carreers! 
Guido, dank voor het fabriceren van de ene na de andere PCA plot, en de ‘Guido’s special’: 
de weergave van de GSEA resultaten in macrofagen. Wat – al dan niet verhulde – zuchtjes 
hier en daar hebben je niet belet om keer op keer weer kleine aanpassingen door te 
voeren. Waarvoor veel dank! En natuurlijk ook dank voor het arsenaal aan gekke geluiden 
waar geen muur tegen opgewassen is. Kamergenoten Karin, Marlies en Pieter. Karin, dank 
je wel voor je gezelligheid, en voor de heerlijke baksels en groeten! Pieter en Marlies, ik 
vond het leuk en gezellig om met jullie de kamer te mogen delen. Shohreh, besides the 
exceptional achievement of growing younger than me over the years, I would like to thank 
you for your expertise and help with RNA isolations and Western Blots that have challenged 
our enthousiasm and planning;-). Jenny, bedankt voor je super bioanalyzer- en microarray-
expertise, en voor je toestemming om af en toe (vaak) stiekem de pipet uit het microarray 
lab te confisqueren ;-)... Mechteld, dankjewel voor de last-minute hulp met qPCRs! Mieke 
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en Carolien, dank jullie wel voor het op orde houden van twee ruimten waar ik me veel 
bewogen heb de afgelopen vier jaar: de celkweek en het qPCR lab. En natuurlijk voor de 
gezellige gesprekken! Jocelijn, Klaske, Lydia, Marco, Mark, Michiel en Wilma, dank jullie wel 
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interessante onderwerpen. Diederik! Hoewel alle ‘horseshit’ van de afgelopen jaren me 
toch waarschijnlijk vooral bijblijft, zal ik ook zeker de absolute geweldenaarsrol die jij aannam 
door geduldig te wachten om mij en de cellen (beiden in een staat van totale paniek) drie uur 
later dan gepland als koningen naar Amsterdam te rijden, in ere herinneren…Dat er absoluut 
niks te meten was lag zeker niet aan dit deel van het vervoer ;-)!
Thanks to all the PhDs, technicians, and everyone attending the Cytokine meetings in 
Nijmegen. For the critical questions, the fun talks, the nice gatherings, and the great 
atmosphere: I have really enjoyed my not-so regular visits to Nijmegen! Speciale dank aan 
Anneke and Cor voor alle ondersteuning bij plasma metingen, histologie en het FACSen. En 
aan Janna, voor de interesse en leuke gesprekken. Thanks to Andreea for the teamwork on 
the TLR10 project! Kathr, weil du es wert bist. Selbstverständlich. Jacqueline, dankjewel 
for your patience, for the pastaevenings and just for being great company! I appreciated 
your and Ekta’s counterbalance to my ‘energy’ ;-), and our long (and very long) discussions 
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De CKP-crew: René, Bert, en Wilma (Lisette en Judith), jullie hebben mijn chaotische aanpak 
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hulp bij experimenten, en voor alle leuke en serieuze gesprekken. Ik wens jullie alle geluk! 
I would like to thank all our collaborators, Jan Willem Borst, Claudia Carmone, Robert 
Cramer, Sourabh Dhingra, Jack Fransen, Riekelt Houtkooper, René Leen and Richard 
Rodenburg for welcoming us in their lab and helping with experiments.
Ook alle studenten die hebben geholpen in het lab en mij dwongen te plannen en me aan 
een plan te houden, wil ik bedanken. Dank jullie wel Jiska, Alexandra, Mike, Nadja, Xanthe, 
Gina, Lubna, Simone, Kelly en Wendy. Alle succes gewenst!
Ad Arma, de vreugde die kunst brengt! Nu ook op mijn boekje: waarvoor veel dank.
Lieve Juul, Judith, Anouk en Laurie, jullie hebben ieder op jullie eigenzinnige wijze voor 
de nodige mentale ondersteuning, ontspanning, goede voorbeelden, slechte grappen, 
gedeelde twijfels, relativering, (on)interessante weetjes, en grootse wijsheden gezorgd. Ik 
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ben trots op jullie! Ook een eervolle vermelding voor het Friesland collectief (+ aanwinsten) 
en Sjoerd: super dat jullie erbij zijn! 
Lieve Corrie, de bezoekjes bij jou en Wouter in Den Haag heb ik als heel bijzonder ervaren. Ik 
hoop dat we ze in stand houden. Wouter, lieve, gekke oom: alles is golven. 
Natuurlijk mag innige dank aan mijn huisgenoten Sipke en Leanne niet ontbreken. Ik vind 
jullie bijzondere topschoonouders! Dank jullie wel voor jullie generositeit en steun: zowel 
mentaal als nu ook in keiharde (koude) stenen. Side, Marrit, Pier, Fre, dank jullie wel voor de 
gezelligheid en interesse KANJERS!
Lieve Mama, dankjewel voor je rotsvaste vertrouwen. Je ontvangt ons altijd met open armen, 
en die onvoorwaardelijke liefde is fantastisch. Jij hebt altijd al gezegd dat dit ging lukken en nu 
is het zover: het is klááááár ;-)! Ook nog wat woorden voor het stelletje mafkezen a.k.a. toffe, 
kleine, grote broertjes Sebastiaan en Casper. Lieve Seb, ik ben altijd weer verbaasd over de 
enorme berg weetjes over werkelijk waar alles en nog wat, die je er net zo hard inknalt als 
het vuurwerk van de HUBO (Oké, best flauw). Ik hoop nog veel (on)zin van je te leren ;-)! Lieve 
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nog veel mooie jaren, met als eerstvolgende ijkpunt ons maffiose stulpje in Kanaleneiland! 
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